US20170199204A1 - Urine Biomarkers for Prediction of Recovery After Acute Kidney Injury: Proteomics

Info

Abstract

Description

Claims

US20170199204A1

Publication number: US20170199204A1
Application number: US15/399,994
Authority: US
Inventors: Kai Singbartl; John A. Kellum
Original assignee: University of Pittsburgh
Current assignee: University of Pittsburgh
Priority date: 2011-01-26
Filing date: 2017-01-06
Publication date: 2017-07-13
Also published as: US9551720B2; EP2668497A4; EP2668497A1; EP2668497B1; US20130323751A1; EP3761034A3; EP3761034A2; WO2012102963A1

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, a normalized time course of approximately fourteen Days measuring urinary proteins can be used to establish the risk of recovery versus non-recovery in patient's having suffered an acute kidney injury. Alternatively, the invention describes signature protein expression profiles to establish the probability of renal recovery and/or renal non-recovery.

STATEMENT OF GOVERNMENT SUPPORT

This invention was made with government support under grant #DK 070910 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE INVENTION

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.

BACKGROUND

Acute Kidney Injury (AKI) has an estimated incidence rate of approximately 2000 per million population and this rate is increasing. Ali et al. “Incidence and outcomes in acute kidney injury: a comprehensive population-based study” J Am Soc Nephrol 18:1292-1298 (2007). Approximately 5% of all people admitted to intensive care units around the world develop severe AKI requiring dialysis. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA 294:813-818 (2005). A recent, multi-center study found that fewer than only about 60% patients surviving severe AKI recovered renal function by two months. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). Thus, a large number of patients with AKI go on to have end-stage renal disease (ESRD).
However, since only a fraction of patients with AKI fail to recover renal function, interventions aimed at improving recovery or providing renal support (e.g. early dialysis) cannot be targeted appropriately without some means of determining which patients will recover and which will not. Unfortunately, clinical risk prediction for recovery after AKI is extremely limited. Research efforts to treat AKI and prevent ESRD could be tailored according to long-term-prognosis. In other words, with an accurate prediction of which patients will not recover kidney function, medical efforts could focus the development and application of aggressive treatment interventions on just these patients. Conversely, patients with a favorable prognosis would be spared from more aggressive interventions and their potential adverse effects.
Thus, development of a biomarker or biomarker panel that allows early prediction of recovery of kidney function would be an extremely valuable clinical tool. What is needed in the art are a panel of biomarkers to predict renal recovery after AKI.

SUMMARY

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.
In one embodiment, the present invention contemplates a composition comprising an renal injury biomarker, wherein said biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor. In one embodiment, the composition further comprises a urine sample. In one embodiment, the urine sample is collected between 1 day and 14 days after a kidney injury. In one embodiment, the urine sample is a human urine sample. In one embodiment, the biomarker is at least 2.5 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.0 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.5 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.25 fold higher as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.5 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 2.0 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.5 fold lower as compared to an expected level in a renal recovery group. In one embodiment, the biomarker is at least 1.25 fold lower as compared to an expected level in a renal recovery group.
In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of an acute renal injury; and ii) a biological fluid sample obtained from said patient, wherein said sample comprises a renal injury biomarker; b) measuring a renal recovery biomarker value; c) comparing said renal biomarker value to an expected value from a renal recovery group; and d) predicting a probability of renal recovery for said patient based upon said comparison. In one embodiment, the probability of renal recovery is greater than 90%. In one embodiment, the probability of renal recovery is greater than 75%. In one embodiment, the probability of renal recovery is greater than 50%. In one embodiment, the probability of renal recovery is less than 50%. In one embodiment, the probability of renal recovery is less than 25%. In one embodiment, the probability of renal recovery is less than 10%. In one embodiment, the biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor.
In one embodiment, the present invention contemplates a kit, comprising; a) a first container comprising an antibody specifically directed to an renal injury biomarker, wherein said biomarker comprises at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotien, carbonic anhydrase, and uromodulin precursor; b) instructions for determining whether said biomarker is overexpressed as compared to an expected value from a renal recovery group; c) instructions for determining whether said biomarker is underexpressed as compared to an expected value from a renal recovery group; and d) instructions for determining the probability of renal recovery. In one embodiment, the antibody is a monoclonal antibody. In one embodiment, the monoclonal antibody is specifically directed to said biomarker protein fragment.
In one embodiment, the present invention contemplates a signature expression profile comprising a urinary protein biomarker panel, wherein said profile predicts renal recovery. In one embodiment, the biomarker panel comprises a plurality of overexpressed urinary proteins. In one embodiment, the biomarker panel comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.
In one embodiment, the present invention contemplates a signature expression profile comprising a urinary protein biomarker panel, wherein said profile predicts renal non-recovery. In one embodiment, the biomarker panel comprises a plurality of overexpressed urinary proteins. In one embodiment, the biomarker panel comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.
In one embodiment, the present invention contemplates a method, comprising: a) providing; i) a patient exhibiting at least one symptom of an acute renal injury; and ii) a biological fluid sample obtained from said patient, wherein said sample comprises a plurality of renal biomarker nucleic acids; b) expressing said plurality of renal biomarker nucleic acids, thereby creating a signature expression profile; and c) predicting a probability of renal recovery for said patient based upon said signature expression profile. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 90%. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 75%. In one embodiment, the signature expression profile predicts a probability of renal recovery of greater than 50%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 50%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 25%. In one embodiment, the signature expression profile predicts a probability of renal recovery of less than 10%. In one embodiment, the signature expression profile comprises a plurality of overexpressed urinary proteins. In one embodiment, the signature expression profile comprises a plurality of underexpressed urinary proteins. In one embodiment, the plurality of overexpressed urinary proteins are selected from the group consisting of beta globin, catalase, alpha globin, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, and annexin A2. In one embodiment, the plurality of underexpressed urinary proteins are selected from the group consisting of myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, and uromodulin precursor.
In one embodiment, the present invention contemplates a kit, comprising; a) a first container comprising reagents for creating a signature expression profile using a biological sample, wherein said signature expression profile comprises a plurality of renal biomarker nucleic acids; b) a second container comprising monoclonal antibodies specific for said renal biomarker nucleic acids; c) a set of instructions for creating said signature expression profile; d) a set of instructions for determining overexpressed renal biomarker nucleic acids; e) a set of instructions for determining underexpressed renal biomarker nucleic acids; f) a set of instructions for predicting the probability of renal recovery; and g) a set of instructions for predicting the probability of renal non-recovery.

Definitions

As used herein, an “injury to renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) measurable reduction in a measure of renal function. Such an injury to renal function may be identified, for example, by a decrease in glomerular filtration rate (GFR) or estimated GFR (eGFR), a reduction in urine output, an increase in serum creatinine, an increase in serum cystatin C, a requirement for renal replacement therapy (i.e., for example, dialysis), etc.
As used herein, an “improvement in renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) measurable increase in a measure of renal function. Preferred methods for measuring and/or estimating GFR are described hereinafter.
As used herein, “reduced renal function” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.1 mg/dL (≧8.8 μmol/L), a percentage increase in serum creatinine of greater than or equal to 20% (1.2-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour).
As used herein, “acute renal failure” or “ARF” is an abrupt (i.e., for example, within 14 Days, preferably within 7 Days, more preferably within 72 hours, and still more preferably within 48 hours) reduction in kidney function identified by an absolute increase in serum creatinine of greater than or equal to 0.3 mg/dl (≧26.4 μmol/l), a percentage increase in serum creatinine of greater than or equal to 50% (1.5-fold from baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg per hour for at least 6 hours). This term is synonymous with “acute kidney injury” or “AKI.”
As used herein, the term “relating a signal to the presence or amount” of an analyte refers to assay measurements using a standard curve calculated with known concentrations of the analyte of interest. The skilled artisan will understand that the signals obtained from an assay are often a direct result of complexes formed between, for example, one or more antibodies and a target biomolecule (i.e., for example, an analyte) and/or polypeptides containing an epitope(s) to which, for example, antibodies bind. While such assays may detect a full length biomarker and the assay result may be expressed as a concentration of a biomarker of interest, the signal from the assay is actually a result of all such “immunoreactive” polypeptides present in the sample.
As the term is used herein, an assay is “configured to detect” an analyte if an assay can generate a detectable signal indicative of the presence or amount of a physiologically relevant concentration of the analyte. For example, an antibody epitope is usually on the order of 8 amino acids, such that an immunoassay can be configured to detect a marker of interest that will also detect polypeptides related to the marker sequence, so long as those polypeptides contain the epitope(s) necessary to bind to the antibody or antibodies used in the assay.
The term “related marker” or “biomarker” as used herein with regard to a physiological substance such as one of the proteins as described herein. A related marker may also refer to one or more fragments, variants, etc., of a particular protein and/or peptide or its biosynthetic parent that may be detected as a surrogate for the marker itself or as independent biomarkers. The term also refers to one or more polypeptides present in a biological sample that are derived from the biomarker precursor complexed to additional species, such as binding proteins, receptors, heparin, lipids, sugars, etc.
The term “subject” or “patient” as used herein, refers to a human or non-human organism. Thus, the methods and compositions described herein are equally applicable to both human and veterinary disease. Further, while a subject or patient is preferably a living organism, the invention described herein may be used in post-mortem analysis as well. Preferred subjects or patients are humans, which as used herein refer to living humans that are receiving medical care for a disease or condition.
The term “analyte” as used herein, refers to any measured compound or molecule. Preferably, an analyte is measured in a sample (i.e., for example, a body fluid sample). Such a sample may be obtained from a subject or patient, or may be obtained from biological materials intended to be provided to the subject or patient. For example, a sample may be obtained from a kidney being evaluated for possible transplantation into a subject, such that an analyte measurement may be used to evaluate the kidney for preexisting damage.
The term “body fluid sample” as used herein, refers to any sample of bodily fluid obtained for the purpose of diagnosis, prognosis, classification or evaluation of a subject of interest, such as a patient or transplant donor. In certain embodiments, such a sample may be obtained for the purpose of determining the outcome of an ongoing medical condition or the effect of a treatment regimen on a medical condition. Preferred body fluid samples include but are not limited to, blood, serum, plasma, cerebrospinal fluid, urine, saliva, sputum, or pleural effusions. In addition, certain body fluid samples may be more readily analyzed following a fractionation or purification procedure, for example, separation of whole blood into serum or plasma components.
The term “diagnosis” as used herein, refers to methods by which trained medical personnel can estimate and/or determine the probability (i.e., for example, a likelihood) of whether or not a patient is suffering from a given disease or condition. In the case of the present invention, “diagnosis” includes correlating the results of an assay (i.e., for example, an immunoassay) for a renal biomarker of the present invention, optionally together with other clinical indicia, to determine the occurrence or nonoccurrence of an acute renal injury or acute renal failure for a subject or patient from which a sample was obtained and assayed. That such a diagnosis is “determined” is not meant to imply that the diagnosis is 100% accurate. Thus, for example, a measured biomarker level below a predetermined diagnostic threshold may indicate a greater likelihood of the occurrence of a disease in the subject relative to a measured biomarker level above the predetermined diagnostic threshold may indicate a lesser likelihood of the occurrence of the same disease.
The term “prognosis” as used herein, refers to a probability (i.e., for example, a likelihood) that a specific clinical outcome will occur. For example, a level or a change in level of a prognostic indicator, which in turn is associated with an increased probability of morbidity (e.g., worsening renal function, future ARF, or death) is referred to as being “indicative of an increased likelihood” of an adverse outcome in a patient.
The term “RIFLE” criteria, as used herein, refers to any quantitative clinical evaluation of renal status used to establish renal classifications of Risk, Injury, Failure, Loss, & End Stage Renal Disease based upon a uniform definition of acute kidney injury (AKI). Kellum, Crit. Care Med. 36: S141-45 (2008); and Ricci et al., Kidney Int. 73, 538-546 (2008), each hereby incorporated by reference in its entirety.
The term, “modified RIFLE criteria”, as used herein, provide alternative classifications for stratifying AKI patients, and may include, Stage I, Stage II, and/or Stage III. Mehta et al., Crit. Care 11:R31 (2007), hereby incorporated by reference in its entirety.
The term, “Stage I”, as used herein, refers to a risk stratification comprising a RIFLE Risk category, characterized by an increase in serum creatinine of more than or equal to 0.3 mg/dL (≧26.4 μmol/L) and/or an increase to more than or equal to 150% (1.5-fold) from baseline. Alternatively, the category may be defined by a urine output less than 0.5 mL/kg per hour for more than 6 hours.
The term, “Stage II”, as used herein, refers a risk stratification comprising a RIFLE Injury category, characterized by an increase in serum creatinine to more than 200% (>2-fold) from baseline. Alternatively, the category may be defined by a urine output less than 0.5 mL/kg per hour for more than 12 hours.
The term, “Stage III”, as used herein, refers to a risk stratification comprising a RIFLE Failure category, characterized by an increase in serum creatinine to more than 300% (>3-fold) from baseline and/or serum creatinine ≧354 μmol/L accompanied by an acute increase of at least 44 μmol/L. Alternatively, the category may be defined by a urine output less than 0.3 mL/kg per hour for 24 hours or anuria for 12 hours.
The term “Risk category”, as used herein, refers to a RIFLE classification wherein, in terms of serum creatinine, means any increase of at least 1.5 fold from baseline, or urine production of <0.5 ml/kg body weight/hr for approximately 6 hours.
The term “Injury category” as used herein includes, refers to a RIFLE classification wherein, in terms of serum creatinine, means any increase of at least 2.0 fold from baseline or urine production <0.5 ml/kg/hr for 12 h.
The term “Failure category” as used herein includes, refers to a RIFLE classification wherein, in terms of serum creatinine means any increase of at least 3.0 fold from baseline or a urine creatinine >355 μmol/l (with a rise of >44) or urine output below 0.3 ml/kg/hr for 24 h, or anuria for at least 12 hours.
The term “Loss category” as used herein, refers to a clinical outcome risk and/or a RIFLE classification wherein the clinical outcome risk is characterized by a persistent need for renal replacement therapy for more than four weeks.
The term “End Stage Renal Disease category” or “ESRD category” as used herein, refers to a clinical outcome risk and/or a RIFLE classification characterized by a need for dialysis for more than 3 months.
The term “clinical outcome risk” as used herein, refers to a medical prognosis directed towards either renal recovery or renal non-recovery.
The term “renal biomarker” as used herein, refers to any biological compound related to the progressive development of chronic kidney disease. In particular, a renal biomarker may be a kidney injury marker. For example, a renal biomarker may comprise a urinary protein, or any metabolite and/or derivative thereof, wherein the renal biomarker is either overexpressed or underexpressed as a result of an AKI.
The term “positive going biomarker” as that term is used herein, refers to any biomarker that is determined to be elevated in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.
The term “negative going biomarker” as that term is used herein, refer to any biomarker that is determined to be reduced in subjects suffering from a disease or condition, relative to subjects not suffering from that disease or condition.
The term “positive going renal biomarker value” as used herein, refers to any increased likelihood (i.e., for example, increased probability) of suffering a future injury to renal function assigned to a subject when the measured biomarker concentration is above a specified threshold value, relative to a likelihood assigned when the measured biomarker concentration is below the specified threshold value. Alternatively, when the measured biomarker concentration is below a specified threshold value, an increased likelihood of a non-occurrence of an injury to renal function may be assigned to the subject relative to the likelihood assigned when the measured biomarker concentration is above the specified threshold value. Alternatively, when the measured biomarker concentration is below the threshold value, an improvement of renal function may be assigned to the subject. A positive going kidney injury marker may include, but not be limited to, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc.
The term “negative going renal biomarker value” as used herein, refers to any increased likelihood (i.e., for example, an increased probability) of suffering a future injury to renal function assigned to the subject when the measured biomarker concentration is below a specified threshold value, relative to a likelihood assigned when the measured biomarker concentration is above the threshold value. Alternatively, when the measured biomarker concentration is above the threshold value, an increased likelihood of a non-occurrence of an injury to renal function may be assigned to the subject relative to the likelihood assigned when the measured biomarker concentration is below the threshold value. Alternatively, when the measured biomarker concentration is above the threshold value, an improvement of renal function may be assigned to the subject. A negative going kidney injury marker may include, but not be limited to, an increased likelihood of one or more of: acute kidney injury, progression to a worsening stage of AKI, mortality, a requirement for renal replacement therapy, a requirement for withdrawal of renal toxins, end stage renal disease, heart failure, stroke, myocardial infarction, progression to chronic kidney disease, etc.
The term “pre-existing” and “pre-existence” as used herein, means any risk factor (i.e., for example, a renal biomarker) existing at the time a body fluid sample is obtained from the subject.
The term “predicting” as used herein, refers to a method of forming a prognosis and/or a stratification risk assignment, wherein a medically trained person analyzes biomarker information, and optionally with relevant clinical indicia and/or demographic information.
The term “acute renal disease/failure/injury” as used herein, refers to any progressive worsening of renal function over hours to Days, resulting in the retention of nitrogenous wastes (such as urea nitrogen) and creatinine in the blood. Retention of these substances may also be referred to as, azotemia. In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, herein incorporated by reference in their entirety.
The term “chronic renal disease/failure/injury” as used herein, refers to a medical condition wherein exemplary symptoms may include, but are not limited to, hyperphosphatemia (i.e., for example, >4.6 mg/dl) or low glomerular filtration rates (i.e., for example, <90 ml/minute per 1.73 m2 of body surface). However, many CKD patients may have normal serum phosphate levels in conjunction with a sustained reduction in glomerular filtration rate for 3 or more months, or a normal GFR in conjunction with sustained evidence of a structural abnormality of the kidney. In some cases, patients diagnosed with chronic kidney disease are placed on hemodialysis to maintain normal blood homeostasis (i.e., for example, urea or phosphate levels). Alternatively, “chronic kidney disease” refers to a medical condition wherein a patients has either i) a sustained reduction in GFR<60 mi/min per 1.73 m2 of body surface for 3 or more months; or ii) a structural or functional abnormality of renal function for 3 or more months even in the absence of a reduced GFR. Structural or anatomical abnormalities of the kidney could be defined as, but not limited to, persistent microalbuminuria or proteinuria or hematuria or presence of renal cysts. Chronic renal failure (chronic kidney disease) may also result from an abnormal loss of renal function over months to years. In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, herein incorporated by reference in their entirety.
The term “about” as used herein in the context of any of any assay measurements refers to +/−5% of a given measurement.
The term “asymptomatic” as used herein, refers to a patient and/or subject that does not have a renal disease and/or injury, wherein a renal disease and/or injury symptom may include, but is not limited to, having a reduced glomerular filtration rate (i.e., for example, between approximately 70-89 ml/min per 1.73 m2 of body surface) for less than three months.
The term “glomerular filtration rate” as used herein, refers to any measurement capable of determining kidney function. In general, a normal glomerular filtration rate ranges between approximately 120-90 ml/minute per 1.73 m2 of body surface. Compromised kidney function is assumed when glomerular filtration rates are less than 90 ml/minute per 1.73 m2 of body surface. Kidney failure is probable when glomerular filtration rates fall below approximately 30 ml/minute per 1.73 m2 of body surface. Dialysis is frequently initiated when glomerular filtration rates fall below approximately 15 ml/minute per 1.73 m2 of body surface.
The term “renal failure” as used herein, refers to any acute, sudden, and/or chronic loss of the ability of the kidneys to remove waste and concentrate urine without losing electrolytes.
The term “biological sample” as used herein, refers to any substance derived from a living organism. For example, a sample may be derived from blood as a urine sample, serum sample, a plasma sample, and or a whole blood sample. Alternatively, a sample may be derived from a tissue collected, for example, by a biopsy. Such a tissue sample may comprise, for example, kidney tissue, vascular tissue and/or heart tissue. A biological sample may also comprise body fluids including, but not limited to, urine, saliva, or perspiration.
The term “reagent” as used herein, refers to any substance employed to produce a chemical reaction so as to detect, measure, produce, etc., other substances. The term “antibody” as used herein refers to any peptide or polypeptide derived from, modeled after, or substantially encoded by, an immunoglobulin gene or immunoglobulin genes, or fragments thereof, capable of specifically binding an antigen or epitope. See, e.g. In: Fundamental Immunology, 3rd Edition, W. E. Paul, ed., Raven Press, N.Y. (1993); Wilson et al., J. Immunol. Methods 175:267-273 (1994); and Yarmush et al., J. Biochem. Biophys. Methods 25:85-97 (1992). The term antibody includes, but is not limited to, antigen-binding portions, i.e., “antigen binding sites” exemplified by fragments, subsequences, and/or complementarity determining regions (CDRs)) that retain capacity to bind antigen, including, but not limited to: (i) a Fab fragment, a monovalent fragment comprising VL, VH, CL or CHI domains; (ii) a F(ab′)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment comprising VH and CHI domains; (iv) a Fv fragment comprising VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., Nature 341:544-546 (1989)), which comprises a VH domain; or (vi) an isolated complementarity determining region (CDR). Single chain antibodies are also included by reference in the term “antibody.”
The term “epitope” as used herein, refers to any antigenic determinant capable of specific binding to an antibody. Epitopes usually display chemically active surface molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Conformational and nonconformational epitopes may be distinguished in that the binding to the former but not the latter can be lost in the presence of denaturing solvents.
The term “correlating” as used herein, in reference to the use of biomarkers, refers to comparing the presence and/or amount of any biomarker(s) in a patient to its presence and/or amount in persons known to suffer from, or known to be at risk of, a given condition; or in persons known to be free of a given condition. Often, this takes the form of comparing an assay result in the form of a biomarker concentration to a predetermined threshold selected to be indicative of the occurrence or nonoccurrence of a disease or the likelihood of some future outcome.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 presents exemplary subject information relevant to the Biological Markers of Recovery for the Kidney (BioMaRK) study cohort used as the basis for some of the data analysis presented herein.

FIG. 2: Representative protein biomarker familes identified by a proteomics platform.

FIG. 3 Representative single biomarker peptides Identified by a proteomics platform.

DETAILED DESCRIPTION

This invention is related to the field of the prevention and treatment of kidney disease. The treatment of kidney disease may be tailored depending upon the need for, or expectation of, renal recovery. For example, prediction of renal recovery can be determined by monitoring urine biomarkers related to the development of chronic kidney disease. For example, differential expression platforms can be used to identify biomarker proteins in order to establish the risk of renal recovery versus renal non-recovery in patient's having suffered an acute kidney injury.
Despite significant advances in the epidemiology of acute kidney injury (AKI), prognostication remains a major clinical challenge. Unfortunately, there is no reliable method to predict renal recovery. The discovery of biomarkers to aid in clinical risk prediction for recovery after AKI would represent a significant advance over current practice.
I. Kidney Injury and/or Disease
The kidney is responsible for water and solute excretion from the body. Its functions include maintenance of acid-base balance, regulation of electrolyte concentrations, control of blood volume, and regulation of blood pressure. As such, loss of kidney function through injury and/or disease results in substantial morbidity and mortality. A detailed discussion of renal injuries is provided in Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830, which are hereby incorporated by reference in their entirety. The kidneys are located in the flank (back of the upper abdomen at either side of the spinal column). They are deep within the abdomen and are protected by the spine, lower rib cage, and the strong muscles of the back. This location protects the kidneys from many external forces. They are well-padded for a reason—kidneys are highly vascular organs, which means that they have a large blood supply. If injury occurs, severe bleeding may result.
Kidneys may be injured by damage to the blood vessels that supply or drain them. This may be in the form of aneurysm, arteriovenous fistula, arterial blockage, or renal vein thrombosis. The extent of bleeding depends on the location and the degree of injury. Kidneys may also bleed profusely if they are damaged centrally (on the inside)—this is a life-threatening injury. Fortunately, most kidney injuries caused by blunt trauma occur peripherally, only causing bruising of the kidney (usually a self-limiting process).
People with undiagnosed kidney conditions—such as angiomyolipoma (benign tumor), ureteropelvic junction obstruction (congenital or acquired UPJ Obstruction), and other disorders—are more susceptible to kidney injuries and more likely to have serious complications if they occur. Other causes of kidney injury and bleeding are medical procedures. Kidney biopsies, nephrostomy tube placements, or other surgeries can cause an abnormal connection between an artery and vein (arteriovenous fistula). This is usually a self-limiting problem, but close observation is usually needed. Injury to the kidney can also disrupt the urinary tract, causing leakage of the urine from the kidney.
Each kidney filters about 1700 liters of blood per Day and concentrates fluid and waste products into about 1 liter of urine per Day. Because of this, the kidneys receive more exposure to toxic substances in the body than almost any other organ. Therefore, they are highly susceptible to injury from toxic substances. Analgesic nephropathy is one of the most common types of toxic damage to the kidney. Exposure to lead, cleaning products, solvents, fuels, or other nephrotoxic chemicals (those which can be toxic to the kidney) can damage kidneys. Excessive buildup of body waste products, such as uric acid (that can occur with gout or with treatment of bone marrow, lymph node, or other disorders) can also damage the kidneys.
Inflammation (irritation with swelling and presence of extra immune cells) caused by immune responses to medications, infection, or other disorders may also injure the structures of the kidney, usually causing various types of glomerulonephritis or acute tubular necrosis (tissue death). Autoimmune disorders may also damage the kidneys. Injury to the kidney may result in short-term damage with minimal or no symptoms. Alternately, it can be life-threatening because of bleeding and associated shock, or it may result in acute renal failure or chronic renal failure.
Ureteral injuries (injuries to the tubes which carry urine from the kidneys to the bladder) can also be caused by trauma (blunt or penetrating), complications from medical procedures, and other diseases in the retroperitoneum such as retroperitoneal fibrosis (RPF), retroperitoneal sarcomas, or metastatic lymph node positive cancers. Medical therapies (such as OB/GYN surgeries, prior radiation or chemotherapy, and previous abdominopelvic surgeries) increase the risk for ureteral injuries.
A. Acute Kidney Failure
Acute (sudden) kidney failure is the sudden loss of the ability of the kidneys to remove waste and concentrate urine without losing electrolytes. There are many possible causes of kidney damage including, but are not limited to, decreased blood flow, which may occur with extremely low blood pressure caused by trauma, surgery, serious illnesses, septic shock, hemorrhage, burns, or dehydration, acute tubular necrosis (ATN), infections that directly injury the kidney such as acute pyelonephritis or septicemia, urinary tract obstruction (obstructive uropathy), autoimmune kidney disease such as interstitial nephritis or acute nephritic syndrome, disorders that cause clotting within the thin blood vessels of the kidney, idiopathic thrombocytopenic thrombotic purpura (ITTP), transfusion reaction, malignant hypertension, scleroderma, hemolytic-uremic syndrome, disorders of childbirth, such as bleeding placenta abruptio or placenta previa
Symptoms of acute kidney failure may include, but are not limited to, decrease in amount of urine (oliguria), urination stops (anuria), excessive urination at night, ankle, feet, and leg swelling, generalized swelling, fluid retention, decreased sensation, especially in the hands or feet, decreased appetite, metallic taste in mouth, persistent hiccups, changes in mental status or mood, agitation, drowsiness, lethargy, delirium or confusion, coma, mood changes, trouble paying attention, hallucinations, slow, sluggish, movements, seizures, hand tremor (shaking), nausea or vomiting, may last for Days, bruising easily, prolonged bleeding, nosebleeds, bloody stools, flank pain (between the ribs and hips), fatigue, breath odor, or high blood pressure.
Acute renal failure (ARF) may also be referred to as acute kidney injury (AKI) and may be characterized by an abrupt (i.e., for example, typically detected within about 48 hours to 1 week) reduction in glomerular filtration rate (GFR). This loss of filtration capacity results in retention of nitrogenous (urea and creatinine) and non-nitrogenous waste products that are normally excreted by the kidney, a reduction in urine output, or both. It is reported that ARF complicates about 5% of hospital admissions, 4-15% of cardiopulmonary bypass surgeries, and up to 30% of intensive care admissions. ARF may be categorized as prerenal, intrinsic renal, or postrenal in causation. Intrinsic renal disease can be further divided into glomerular, tubular, interstitial, and vascular abnormalities. Major causes of ARF are described in association with their respective risk factors are summarized below. See, Table 4; In: Merck Manual, 17th ed., Chapter 222, and which is hereby incorporated by reference in their entirety.

TABLE 4

Representative Acute Renal Failure Risk Factors

Type of Renal
Failure	Risk Factors

Prerenal
ECF volume	Excessive diuresis, hemorrhage, GI losses, loss of
depletion	intravascular fluid into the extravascular space (due to
	ascites, peritonitis, pancreatitis, or burns), loss of skin
	and mucus membranes, renal salt- and water-wasting
	states
Low cardiac	Cardiomyopathy, MI, cardiac tamponade, pulmonary
output	embolism, pulmonary hypertension, positive-pressure
	mechanical ventilation
Low systemic	Septic shock, liver failure, antihypertensive drugs
vascular
resistance
Increased renal	NSAIDs, cyclosporines, tacrolimus, hypercalcemia,
vascular	anaphylaxis, anesthetics, renal artery obstruction, renal
resistance	vein thrombosis, sepsis, hepatorenal syndrome
Decreased	ACE inhibitors or angiotensin II receptor blockers
efferent
arteriolar tone
(leading to
decreased
GFR from
reduced
glomerular
transcapillary
pressure,
especially in
patients with
bilateral renal
artery stenosis)
Intrinsic Renal
Acute tubular	Ischemia (prolonged or severe prerenal state): surgery,
injury	hemorrhage, arterial or venous obstruction; Toxins:
	NSAIDs, cyclosporines, tacrolimus, aminoglycosides,
	foscarnet, ethylene glycol, hemoglobin, myoglobin,
	ifosfamide, heavy metals, methotrexate, radiopaque
	contrast agents, streptozotocin
Acute	ANCA-associated: Crescentic glomerulonephritis,
glomerul-	polyarteritis nodosa, Wegener's granulomatosis; Anti-
onephritis	GBM glomerulonephritis: Goodpasture's syndrome;
	Immune-complex: Lupus glomerulonephritis,
	postinfectious glomerulonephritis, cryoglobulinemic
	glomerulonephritis
Acute	Drug reaction (eg, β-lactams, NSAIDs, sulfonamides,
tubulointerstitial	ciprofloxacin, thiazide diuretics, furosemide, phenytoin,
nephritis	allopurinol, pyelonephritis, papillary necrosis
Acute vascular	Vasculitis, malignant hypertension, thrombotic
nephropathy	microangiopathies, scleroderma, atheroembolism
Infiltrative	Lymphoma, sarcoidosis, leukemia
diseases
Postrenal
Tubular	Uric acid (tumor lysis), sulfonamides, triamterene,
precipitation	acyclovir, indinavir, methotrexate, ethylene glycol
	ingestion, myeloma protein, myoglobin
Ureteral	Intrinsic: Calculi, clots, sloughed renal tissue, fungus
obstruction	ball, edema, malignancy, congenital defects; Extrinsic:
	Malignancy, retroperitoneal fibrosis, ureteral trauma
	during surgery or high impact injury
Bladder	Mechanical: Benign prostatic hyperplasia, prostate
obstruction	cancer, bladder cancer, urethral strictures, phimosis,
	paraphimosis, urethral valves, obstructed indwelling
	urinary catheter; Neurogenic: Anticholinergic drugs,
	upper or lower motor neuron lesion

In the case of ischemic ARF, the course of the disease may be divided into four phases. During an initiation phase, which lasts hours to Days, reduced perfusion of the kidney is evolving into injury. Glomerular ultrafiltration reduces, the flow of filtrate is reduced due to debris within the tubules, and back leakage of filtrate through injured epithelium occurs. Renal injury can be mediated during this phase by reperfusion of the kidney. Initiation is followed by an extension phase which is characterized by continued ischemic injury and inflammation and may involve endothelial damage and vascular congestion. During the maintenance phase, lasting from 1 to 2 weeks, renal cell injury occurs, and glomerular filtration and urine output reaches a minimum. A recovery phase can follow in which the renal epithelium is repaired and GFR gradually recovers. Despite this, the survival rate of subjects with ARF may be as low as about 60%.
Acute kidney injury caused by radiocontrast agents (also called contrast media) and other nephrotoxins such as cyclosporine, antibiotics including aminoglycosides and anticancer drugs such as cisplatin manifests over a period of Days to about a week. Contrast induced nephropathy (CIN, which is AKI caused by radiocontrast agents) is thought to be caused by intrarenal vasoconstriction (leading to ischemic injury) and from the generation of reactive oxygen species that are directly toxic to renal tubular epithelial cells. CIN classically presents as an acute (onset within 24-48 h) but reversible (peak 3-5 Days, resolution within 1 week) rise in blood urea nitrogen and serum creatinine.
A commonly reported criteria for defining and detecting AKI is an abrupt (typically within about 2-7 Days or within a period of hospitalization) elevation of serum creatinine. Although the use of serum creatinine elevation to define and detect AKI is well established, the magnitude of the serum creatinine elevation and the time over which it is measured to define AKI varies considerably among publications. Traditionally, relatively large increases in serum creatinine such as 100%, 200%, an increase of at least 100% to a value over 2 mg/dL and other definitions were used to define AKI. However, the recent trend has been towards using smaller serum creatinine rises to define AKI.
For example, relationships between elevated serum creatinine and AKI has been reported to be associated with health risks. Praught et al., Curr Opin Nephrol Hypertens 14:265-270 (2005); and Chertow et al., J Am Soc Nephrol 16:3365-3370 (2005) (both references are herein incorporated by reference in their entirety). As described in these publications, acute worsening renal function (AKI) and increased risk of death and other detrimental outcomes are now known to be associated with very small increases in serum creatinine. These creatinine increases may be determined as a relative (percent) value or a nominal value. Relative increases in serum creatinine as small as 20% from the pre-injury value have been reported to indicate acutely worsening renal function (AKI) and increased health risk, but the more commonly reported value to define AKI and increased health risk is a relative increase of at least 25%. Nominal increases as small as 0.3 mg/dL, 0.2 mg/dL or even 0.1 mg/dL have been reported to indicate worsening renal function and increased risk of death. Various time periods for the serum creatinine to rise to these threshold values have been used to define AKI, for example, ranging from 2 Days, 3 Days, 7 Days, or a variable period defined as the time the patient is in the hospital or intensive care unit. These studies indicate there is not a particular threshold serum creatinine rise (or time period for the rise) for worsening renal function or AKI, but rather a continuous increase in risk with increasing magnitude of serum creatinine rise.
Another study correlated serum creatinine levels with post-surgical mortality rates. Following heart surgery, patients with a mild fall in serum creatinine (i.e., for example, between approximately −0.1 to −0.3 mg/dL) had the lowest mortality rate, wherein patients had a larger mortality rate associated with either large falls in serum creatinine (i.e., for example, more than or equal to −0.4 mg/dL), or an increase in serum creatinine. Lassnigg et al., J Am Soc Nephrol 15:1597-1605 (2004), herein incorporated by reference in its entirety. These findings suggested that even very subtle changes in renal function, as detected by small creatinine changes within 48 hours of surgery, can be predictive of a patient's outcome.
A unified classification system using serum creatinine to define AKI in clinical trials and in clinical practice was proposed to stratify AKI patients. Bellomo et al., Crit Care 8(4):R204-212 (2004), which is herein incorporated by reference in its entirety. For example, a serum creatinine rise of 25% may define contrast-induced nephropathy. McCollough et al, Rev Cardiovasc Med. 7(4): 177-197 (2006), herein incorporated by reference in its entirety. Although various groups propose slightly different criteria for using serum creatinine to detect AKI, the consensus is that small changes in serum creatinine, such as 0.3 mg/dL (i.e., for example, approximately 25%) are sufficient to detect AKI that characterizes a worsening renal function and that the magnitude of the serum creatinine change may be an indicator of the severity of the AKI and mortality risk.
Although serial measurement of serum creatinine over a period of Days is an accepted method of detecting and diagnosing AKI patients, serum creatinine is generally regarded to have several limitations in the diagnosis, assessment and monitoring of AKI patients. The time period for serum creatinine to rise to approximately 0.3 mg/dL (25%) is considered diagnostic for AKI can be 48 hours or longer depending on the definition used.
Since cellular injury in AKI can occur over a period of hours, serum creatinine elevations detected at 48 hours or longer can be a late indicator of injury, and relying on serum creatinine can thus delay diagnosis of AKI. Furthermore, serum creatinine is not a good indicator of the exact kidney status and treatment needs during the most acute phases of AKI when kidney function is changing rapidly. Until defined by some embodiments of the present invention, there were no methods to determine whether some patients with AKI would recover fully, or whether some would need dialysis (either short term or long term), or whether some would have other detrimental outcomes including, but not limited to, death, major adverse cardiac events or chronic kidney disease. Because serum creatinine is a marker of filtration rate, it does not differentiate between the causes of AKI (pre-renal, intrinsic renal, post-renal obstruction, atheroembolic, etc) or the category or location of injury in intrinsic renal disease (for example, tubular, glomerular or interstitial in origin). Urine output is similarly limited.
These limitations underscore the need for better methods to detect and assess AKI, particularly in the early and subclinical stages, but also in later stages when recovery and repair of the kidney can occur. Furthermore, there is a need to better identify patients who are at risk of having an AKI.
B. Chronic Kidney Failure
Unlike acute renal failure, chronic renal failure slowly gets worse. It most often results from any disease that causes gradual loss of kidney function. It can range from mild dysfunction to severe kidney failure. Chronic renal failure may lead to end-stage renal disease (ESRD).
Chronic renal failure usually occurs over a number of years as the internal structures of the kidney are slowly damaged. In the early stages, there may be no symptoms. In fact, progression may be so slow that symptoms do not occur until kidney function is less than one-tenth of normal.
Chronic renal failure and ESRD affect more than 2 out of 1,000 people in the United States. Diabetes and high blood pressure are the two most common causes and account for most cases. Other major causes include, but are not limited to, Alport syndrome, analgesic nephropathy, glomerulonephritis of any type (one of the most common causes), kidney stones and infection, obstructive uropathy, polycystic kidney disease, or reflux nephropathy. Chronic renal failure results in an accumulation of fluid and waste products in the body, leading to a build up of nitrogen waste products in the blood (azotemia) and general ill health. Most body systems are affected by chronic renal failure.
Initial symptoms may include, but are not limited to, fatigue, frequent hiccups, general ill feeling, generalized itching (pruritus), headache, nausea, vomiting, or unintentional weight loss. Further, later symptoms may include, but are not limited to, blood in the vomit or in stools,
decreased alertness, including drowsiness, confusion, delirium, orcoma, decreased sensation in the hands, feet, or other areas, easy bruising or bleeding, increased or decreased urine output, muscle twitching or cramps, seizures, or white crystals in and on the skin (uremic frost).
Circulating levels of cytokines and other inflammation markers are markedly elevated in patients with chronic renal failure. This could be caused by increased generation, decreased removal, or both. However, it is not well established to what extent renal function per se contributes to the uremic proinflammatory milieu. Relationships between inflammation and glomerular filtration rate (GFR) were reported in 176 patients (age, 52+/−1 years; GFR, 6.5+/−0.1 mL/min) close to the initiation of renal replacement therapy. Pecoits-Filho et al., “Associations between circulating inflammatory markers and residual renal function in CRF patients” Am J Kidney Dis. 41(6):1212-1218 (2003). For example, circulating levels of high-sensitivity C-reactive protein (hsCRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), hyaluronan, and neopterin were measured after an overnight fast. Patients subsequently were subdivided into two groups according to median GFR (6.5 mL/min). Despite the narrow range of GFR (1.8 to 16.5 mL/min), hsCRP, hyaluronan, and neopterin levels were significantly greater in the subgroup with lower GFRs, and significant negative correlations were noted between GFR and IL-6 (rho=−0.18; P<0.05), hyaluronan (rho=−0.25; P<0.001), and neopterin (rho=−0.32; P<0.0005). In a multivariate analysis, age and GFR were associated with inflammation but cardiovascular disease and diabetes mellitus were not. These results show that a low GFR per se is associated with an inflammatory state, suggesting impaired renal elimination of proinflammatory cytokines, increased generation of cytokines in uremia, or an adverse effect of inflammation on renal function.
C. Dialysis
Dialysis (i.e., for example, renal replacement therapy) is a method of removing toxic substances (impurities or wastes) from the blood when the kidneys are unable to do so and can be performed using several different methods. For example, peritoneal dialysis may filter waste by using the peritoneal membrane inside the abdomen. The abdomen is filled with special solutions that help remove toxins. The solutions remain in the abdomen for a time and then are drained out. This form of dialysis can be performed at home, but must be done every Day. Alternatively, hemodialysis may be performed by circulating the blood through special filters outside the body. The blood flows across a filter, along with solutions that help remove toxins.
Dialysis uses special ways of accessing the blood in the blood vessels. The access can be temporary or permanent. Temporary access takes the form of dialysis catheters—hollow tubes placed in large veins that can support acceptable blood flows. Most catheters are used in emergency situations for short periods of time. However, catheters called tunneled catheters can be used for prolonged periods of time, often weeks to months. Permanent access is created by surgically joining an artery to a vein. This allows the vein to receive blood at high pressure, leading to a thickening of the vein's wall. This vein can handle repeated puncture and also provides excellent blood flow rates. The connection between an artery and a vein can be made using blood vessels (an arteriovenous fistula, or AVF) or a synthetic bridge (arteriovenous graft, or AVG). Blood is diverted from the access point in the body to a dialysis machine. Here, the blood flows counter-current to a special solution called the dialysate. The chemical imbalances and impurities of the blood are corrected and the blood is then returned to the body. Typically, most patients undergo hemodialysis for three sessions every week. Each session lasts 3-4 hours.
The purpose of dialysis is to assist kidney functions including, filters for the blood, removing waste products, regulating body water, maintaining electrolyte balance, or maintaining blood pH remains between 7.35 and 7.45. Further, dialysis may replace some of the functions for kidneys that aren't working properly that would otherwise result in the death of a patient.
Dialysis is most often used for patients who have kidney failure, but it can also quickly remove drugs or poisons in acute situations. This technique can be life saving in people with acute or chronic kidney failure.

II. Urinary Renal Biomarkers

Currently, no effective treatments exist to improve renal recovery, or to improve short and long-term renal outcome, after AKI. Furthermore, methods to predict recovery are also lacking. The emerging role of biomarkers for early detection of renal disease and/or renal injury may help identify new prognostic tools to predict renal clinical outcomes. Potential candidates for biomarkers of renal recovery include, but are not limited to, molecules expressed in pathways leading to regeneration and proliferation as well as markers of fibrosis and apoptosis. In addition, renal injury biomarkers may also serve to distinguish early resolution, and hence increased odds of recovery.
Acute kidney injury (AKI) has an estimated incidence rate of approximately 2000 per million population and this rate is increasing. Ali et al., “Incidence and outcomes in acute kidney injury: a comprehensive population-based study” J Am Soc Nephrol 18:1292-1298 (2007). Approximately 5% of all people admitted to intensive care units around the world develop severe AKI requiring dialysis. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA 294:813-818 (2005). A recent, United States multi-center study found that fewer than only about 60% patients surviving severe AKI recovered renal function by two months. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). Thus, a large number of patients with AKI progress into end-stage renal disease (ESRD).
However, since only a fraction of patients with AKI fail to recover renal function, interventions aimed at improving recovery or at providing renal support (e.g. early dialysis) cannot be selectively targeted appropriately without some means of determining which patients will recover and which will not recover (i.e., for example, the availability of non-invasive biomarkers). Currently, clinical risk prediction for recovery after AKI is extremely limited. Thus, development of a non-invasive biomarker that allows early prediction of recovery of kidney function is a long felt need in the art of renal disease management.
The identification of such non-invasive biomarkers (i.e., for example, a urinary biomarker) would greatly improve long-term prognosis thereby tailoring research efforts to treat AKI and prevent ESRD. In other words, having the ability to predict which patients will not recover kidney function allows a clinician to focus limited resources on the development and application of aggressive treatment interventions on these predicted at-risk patients. Conversely, patients with a favorable prognosis would be spared from more aggressive interventions and their potential adverse effects, thereby releasing medical resources to those in need and reducing overall medical costs.
In one embodiment, the present invention contemplates methods and compositions for evaluating renal function in a subject. As described herein, measurement of various kidney injury markers described herein can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and a determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure (also called acute kidney injury).
Renal biomarkers as described herein may be used individually, or in panels, comprising a plurality of renal biomarkers, for risk stratification. In one embodiment, risk stratification identifies subjects at risk for a future: i) injury to renal function; ii) progression to reduced renal function; iii) progression to ARF; or iv) improvement in renal function, etc. In one embodiment, risk stratification diagnoses an existing disease, comprising identifying subjects who have: i) suffered an injury to renal function; ii) progressed to reduced renal function; or iii) progressed to ARF, etc. In one embodiment, risk stratification monitors for deterioration and/or improvement of renal function. In one embodiment, risk stratification predicts a future medical outcome including, but not limited to, an improved or worsening renal function, a decreased or increased mortality risk, a decreased or increased risk that a subject will require initiation or continuation of renal replacement therapy (i.e., hemodialysis, peritoneal dialysis, hemofiltration, and/or renal transplantation, a decreased or increased risk that a subject will recover from an injury to renal function, a decreased or increased risk that a subject will recover from ARF, a decreased or increased risk that a subject will progress to end stage renal disease, a decreased or increased risk that a subject will progress to chronic renal failure, a decreased or increased risk that a subject will suffer rejection of a transplanted kidney, etc.

III. Clinical Renal Biomarker Studies

The results of a large multicenter clinical trial has recently been reported comparing two intensities of renal support for critically ill patients with acute kidney injury (AKI) in which recovery of renal function was less than 25% at 28 days and not different between the two treatment strategies. Palevsky et al., “Intensity of renal support in critically ill patients with acute kidney injury” N Engl J Med 359:7-20 (2008). These results emphasize that incomplete renal recovery is a common problem in the patients who survive severe AKI. Uchino et al., “Acute renal failure in critically ill patients: a multinational, multicenter study” JAMA, 294: 813-818 (2005). Failure to recover renal function can have tremendous negative effects on quality of life and health care costs. Manns et al., “Cost of acute renal failure requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery” Crit Care Med, 31:449-455 (2003). Therefore, treatments to hasten and facilitate renal recovery are eagerly being sought by both the critical care and nephrology communities. Unfortunately, there are no effective treatments to improve renal recovery. One possible barrier to progress in this area has been the inability to forecast recovery in individual patients. The ability to prognosticate in an AKI patient population would be extremely valuable both for clinical decisions as well as to guide future research on therapy to promote recovery of renal function.
One clinical study reported that patients who recovered from AKI did not appear to differ in clinical characteristics (i.e., for example, age, gender, mechanical ventilation status, or clinical severity scores) from the non-recovery group. Bhandari et al., “Survivors of acute renal failure who do not recover renal function” QJM, 89:415-421 (1996). Secondary analysis from three randomized controlled trials (RCTs) comparing efficacy of continuous renal replacement therapy (RRT) versus intermittent RRT found that: i) APACHE III scores >100; ii) cardiovascular instability; and iii) pre-existing renal impairment were all associated with renal non-recovery. Mehta et al., “A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure” Kidney Int, 60:1154-1163 (2001); Augustine et al., “A randomized controlled trial comparing intermittent with continuous dialysis in patients with ARF” Am J Kidney Dis, 44:1000-1007 (2004); and Uehlinger et al., “Comparison of continuous and intermittent renal replacement therapy for acute renal failure” Nephrol Dial Transplant, 20:1630-1637 (2005), respectively. However, these studies did not adhere to a uniform definition of, or standard timing, to assess renal recovery.
Other studies have suggested that baseline creatinine and urine output at the time of discontinuation of RRT were most predictive of recovery. Uchino et al., “Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study” Crit Care Med, 37:2576-2582 (2009). However, urine output was analyzed after RRT had ended based on a clinical decision rather than at a fixed time point (e.g. 14 Days post AKI) to predict renal recovery. Therefore, these data are compromised to suggest that urine output was predictive of renal recovery, and further, baseline creatinine might have been less valuable because patients with stage 4 and 5 CKD were excluded.
Recently, a number of urinary biomarkers have been investigated for the purpose of early diagnosis of AKI. Since these markers correlate with renal tubular cell injury or function, their patterns in the urine, either alone or in combination, could provide new prognostic information regarding renal recovery. For example, several reports have suggested possible candidate renal biomarkers relating to three aspects of the physiology of renal recovery:
i) inflammatory markers including; a) urinary neutrophil gelatinase-associated lipocalin (uNGAL), which has been extensively studied for predicting AKI (Supavekin et al., “Differential gene expression following early renal ischemia/reperfusion” Kidney Int, 63:1714-1724 (2003); Mishra et al., “Kidney NGAL is a novel early marker of acute injury following transplantation” Pediatr Nephrol, 21:856-863 (2006); Hirsch et al., “NGAL is an early predictive biomarker of contrast-induced nephropathy in children” Pediatr Nephrol, 22: 2089-2095 (2007); and Zappitelli et al., “Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study” Crit Care, 11: R84 (2007); b) matrix metalloproteinase protein-9 (MMP-9), a matrix degradation enzyme which is up-regulated after ischemic injury in animal models and links to NGAL by a disulfide bond forming urinary NGAL/MMP-9 (uNGAL/MMP-9) (Ronco et al., “Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin” Semin Nephrol, 27:352-362 (2007); and c) urinary interleukin-18 (uIL-18), an inflammatory cytokine which is found to potentiate ischemic AKI and has been tested in many clinical settings (Parikh et al., “Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit” J Am Soc Nephrol, 16:3046-3052 (2005); and Parikh et al., “Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery” Kidney Int, 70:199-203 (2006);
ii) growth factors including urinary hepatocyte growth factor (uHGF), a biomarker linked to renal tubular epithelial cell regeneration (Liu et al., “Hepatocyte growth factor: new arsenal in the fights against renal fibrosis? Kidney Int, 70:238-240 (2006); and
iii) filtration and tubular reabsorption markers, such as cystatin C, which is freely filtered and is normally completely reabsorbed by proximal tubular epithelial cells and urine creatinine. Herget-Rosenthal et al., “Measurement of urinary cystatin C by particle-enhanced nephelometric immunoassay: precision, interferences, stability and reference range” Ann Clin Biochem, 41:111-118 (2004).
Despite these reports, only a few suggest biomarkers having an ability to predict AKI severity. But no study has identified a biomarker as a predictor of renal recovery. Coca et al., “Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review” Kidney Int, 73:1008-1016 (2008). The data presented herein provide heretofore unknown renal biomarkers identified by proteomic gene expression analysis. The data was obtained from urine samples collected during a clinical study as described below.
The data presented herein was collected from 109 patients in the BioMaRK clinical study where 76 patients had complete data available including urine samples. Exactly half (38 patients) recovered renal function (alive and without requirement for dialysis) by day 60. See, FIG. 1. Baseline clinical characteristics of the study patients were taken. See, Table 1.

TABLE 1

Summary of baseline and clinical characteristics of the study patients

	All subjects	Recovery	Non-recovery
Characteristics	(n = 76)	(n = 38)	(n = 38)	P value

Age, mean (SD), -yr	58.4(17.0)	52.2(15.7)	64.7(16.2)	<0.001
Gender: Female (%)	30(39.5)	15(39.5)	15(39.5)	1.00
Race: White (%)	64(84.2)	30(79.0)	34(89.5)	0.21
Baseline serum creatinine, mean (SD) (mg/dl)	1.1(0.4)	1.1(0.4)	1.2(0.5)	0.45
BUN at initiation of RRT, mean (SD) (mg/dl)	55.6(29.9)	51.3(28.8)	59.9(30.8)	0.23
Cause of acute kidney injury
Ischemia (%)	66(86.8)	29(76.3)	37(97.4)	0.007
Nephrotoxins (%)	16(21.3)	10(26.3)	6(16.2)	0.29
Sepsis (%)	50(65.8)	23(60.5)	27(71.1)	0.33
Multifunctional causes (%)	51(68.0)	25(65.8)	26(70.3)	0.68
Length of ICU stay before randomization-days, mean (SD)	5.4(4.1)	4.2(2.8)	6.5(4.9)	0.03
Length of hospital stay before randomization-days, mean (SD)	8.5(7.1)	6.7(5.0)	10.2(8.5)	0.08
Charlson comorbidity index^a, mean (SD)	4.1(3.3)	3.3(3.8)	4.9(2.7)	0.008
Mechanical ventilation (%)	69(90.8)	34(89.5)	35(92.1)	1.00
Sepsis^b(%)	47(62.7)	22(57.9)	25(67.6)	0.39
APACHE II score^c, mean (SD)	23.4(7.2)	21.8(7.2)	25.0(6.8)	0.06
Non-renal SOFA organ-system score^d, mean (SD)
Respiratory	2.1(1.3)	2.1(1.5)	2.1(1.2)	0.98
Coagulation	1.5(1.3)	1.4(1.3)	1.5(1.3)	0.58
Liver	0.9(1.3)	1.2(1.5)	0.6(1.0)	0.08
Cardiovascular	2.2(1.7)	2.0(1.7)	2.5(1.6)	0.17
Central nervous system	2.2(1.4)	2.3(1.3)	2.1(1.5)	0.45
Total	8.9(4.0)	9.2(4.6)	8.5(3.3)	0.43
Cleveland Clinic ICU ARF Renal Failure score^e, mean (SD)	11.9(3.0)	11.6(3.0)	12.2(3.0)	0.49
Intensive category^f(%)	34(44.7)	18(47.4)	16(42.1)	0.64

Abbreviations: RRT, Renal Replacement Therapy.
ICU, Intensive Care Unit.
APACHE II, Acute Physiology and Chronic Health Evaluation II.
SOFA, Sequential Organ Failure Assessment.
ARF, Acute Renal Failure.
^aAccording to the method of Charlson et al.²³
^bDefined as sepsis plus acute organ dysfunction according to 2001 international consensus criteria for sever sepsis.²⁶
^cAccording to the method of Knaus et al.²⁹
^dNon renal SOFA score, excluding the renal part, assessed on the first day according to the method of Vincent et al.³⁰
^eAccording to the method of Thakar et al.³¹
^fIntensive strategy, intermittent hemodialysis and sustained low-efficiency dialysis were provided six times per week (every day except Sunday), and continuous venovenous hemodiafiltration was prescribed to provide a flow rate of the total effluent (the sum of the dialysate and ultrafiltrate) of 35 ml per kilogram of body weight per hour, based on the weight before the onset of acute illness.¹

Patients recovering from renal injury were more likely to be younger, had a shorter length of intensive care unit (ICU) stay before randomization, lower Charlson comorbidity index, and lower nonrenal SOFA score as compared to those not recovering renal function. By contrast, there were no statistical differences in gender, ethnicity, baseline serum creatinine, blood urea nitrogen (BUN) at initiation of RRT, length of hospital stay, length of ICU stay, requirement for mechanical ventilation, Cleveland Clinic ICU Acute Renal Failure (ARF) score, or intensity of RRT. The primary etiology of AKI was ischemia in both groups. However, a significantly lower percentage of ischemia (76.3%) was noted as the cause of AKI in the recovery group compared to 97.4% in non-recovery group. Of the 38 participants who recovered renal function, 26 (68.4%) had complete recovery. Among those failing to recover renal function, 25 patients (65.8%), did not survive past day 60.

IV. Proteomics Gene Expression Platforms

In one embodiment, the present invention contemplates a method for identifying urinary biomarkers using a proteomics platform. In one embodiment, the proteomics platform detects protein expression profiles. In one embodiment, the method further comprises comparing a first protein expression profile to a second protein expression profile. In one embodiment, the comparing identifies an overexpressed protein in the first protein expression profile relative to the second protein expression profile. In one embodiment, the comparing identifies an underexpressed protein in the first protein expression profile relative to the second protein expression profile.
A Introduction
In one embodiment, the present invention contemplates a method comprising a proteomics platform (i.e., for example, iTRAQ) capable of summarizing an analysis of relative protein biomarker expression. For example, the proteomics platform may use reporter ion peak area measurements (i.e., for example, supplied by ABI software) to estimate treatment-dependent peptide and protein biomarker relative expression. Such estimations may be accomplished using a Bayesian approach. The proteomics platform described herein includes a protein biomarker relative expression summary and a per-protein biomarker detailed analysis.
B Experiment and Model Description
1. Experiment Design
Proteomic platforms contemplated herein may summarize data from one or more experiments addressing a common comparison. For example, a possible experimental design for such an analysis is presented below. See, Table 5.

TABLE 5

Representative Proteomic Experimental Designs

	Experiment	Treatment	Channel	Sample

1	A	A	113	A1
2	A	A		114	A2
3	A	A	115	A3
4	A	A	116	A4
5	A	B	117	B1
6	A	B	118	B2
7	A	B	119	B4
8	A	B	121	B4

2. Input Files
Data for proteomic analyses may be extracted from input files including but not limited to a tandem mass spectra (MSMS) summary file, such as:
$\frac{Experiment MSMS Summary File}{A ?}$ $? indicates text missing or illegible when filed$
3. Statistical Modeling Statistical models to estimate the treatment-dependent effects may including but not limited to: LogIntensity^˜Channel+Spectrum+Protein+Peptide+Protein:Treatment+Peptide:Treatment.
4. Data Summarization
The proteomics platform may comprise filtering the data supplied in the MSMS summary to remove unidentified proteins, contaminants, and/or peptides containing selected modifications. A representative analysis may provide a data summary as presented below. See, Table 6.

TABLE 6

Representative Data Summary

	A	Combined

Supplied Spectra	4608	4608
Unidentified Spectra	0	0
Disallowed Modifications	249	249
Spectra from Contaminants	1210	1210
Missing Data	115	115
Low Confidence Spectra	0	0
Degenerate Peptides	379	379
Remaining Spectra		2655
Unique Proteins		360
Unique Peptides		1473
Model R2		0.767

C. Protein Biomarker Summary
In one embodiment, the proteomics platform may identify each protein biomarker in one or more of the MSMS summaries, for example, in decreasing order of expression change magnitude. See, FIG. 2. The median and estimated credible interval for each protein biomarker is given to the left in the table. Similar data is shown where protein biomarkers are identified by a single peptide. See FIG. 3.
D. Protein Biomarker Details
A detailed summary of each protein biomarker is given below, wherein each protein biomarker is designated as 5.###. These sections include protein biomarker relative expression estimates in addition to protein-level estimates.
5.1 beta globin [Homo sapiens]
Protein Accession gi|4504349

Mean Expression Ratio 2.31

Median Expression Ratio 2.31

Credible Interval (1.9, 2.82)

Associated Peptides 7

Associated Spectra 29

Coverage 0.51


A	2.5	50	97.5	SEQ ID NO:	Sequence

1	1.6	2.2	3.0	SEQ ID NO: 1	EFTPPVQAAYQK

3	1.8	2.4	3.1	SEQ ID NO: 2	FESFGDLSTPDA
					VMGNPK


4	1.8	2.4	3.2	SEQ ID NO: 3	FFESFGDLSTPD
					AVMGNPK


4	1.9	2.5	3.3	SEQ ID NO: 4	GTFATLSELHCD
					K


13	2.1	2.6	3.2	SEQ ID NO: 5	LLGNVLVCVLAH
					HFGK


3	1.6	2.2	2.9	SEQ ID NO: 6	VNVDEVGGEALG
					R


1	1.7	2.4	3.3	SEQ ID NO: 7	FRLLGNVLVCVL
					AHHFGK

SEQ ID NO: 8

1	M V H L T P E E K S A V T A L W G K V N V D
	E V G G E A L G R L L V V Y P W T Q R F F E
	S F G D L S T P D A V M G N P K V K A H G K
	K V L G A F S D G L A H L D

81	N L K G T F A T L S E L H C D K L H V D P E
	N F R L L G N V L V C V L A H H F G K E F T
	P P V Q A A Y Q K V V A G V A N A L A H K Y
	H

5.2 catalase [Homo sapiens]
Protein Accession gi|4557014

Mean Expression Ratio 1.97

Median Expression Ratio 1.97

Credible Interval (1.61, 2.40)

Associated Peptides 13

Associated Spectra 20

Coverage 0.279


				Sequence
A	2.5	50	97.5	ID No.	Sequence

2	1.4	1.8	2.5	SEQ ID NO: 9	AFYVNVLNEEQR

2	1.4	2.0	2.6	SEQ ID NO: 10	DPILFPSFIHSQ
					K

1	1.5	2	2.8	SEQ ID NO: 11	FSTVAGESGSAD
					TVR

4	1.7	2.2	2.9	SEQ ID NO: 12	GPLLVQDVVFTD
					EMAHFDR

1	1.6	2.2	3	SEQ ID NO: 13	GPRGPLLVQDVV
					FTDEMAHFDR

1	1.6	2.1	3.0	SEQ ID NO: 14	IRDPILFPSFIH
					SQK

1	1.5	2	2.7	SEQ ID NO: 15	LFAYPDTHR

1	1.4	1.9	2.6	SEQ ID NO: 16	LSQEDPDYGIR

2	1.4	2.0	2.7	SEQ ID NO: 17	LVQDVVFTDEMA
					HFDR

2	1.5	2.0	2.7	SEQ ID NO: 18	NFTEVHPDYGSH
					IQALLDK

1	1.4	2.0	2.7	SEQ ID NO: 19	FAEVEQIAFDPS
					NMPPGIEASPDK

1	1.4	1.9	2.7	SEQ ID NO: 20	VFEHIGK

1	1.4	2.0	2.7	SEQ ID NO: 21	FNTANDDNVTQV
					R

SEQ ID NO: 22

1	M A D S R D P A S D Q M Q H W K E Q R A A Q
	K A D V L T T G A G N P V G D K L N V I T V
	G P R G P L L V Q D V V F T D E M A H F D R
	E R I P E R V V H A K G A G

81	A F G Y F E V T H D I T K Y S K A K V F E H
	I G K K T P I A V R F S T V A G E S G S A D
	T V R D P R G F A V K F Y T E D G N W D L V
	G N N T P I F F I R D P I L

161	F P S F I H S Q K R N P Q T H L K D P D M V
	W D F W S L R P E S L H Q V S F L F S D R G
	I P D G H R H M N G Y G S H T F K L V N A N
	G E A V Y C K F H Y K T D Q

241	G I K N L S V E D A A R L S Q E D P D Y G I
	R D L F N A I A T G K Y P S W T F Y I Q V M
	T F N Q A E T F P F N P F D L T K V W P H K
	D Y P L I P V G K L V L N R

321	N P V N Y F A E V E Q I A F D P S N M P P G
	I E A S P D K M L Q G R L F A Y P D T H R H
	R L G P N Y L H I P V N C P Y R A R V A N Y
	Q R D G P M C M Q D N Q G G

401	A P N Y Y P N S F G A P E Q Q P S A L E H S
	I Q Y S G E V R R F N T A N D D N V T Q V R
	A F Y V N V L N E E Q R K R L C E N I A G H
	L K D A Q I F I Q K K A V K

481	N F T E V H P D Y G S H I Q A L L D K Y N A
	E K P K N A I H T F V Q S G S H L A A R E K
	A N L

5.3 myoglobin [Homo sapiens]; myoglobin [Homo sapiens]; myoglobin [Homo sapiens]
Protein Accession gi|4885477 gi|44955888 gi|44955885

Mean Expression Ratio 0.525

Median Expression Ratio 0.526

Credible Interval (0.373, 0.736)

Associated Peptides 3

Associated Spectra 5

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.35	0.53	0.8	SEQ ID NO: 23	GLSDGEWQLVLN
					VWGK


2	0.36	0.53	0.77	SEQ ID NO: 24	HGATVLTALGGI
					LK


2	0.31	0.45	0.65	SEQ ID NO: 25	VEADIPGHGQEV
					LIR

5.4 alpha 1 globin [Homo sapiens]; alpha 2 globin [Homo sapiens]
Protein Accession gi|4504347 gi|4504345

Mean Expression Ratio 1.86

Median Expression Ratio 1.86

Credible Interval (1.56, 2.22)

Associated Peptides 12

Associated Spectra 36

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

2	1.6	2.2	2.9	SEQ ID NO: 26	AAHLPAEFTPAV
					HASLDK


1	1.4	1.9	2.7	SEQ ID NO: 27	ALSALSDLHAHK

1	1.4	1.9	2.6	SEQ ID NO: 28	FLSFPTTK

1	1.4	1.9	2.6	SEQ ID NO: 29	FPHFDLSHGSAQ
					VK


1	1.4	1.9	2.7	SEQ ID NO: 30	MFLSFPTTK

7	1.6	2.1	2.6	SEQ ID NO: 31	TYFPHFDLSHGS
					AQVK


3	1.4	1.8	2.4	SEQ ID NO: 32	VADALTNAVAHV
					DDMPNAL


2	1.3	1.7	2.3	SEQ ID NO: 33	VADALTNAVAHV
					DDMPNALSALSD
					LHAH


1	1.5	2	2.7	SEQ ID NO: 34	VDDMPNALSALS
					DLHAHK


9	1.2	1.5	1.9	SEQ ID NO: 35	VGAHAGEYGAEA
					LER


6	1.5	1.9	2.4	SEQ ID NO: 36	VADALTNAVAHV
					DDMPNALSALSD
					LHAHK


2	1.4	1.8	2.4	SEQ ID NO: 37	VDPVNFK

5.5 hemopexin [Homo sapiens]
Protein Accession gi|11321561

Mean Expression Ratio 0.547

Median Expression Ratio 0.547

Credible Interval (0.444, 0.676)

Associated Peptides 12

Associated Spectra 17

Coverage 0.297


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.4	0.55	0.77	SEQ ID NO: 38	DYFMPCPGR

1	0.4	0.55	0.76	SEQ ID NO: 39	EWFWDLATGTMK

1	0.40	0.56	0.79	SEQ ID NO: 40	FDPVRGEVPPR

1	0.39	0.54	0.76	SEQ ID NO: 41	FQGDREWFWDLA
					TGTMK

4	0.35	0.46	0.62	SEQ ID NO: 42	LLQDEFPGIPSP
					LDAAVECHR

1	0.4	0.56	0.77	SEQ ID NO: 43	NFPSPVDAAFR

2	0.4	0.55	0.75	SEQ ID NO: 44	RLWWLDLK

1	0.39	0.55	0.77	SEQ ID NO: 45	SGAQATWTELPW
					PHEK

2	0.4	0.55	0.75	SEQ ID NO: 46	VAEGETKPDPDV
					TER

1	0.39	0.54	0.75	SEQ ID NO: 47	YYCFQGNQFLR

1	0.39	0.54	0.77	SEQ ID NO: 48	GIILDSVDAAFI
					CPGSSR

1	0.37	0.52	0.73	SEQ ID NO: 49	LWWLDLK

SEQ ID NO: 50

1	M A R V L G A P V A L G L W S L C W S L A I
	A T P L P P T S A H G N V A E G E T K P D P
	D V T E R C S D G W S F D A T T L D D N G T
	M L F F K G E F V W K S H K

81	W D R E L I S E R W K N F P S P V D A A F R
	Q G H N S V F L I K G D K V W V Y P P E K K
	E K G Y P K L L Q D E F P G I P S P L D A A
	V E C H R G E C Q A E G V L

161	F F Q G D R E W F W D L A T G T M K E R S W
	P A V G N C S S A L R W L G R Y Y C F Q G N
	Q F L R F D P V R G E V P P R Y P R D V R D
	Y F M P C P G R G H G H R N

241	G T G H G N S T H H G P E Y M R C S P H L V
	L S A L T S D N H G A T Y A F S G T H Y W R
	L D T S R D G W H S W P I A H Q W P Q G P S
	A V D A A F S W E E K L Y L

321	V Q G T Q V Y V F L T K G G Y T L V S G Y P
	K R L E K E V G T P H G I I L D S V D A A F
	I C P G S S R L H I M A G R R L W W L D L K
	S G A Q A T W T E L P W P H

401	E K V D G A L C M E K S L G P N S C S A N G
	P G L Y L I H G P N L Y C Y S D V E K L N A
	A K A L P Q P Q N V T S L L G C T H

5.6 serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]; serine proteinase inhibitor, clade A, member 1 [Homo sapiens]
Protein Accession gi|50363221 gi|50363219 gi|50363217 gi|189163542 gi|189163540 gi|189163538 gi|189163536

Mean Expression Ratio 0.551

Median Expression Ratio 0.551

Credible Interval (0.482, 0.627)

Associated Peptides 27

Associated Spectra 68

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No:	Sequence

9	0.46	0.57	0.7	SEQ ID NO: 51	DTEEEDFH
					VDQVTTVK

1	0.43	0.57	0.77	SEQ ID NO: 52	DTVFALVN
					YIFFK

2	0.40	0.53	0.71	SEQ ID NO: 53	ELDRDTVF
					ALVNYIFF
					K

1	0.42	0.56	0.76	SEQ ID NO: 54	GTEAAGAM
					FLEAIPMS
					IPPEVK

1	0.4	0.54	0.72	SEQ ID NO: 55	ITPNLAEF
					AFSLYR

2	0.43	0.57	0.75	SEQ ID NO: 56	KLSSWVLL
					MK

2	0.44	0.58	0.77	SEQ ID NO: 57	KQINDYVE
					K

1	0.43	0.57	0.77	SEQ ID NO: 58	LAEFAFSL
					YR

4	0.4	0.52	0.67	SEQ ID NO: 59	LGMFNIQH
					CK

18	0.39	0.46	0.55	SEQ ID NO: 60	LQHLENEL
					THDIITK

5	0.42	0.53	0.68	SEQ ID NO: 61	LVDKFLED
					VK

2	0.42	0.56	0.74	SEQ ID NO: 62	QINDYVEK

2	0.44	0.59	0.78	SEQ ID NO: 63	SASLHLPK

1	0.4	0.54	0.73	SEQ ID NO: 64	SVLGQLGI
					TK

1	0.42	0.57	0.77	SEQ ID NO: 65	TLNQPDSQ
					LQLTTGNG
					LFLSEGLK

1	0.4	0.54	0.73	SEQ ID NO: 66	TVNFGDTE
					EAKK

3	0.41	0.53	0.69	SEQ ID NO: 67	VFSNGADL
					SGVTEEAP
					LK

2	0.39	0.52	0.69	SEQ ID NO: 68	WERPFEVK

1	0.41	0.54	0.73	SEQ ID NO: 69	LVDKFLED
					VKK

1	0.39	0.53	0.71	SEQ ID NO: 70	GKWERPFE
					VK

1	0.42	0.57	0.76	SEQ ID NO: 71	AVLTIDEK

1	0.4	0.54	0.73	SEQ ID NO: 72	FLEDVKK

1	0.41	0.56	0.75	SEQ ID NO: 73	LSITGTYD
					LK

2	0.42	0.56	0.73	SEQ ID NO: 74	FLEDVK

1	0.39	0.53	0.71	SEQ ID NO: 75	EEEDFHVD
					QVTTVK

1	0.43	0.58	0.77	SEQ ID NO: 76	GLFLSEGL
					K

1	0.41	0.55	0.74	SEQ ID NO: 77	FNKPFVF

5.7 mucin 1 isoform 3 precursor [Homo sapiens]; mucin 1 isoform 2 precursor [Homo sapiens]; mucin 1 isoform 1 precursor [Homo sapiens]
Protein Accession gi|67189069 gi|67189007 gi|65301117

Mean Expression Ratio 1.81

Median Expression Ratio 1.81

Credible Interval (1.45, 2.27)

Associated Peptides 6

Associated Spectra 22

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	1.3	1.8	2.5	SEQ ID NO: 78	DISEMFLQIYK

2	1.4	1.9	2.6	SEQ ID NO: 79	HDVETQFNQYK

2	1.3	1.7	2.4	SEQ ID NO: 80	KNYGQLDIFPAR

4	1.5	1.9	2.6	SEQ ID NO: 81	NYGQLDIFPAR

1	1.3	1.8	2.4	SEQ ID NO: 82	QGGFLGLSNIK

12	1.6	2.0	2.5	SEQ ID NO: 83	EGTINVHDVETQ
					FNQYK

5.8 serpin peptidase inhibitor, clade A, member 3 precursor [Homo sapiens]
Protein Accession gi|50659080

Mean Expression Ratio 0.563

Median Expression Ratio 0.563

Credible Interval (0.463, 0.681)

Associated Peptides 15

Associated Spectra 21

Coverage 0.388


				Sequence
A	2.5	50	97.5	ID No.	Sequence

2	0.41	0.55	0.74	SEQ ID NO: 84	AVLDVFEEGTEA
					SAATAVK

1	0.39	0.54	0.75	SEQ ID NO: 85	DYNLNDILLQLG
					IEEAFTSK

1	0.42	0.58	0.8	SEQ ID NO: 86	EIGELYLPK

2	0.37	0.51	0.68	SEQ ID NO: 87	HPNSPLDEENLT
					QENQDR

1	0.38	0.53	0.73	SEQ ID NO: 88	ITLLSALVETR

1	0.42	0.57	0.8	SEQ ID NO: 89	KLINDYVK

1	0.4	0.55	0.76	SEQ ID NO: 90	LYGSEAFATDFQ
					DSAAAK

3	0.45	0.6	0.8	SEQ ID NO: 91	MEEVEAMLLPET
					LK

1	0.42	0.57	0.79	SEQ ID NO: 92	MEEVEAMLLPET
					LKR

2	0.42	0.57	0.77	SEQ ID NO: 93	NLAVSQVVHK

2	0.42	0.56	0.76	SEQ ID NO: 94	NSPLDEENLTQE
					NQDR

1	0.40	0.55	0.76	SEQ ID NO: 95	SPLDEENLTQEN
					QDR

1	0.41	0.57	0.77	SEQ ID NO: 96	WEMPFDPQDTHQ
					SR

1	0.4	0.55	0.76	SEQ ID NO: 97	WRDSLEFR

1	0.41	0.57	0.78	SEQ ID NO: 98	EQLSLLDRFTED
					AK

SEQ ID NO: 99

1	M E R M L P L L A L G L L A A G F C P A V L
	C H P N S P L D E E N L T Q E N Q D R G T H
	V D L G L A S A N V D F A F S L Y K Q L V L
	K A P D K N V I F S P L S I

81	S T A L A F L S L G A H N T T L T E I L K G
	L K F N L T E T S E A E I H Q S F Q H L L R
	T L N Q S S D E L Q L S M G N A M F V K E Q
	L S L L D R F T E D A K R L

161	Y G S E A F A T D F Q D S A A A K K L I N D
	Y V K N G T R G K I T D L I K D L D S Q T M
	M V L V N Y I F F K A K W E M P F D P Q D T
	H Q S R F Y L S K K K W V M

241	V P M M S L H H L T I P Y F R D E E L S C T
	V V E L K Y T G N A S A L F I L P D Q D K M
	E E V E A M L L P E T L K R W R D S L E F R
	E I G E L Y L P K F S I S R

321	D Y N L N D I L L Q L G I E E A F T S K A D
	L S G I T G A R N L A V S Q V V H K A V L D
	V F E E G T E A S A A T A V K I T L L S A L
	V E T R T I V R F N R P F L

401	M I I V P T D T Q N I F F M S K V T N P K Q
	A

5.9 CD14 antigen precursor [Homo sapiens]; CD14 antigen precursor [Homo sapiens]
Protein Accession gi|91105159 gi|4557417

Mean Expression Ratio 0.567

Median Expression Ratio 0.567

Credible Interval (0.452, 0.707)

Associated Peptides 9

Associated Spectra 16

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

4	0.4	0.53	0.71	SEQ ID NO: 100	AFPALTSL
					DLSDNPGL
					GER


1	0.41	0.58	0.81	SEQ ID NO: 101	GLMAALCP
					HK


1	0.42	0.58	0.8	SEQ ID NO: 102	GLMAALCP
					HKFPAIQN
					L


1	0.40	0.56	0.79	SEQ ID NO: 103	GLMAALCP
					HKFPAIQN
					LALR


2	0.43	0.58	0.8	SEQ ID NO: 104	ITGTMPPL
					PLEATGLA
					LSSLR


3	0.39	0.53	0.72	SEQ ID NO: 105	LTVGAAQV
					PAQLLVGA
					LR


1	0.4	0.56	0.78	SEQ ID NO: 106	SWLAELQQ
					WLKPGLK


2	0.41	0.56	0.77	SEQ ID NO: 107	TTPEPCEL
					DDEDFR


1	0.39	0.54	0.76	SEQ ID NO: 108	VLSIAQAH
					SPAFSCEQ
					VR

5.10 brain abundant, membrane attached signal protein 1 [Homo sapiens]
Protein Accession gi|30795231

Mean Expression Ratio 1.75

Median Expression Ratio 1.75

Credible Interval (1.30, 2.35)

Associated Peptides 5

Associated Spectra 7

Coverage 0.396


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	1.2	1.8	2.7	SEQ ID NO: 109	AAEAAAAP
					AESAAPAA
					GEEPSKEE
					GEPK

1	1.2	1.7	2.5	SEQ ID NO: 110	AEPPKAPE
					QEQAAPGP
					AAGGEAPK

2	1.3	1.8	2.6	SEQ ID NO: 111	APEQEQAA
					PGPAAGGE
					APK

1	1.2	1.8	2.7	SEQ ID NO: 112	AQGPAASA
					EEPKPVEA
					PAANSDQT
					VTVK

2	1.3	1.8	2.6	SEQ ID NO: 113	EKPDQDAE
					GK

SEQ ID NO: 114

1	M G G K L S K K K K G Y N V N D E K A K E K
	D K K A E G A A T E E E G T P K E S E P Q A
	A A E P A E A K E G K E K P D Q D A E G K A
	E E K E G E K D A A A A K E

81	E A P K A E P E K T E G A A E A K A E P P K
	A P E Q E Q A A P G P A A G G E A P K A A E
	A A A A P A E S A A P A A G E E P S K E E G
	E P K K T E A P A A P A A Q

161	E T K S D G A P A S D S K P G S S E A A P S
	S K E T P A A T E A P S S T P K A Q G P A A
	S A E E P K P V E A P A A N S D Q T V T V K
	E

5.11 dipeptidase 1 [Homo sapiens]; dipeptidase 1 [Homo sapiens]
Protein Accession gi|4758190 gi|89458885

Mean Expression Ratio 1.72

Median Expression Ratio 1.72

Credible Interval (1.25, 2.37)

Associated Peptides 5

Associated Spectra 6

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	1.2	1.7	2.6	SEQ ID NO: 115	AVGFGGDF
					DGVPR


1	1.2	1.8	2.6	SEQ ID NO: 116	DSPVIDGH
					NDLPWQLL
					DMFNNR


1	1.2	1.8	2.7	SEQ ID NO: 117	VPEGLEDV
					SKYPDLIA
					ELLR


1	1.2	1.8	2.7	SEQ ID NO: 118	YPDLIAEL
					LR


2	1.2	1.8	2.5	SEQ ID NO: 119	VASLIGVE
					GGHSIDSS
					LGVLR

5.12 fibronectin 1 isoform 5 preproprotein [Homo sapiens]
Protein Accession gi|47132553

Mean Expression Ratio 0.586

Median Expression Ratio 0.585

Credible Interval (0.475, 0.724)

Associated Peptides 11

Associated Spectra 17

Coverage 0.0758


				Sequence
A	2.5	50	97.5	ID No.	Sequence

3	0.40	0.55	0.74	SEQ ID NO: 120	AVEENQES
					TPVVIQQE
					TTGTPR

2	0.43	0.58	0.79	SEQ ID NO: 121	EESPLLIG
					QQSTVSDV
					PR

2	0.41	0.57	0.77	SEQ ID NO: 122	ESVPISDT
					IIPAVPPP
					TDLR

1	0.45	0.63	0.88	SEQ ID NO: 123	LISWDAPA
					VTVR

1	0.42	0.58	0.81	SEQ ID NO: 124	QVDAVPAN
					GQTPIQR

1	0.43	0.59	0.82	SEQ ID NO: 125	SSPVVIDA
					STAIDAPS
					NLR

2	0.43	0.59	0.81	SEQ ID NO: 126	TETITGFQ
					VDAVPANG
					QTPIQR

2	0.42	0.57	0.78	SEQ ID NO: 127	VDVIPVNL
					PGEHGQR

1	0.43	0.6	0.84	SEQ ID NO: 128	VTWAPPPS
					IDLTNFLV
					R

1	0.43	0.6	0.83	SEQ ID NO: 129	DLEVVAAT
					PTSLLISW
					DAPAVTVR

1	0.37	0.51	0.7	SEQ ID NO: 130	IISCHPVG
					TDEEPLQF
					R

SEQ ID NO: 131

1	M L R G P G P G L L L L A V Q C L G T A V P
	S T G A S K S K R Q A Q Q M V Q P Q S P V A
	V S Q S K P G C Y D N G K H Y Q I N Q Q W E
	R T Y L G N A L V C T C Y G

81	G S R G F N C E S K P E A E E T C F D K Y T
	G N T Y R V G D T Y E R P K D S M I W D C T
	C I G A G R G R I S C T I A N R C H E G G Q
	S Y K I G D T W R R P H E T

161	G G Y M L E C V C L G N G K G E W T C K P I
	A E K C F D H A A G T S Y V V G E T W E K P
	Y Q G W M M V D C T C L G E G S G R I T C T
	S R N R C N D Q D T R T S Y

241	R I G D T W S K K D N R G N L L Q C I C T G
	N G R G E W K C E R H T S V Q T T S S G S G
	P F T D V R A A V Y Q P Q P H P Q P P P Y G
	H C V T D S G V V Y S V G M

321	Q W L K T Q G N K Q M L C T C L G N G V S C
	Q E T A V T Q T Y G G N S N G E P C V L P F
	T Y N G R T F Y S C T T E G R Q D G H L W C
	S T T S N Y E Q D Q K Y S F

401	C T D H T V L V Q T R G G N S N G A L C H F
	P F L Y N N H N Y T D C T S E G R R D N M K
	W C G T T Q N Y D A D Q K F G F C P M A A H
	E E I C T T N E G V M Y R I

481	G D Q W D K Q H D M G H M M R C T C V G N G
	R G E W T C I A Y S Q L R D Q C I V D D I T
	Y N V N D T F H K R H E E G H M L N C T C F
	G Q G R G R W K C D P V D Q

561	C Q D S E T G T F Y Q I G D S W E K Y V H G
	V R Y Q C Y C Y G R G I G E W H C Q P L Q T
	Y P S S S G P V E V F I T E T P S Q P N S H
	P I Q W N A P Q P S H I S K

641	Y I L R W R P K N S V G R W K E A T I P G H
	L N S Y T I K G L K P G V V Y E G Q L I S I
	Q Q Y G H Q E V T R F D F T T T S T S T P V
	T S N T V T G E T T P F S P

721	L V A T S E S V T E I T A S S F V V S W V S
	A S D T V S G F R V E Y E L S E E G D E P Q
	Y L D L P S T A T S V N I P D L L P G R K Y
	I V N V Y Q I S E D G E Q S

801	L I L S T S Q T T A P D A P P D P T V D Q V
	D D T S I V V R W S R P Q A P I T G Y R I V
	Y S P S V E G S S T E L N L P E T A N S V T
	L S D L Q P G V Q Y N I T I

881	Y A V E E N Q E S T P V V I Q Q E T T G T P
	R S D T V P S P R D L Q F V E V T D V K V T
	I M W T P P E S A V T G Y R V D V I P V N L
	P G E H G Q R L P I S R N T

961	F A E V T G L S P G V T Y Y F K V F A V S H
	G R E S K P L T A Q Q T T K L D A P T N L Q
	F V N E T D S T V L V R W T P P R A Q I T G
	Y R L T V G L T R R G Q P R

1041	Q Y N V G P S V S K Y P L R N L Q P A S E Y
	T V S L V A I K G N Q E S P K A T G V F T T
	L Q P G S S I P P Y N T E V T E T T I V I T
	W T P A P R I G F K L G V R

1121	P S Q G G E A P R E V T S D S G S I V V S G
	L T P G V E Y V Y T I Q V L R D G Q E R D A
	P I V N K V V T P L S P P T N L H L E A N P
	D T G V L T V S W E R S T T

1201	P D I T G Y R I T T T P T N G Q Q G N S L E
	E V V H A D Q S S C T F D N L S P G L E Y N
	V S V Y T V K D D K E S V P I S D T I I P A
	V P P P T D L R F T N I G P

1281	D T M R V T W A P P P S I D L T N F L V R Y
	S P V K N E E D V A E L S I S P S D N A V V
	L T N L L P G T E Y V V S V S S V Y E Q H E
	S T P L R G R Q K T G L D S

1361	P T G I D F S D I T A N S F T V H W I A P R
	A T I T G Y R I R H H P E H F S G R P R E D
	R V P H S R N S I T L T N L T P G T E Y V V
	S I V A L N G R E E S P L L

1441	I G Q Q S T V S D V P R D L E V V A A T P T
	S L L I S W D A P A V T V R Y Y R I T Y G E
	T G G N S P V Q E F T V P G S K S T A T I S
	G L K P G V D Y T I T V Y A

1521	V T G R G D S P A S S K P I S I N Y R T E I
	D K P S Q M Q V T D V Q D N S I S V K W L P
	S S S P V T G Y R V T T T P K N G P G P T K
	T K T A G P D Q T E M T I E

1601	G L Q P T V E Y V V S V Y A Q N P S G E S Q
	P L V Q T A V T T I P A P T D L K F T Q V T
	P T S L S A Q W T P P N V Q L T G Y R V R V
	T P K E K T G P M K E I N L

1681	A P D S S S V V V S G L M V A T K Y E V S V
	Y A L K D T L T S R P A Q G V V T T L E N V
	S P P R R A R V T D A T E T T I T I S W R T
	K T E T I T G F Q V D A V P

1761	A N G Q T P I Q R T I K P D V R S Y T I T G
	L Q P G T D Y K I Y L Y T L N D N A R S S P
	V V I D A S T A I D A P S N L R F L A T T P
	N S L L V S W Q P P R A R I

1841	T G Y I I K Y E K P G S P P R E V V P R P R
	P G V T E A T I T G L E P G T E Y T I Y V I
	A L K N N Q K S E P L I G R K K T D E L P Q
	L V T L P H P N L H G P E I

1921	L D V P S T V Q K T P F V T H P G Y D T G N
	G I Q L P G T S G Q Q P S V G Q Q M I F E E
	H G F R R T T P P T T A T P I R H R P R P Y
	P P N V G E E I Q I G H I P

2001	R E D V D Y H L Y P H G P G L N P N A S T G
	Q E A L S Q T T I S W A P F Q D T S E Y I I
	S C H P V G T D E E P L Q F R V P G T S T S
	A T L T G L T R G A T Y N I

2081	I V E A L K D Q Q R H K V R E E V V T V G N
	S V N E G L N Q P T D D S C F D P Y T V S H
	Y A V G D E W E R M S E S G F K L L C Q C L
	G F G S G H F R C D S S R W

2161	C H D N G V N Y K I G E K W D R Q G E N G Q
	M M S C T C L G N G K G E F K C D P H E A T
	C Y D D G K T Y H V G E Q W Q K E Y L G A I
	C S C T C F G G Q R G W R C

2241	D N C R R P G G E P S P E G T T G Q S Y N Q
	Y S Q R Y H Q R T N T N V N C P I E C F M P
	L D V Q A D R E D S R E

5.13 angiotensinogen preproprotein [Homo sapiens]
Protein Accession gi|4557287

Mean Expression Ratio 0.59

Median Expression Ratio 0.59

Credible Interval (0.482, 0.718)

Associated Peptides 10

Associated Spectra 25

Coverage 0.293


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.42	0.57	0.77	SEQ ID NO: 132	AAMVGMLANFLGFR
2	0.4	0.54	0.73	SEQ ID NO: 133	ADSQAQLLLSTVVGVFTAPGLHLK
1	0.44	0.6	0.83	SEQ ID NO: 134	ALQDQLVLVAAK
2	0.46	0.62	0.85	SEQ ID NO: 135	DPTFIPAPIQAK
1	0.45	0.63	0.87	SEQ ID NO: 136	FMQAVTGWK
1	0.42	0.56	0.78	SEQ ID NO: 137	QPFVQGLALYTPVVLPR
2	0.46	0.62	0.85	SEQ ID NO: 138	VGEVLNSIFFELEADER
2	0.43	0.58	0.79	SEQ ID NO: 139	VLSALQAVQGLLVAQGR
11	0.4	0.5	0.61	SEQ ID NO: 140	DRVYIHPFHL
1	0.44	0.6	0.84	SEQ ID NO: 141	LQAILGVPWK

SEQ ID NO: 142

1 M R K R A P Q S E M A P A G V S L R A T I L C L L A W A G L A A G D R V Y I H P

F H L V I H N E S T C E Q L A K A N A G K P K D P T F I P A P I Q A K T S P V D

81 E K A L Q D Q L V L V A A K L D T E D K L R A A M V G M L A N F L G F R I Y G

M H S E L W G V V H G A T V L S P T A V F G T L A S L Y L G A L D H T A D R L Q

A

161 I L G V P W K D K N C T S R L D A H K V L S A L Q A V Q G L L V A Q G R A D

S Q A Q L L L S T V V G V F T A P G L H L K Q P F V Q G L A L Y T P V V L P R S L

D

241 F T E L D V A A E K I D R F M Q A V T G W K T G C S L M G A S V D S T L A F N

T Y V H F Q G K M K G F S L L A E P Q E F W V D N S T S V S V P M L S G M G T F Q

321 H W S D I Q D N F S V T Q V P F T E S A C L L L I Q P H Y A S D L D K V E G L T

F Q Q N S L N W M K K L S P R T I H L T M P Q L V L Q G S Y D L Q D L L A Q A E

401 L P A I L H T E L N L Q K L S N D R I R V G E V L N S I F F E L E A D E R E P T E

S T Q Q L N K P E V L E V T L N R P F L F A V Y D Q S A T A L H F L G R V A N

481 P L S T A

5.14 complement component 3 precursor [Homo sapiens]
Protein Accession gi|115298678

Mean Expression Ratio 0.601

Median Expression Ratio 0.602

Credible Interval (0.532, 0.678)

Associated Peptides 39

Associated Spectra 69

Coverage 0.301


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.46	0.61	0.82	SEQ ID NO: 143	CAEENCFIQK
1	0.45	0.6	0.8	SEQ ID NO: 144	DAPDHQELNLDVSLQLPSR
2	0.44	0.58	0.77	SEQ ID NO: 145	DFDFVPPVVR
1	0.45	0.6	0.81	SEQ ID NO: 146	DTWVEHWPEEDECQDEENQK
11	0.35	0.43	0.53	SEQ ID NO: 147	EDIPPADLSDQVPDTESETR
3	0.45	0.59	0.76	SEQ ID NO: 148	EPGQDLVVLPLSITTDFIPSFR
1	0.45	0.6	0.81	SEQ ID NO: 149	EYVLPSFEVIVEPTEK
1	0.46	0.6	0.81	SEQ ID NO: 150	FYHPEKEDGK
1	0.46	0.61	0.83	SEQ ID NO: 151	HQQTVTIPPK
1	0.46	0.61	0.82	SEQ ID NO: 152	IHWESASLLR
5	0.44	0.56	0.71	SEQ ID NO: 153	ILLQGTPVAQMTEDAVDAER
3	0.48	0.62	0.81	SEQ ID NO: 154	IPIEDGSGEVVLSR
1	0.44	0.59	0.79	SEQ ID NO: 155	IWDVVEK
2	0.46	0.61	0.8	SEQ ID NO: 156	KQELSEAEQATR
2	0.47	0.62	0.83	SEQ ID NO: 157	LESEETMVLEAHDAQGDVPVTVTVHD
					FPGK
1	0.46	0.61	0.82	SEQ ID NO: 158	LMNIFL K
3	0.48	0.62	0.81	SEQ ID NO: 159	QKPDGVFQEDAPVIHQEMIGGLR
1	0.47	0.63	0.85	SEQ ID NO: 160	SGQSEDRQPVPGQQMTLK
1	0.45	0.59	0.8	SEQ ID NO: 161	SITTDFIPSFR
2	0.45	0.59	0.78	SEQ ID NO: 162	SNLDEDIIAEENIVSR
1	0.44	0.59	0.79	SEQ ID NO: 163	SWDIPELVNMGQWK
1	0.45	0.61	0.81	SEQ ID NO: 164	TELRPGETLNVNF
2	0.46	0.61	0.81	SEQ ID NO: 165	TELRPGETLNVNFLLR
2	0.47	0.63	0.83	SEQ ID NO: 166	TVMVNIENPEGIPVK
1	0.46	0.61	0.81	SEQ ID NO: 167	VFVTNPDGSPAYR
1	0.45	0.61	0.82	SEQ ID NO: 168	VIFGIQDGEQR
1	0.45	0.6	0.8	SEQ ID NO: 169	VLLDGVQNPR
3	0.44	0.58	0.75	SEQ ID NO: 170	VQLSNDFDEYIMAIEQTIK
3	0.45	0.58	0.76	SEQ ID NO: 171	VTIKPAPETEK
1	0.46	0.61	0.81	SEQ ID NO: 172	AGDFLEANYMNLQR
1	0.45	0.6	0.8	SEQ ID NO: 173	GICVADPFEVTVMQDFFIDLR
1	0.46	0.61	0.81	SEQ ID NO: 174	LKGPLLNK
1	0.41	0.54	0.72	SEQ ID NO: 175	FYYIYNEK
1	0.47	0.63	0.84	SEQ ID NO: 176	QPVPGQQMTLK
1	0.46	0.62	0.83	SEQ ID NO: 177	RIPIEDGSGEVVLSR
1	0.47	0.62	0.83	SEQ ID NO: 178	VSHSEDDCLAFK
1	0.45	0.6	0.8	SEQ ID NO: 179	LSINTHPSQKPL
1	0.45	0.6	0.8	SEQ ID NO: 180	GLSSDFWGEKPNLSY
1	0.48	0.64	0.85	SEQ ID NO: 181	QIHFTK

SEQ ID NO: 182

1 M G P T S G P S L L L L L L T H L P L A L G S P M Y S I I T P N I L R L E S E E T M

V L E A H D A Q G D V P V T V T V H D F P G K K L V L S S E K T V L T P A T

81 N H M G N V T F T I P A N R E F K S E K G R N K F V T V Q A T F G T Q V V E K

V V L V S L Q S G Y L F I Q T D K T I Y T P G S T V L Y R I F T V N H K L L P V G

161 R T V M V N I E N P E G I P V K Q D S L S S Q N Q L G V L P L S W D I P E L V N

M G Q W K I R A Y Y E N S P Q Q V F S T E F E V K E Y V L P S F E V I V E P T E

241 K F Y Y I Y N E K G L E V T I T A R F L Y G K K V E G T A F V I F G I Q D G E Q

R I S L P E S L K R I P I E D G S G E V V L S R K V L L D G V Q N P R A E D L V

321 G K S L Y V S A T V I L H S G S D M V Q A E R S G I P I V T S P Y Q I H F T K T P

K Y F K P G M P F D L M V F V T N P D G S P A Y R V P V A V Q G E D T V Q S L

401 T Q G D G V A K L S I N T H P S Q K P L S I T V R T K K Q E L S E A E Q A T R T

M Q A L P Y S T V G N S N N Y L H L S V L R T E L R P G E T L N V N F L L R M D

481 R A H E A K I R Y Y T Y L I M N K G R L L K A G R Q V R E P G Q D L V V L P L

S I T T D F I P S F R L V A Y Y T L I G A S G Q R E V V A D S V W V D V K D S C V

561 G S L V V K S G Q S E D R Q P V P G Q Q M T L K I E G D H G A R V V L V A V D

K G V F V L N K K N K L T Q S K I W D V V E K A D I G C T P G S G K D Y A G V F S

641 D A G L T F T S S S G Q Q T A Q R A E L Q C P Q P A A R R R R S V Q L T E K R

M D K V G K Y P K E L R K C C E D G M R E N P M R F S C Q R R T R F I S L G E A C

721 K K V F L D C C N Y I T E L R R Q H A R A S H L G L A R S N L D E D I I A E E N

I V S R S E F P E S W L W N V E D L K E P P K N G I S T K L M N I F L K D S I T

801 T W E I L A V S M S D K K G I C V A D P F E V T V M Q D F F I D L R L P Y S V V

R N E Q V E I R A V L Y N Y R Q N Q E L K V R V E L L H N P A F C S L A T T K R

881 R H Q Q T V T I P P K S S L S V P Y V I V P L K T G L Q E V E V K A A V Y H H F

I S D G V R K S L K V V P E G I R M N K T V A V R T L D P E R L G R E G V Q K E

961 D I P P A D L S D Q V P D T E S E T R I L L Q G T P V A Q M T E D A V D A E R L

K H L I V T P S G C G E Q N M I G M T P T V I A V H Y L D E T E Q W E K F G L E

1041 K R Q G A L E L I K K G Y T Q Q L A F R Q P S S A F A A F V K R A P S T W L T

A Y V V K V F S L A V N L I A I D S Q V L C G A V K W L I L E K Q K P D G V F Q E

1121 D A P V I H Q E M I G G L R N N N E K D M A L T A F V L I S L Q E A K D I C E

E Q V N S L P G S I T K A G D F L E A N Y M N L Q R S Y T V A I A G Y A L A Q M G

1201 R L K G P L L N K F L T T A K D K N R W E D P G K Q L Y N V E A T S Y A L L

A L L Q L K D F D F V P P V V R W L N E Q R Y Y G G G Y G S T Q A T F M V F Q A

L A

1281 Q Y Q K D A P D H Q E L N L D V S L Q L P S R S S K I T H R I H W E S A S L L

R S E E T K E N E G F T V T A E G K G Q G T L S V V T M Y H A K A K D Q L T C N

K

1361 F D L K V T I K P A P E T E K R P Q D A K N T M I L E I C T R Y R G D Q D A T

M S I L D I S M M T G F A P D T D D L K Q L A N G V D R Y I S K Y E L D K A F S D

1441 R N T L I T Y L D K V S H S E D D C L A F K V H Q Y F N V E L I Q P G A V K V

Y A Y Y N L E E S C T R F Y H P E K E D G K L N K L C R D E L C R C A E E N C F I

1521 Q K S D D K V T L E E R L D K A C E P G V D Y V Y K T R L V K V Q L S N D F

D E Y I M A I E Q T I K S G S D E V Q V G Q Q R T F I S P I K C R E A L K L E E K K

1601 H Y L M W G L S S D F W G E K P N L S Y I I G K D T W V E H W P E E D E C Q

D E E N Q K Q C Q D L G A F T E S M V V F G C P N

5.15 carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens]; carbonic anhydrase I [Homo sapiens]
Protein Accession gi|4502517 gi|92447434 gi|92447432 gi|92447430

Mean Expression Ratio 0.602

Median Expression Ratio 0.604

Credible Interval (0.499, 0.718)

Associated Peptides 13

Associated Spectra 28

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.47	0.63	0.85	SEQ ID NO: 183	ADGLAVIGVLMK

3	0.47	0.63	0.83	SEQ ID NO: 184	EIINVGHSFHVNFEDNDNR

1	0.43	0.59	0.82	SEQ ID NO: 185	ESISVSSEQLAQFR

1	0.43	0.58	0.8	SEQ ID NO: 186	HDTSLKPISVSYNPATAK

1	0.43	0.59	0.8	SEQ ID NO: 187	LFQFHF

6	0.45	0.58	0.74	SEQ ID NO: 188	LYPIANGNNQSPVDIK

2	0.45	0.6	0.81	SEQ ID NO: 189	NGPEQWSK

2	0.46	0.62	0.83	SEQ ID NO: 190	SFHVNFEDNDNR

1	0.43	0.6	0.82	SEQ ID NO: 191	SLLSNVEGDNAVPMQHN

1	0.41	0.57	0.78	SEQ ID NO: 192	VLDALQAIK

2	0.45	0.61	0.81	SEQ ID NO: 193	YSAELHVAHW

1	0.46	0.63	0.87	SEQ ID NO: 194	YSAELHVAHWNSAK

5	0.41	0.53	0.68	SEQ ID NO: 195	SLLSNVEGDNAVPMQHNNR
					PTQPLK

5.16 uromodulin precursor [Homo sapiens]; uromodulin precursor [Homo sapiens]
Protein Accession gi|59850812 gi|56550049

Mean Expression Ratio 0.608

Median Expression Ratio 0.607

Credible Interval (0.528, 0.701)

Associated Peptides 25

Associated Spectra 50

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.47	0.63	0.86	SEQ ID NO: 196	ACSYPLDMK

9	0.51	0.64	0.79	SEQ ID NO: 197	DSTIQVVENGESSQGR

3	0.46	0.6	0.8	SEQ ID NO: 198	DWVSVVTPAR

1	0.45	0.59	0.8	SEQ ID NO: 199	FSVQMFR

1	0.44	0.59	0.8	SEQ ID NO: 200	INFACSYPLDMK

4	0.47	0.6	0.78	SEQ ID NO: 201	LADEIIIR

1	0.45	0.62	0.83	SEQ ID NO: 202	LECGANDMK

1	0.46	0.61	0.83	SEQ ID NO: 203	LSPGLGCTDVDECAEP
					GLSHCH

2	0.46	0.61	0.8	SEQ ID NO: 204	LYVGTMLDGGDLSR

5	0.45	0.58	0.73	SEQ ID NO: 205	MAETCVPVLR

1	0.44	0.59	0.8	SEQ ID NO: 206	SCVCPEGFR

1	0.43	0.59	0.79	SEQ ID NO: 207	SNTLYLADEIIIR

3	0.46	0.6	0.79	SEQ ID NO: 208	STEYGEGYACDTDLR

1	0.45	0.6	0.8	SEQ ID NO: 209	TALQPMVSALNIR

2	0.43	0.57	0.76	SEQ ID NO: 210	TLDEYWR

1	0.44	0.6	0.81	SEQ ID NO: 211	VFMYLSDSR

1	0.45	0.61	0.82	SEQ ID NO: 212	VGTMLDGGDLSR

1	0.47	0.64	0.86	SEQ ID NO: 213	VLNLGPITR

1	0.43	0.58	0.79	SEQ ID NO: 214	WHCQCK

5	0.46	0.58	0.74	SEQ ID NO: 215	YFIIQDR

1	0.48	0.64	0.86	SEQ ID NO: 216	SLGFDKVFMYLSDSR

1	0.46	0.61	0.83	SEQ ID NO: 217	SLGFDK

1	0.46	0.62	0.83	SEQ ID NO: 218	SYPLDMK

1	0.45	0.6	0.8	SEQ ID NO: 219	CSGFNDR

1	0.46	0.61	0.82	SEQ ID NO: 220	DLNIK

5.17 heparan sulfate proteoglycan 2 [Homo sapiens]
Protein Accession gi|126012571

Mean Expression Ratio 0.614

Median Expression Ratio 0.614

Credible Interval (0.488, 0.761)

Associated Peptides 9

Associated Spectra 16

Coverage 0.0239


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.42	0.58	0.79	SEQ ID NO: 221	DFISLGLQDGHLVFR
2	0.43	0.6	0.82	SEQ ID NO: 222	FHDDGFLAFPGHVF
1	0.42	0.6	0.83	SEQ ID NO: 223	FHDDGFLAFPGHVFSR
1	0.45	0.63	0.9	SEQ ID NO: 224	GSIQVDGEELVSGR
2	0.47	0.64	0.88	SEQ ID NO: 225	GSVYIGGAPDVATLTGGR
2	0.42	0.59	0.8	SEQ ID NO: 226	LVSEDPINDGEWHR
2	0.44	0.61	0.83	SEQ ID NO: 227	PGAPPPQPLDLQHR
3	0.44	0.59	0.8	SEQ ID NO: 228	SLPEVPETIELEVR
1	0.44	0.63	0.87	SEQ ID NO: 229	IGGAPDVATLTGGR

SEQ ID NO: 230

1 M G W R A A G A L L L A L L L H G R L L A V T H G L R A Y D G L S L P E D I E T

V T A S Q M R W T H S Y L S D D E D M L A D S I S G D D L G S G D L G S G D F Q

81 M V Y F R A L V N F T R S I E Y S P Q L E D A G S R E F R E V S E A V V D T L E

S E Y L K I P G D Q V V S V V F I K E L D G W V F V E L D V G S E G N A D G A Q

161 I Q E M L L R V I S S G S V A S Y V T S P Q G F Q F R R L G T V P Q F P R A C T

E A E F A C H S Y N E C V A L E Y R C D R R P D C R D M S D E L N C E E P V L G

241 I S P T F S L L V E T T S L P P R P E T T I M R Q P P V T H A P Q P L L P G S V R P

L P C G P Q E A A C R N G H C I P R D Y L C D G Q E D C E D G S D E L D C G

321 P P P P C E P N E F P C G N G H C A L K L W R C D G D F D C E D R T D E A N C

P T K R P E E V C G P T Q F R C V S T N M C I P A S F H C D E E S D C P D R S D E

401 F G C M P P Q V V T P P R E S I Q A S R G Q T V T F T C V A I G V P T P I I N W R

L N W G H I P S H P R V T V T S E G G R G T L I I R D V K E S D Q G A Y T C E

481 A M N A R G M V F G I P D G V L E L V P Q R G P C P D G H F Y L E H S A A C L

P C F C F G I T S V C Q S T R R F R D Q I R L R F D Q P D D F K G V N V T M P A Q

561 P G T P P L S S T Q L Q I D P S L H E F Q L V D L S R R F L V H D S F W A L P E

Q F L G N K V D S Y G G S L R Y N V R Y E L A R G M L E P V Q R P D V V L M G A

641 G Y R L L S R G H T P T Q P G A L N Q R Q V Q F S E E H W V H E S G R P V Q R

A E L L Q V L Q S L E A V L I Q T V Y N T K M A S V G L S D I A M D T T V T H A T

721 S H G R A H S V E E C R C P I G Y S G L S C E S C D A H F T R V P G G P Y L G T

C S G C N C N G H A S S C D P V Y G H C L N C Q H N T E G P Q C N K C K A G F F

801 G D A M K A T A T S C R P C P C P Y I D A S R R F S D T C F L D T D G Q A T C

D A C A P G Y T G R R C E S C A P G Y E G N P I Q P G G K C R P V N Q E I V R C D

881 E R G S M G T S G E A C R C K N N V V G R L C N E C A D G S F H L S T R N P D

G C L K C F C M G V S R H C T S S S W S R A Q L H G A S E E P G H F S L T N A A S

961 T H T T N E G I F S P T P G E L G F S S F H R L L S G P Y F W S L P S R F L G D K

V T S Y G G E L R F T V T Q R S Q P G S T P L H G Q P L V V L Q G N N I I L E

1041 H H V A Q E P S P G Q P S T F I V P F R E Q A W Q R P D G Q P A T R E H L L M

A L A G I D T L L I R A S Y A Q Q P A E S R V S G I S M D V A V P E E T G Q D P A

1121 L E V E Q C S C P P G Y R G P S C Q D C D T G Y T R T P S G L Y L G T C E R C

S C H G H S E A C E P E T G A C Q G C Q H H T E G P R C E Q C Q P G Y Y G D A Q R

1201 G T P Q D C Q L C P C Y G D P A A G Q A A H T C F L D T D G H P T C D A C S

P G H S G R H C E R C A P G Y Y G N P S Q G Q P C Q R D S Q V P G P I G C N C D P

Q

1281 G S V S S Q C D A A G Q C Q C K A Q V E G L T C S H C R P H H F H L S A S N

P D G C L P C F C M G I T Q Q C A S S A Y T R H L I S T H F A P G D F Q G F A L V N

1361 P Q R N S R L T G E F T V E P V P E G A Q L S F G N F A Q L G H E S F Y W Q L

P E T Y Q G D K V A A Y G G K L R Y T L S Y T A G P Q G S P L S D P D V Q I T G N

1441 N I M L V A S Q P A L Q G P E R R S Y E I M F R E E F W R R P D G Q P A T R E

H L L M A L A D L D E L L I R A T F S S V P L A A S I S A V S L E V A Q P G P S N

1521 R P R A L E V E E C R C P P G Y I G L S C Q D C A P G Y T R T G S G L Y L G H

C E L C E C N G H S D L C H P E T G A C S Q C Q H N A A G E F C E L C A P G Y Y G

1601 D A T A G T P E D C Q P C A C P L T N P E N M F S R T C E S L G A G G Y R C T

A C E P G Y T G Q Y C E Q C G P G Y V G N P S V Q G G Q C L P E T N Q A P L V V E

1681 V H P A R S I V P Q G G S H S L R C Q V S G S P P H Y F Y W S R E D G R P V P

S G T Q Q R H Q G S E L H F P S V Q P S D A G V Y I C T C R N L H Q S N T S R A E

1761 L L V T E A P S K P I T V T V E E Q R S Q S V R P G A D V T F I C T A K S K S P

A Y T L V W T R L H N G K L P T R A M D F N G I L T I R N V Q L S D A G T Y V C

1841 T G S N M F A M D Q G T A T L H V Q A S G T L S A P V V S I H P P Q L T V Q P

G Q L A E F R C S A T G S P T P T L E W T G G P G G Q L P A K A Q I H G G I L R L

1921 P A V E P T D Q A Q Y L C R A H S S A G Q Q V A R A V L H V H G G G G P R V

Q V S P E R T Q V H A G R T V R L Y C R A A G V P S A T I T W R K E G G S L P P Q

A

2001 R S E R T D I A T L L I P A I T T A D A G F Y L C V A T S P A G T A Q A R I Q V

V V L S A S D A S P P P V K I E S S S P S V T E G Q T L D L N C V V A G S A H A

2081 Q V T W Y R R G G S L P P H T Q V H G S R L R L P Q V S P A D S G E Y V C R

V E N G S G P K E A S I T V S V L H G T H S G P S Y T P V P G S T R P I R I E P S S

2161 S H V A E G Q T L D L N C V V P G Q A H A Q V T W H K R G G S L P A R H Q T

H G S L L R L H Q V T P A D S G E Y V C H V V G T S G P L E A S V L V T I E A S V I

2241 P G P I P P V R I E S S S S T V A E G Q T L D L S C V V A G Q A H A Q V T W Y

K R G G S L P A R H Q V R G S R L Y I F Q A S P A D A G Q Y V C R A S N G M E A S

2321 I T V T V T G T Q G A N L A Y P A G S T Q P I R I E P S S S Q V A E G Q T L D L

N C V V P G Q S H A Q V T W H K R G G S L P V R H Q T H G S L L R L Y Q A S P A

2401 D S G E Y V C R V L G S S V P L E A S V L V T I E P A G S V P A L G V T P T V

R I E S S S S Q V A E G Q T L D L N C L V A G Q A H A Q V T W H K R G G S L P A R

2481 H Q V H G S R L R L L Q V T P A D S G E Y V C R V V G S S G T Q E A S V L V

T I Q Q R L S G S H S Q G V A Y P V R I E S S S A S L A N G H T L D L N C L V A S Q

2561 A P H T I T W Y K R G G S L P S R H Q I V G S R L R I P Q V T P A D S G E Y V

C H V S N G A G S R E T S L I V T I Q G S G S S H V P S V S P P I R I E S S S P T

2641 V V E G Q T L D L N C V V A R Q P Q A I I T W Y K R G G S L P S R H Q T H G S

H L R L H Q M S V A D S G E Y V C R A N N N I D A L E A S I V I S V S P S A G S P

2721 S A P G S S M P I R I E S S S S H V A E G E T L D L N C V V P G Q A H A Q V T

W H K R G G S L P S H H Q T R G S R L R L H H V S P A D S G E Y V C R V M G S S G

2801 P L E A S V L V T I E A S G S S A V H V P A P G G A P P I R I E P S S S R V A E

G Q T L D L K C V V P G Q A H A Q V T W H K R G G N L P A R H Q V H G P L L R L

2881 N Q V S P A D S G E Y S C Q V T G S S G T L E A S V L V T I E P S S P G P I P A

P G L A Q P I Y I E A S S S H V T E G Q T L D L N C V V P G Q A H A Q V T W Y K

2961 R G G S L P A R H Q T H G S Q L R L H L V S P A D S G E Y V C R A A S G P G P

E Q E A S F T V T V P P S E G S S Y R L R S P V I S I D P P S S T V Q Q G Q D A S

3041 F K C L I H D G A A P I S L E W K T R N Q E L E D N V H I S P N G S I I T I V G

T R P S N H G T Y R C V A S N A Y G V A Q S V V N L S V H G P P T V S V L P E G

3121 P V W V K V G K A V T L E C V S A G E P R S S A R W T R I S S T P A K L E Q R

T Y G L M D S H A V L Q I S S A K P S D A G T Y V C L A Q N A L G T A Q K Q V E V

3201 I V D T G A M A P G A P Q V Q A E E A E L T V E A G H T A T L R C S A T G S P

A P T I H W S K L R S P L P W Q H R L E G D T L I I P R V A Q Q D S G Q Y I C N A

3281 T S P A G H A E A T I I L H V E S P P Y A T T V P E H A S V Q A G E T V Q L Q

C L A H G T P P L T F Q W S R V G S S L P G R A T A R N E L L H F E R A A P E D S

3361 G R Y R C R V T N K V G S A E A F A Q L L V Q G P P G S L P A T S I P A G S T

P T V Q V T P Q L E T K S I G A S V E F H C A V P S D R G T Q L R W F K E G G Q L

3441 P P G H S V Q D G V L R I Q N L D Q S C Q G T Y I C Q A H G P W G K A Q A S

A Q L V I Q A L P S V L I N I R T S V Q T V V V G H A V E F E C L A L G D P K P Q V

3521 T W S K V G G H L R P G I V Q S G G V V R I A H V E L A D A G Q Y R C T A T

N A A G T T Q S H V L L L V Q A L P Q I S M P Q E V R V P A G S A A V F P C I A S G

3601 Y P T P D I S W S K L D G S L P P D S R L E N N M L M L P S V R P Q D A G T Y

V C T A T N R Q G K V K A F A H L Q V P E R V V P Y F T Q T P Y S F L P L P T I K

3681 D A Y R K F E I K I T F R P D S A D G M L L Y N G Q K R V P G S P T N L A N R

Q P D F I S F G L V G G R P E F R F D A G S G M A T I R H P T P L A L G H F H T V

3761 T L L R S L T Q G S L I V G D L A P V N G T S Q G K F Q G L D L N E E L Y L G

G Y P D Y G A I P K A G L S S G F I G C V R E L R I Q G E E I V F H D L N L T A H

3841 G I S H C P T C R D R P C Q N G G Q C H D S E S S S Y V C V C P A G F T G S R

C E H S Q A L H C H P E A C G P D A T C V N R P D G R G Y T C R C H L G R S G L R

3921 C E E G V T V T T P S L S G A G S Y L A L P A L T N T H H E L R L D V E F K P

L A P D G V L L F S G G K S G P V E D F V S L A M V G G H L E F R Y E L G S G L A

4001 V L R S A E P L A L G R W H R V S A E R L N K D G S L R V N G G R P V L R S

S P G K S Q G L N L H T L L Y L G G V E P S V P L S P A T N M S A H F R G C V G E

V

4081 S V N G K R L D L T Y S F L G S Q G I G Q C Y D S S P C E R Q P C Q H G A T C

M P A G E Y E F Q C L C R D G F K G D L C E H E E N P C Q L R E P C L H G G T C Q

4161 G T R C L C L P G F S G P R C Q Q G S G H G I A E S D W H L E G S G G N D A P

G Q Y G A Y F H D D G F L A F P G H V F S R S L P E V P E T I E L E V R T S T A S

4241 G L L L W Q G V E V G E A G Q G K D F I S L G L Q D G H L V F R Y Q L G S G

E A R L V S E D P I N D G E W H R V T A L R E G R R G S I Q V D G E E L V S G R S P

4321 G P N V A V N A K G S V Y I G G A P D V A T L T G G R F S S G I T G C V K N L

V L H S A R P G A P P P Q P L D L Q H R A Q A G A N T R P C P S

5.18 clusterin isoform 1 [Homo sapiens]
Protein Accession gi|42716297

Mean Expression Ratio 0.62

Median Expression Ratio 0.619

Credible Interval (0.484, 0.788)

Associated Peptides 9

Associated Spectra 12

Coverage 0.194


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.42	0.59	0.82	SEQ ID NO: 231	ASSIIDELFQDR
1	0.45	0.63	0.89	SEQ ID NO: 232	ASSIIDELFQDRF
1	0.44	0.62	0.87	SEQ ID NO: 233	EILSVDCSTNNPSQAK
1	0.45	0.63	0.9	SEQ ID NO: 234	ELDESLQVAER
3	0.42	0.57	0.77	SEQ ID NO: 235	LFDSDPITVTVPVEVSR
1	0.44	0.63	0.89	SEQ ID NO: 236	MLDVMQDHF
1	0.44	0.63	0.89	SEQ ID NO: 237	PITVTVPVEVSR
1	0.44	0.62	0.88	SEQ ID NO: 238	VTTVASHTSDSDVPSGVTEVVVK
1	0.43	0.6	0.85	SEQ ID NO: 239	RPHFFFPK

SEQ ID NO: 240

1 M Q V C S Q P Q R G C V R E Q S A I N T A P P S A H N A A S P G G A R G H R V P

L T E A C K D S R I G G M M K T L L L F V G L L L T W E S G Q V L G D Q T V S D

81 N E L Q E M S N Q G S K Y V N K E I Q N A V N G V K Q I K T L I E K T N E E R K

T L L S N L E E A K K K K E D A L N E T R E S E T K L K E L P G V C N E T M M A

161 L W E E C K P C L K Q T C M K F Y A R V C R S G S G L V G R Q L E E F L N Q S

S P F Y F W M N G D R I D S L L E N D R Q Q T H M L D V M Q D H F S R A S S I I D

241 E L F Q D R F F T R E P Q D T Y H Y L P F S L P H R R P H F F F P K S R I V R S L

M P F S P Y E P L N F H A M F Q P F L E M I H E A Q Q A M D I H F H S P A F Q

321 H P P T E F I R E G D D D R T V C R E I R H N S T G C L R M K D Q C D K C R E I

L S V D C S T N N P S Q A K L R R E L D E S L Q V A E R L T R K Y N E L L K S Y

401 Q W K M L N T S S L L E Q L N E Q F N W V S R L A N L T Q G E D Q Y Y L R V

T T V A S H T S D S D V P S G V T E V V V K L F D S D P I T V T V P V E V S R K N P

481 K F M E T V A E K A L Q E Y R K K H R E E

5.19 ezrin [Homo sapiens]; ezrin [Homo sapiens]
Protein Accession gi|21614499 gi|161702986

Mean Expression Ratio 1.62

Median Expression Ratio 1.61

Credible Interval (1.23, 2.13)

Associated Peptides 7

Associated Spectra 8

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

2	1.2	1.7	2.5	SEQ ID NO: 241	FYPEDVAEELIQDITQK

1	1.1	1.6	2.3	SEQ ID NO: 242	KEDEVEEWQHR

1	1.1	1.6	2.4	SEQ ID NO: 243	QLLTLSSELSQAR

1	1.1	1.6	2.4	SEQ ID NO: 244	QQLETEK

1	1.2	1.7	2.4	SEQ ID NO: 245	GFPTWLK

1	1.1	1.6	2.3	SEQ ID NO: 246	IAQDLEMYGINYFEIK

1	1.1	1.6	2.3	SEQ ID NO: 247	ILQLCMGNHELYMR

5.20 delta globin [Homo sapiens]
Protein Accession gi|4504351

Mean Expression Ratio 1.60

Median Expression Ratio 1.60

Credible Interval (1.12, 2.29)

Associated Peptides 3

Associated Spectra 4

Coverage 0.306


A	2.5	50	97.5	Sequence ID No.	Sequence

2	1.2	1.7	2.6	SEQ ID NO: 248	F F E S F G D L S S P D A V M G N P K
1	1.1	1.6	2.5	SEQ ID NO: 249	V N V D A V G G E A L G R
1	1.1	1.6	2.5	SEQ ID NO: 250	G T F S Q L S E L H C D K

SEQ ID NO: 251

1 M V H L T P E E K T A V N A L W G K V N V D A V G G E A L G R L L V V Y P W T

Q R F F E S F G D L S S P D A V M G N P K V K A H G K K V L G A F S D G L A H L D

81 N L K G T F S Q L S E L H C D K L H V D P E N F R L L G N V L V C V L A R N F G

K E F T P Q M Q A A Y Q K V V A G V A N A L A H K Y H

5.21 fibrinogen, beta chain preproprotein [Homo sapiens]
Protein Accession gi|70906435

Mean Expression Ratio 0.633

Median Expression Ratio 0.633

Credible Interval (0.527, 0.76)

Associated Peptides 14

Associated Spectra 27

Coverage 0.291


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.49	0.66	0.87	SEQ ID NO: 252	AHYGGFTVQNEANK
1	0.46	0.62	0.85	SEQ ID NO: 253	DNENVVNEYSSELEK
1	0.5	0.68	0.92	SEQ ID NO: 254	ETVNSNIPTNLR
1	0.47	0.64	0.88	SEQ ID NO: 255	GGETSEMYLIQPDSSVKPYR
7	0.47	0.59	0.75	SEQ ID NO: 256	HQLYIDETVNSNIPTNLR
1	0.47	0.65	0.9	SEQ ID NO: 257	IDETVNSNIPTNLR
2	0.45	0.6	0.8	SEQ ID NO: 258	LIQPDSSVKPYR
2	0.44	0.59	0.8	SEQ ID NO: 259	MGPTELLIEMEDWK
1	0.45	0.62	0.85	SEQ ID NO: 260	NYCGLPGEYWLGNDK
1	0.45	0.62	0.86	SEQ ID NO: 261	QGFGNVATNTDGK
1	0.46	0.63	0.87	SEQ ID NO: 262	YIDETVNSNIPTNLR
4	0.45	0.6	0.78	SEQ ID NO: 263	QGVNDNEEGFFSAR
1	0.47	0.65	0.9	SEQ ID NO: 264	LESDVSAQMEYCR
1	0.46	0.64	0.88	SEQ ID NO: 265	SILENLR

SEQ ID NO: 266

1 M K R M V S W S F H K L K T M K H L L L L L L C V F L V K S Q G V N D N E E G

F F S A R G H R P L D K K R E E A P S L R P A P P P I S G G G Y R A R P A K A A A

81 T Q K K V E R K A P D A G G C L H A D P D L G V L C P T G C Q L Q E A L L Q Q

E R P I R N S V D E L N N N V E A V S Q T S S S S F Q Y M Y L L K D L W Q K R Q K

161 Q V K D N E N V V N E Y S S E L E K H Q L Y I D E T V N S N I P T N L R V L R S

I L E N L R S K I Q K L E S D V S A Q M E Y C R T P C T V S C N I P V V S G K E

241 C E E I I R K G G E T S E M Y L I Q P D S S V K P Y R V Y C D M N T E N G G W

T V I Q N R Q D G S V D F G R K W D P Y K Q G F G N V A T N T D G K N Y C G L P

G

321 E Y W L G N D K I S Q L T R M G P T E L L I E M E D W K G D K V K A H Y G G

F T V Q N E A N K Y Q I S V N K Y R G T A G N A L M D G A S Q L M G E N R T M T

I H

401 N G M F F S T Y D R D N D G W L T S D P R K Q C S K E D G G G W W Y N R C H

A A N P N G R Y Y W G G Q Y T W D M A K H G T D D G V V W M N W K G S W Y S

M R K M

481 S M K I R P F F P Q Q

5.22 moesin [Homo sapiens]
Protein Accession gi|4505257

Mean Expression Ratio 1.57

Median Expression Ratio 1.57

Credible Interval (1.18, 2.08)

Associated Peptides 5

Associated Spectra 9


A	2.5	50	97.5	Sequence ID No.	Sequence

4	1.3	1.8	2.4	SEQ ID NO: 267	FYPEDVSEELIQDITQR
2	1.1	1.5	2.2	SEQ ID NO: 268	GSELWLGVDALGLNIYEQNDR
1	1.1	1.6	2.3	SEQ ID NO: 269	TQEQLALEMAELTAR
1	1.1	1.6	2.3	SEQ ID NO: 270	ERQEAEEAK
1	1.1	1.6	2.3	SEQ ID NO: 271	KTQEQLALEMAELTAR

SEQ ID NO: 272

1 M P K T I S V R V T T M D A E L E F A I Q P N T T G K Q L F D Q V V K T I G L R E

V W F F G L Q Y Q D T K G F S T W L K L N K K V T A Q D V R K E S P L L F K F

81 R A K F Y P E D V S E E L I Q D I T Q R L F F L Q V K E G I L N D D I Y C P P E T

A V L L A S Y A V Q S K Y G D F N K E V H K S G Y L A G D K L L P Q R V L E Q

161 H K L N K D Q W E E R I Q V W H E E H R G M L R E D A V L E Y L K I A Q D L

E M Y G V N Y F S I K N K K G S E L W L G V D A L G L N I Y E Q N D R L T P K I G

F

241 P W S E I R N I S F N D K K F V I K P I D K K A P D F V F Y A P R L R I N K R I L

A L C M G N H E L Y M R R R K P D T I E V Q Q M K A Q A R E E K H Q K Q M E R

321 A M L E N E K K K R E M A E K E K E K I E R E K E E L M E R L K Q I E E Q T K

K A Q Q E L E E Q T R R A L E L E Q E R K R A Q S E A E K L A K E R Q E A E E A K

401 E A L L Q A S R D Q K K T Q E Q L A L E M A E L T A R I S Q L E M A R Q K K E

S E A V E W Q Q K A Q M V Q E D L E K T R A E L K T A M S T P H V A E P A E N E

Q

481 D E Q D E N G A E A S A D L R A D A M A K D R S E E E R T T E A E K N E R V

Q K H L K A L T S E L A N A R D E S K K T A N D M I H A E N M R L G R D K Y K T

L R

561 Q I R Q G N T K Q R I D E F E S M

5.23 transferrin [Homo sapiens]
Protein Accession gi|4557871

Mean Expression Ratio 0.648

Median Expression Ratio 0.648

Credible Interval (0.535, 0.786)

Associated Peptides 12

Associated Spectra 22

Coverage 0.216


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.46	0.64	0.88	SEQ ID NO: 273	CSTSSLLEACTFR
1	0.46	0.63	0.88	SEQ ID NO: 274	DCHLAQVPSHTVVAR
3	0.47	0.62	0.83	SEQ ID NO: 275	EDLIWELLNQAQEHFGK
2	0.45	0.61	0.83	SEQ ID NO: 276	EGTCPEAPTDECKPVK
3	0.53	0.7	0.93	SEQ ID NO: 277	HQTVPQNTGGK
2	0.47	0.63	0.85	SEQ ID NO: 278	HSTIFENLANK
3	0.48	0.64	0.86	SEQ ID NO: 279	KPVEEYANCHLAR
1	0.47	0.64	0.9	SEQ ID NO: 280	MYLGYEYVTAIR
1	0.48	0.66	0.9	SEQ ID NO: 281	NIPIGLLYCDLPEPR
2	0.47	0.64	0.87	SEQ ID NO: 282	NLNEKDYELLCLDGTR
2	0.47	0.63	0.86	SEQ ID NO: 283	SAGWNIPIGLLYCDLPEPR
1	0.48	0.66	0.91	SEQ ID NO: 284	YLGEEYVK

SEQUENCE ID NO: 285

1 M R L A V G A L L V C A V L G L C L A V P D K T V R W C A V S E H E A T K C Q

S F R D H M K S V I P S D G P S V A C V K K A S Y L D C I R A I A A N E A D A V T

81 L D A G L V Y D A Y L A P N N L K P V V A E F Y G S K E D P Q T F Y Y A V A V

V K K D S G F Q M N Q L R G K K S C H T G L G R S A G W N I P I G L L Y C D L P E

161 P R K P L E K A V A N F F S G S C A P C A D G T D F P Q L C Q L C P G C G C S T

L N Q Y F G Y S G A F K C L K D G A G D V A F V K H S T I F E N L A N K A D R D

241 Q Y E L L C L D N T R K P V D E Y K D C H L A Q V P S H T V V A R S M G G K

E D L I W E L L N Q A Q E H F G K D K S K E F Q L F S S P H G K D L L F K D S A H

G

321 F L K V P P R M D A K M Y L G Y E Y V T A I R N L R E G T C P E A P T D E C K

P V K W C A L S H H E R L K C D E W S V N S V G K I E C V S A E T T E D C I A K I

401 M N G E A D A M S L D G G F V Y I A G K C G L V P V L A E N Y N K S D N C E

D T P E A G Y F A V A V V K K S A S D L T W D N L K G K K S C H T A V G R T A G

W N G L N L C E P N N K E G Y Y G Y T G A F R C L V E K G D V A F V K H Q T V P

Q N

561 T G G K N P D P W A K N L N E K D Y E L L C L D G T R K P V E E Y A N C H L

A R A P N H A V V T R K D K E A C V H K I L R Q Q Q H L F G S N V T D C S G N F C

L

641 F R S E T K D L L F R D D T V C L A K L H D R N T Y E K Y L G E E Y V K A V G

N L R K C S T S S L L E A C T F R R P

5.24 secreted phosphoprotein 1 isoform c [Homo sapiens]; secreted phosphoprotein 1 isoform a [Homo sapiens]; secreted phosphoprotein 1 isoform b [Homo sapiens]
Protein Accession gi|91598939 gi|91206462 gi|4759166

Mean Expression Ratio 1.53

Median Expression Ratio 1.52

Credible Interval (1.10, 2.13)

Associated Peptides 4

Associated Spectra 5

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

2	1	1.5	2.1	SEQ ID NO: 286	AIPVAQDLNAPSDWDSR

1	1.1	1.7	2.5	SEQ ID NO: 287	GKDSYETSQLDDQSAETHSHK

1	1.0	1.5	2.3	SEQ ID NO: 288	KANDESNEHSDVIDSQELSK

1	1.1	1.6	2.4	SEQ ID NO: 289	SKEEDK

5.25 pancreatic amylase alpha 2A precursor [Homo sapiens]
Protein Accession gi|4502085

Mean Expression Ratio 0.664

Median Expression Ratio 0.664

Credible Interval (0.527, 0.841)

Associated Peptides 8

Associated Spectra 14

Coverage 0.213


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.46	0.63	0.86	SEQ ID NO: 290	ALVFVDNHDNQR
1	0.49	0.69	0.97	SEQ ID NO: 291	EVTINPDTTCGNDWVCEHR
5	0.48	0.64	0.84	SEQ ID NO: 292	IAEYMNHLIDIGVAGFR
1	0.47	0.66	0.95	SEQ ID NO: 293	LTGLLDLALEK
2	0.46	0.64	0.89	SEQ ID NO: 294	LTGLLDLALEKDYVR
1	0.48	0.68	0.95	SEQ ID NO: 295	NVVDGQPFTNWYDNGSNQVAFGR
1	0.47	0.66	0.93	SEQ ID NO: 296	NWGEGWGFVPSDR
1	0.46	0.66	0.93	SEQ ID NO: 297	WVDIALECER

SEQ ID NO: 298

1 M K F F L L L F T I G F C W A Q Y S P N T Q Q G R T S I V H L F E W R W V D I A L

E C E R Y L A P K G F G G V Q V S P P N E N V A I Y N P F R P W W E R Y Q P V

81 S Y K L C T R S G N E D E F R N M V T R C N N V G V R I Y V D A V I N H M C G

N A V S A G T S S T C G S Y F N P G S R D F P A V P Y S G W D F N D G K C K T G S

161 G D I E N Y N D A T Q V R D C R L T G L L D L A L E K D Y V R S K I A E Y M N

H L I D I G V A G F R L D A S K H M W P G D I K A I L D K L H N L N S N W F P A G

241 S K P F I Y Q E V I D L G G E P I K S S D Y F G N G R V T E F K Y G A K L G T V

I R K W N G E K M S Y L K N W G E G W G F V P S D R A L V F V D N H D N Q R G

H

321 G A G G A S I L T F W D A R L Y K M A V G F M L A H P Y G F T R V M S S Y R

W P R Q F Q N G N D V N D W V G P P N N N G V I K E V T I N P D T T C G N D W V

C E

401 H R W R Q I R N M V I F R N V V D G Q P F T N W Y D N G S N Q V A F G R G N

R G F I V F N N D D W S F S L T L Q T G L P A G T Y C D V I S G D K I N G N C T G I

481 K I Y V S D D G K A H F S I S N S A E D P F I A I H A E S K L

5.26 annexin A2 isoform 1 [Homo sapiens]
Protein Accession gi|50845388

Mean Expression Ratio 1.50

Median Expression Ratio 1.5

Credible Interval (1.07, 2.11)

Associated Peptides 3

Associated Spectra 5

Coverage 0.129


A	2.5	50	97.5	Sequence ID No.	Sequence

2	1.1	1.6	2.4	SEQ ID NO: 299	GLGTDEDSLIEIICSR

2	1.0	1.5	2.2	SEQ ID NO: 300	RAEDGSVIDYELIDQDAR

1	1.0	1.5	2.4	SEQ ID NO: 301	SYSPYDMLESIR

SEQ ID NO: 302

1	MGRQLAGCGDAGKKASFKMSTVHEILCKLSLEGDHSTPPS
	AYGSVKAYTNFDAERDALNIETAIKTKGVDEVTIVNILTN

5.27 complement component 4 binding protein, alpha chain precursor [Homo sapiens]
Protein Accession gi|4502503

Mean Expression Ratio 0.673

Median Expression Ratio 0.675

Credible Interval (0.48, 0.94)

Associated Peptides 5

Associated Spectra 5

Coverage 0.104


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.44	0.66	0.99	SEQ ID NO: 303	EDVYVVGTVLR

1	0.42	0.64	0.95	SEQ ID NO: 304	LSLEIEQLELQR

1	0.45	0.68	1.0	SEQ ID NO: 305	FSAICQGDGTWSPR

1	0.44	0.67	1	SEQ ID NO: 306	YTCLPGYVR

1	0.44	0.66	1	SEQ ID NO: 307	CEWETPEGCEQVLTGK

SEQUENCE ID NO: 308

1	MHPPKTPSGALHRKRKMAAWPFSRLWKVSDPILFQMTLIA
	ALLPAVLGNCGPPPTLSFAAPMDITLTETRFKTGTTLKYT

81	CLPGYVRSHSTQTLTCNSDGEWVYNTFCIYKRCRHPGELR
	NGQVEIKTDLSFGSQIEFSCSEGFFLIGSTTSRCEVQDRG

161	VGWSHPLPQCEIVKCKPPPDIRNGRHSGEENFYAYGFSVT
	YSCDPRFSLLGHASISCTVENETIGVWRPSPPTCEKITCR

241	KPDVSHGEMVSGFGPIYNYKDTIVFKCQKGFVLRGSSVIH
	CDADSKWNPSPPACEPNSCINLPDIPHASWETYPRPTKED

321	VYVVGTVLRYRCHPGYKPTTDEPTTVICQKNLRWTPYQG
	CEALCCPEPKLNNGEITQHRKSRPANHCVYFYGDEISFSCH

401	ET5RFSAICQGDGTWSPRTPSCGDICNFPPKIAHGHYKQS
	SSYSFFKEEIIYECDKGYILVGQAKLSCSYSHWSAPAPQC

5.28 albumin preproprotein [Homo sapiens]
Protein Accession gi|4502027

Mean Expression Ratio 0.681

Median Expression Ratio 0.681

Credible Interval (0.626, 0.74)

Associated Peptides 65

Associated Spectra 259

Coverage 0.744


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.49	0.64	0.86	SEQ ID NO: 309	AAFTECCQAADK

5	0.46	0.58	0.74	SEQ ID NO: 310	ADDKETCFAEEGK

1	0.49	0.64	0.85	SEQ ID NO: 311	ADDKETCFAEEGKK

3	0.55	0.7	0.9	SEQ ID NO: 312	AEFAEVSK

10	0.56	0.68	0.83	SEQ ID NO: 313	ALVLIAFAQYLQQCPFEDHVK

1	0.52	0.69	0.9	SEQ ID NO: 314	AQYLQQCPFEDHVK

9	0.51	0.63	0.77	SEQ ID NO: 315	AVMDDFAAFVEK

1	0.5	0.66	0.87	SEQ ID NO: 316	CCTESLVNR

5	0.62	0.78	0.99	SEQ ID NO: 317	CIAEVENDEMPADLPSLAADFVESK

7	0.61	0.76	0.94	SEQ ID NO: 318	CTAFHDNEETFLK

1	0.5	0.66	0.87	SEQ ID NO: 319	DDNPNLPR

2	0.52	0.69	0.9	SEQ ID NO: 320	DLGEENFK

2	0.48	0.63	0.82	SEQ ID NO: 321	ECCEKPLLEK

2	0.56	0.74	0.96	SEQ ID NO: 322	ETCFAEEGK

2	0.5	0.65	0.85	SEQ ID NO: 323	ETCFAEEGKK

1	0.51	0.68	0.89	SEQ ID NO: 324	ETYGEMADCCAK

4	0.49	0.63	0.8	SEQ ID NO: 325	FKDLGEENFK

3	0.49	0.64	0.82	SEQ ID NO: 326	FQNALLVR

1	0.52	0.69	0.9	SEQ ID NO: 327	FSALEVDETYVPK

1	0.53	0.7	0.92	SEQ ID NO: 328	FYAPELLFFAK

1	0.54	0.72	0.96	SEQ ID NO: 329	HDNEETFLK

2	0.53	0.7	0.91	SEQ ID NO: 330	HPDYSVVLLLR

1	0.55	0.72	0.95	SEQ ID NO: 331	IAEVENDEMPADLPSLAADFVESK

4	0.54	0.68	0.87	SEQ ID NO: 332	KQTALVELVK

15	0.55	0.65	0.79	SEQ ID NO: 333	KVPQVSTPTLVEVSR

2	0.5	0.65	0.85	SEQ ID NO: 334	KYLYEIAR

2	0.51	0.67	0.87	SEQ ID NO: 335	LCTVATLR

3	0.52	0.66	0.86	SEQ ID NO: 336	LDELRDEGK

1	0.48	0.64	0.85	SEQ ID NO: 337	LKECCEKPLLEK

4	0.52	0.67	0.85	SEQ ID NO: 338	LVNEVTEFAK

7	0.52	0.64	0.8	SEQ ID NO: 339	LVRPEVDVMCTAFHDNEETFLK

2	0.54	0.7	0.9	SEQ ID NO: 340	LVTDLTK

3	0.51	0.66	0.86	SEQ ID NO: 341	MPCAEDYLSVVLNQLCVLHEK

7	0.6	0.74	0.92	SEQ ID NO: 342	NECFLQHK

1	0.54	0.7	0.93	SEQ ID NO: 343	PLVEEPQNLIK

4	0.51	0.65	0.83	SEQ ID NO: 344	QEPERNECFLQHK

2	0.53	0.7	0.91	SEQ ID NO: 345	QLCVLHEK

2	0.54	0.7	0.91	SEQ ID NO: 346	QTALVELVK

4	0.49	0.63	0.8	SEQ ID NO: 347	RPCFSALEVDETYVPK

1	0.52	0.69	0.91	SEQ ID NO: 348	SALEVDETYVPK

18	0.5	0.59	0.7	SEQ ID NO: 349	SHCIAEVENDEMPADLPSLAADFVESK

23	0.64	0.75	0.88	SEQ ID NO: 350	SLHTLFGDK

1	0.52	0.69	0.9	SEQ ID NO: 351	TAFHDNEETFLK

2	0.52	0.69	0.9	SEQ ID NO: 352	TCVADESAENCDK

2	0.52	0.68	0.9	SEQ ID NO: 353	TFHADICTLSEK

1	0.53	0.7	0.93	SEQ ID NO: 354	VFDEFKPL

1	0.51	0.68	0.9	SEQ ID NO: 355	VFDEFKPLVEEPQNL

46	0.59	0.67	0.75	SEQ ID NO: 356	VFDEFKPLVEEPQNLIK

4	0.52	0.67	0.86	SEQ ID NO: 357	VHTECCHGDLLECADDR

4	0.57	0.72	0.93	SEQ ID NO: 358	VPQVSTPTLVEVSR

1	0.52	0.7	0.93	SEQ ID NO: 359	VSTPTLVEVSR

1	0.52	0.69	0.91	SEQ ID NO: 360	YLYEIAR

1	0.52	0.69	0.91	SEQ ID NO: 361	YTKKVPQVSTPTLVEVSR

9	0.62	0.76	0.94	SEQ ID NO: 362	DVFLGMFLYEYAR

2	0.51	0.67	0.87	SEQ ID NO: 363	QNCELFEQLGEYK

2	0.54	0.71	0.92	SEQ ID NO: 364	YICENQDSISSK

1	0.52	0.68	0.91	SEQ ID NO: 365	CASLQK

1	0.51	0.68	0.9	SEQ ID NO: 366	KLVAASQAALGL

1	0.51	0.67	0.89	SEQ ID NO: 367	LQQCPFEDHVK

3	0.52	0.67	0.86	SEQ ID NO: 368	FYAPELLFFAKR

1	0.52	0.7	0.92	SEQ ID NO: 369	AACLLPKLDELR

1	0.53	0.7	0.92	SEQ ID NO: 370	VFDEFK

1	0.51	0.67	0.9	SEQ ID NO: 371	RHPDYSVVLLLR

1	0.51	0.68	0.9	SEQ ID NO: 372	RHPYFYAPELLFFAK

1	0.52	0.69	0.91	SEQ ID NO: 373	AACLLPK

SEQ ID NO: 374

1	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEE
	NFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVAD

81	ESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQE
	PERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLK

161	KYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKA
	ACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV

241	ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECAD
	DRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVEND

321	EMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEY
	ARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFD
	E

401	FKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVP
	QVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV

481	LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDET
	YVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHK

561	PKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKK
	LVAASQAALGL

5.29 epidermal growth factor receptor pathway substrate 8 [Homo sapiens]
Protein Accession gi|56682953

Mean Expression Ratio 1.46

Median Expression Ratio 1.46

Credible Interval (1.13, 1.86)

Associated Peptides 9

Associated Spectra 11

Coverage 0.153


A	2.5	50	97.5	Sequence ID No.	Sequence

1	1.1	1.6	2.3	SEQ ID NO: 376	APAPAPPGTVTQVDVR

1	1.1	1.5	2.1	SEQ ID NO: 377	EQFIPPYVPR

2	1.1	1.5	2.0	SEQ ID NO: 378	ISAAASDSGVESFDEGSSH

1	1.0	1.5	2.1	SEQ ID NO: 379	NILDIVRPPESGLGR

1	1.0	1.4	2.0	SEQ ID NO: 380	SQMEEVQDELIHR

1	1	1.4	2.0	SEQ ID NO: 381	VWTQDMILQVDDR

1	1	1.4	2	SEQ ID NO: 382	DDILEILDDR

2	1.0	1.4	2.0	SEQ ID NO: 383	MISNADPSIPPPPR

1	1.0	1.5	2.0	SEQ ID NO: 384	ANLISEDIESAISDSK

SEQ ID NO: 385

1	MNGHISNHPSSFGMYPSQMNGYGSSPTFSQTDREHGSKTS
	AKALYEQRKNYARDSVSSVSDISQYRVEHLTTFVLDRKDA

81	MITVDDGIRKLKLLDAKGKVWTQDMILQVDDRAVSLIDLE
	SKNELENFPLNTIQHCQAVMHSCSYDSVLALVCKEPTQNK

161	PDLHLFQCDEVKANLISEDIESAISDSKGGKQKRRPDALR
	MISNADPSIPPPPRAPAPAPPGTVTQVDVRSRVAAWSAWA

241	ADQGDFEKPRQYHEQEETPEMMAARIDRDVQILNHILDDI
	EFFITKLQKAAEAFSELSKRKKNKKGKRKGPGEGVLTLRA

321	KPPPPDEFLDCFQKFKHGFNLLAKLKSHIQNPSAADLVHF
	LFTPLNMVVQATGGPELASSVLSPLLNKDTIDFLNYTVNG

401	DERQLWMSLGGTWMKARAEWPKEQFIPPYVPRFRNGWE
	PPMLNFMGATMEQDLYQLAESVANVAEHQRKQEIKRLSTEH
	S

481	SVSEYHPADGYAFSSNIYTRGSHLDQGEAAVAFKPTSNR
	HIDRNYEPLKTQPKKYAKSKYDFVARNNSELSVLKDDILEI

561	LDDRKQWWKVRNASGDSGFVPNNILDIVRPPESGLGRAD
	PPYTHTIQKQRMEYGPRPADTPPAPSPPPTPAPVPVPLPPS

641	TPAPVPVSKVPANITRQNSSSSDSGGSIVRDSQRHKQLPV
	DRRKSQMEEVQDELIHRLTIGRSAAQKKFHVPRQNVPVIN

721	ITYD5TPEDVKTWLQSKGFNPVTVNSLGVLNGAQLFSLN
	KDELRTVCPEGARVYSQITVQKAALEDSSGSSELQEIMRRR

801	QEKISAAASDSGVESFDEGSSH

5.30 apolipoprotein B precursor [Homo sapiens]
Protein Accession gi|105990532

Mean Expression Ratio 0.688

Median Expression Ratio 0.688

Credible Interval (0.585, 0.815)

Associated Peptides 27

Associated Spectra 30

Coverage 0.073


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.5	0.68	0.92	SEQ ID NO: 386	AHLDIAGSLEGHLR

1	0.48	0.65	0.88	SEQ ID NO: 387	ATFQTPDFIVPLTDLR

1	0.47	0.65	0.88	SEQ ID NO: 388	DKDQEVLLQTFLDDASPGDKR

1	0.5	0.69	0.93	SEQ ID NO: 389	ELPVLHVPR

1	0.51	0.7	0.95	SEQ ID NO: 390	FLDMLIK

1	0.52	0.7	0.96	SEQ ID NO: 391	HSITNPLAVLCEFISQSIK

2	0.5	0.68	0.9	SEQ ID NO: 392	ILGEELGFASLHDLQLLGK

1	0.5	0.69	0.94	SEQ ID NO: 393	LELELRPTGEIEQY

1	0.52	0.7	0.96	SEQ ID NO: 394	LHVAGNLK

1	0.51	0.69	0.94	SEQ ID NO: 395	LIDVISMYR

1	0.49	0.67	0.92	SEQ ID NO: 396	LVALIPEPSAQQLR

2	0.51	0.67	0.9	SEQ ID NO: 397	NMGLPDFHIPENLFLK

1	0.51	0.69	0.94	SEQ ID NO: 398	QSMTLSSEVQIPDFDVDLGTILR

1	0.5	0.68	0.93	SEQ ID NO: 399	QTIIVVLENVQR

1	0.49	0.67	0.9	SEQ ID NO: 400	SSEVQIPDFDVDLGTILR

1	0.5	0.68	0.92	SEQ ID NO: 401	TEVIPPLIENR

1	0.51	0.69	0.95	SEQ ID NO: 402	TLQGIPQMIGEVIR

1	0.52	0.7	0.96	SEQ ID NO: 403	TLSSEVQIPDFDVDLGTILR

1	0.49	0.67	0.92	SEQ ID NO: 404	TQFNNNEYSQDLDAYNTK

2	0.53	0.72	0.95	SEQ ID NO: 405	VAWHYDEEK

1	0.49	0.68	0.92	SEQ ID NO: 406	YTYNYEAESSSGVPGTADSR

1	0.51	0.7	0.95	SEQ ID NO: 407	QSFDLSVK

1	0.51	0.69	0.94	SEQ ID NO: 408	VTNMGIIIPDFAR

1	0.51	0.7	0.95	SEQ ID NO: 409	HIQNIDIQHLAGK

1	0.53	0.72	0.99	SEQ ID NO: 410	VLLDQLGTTISFER

1	0.52	0.71	0.97	SEQ ID NO: 411	LALWGEHTGQLY

1	0.51	0.68	0.94	SEQ ID NO: 412	MGIIIPDFAR

SEQ ID NO: 413

1	MDPPRPALLALLALPALLLLLLAGARAEEEMLENVSLVCP
	KDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKV

81	ELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEE
	FAAAMSRYELKLAIPEGKQVFLYPEKDEPTYILNIKRGI

161	ISALLVPPETEEAKQVLFLDTVYGNCSTHFTVKTRKGNVA
	TEISTERDLGQCDRFKPIRTGISPLALIKGMTRPLSTLIS

241	SSQSCQYTLDAKRKHVAEAICKEQHLFLPFSYKNKYGMV
	AQVTQTLKLEDTPKINSRFFGEGTKKMGLAFESTKSTSPPK

321	QAEAVLKTLQELKKLTISEQNIQRANLFNKLVTELRGLSD
	EAVTSLLPQLIEVSSPITLQALVQCGQPQCSTHILQWLKR

401	VHANPLLIDVVTYLVALIPEPSAQQLREIFNMARDQRSRA
	TLYALSHAVNNYHKTNPTGTQELLDIANYLMEQIQDDCTG

481	DEDYTYLILRVIGNMGQTMEQLTPELKSSILKCVQSTKPS
	LMIQKAAIQALRKMEPKDKDQEVLLQTFLDDASPGDKRLA

561	AYLMLMRSPSQADINKIVQILPWEQNEQVKNFVASHIANI
	LNSEELDIQDLKKLVKEALKESQLPTVMDFRKFSRNYQLY

641	KSVSLPSLDPASAKIEGNLIFDPNNYLPKESMLKTTLTAF
	GFASADLIEIGLEGKGFEPTLEALFGKQGFFPDSVNKALY

721	WVNGQVPDGVSKVLVDHFGYTKDDKHEQDMVNGIMLSV
	EKLIKDLKSKEVPEARAYLRILGEELGFASLHDLQLLGKLLL

801	MGARTLQGIPQMIGEVIRKGSKNDFFLHYIFMENAFELPT
	GAGLQLQISSSGVIAPGAKAGVKLEVANMQAELVAKPSVS

881	VEFVTNMGIIIPDFARSGVQMNTNFFHESGLEAHVALKAG
	KLKFIIPSPKRPVKLLSGGNTLHLVSTTKTEVIPPLIENR

961	QSWSVCKQVFPGLNYCTSGAYSNASSTDSASYYPLTGDT
	RLELELRPTGEIEQYSVSATYELQREDRALVDTLKFVTQAE

1041	GAKQTEATMTFKYNRQSMTLSSEVQIPDFDVDLGTILRV
	NDESTEGKTSYRLTLDIQNKKITEVALMGHLSCDTKEERKI

1121	KGVISIPRLQAEARSEILAHWSPAKLLLQMDSSATAYGS
	TVSKRVAWHYDEEKIEFEWNTGTNVDTKKMTSNFPVDLSD
	Y

1201	PKSLHMYANRLLDHRVPQTDMTFRHVGSKLIVAMSSWL
	QKASGSLPYTQTLQDHLNSLKEFNLQNMGLPDFHIPENLFLK

1281	SDGRVKYTLNKNSLKIEIPLPFGGKSSRDLKMLETVRTP
	ALHFKSVGFHLPSREFQVPTFTIPKLYQLQVPLLGVLDLST

1361	NVYSNLYNWSASYSGGNTSTDHFSLRARYHMKADSVVD
	LLSYNVQGSGETTYDHKNTFTLSCDGSLRHKFLDSNIKFSHV

1441	EKLGNNPVSKGLLIFDASSSWGPQMSASVHLDSKKKQHL
	FVKEVKIDGQFRVSSFYAKGTYGLSCQRDPNTGRLNGESNL

1521	RFNSSYLQGTNQITGRYEDGTLSLTSTSDLQSGIIKNTAS
	LKYENYELTLKSDTNGKYKNFATSNKMDMTFSKQNALLRS

1601	EYQADYESLRFFSLLSGSLNSHGLELNADILGTDKINSGA
	HKATLRIGQDGISTSATTNLKCSLLVLENELNAELGLSGA

1681	SMKLTTNGRFREHNAKFSLDGKAALTELSLGSAYQAMIL
	GVDSKNIFNFKVSQEGLKLSNDMMGSYAEMKFDHTNSLNIA

1761	GLSLDFSSKLDNIYSSDKFYKQTVNLQLQPYSLVTTLNS
	DLKYNALDLTNNGKLRLEPLKLHVAGNLKGAYQNNEIKHIY

1841	AISSAALSASYKADTVAKVQGVEFSHRLNTDIAGLASAI
	DMSTNYNSDSLHFSNVFRSVMAPFTMTIDAHTNGNGKLALW

1921	GEHTGQLYSKFLLKAEPLAFTFSHDYKGSTSHHLVSRKS
	ISAALEHKVSALLTPAEQTGTWKLKTQFNNNEYSQDLDAYN

2001	TKDKIGVELTGRTLADLTLLDSPIKVPLLLSEPINIIDALE
	MRDAVEKPQEFTIVAFVKYDKNQDVHSINLPFFETLQEY

2081	FERNRQTIIVVLENVQRNLKHINIDQFVRKYRAALGKLP
	QQANDYLNSFNWERQVSHAKEKLTALTKKYRITENDIQIAL

2161	DDAKINFNEKLSQLQTYMIQFDQYIKDSYDLHDLKIAIA
	NIIDEIIEKLKSLDEHYHIRVNLVKTIHDLHLFIENIDFNK

2241	SGSSTASWIQNVDTKYQIRIQIQEKLQQLKRHIQNIDIQH
	LAGKLKQHIEAIDVRVLLDQLGTTISFERINDVLEHVKHF

2321	VINLIGDFEVAEKINAFRAKVHELIERYEVDQQIQVLMD
	KLVELAHQYKLKETIQKLSNVLQQVKIKDYFEKLVGFIDDA

2401	VKKLNELSFKTFIEDVNKFLDMLIKKLKSFDYHQFVDET
	NDKIREVTQRLNGEIQALELPQKAEALKLFLEETKATVAVY

2481	LESLQDTKITLIINWLQEALSSASLAHMKAKFRETLEDTR
	DRMYQMDIQQELQRYLSLVGQVYSTLVTYISDWWTLAAKN

2561	LTDFAEQYSIQDWAKRMKALVEQGFTVPEIKTILGTMPA
	FEVSLQALQKATFQTPDFIVPLTDLRIPSVQINFKDLKNIK

2641	IPSRFSTPEFTILNTFHIPSFTIDFVEMKVKIIRTIDQMLNS
	ELQWPVPDIYLRDLKVEDIPLARITLPDFRLPEIAIPE

2721	FIIPTLNLNDFQVPDLHIPEFQLPHISHTIEVPTFGKLYSIL
	KIQSPLFTLDANADIGNGTTSANEAGIAASITAKGESK

2801	LEVLNFDFQANAQLSNPKINPLALKESVKFSSKYLRTEH
	GSEMLFFGNAIEGKSNTVASLHTEKNTLELSNGVIVKINNQ

2881	LTLDSNTKYFHKLNIPKLDFSSQADLRNEIKTLLKAGHIA
	WTSSGKGSWKWACPRFSDEGTHESQISFTIEGPLTSFGLS

2961	NKINSKHLRVNQNLVYESGSLNFSKLEIQSQVDSQHVGH
	SVLTAKGMALFGEGKAEFTGRHDAHLNGKVIGTLKNSLFFS

3041	AQPFEITASTNNEGNLKVRFPLRLTGKIDFLNNYALFLSP
	SAQQASWQVSARFNQYKYNQNFSAGNNENIMEAHVGINGE

3121	ANLDFLNIPLTIPEMRLPYTIITTPPLKDFSLWEKTGLKEF
	LKTTKQSFDLSVKAQYKKNKHRHSITNPLAVLCEFISQS

3201	IKSFDRHFEKNRNNALDFVTKSYNETKIKFDKYKAEKSH
	DELPRTFQIPGYTVPVVNVEVSPFTIEMSAFGYVFPKAVSM

3281	PSFSILGSDVRVPSYTLILPSLELPVLHVPRNLKLSLPDFK
	ELCTISHIFIPAMGNITYDFSFKSSVITLNTNAELFNQS

3361	DIVAHLLSSSSSVIDALQYKLEGTTRLTRKRGLKLATALS
	LSNKFVEGSHNSTVSLTTKNMEVSVATTTKAQIPILRMNF

3441	KQELNGNTKSKPTVSSSMEFKYDFNSSMLYSTAKGAVD
	HKLSLESLTSYFSIESSTKGDVKGSVLSREYSGTIASEANTY

3521	LNSKSTRSSVKLQGTSKIDDIWNLEVKENFAGEATLQRI
	YSLWEHSTKNHLQLEGLFFTNGEHTSKATLELSPWQMSALV

3601	QVHASQPSSFHDFPDLGQEVALNANTKNQKIRWKNEVRI
	HSGSFQSQVELSNDQEKAHLDIAGSLEGHLRFLKNIILPVY

3681	DKSLWDFLKLDVTTSIGRRQHLRVSTAFVYTKNPNGYSF
	SIPVKVLADKFIIPGLKLNDLNSVLVMPTFHVPFTDLQVPS

3761	CKLDFREIQIYKKLRTSSFALNLPTLPEVKFPEVDVLTKY
	SQPEDSLIPFFEITVPESQLTVSQFTLPKSVSDGIAALDL

3841	NAVANKIADFELPTIIVPEQTIEIPSIKFSVPAGIVIPSFQA
	LTARFEVDSPVYNATWSASLKNKADYVETVLDSTCSST

3921	VQFLEYELNVLGTHKIEDGTLASKTKGTFAHRDFSAEYE
	EDGKYEGLQEWEGKAHLNIKSPAFTDLHLRYQKDKKGISTS

4001	AASPAVGTVGMDMDEDDDFSKWNFYYSPQSSPDKKLTI
	FKTELRVRESDEETQIKVNWEEEAASGLLTSLKDNVPKATG
	V

4081	LYDYVNKYHWEHTGLTLREVSSKLRRNLQNNAEWVYQ
	GAIRQIDDIDVRFQKAASGTTGTYQEWKDKAQNLYQELLTQ
	EG

4161	QASFQGLKDNVFDGLVRVTQEFHMKVKHLIDSLIDFLNF
	PRFQFPGKPGIYTREELCTMFIREVGTVLSQVYSKVHNGSE

4241	ILFSYFQDLVITLPFELRKHKLIDVISMYRELLKDLSKEA
	QEVFKAIQ SLKTTEVLRNLQDLLQFIFQLIEDNIKQLKEM

4321	KFTYLINYIQDEINTIFSDYIPYVFKLLKENLCLNLHKFN
	EFIQNELQEASQELQQIHQYIMALREEYFDPSIVGWTVKY

4401	YELEEKIVSLIKNLLVALKDFHSEYIVSASNFTSQLSSQV
	EQFLHRNIQEYLSILTDPDGKGKEKIAELSATAQEIIKSQ

4481	AIATKKIISDYHQQFRYKLQDFSDQLSDYYEKFIAESKRL
	IDLSIQNYHTFLIYITELLKKLQSTTVMNPYMKLAPGELT

4561	IIL

5.31 peroxiredoxin 2 isoform a [Homo sapiens]
Protein Accession gi|32189392

Mean Expression Ratio 1.44

Median Expression Ratio 1.43

Credible Interval (1.03, 2.04)

Associated Peptides 3

Associated Spectra 5

Coverage 0.146


A	2.5	50	97.5	Sequence ID No.	Sequence

3	1.1	1.5	2.2	SEQ ID NO: 414	EGGLGPLNIPLLADVTR

1	0.99	1.5	2.2	SEQ ID NO: 415	KEGGLGPLNIPLLADVTR

1	0.96	1.5	2.2	SEQ ID NO: 416	QITVNDLPVGR

SEQ ID NO: 417

1	MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVV
	LFFYPLDFTFVCPTEIIAFSNRAEDFRKLGCEVLGVSVDSQ

81	FTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLKT
	DEGIAYRGLFIIDGKGVLRQITVNDLPVGRSVDEALRLVQ

161	AFQYTDEHGEVCPAGWKPGSDTIKPNVDDSKEYFSKHN

5.32 sphingomyelin phosphodiesterase 1, acid lysosomal isoform 1 precursor [Homo sapiens]
Protein Accession gi|56117840

Mean Expression Ratio 0.703

Median Expression Ratio 0.702

Credible Interval (0.479, 1.03)

Associated Peptides 2

Associated Spectra 3

Coverage 0.0285


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.43	0.65	0.98	SEQ ID NO: 418	AWEPWLPAEALR

1	0.45	0.69	1.1	SEQ ID NO: 419	LCNLLK

SEQ ID NO: 420

1	MPRYGASLRQSCPRSGREQGQDGTAGAPGLLWMGLVLAL
	ALALALALALSDSRVLWAPAEAHPLSPQGHPARLHRIVPRL

81	RDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIK
	LCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACG

161	LLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVS
	RILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASR

241	PGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTG
	DIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGN

321	HESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEA
	LRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTD

401	PAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSW
	NYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAV

481	AFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYI
	LNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVY

561	RMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQL
	SARADSPALCRHLMPDGSLPEAQSLWPRPLFC

5.33 proteasome beta 2 subunit [Homo sapiens]
Protein Accession gi|4506195

Mean Expression Ratio 1.41

Median Expression Ratio 1.41

Credible Interval (0.987, 2.04)

Associated Peptides 3

Associated Spectra 4

Coverage 0.224


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.97	1.5	2.3	SEQ ID NO: 421	FILNLPTFSVR

2	1.0	1.5	2.2	SEQ ID NO: 422	LIGIQGPDYVLVASDR

1	0.91	1.4	2.1	SEQ ID NO: 423	HVNLLLAGYDEHEGPALY

SEQ ID NO: 424

1	MEYLIGIQGPDYVLVASDRVAASNIVQMKDDHDKMFKMSE
	KILLLCVGEAGDTVQFAEYIQKNVQLYKMRNGYELSPTAA

81	ANFTRRNLADCLRSRTPYHVNLLLAGYDEHEGPALYYMD
	YLAALAKAPFAAHGYGAFLTLSILDRYYTPTISRERAVELL

161	RKCLEELQKRFILNLPTFSVRIIDKNGIHDLDNISFPKQGS

5.34 complement component 4B preproprotein [Homo sapiens]
Protein Accession gi|178557739

Mean Expression Ratio 0.712

Median Expression Ratio 0.711

Credible Interval (0.435, 1.15)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.39 0.65 1.1 SEQ ID NO: 425 LLSQQQADGSFQDLSPVIHR

5.35 manganese superoxide dismutase isoform A precursor [Homo sapiens];
manganese superoxide dismutase isoform A precursor [Homo sapiens]
Protein Accession gi|67782307 gi|67782305

Mean Expression Ratio 1.40

Median Expression Ratio 1.40

Credible Interval (1.10, 1.77)

Associated Peptides 9

Associated Spectra 13

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

2	1.0	1.4	1.9	SEQ ID NO: 426	AIWNVINWENVTER

2	1.1	1.5	2.1	SEQ ID NO: 427	DFGSFDKFK

1	1.0	1.4	2.0	SEQ ID NO: 428	FNGGGHINHSIFW

1	1	1.4	2	SEQ ID NO: 429	GDVTAQIALQPALK

2	1.0	1.4	2	SEQ ID NO: 430	GELLEAIKR

1	0.97	1.4	1.9	SEQ ID NO: 431	HHAAYVNNLNVTEEK

2	1	1.4	1.9	SEQ ID NO: 432	NVRPDYLK

1	1.0	1.4	2	SEQ ID NO: 433	GWLGFNK

1	0.96	1.4	1.9	SEQ ID NO: 434	YQEALAK

5.36 transthyretin [Homo sapiens]
Protein Accession gi|4507725

Mean Expression Ratio 0.718

Median Expression Ratio 0.718

Credible Interval (0.572, 0.9)

Associated Peptides 6

Associated Spectra 17

Coverage 0.49


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.54	0.73	1	SEQ ID NO: 435	ALGISPFHEHAEVVF

2	0.56	0.76	1.0	SEQ ID NO: 436	ALGISPFHEHAEVVFTANDSGPR

6	0.48	0.61	0.8	SEQ ID NO: 437	GSPAINVAVHVFR

2	0.5	0.7	0.95	SEQ ID NO: 438	KAADDTWEPFASGK

3	0.54	0.74	1	SEQ ID NO: 439	TSESGELHGLTTEEEFVEGIYK

1	0.51	0.72	1	SEQ ID NO: 440	AADDTWEPFASGK

SEQ ID NO: 441

1	MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAV
	RGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTT

5.37 haptoglobin isoform 1 preproprotein [Homo sapiens]; haptoglobin isoform 2 preproprotein [Homo sapiens]
Protein Accession gi|4826762 gi|186910296

Mean Expression Ratio 0.721

Median Expression Ratio 0.72

Credible Interval (0.565, 0.918)

Associated Peptides 9

Associated Spectra 13

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.52	0.74	1.1	SEQ ID NO: 442	AVHDLEEDTWYATGILSFDK

1	0.51	0.73	1.0	SEQ ID NO: 443	GSFPWQAK

1	0.5	0.71	1.0	SEQ ID NO: 444	HYEGSTVPEKK

2	0.54	0.74	1.0	SEQ ID NO: 445	ILGGHLDAK

1	0.48	0.67	0.95	SEQ ID NO: 446	SPVGVQPILNEHTFCAGMSK

1	0.52	0.72	1.0	SEQ ID NO: 447	VMPICLPSKDYAEVGR

1	0.52	0.73	1.0	SEQ ID NO: 448	VTSIQDWVQK

3	0.51	0.69	0.93	SEQ ID NO: 449	YVMLPVADQDQCIR

2	0.5	0.7	0.97	SEQ ID NO: 450	FTDHLK

5.38 fibulin 1 isoform D [Homo sapiens]
Protein Accession gi|34734066

Mean Expression Ratio 0.726

Median Expression Ratio 0.728

Credible Interval (0.464, 1.12)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0327


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.42	0.68	1.1	SEQ ID NO: 451	EFTRPEEIIFLR

1	0.45	0.73	1.2	SEQ ID NO: 452	IIFDITEGNLR

SEQ ID NO: 453

1	MERAAPSRRVPLPLLLLGGLALLAAGVDADVLLEACCADG
	HRMATHQKDCSLPYATESKECRMVQEQCCHSQLEELHCAT

81	GISLANEQDRCATPHGDNASLEATFVKRCCHCCLLGRAAQ
	AQGQSCEYSLMVGYQCGQVFRACCVKSQETGDLDVGGLQE

161	TDKIIEVEEEQEDPYLNDRCRGGGPCKQQCRDTGDEVVC
	SCFVGYQLLSDGVSCEDVNECITGSHSCRLGESCINTVGSF

241	RCQRDSSCGTGYELTEDNSCKDIDECESGIHNCLPDFICQ
	NTLGSFRCRPKLQCKSGFIQDALGNCIDINECLSISAPCP

321	IGHTCINTEGSYTCQKNVPNCGRGYHLNEEGTRCVDVDE
	CAPPAEPCGKGHRCVNSPGSFRCECKTGYYFDGISRMCVDV

401	NECQRYPGRLCGHKCENTLGSYLCSCSVGFRLSVDGRSC
	EDINECSSSPCSQECANVYGSYQCYCRRGYQLSDVDGVTCE

481	DIDECALPTGGHICSYRCINIPGSFQCSCPSSGYRLAPNGR
	NCQDIDECVTGIHNCSINETCFNIQGGFRCLAFECPENY

561	RRSAATLQQEKTDTVRCIKSCRPNDVTCVFDPVHTISHTV
	ISLPTFREFTRPEEIIFLRAITPPHPASQANIIFDITEGN

641	LRDSFDIIKRYMDGMTVGVVRQVRPIVGPFHAVLKLEMN
	YVVGGVVSHRNVVNVHIFVSEYWF

5.39 serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1
[Homo sapiens]
Protein Accession gi|4502261

Mean Expression Ratio 0.73

Median Expression Ratio 0.73

Credible Interval (0.529, 1.00)

Associated Peptides 5

Associated Spectra 5

Coverage 0.194


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.48	0.72	1.1	SEQ ID NO: 454	AFLEVNEEGSEAAASTAVVIAGR

1	0.49	0.74	1.1	SEQ ID NO: 455	EVPLNTIIFMGR

1	0.48	0.72	1.1	SEQ ID NO: 456	VAEGTQVLELPFK

1	0.49	0.72	1.1	SEQ ID NO: 457	ELTPEVLQEWLDELEEMMLVVHMPR

1	0.47	0.7	1.0	SEQ ID NO: 458	ATEDEGSEQKIPEATNR

SEQ ID NO: 459

1	MYSNVIGTVTSGKRKVYLLSLLLIGFWDCVTCHGSPVDICT
	AKPRDIPMNPMCIYRSPEKKATEDEGSEQKIPEATNRRV

81	WELSKANSRFATTFYQHLADSKNDNDNIFLSPLSISTAFA
	MTKLGACNDTLQQLMEVFKFDTISEKTSDQIHFFFAKLNC

161	RLYRKANKSSKLVSANRLFGDKSLTFNETYQDISELVYG
	AKLQPLDFKENAEQSRAAINKWVSNKTEGRITDVIPSEAIN

241	ELTVLVLVNTIYFKGLWKSKFSPENTRKELFYKADGESCS
	ASMMYQEGKFRYRRVAEGTQVLELPFKGDDITMVLILPKP

321	EKSLAKVEKELTPEVLQEWLDELEEMMLVVHMPRFRIED
	GFSLKEQLQDMGLVDLFSPEKSKLPGIVAEGRDDLYVSDAF

401	HKAFLEVNEEGSEAAASTAVVIAGRSLNPNRVTFKANRPF
	LVFIREVPLNTIIFMGRVANPCVK

5.40 hypothetical protein LOC148362 [Homo sapiens]
Protein Accession gi|124244088

Mean Expression Ratio 1.37

Median Expression Ratio 1.37

Credible Interval (0.994, 1.92)

Associated Peptides 5

Associated Spectra 5

Coverage 0.141


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.92	1.4	2.0	SEQ ID NO: 460	LLELFTDLSCNPEMMK

1	0.94	1.4	2.1	SEQ ID NO: 461	NAADSYFSLLQGFINSLDESTQESK

1	0.93	1.4	2.1	SEQ ID NO: 462	SLLQGFINSLDESTQESK

1	0.94	1.4	2.1	SEQ ID NO: 463	YIQNFK

1	0.92	1.4	2.1	SEQ ID NO: 464	IPTEAPQLELK

SEQ ID NO: 465

1	MTHWFHRNPLKATAPVSFNYYGVVTGPSASKICNDLRSSR
	ARLLELFTDLSCNPEMMKNAADSYFSLLQGFINSLDESTQ

81	ESKLRYIQNFKWTDTLQGQVPSAQQDAVFELISMGFNVAL
	WYTKYASRLAGKENITEDEAKEVHRSLKIAAGIFKHLKES

161	HLPKLITPAEKGRDLESRLIEAYVIQCQAEAQEVTIARAIE
	LKHAPGLIAALAYETANFYQKADHTLSSLEPAYSAKWRK

241	YLHLKMCFYTAYAYCYHGETLLASDKCGEAIRSLQEAEK
	LYAKAEALCKEYGETKGPGPTVKPSGHLFFRKLGNLVKNTL

321	EKCQRENGFIYFQKIPTEAPQLELKANYGLVEPIPFEFPPT
	SVQWTPETLAAFDLTKRPKDDSTKPKPEEEVKPVKEPDI

401	KPQKDTGCYIS

5.41 ferritin, heavy polypeptide 1 [Homo sapiens]
Protein Accession gi|56682959

Mean Expression Ratio 1.36

Median Expression Ratio 1.36

Credible Interval (1.12, 1.67)

Associated Peptides 9

Associated Spectra 21

Coverage 0.41


A	2.5	50	97.5	Sequence ID No.	Sequence

3	1.0	1.4	1.9	SEQ ID NO: 466	ELGDHVTNLR

1	1.1	1.5	2.1	SEQ ID NO: 467	GGRIFLQDIK

2	0.9	1.2	1.6	SEQ ID NO: 468	LCDFIETHYLNEQVK

2	1.0	1.4	1.9	SEQ ID NO: 469	MGAPESGLAEYLFDK

3	1.1	1.5	1.9	SEQ ID NO: 470	NDPHLCDFIETHYLNEQVK

5	1.1	1.4	1.9	SEQ ID NO: 471	NVNQSLLELHK

1	0.97	1.3	1.8	SEQ ID NO: 472	YFLHQSHEER

1	0.96	1.3	1.8	SEQ ID NO: 473	LCDFIETHY

3	1.0	1.4	1.9	SEQ ID NO: 474	IFLQDIK

SEQ ID NO: 475

1	MTTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSY
	YFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGR

81	IFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHK
	LATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMG

161	APESGLAEYLFDKHTLGDSDNES

5.42 serum amyloid A1 preproprotein [Homo sapiens]; serum amyloid A1
preproprotein [Homo sapiens]
Protein Accession gi|40316912 gi|40316910

Mean Expression Ratio 0.738

Median Expression Ratio 0.737

Credible Interval (0.512, 1.06)

Associated Peptides 3

Associated Spectra 4

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.47	0.69	1.0	SEQ ID NO: 476	FFGHGAEDSLADQAANEWGR

1	0.48	0.73	1.1	SEQ ID NO: 477	SFFSFLGEAFDGAR

1	0.48	0.74	1.1	SEQ ID NO: 478	GPGGAWAAEVISDAR

5.43 programmed cell death 6 [Homo sapiens]
Protein Accession gi|7019485

Mean Expression Ratio 1.34

Median Expression Ratio 1.34

Credible Interval (1.02, 1.77)

Associated Peptides 4

Associated Spectra 10

Coverage 0.319


A	2.5	50	97.5	Sequence ID No.	Sequence

4	0.99	1.3	1.8	SEQ ID NO: 479	LSDQFHDILIR

4	1.0	1.4	1.9	SEQ ID NO: 480	SGVISDTELQQALSNGTWTPFNPVTVR

1	0.99	1.4	2.1	SEQ ID NO: 481	YITDWQNVFR

1	0.93	1.3	2.0	SEQ ID NO: 482	AGVNFSEFTGVWK

SEQ ID NO: 483

1	MAAYSYRPGPGAGPGPAAGAALPDQSFLWNVFQRVDKDR
	SGVISDTELQQALSNGTWTPFNPVTVRSIISMFDRENKAGV

81	NFSEFTGVWKYITDWQNVFRTYDRDNSGMIDKNELKQAL
	SGFGYRLSDQFHDILIRKFDRQGRGQIAFDDFIQGCIVLQR

161	LTDIFRRYDTDQDGWIQVSYEQYLSMVFSIV

5.44 complement component 1 inhibitor precursor [Homo sapiens]; complement component 1 inhibitor precursor [Homo sapiens]
Protein Accession gi|73858570 gi|73858568

Mean Expression Ratio 0.745

Median Expression Ratio 0.744

Credible Interval (0.58, 0.953)

Associated Peptides 8

Associated Spectra 12

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.5	0.69	0.93	SEQ ID NO: 484	GVTSVSQIFHSPDLAIR

2	0.55	0.77	1.1	SEQ ID NO: 485	KYPVAHFIDQTLK

1	0.52	0.74	1.0	SEQ ID NO: 486	LEDMEQALSPSVFK

1	0.52	0.75	1.0	SEQ ID NO: 487	LLDSLPSDTR

1	0.53	0.75	1.1	SEQ ID NO: 488	LVLLNAIYLSAK

1	0.52	0.74	1.1	SEQ ID NO: 489	QHQTVLELTETGVEAAAASAISVAR

2	0.53	0.73	1.0	SEQ ID NO: 490	QTVLELTETGVEAAAASAISVAR

1	0.53	0.76	1.1	SEQ ID NO: 491	DFTCVHQALK

5.45 chromatin modifying protein 5 [Homo sapiens]
Protein Accession gi|189409150

Mean Expression Ratio 1.34

Median Expression Ratio 1.34

Credible Interval (0.915, 2.00)

Associated Peptides 3

Associated Spectra 3

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.89	1.4	2.1	SEQ ID NO: 492	APPPSLTDCIGTVDSR

1	0.88	1.4	2.1	SEQ ID NO: 493	IDQIEDLQDQLEDMMEDANEIQEALSR

1	0.9	1.4	2.1	SEQ ID NO: 494	YKDQIK

5.46 vacuolar protein sorting factor 4B [Homo sapiens]
Protein Accession gi|17865802

Mean Expression Ratio 1.33

Median Expression Ratio 1.33

Credible Interval (0.961, 1.84)

Associated Peptides 4

Associated Spectra 5

Coverage 0.146


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.9	1.4	2.0	SEQ ID NO: 495	ENKPSIIFIDEIDSLCGSR

1	0.88	1.3	2.0	SEQ ID NO: 496	LLEPVVSMSDMLR

2	0.94	1.4	2.0	SEQ ID NO: 497	LQNQLQGAIVIERPNVK

1	0.9	1.3	2	SEQ ID NO: 498	SLSNTKPTVNEHDLLK

SEQ ID NO: 499

1	MSSTSPNLQKAIDLASKAAQEDKAGNYEEALQLYQHAVQY
	FLHVVKYEAQGDKAKQSIRAKCTEYLDRAEKLKEYLKNKE

81	KKAQKPVKEGQPSPADEKGNDSDGEGESDDPEKKKLQNQ
	LQGAIVIERPNVKWSDVAGLEGAKEALKEAVILPIKFPHLF

161	TGKRTPWRGILLFGPPGTGKSYLAKAVATEANNSTFFSIS
	SSDLVSKWLGESEKLVKNLFQLARENKPSIIFIDEIDSLC

241	GSRSENESEAARRIKTEFLVQMQGVGVDNDGILVLGATNI
	PWVLDSAIRRRFEKRIYIPLPEPHARAAMFKLHLGTTQNS

321	LTEADFRELGRKTDGYSGADISIIVRDALMQPVRKVQSAT
	HFKKVRGPSRADPNHLVDDLLTPCSPGDPGAIEMTWMDVP

5.47 prominin 1 [Homo sapiens]
Protein Accession gi|5174387

Mean Expression Ratio 1.32

Median Expression Ratio 1.32

Credible Interval (1.05, 1.66)

Associated Peptides 9

Associated Spectra 15

Coverage 0.158


A	2.5	50	97.5	Sequence ID No.	Sequence

3	1 1.	4	1.8	SEQ ID NO: 500	AFTDLNSINSVLGGGILDR

1	0.96	1.3	1.9	SEQ ID NO: 501	LLNEDWEYYLSGK

1	0.96	1.3	1.9	SEQ ID NO: 502	LTFEQVYSDCK

3	0.95	1.3	1.7	SEQ ID NO: 503	QLPPVDAELDNVNNVLR

1	0.96	1.3	1.9	SEQ ID NO: 504	SLHQQSTQLSSSLTSVK

3	1.0	1.4	1.9	SEQ ID NO: 505	TDLDGLVQQGYQSLNDIPDR

1	0.94	1.3	1.8	SEQ ID NO: 506	TLLNETPEQIK

1	0.92	1.3	1.8	SEQ ID NO: 507	VLPIEQSLSTLYQSVK

1	0.94	1.3	1.9	SEQ ID NO: 508	VNLNIFLLGAAGR

SEQ ID NO: 509

1	MALVLGSLLLLGLCGNSFSGGQPSSTDAPKAWNYELPATN
	YETQDSHKAGPIGILFELVHIFLYVVQPRDFPEDTLRKFL

81	QKAYESKIDYDKPETVILGLKIVYYEAGIILCCVLGLLFIIL
	MPLVGYFFCMCRCCNKCGGEMHQRQKENGPFLRKCFAI

161	SLLVICIIISIGIFYGFVANHQVRTRIKRSRKLADSNFKDLR
	TLLNETPEQIKYILAQYNTTKDKAFTDLNSINSVLGGG

241	ILDRLRPNIIPVLDEIKSMATAIKETKEALENMNSTLKSLH
	QQSTQLSSSLTSVKTSLRSSLNDPLCLVHPSSETCNSIR

321	LSLSQLNSNPELRQLPPVDAELDNVNNVLRTDLDGLVQQ
	GYQSLNDIPDRVQRQTTTVVAGIKRVLNSIGSDIDNVTQRL

401	PIQDILSAFSVYVNNTESYIHRNLPTLEEYDSYWWLGGLV
	ICSLLTLIVIFYYLGLLCGVCGYDRHATPTTRGCVSNTGG

481	VFLMVGVGLSFLFCWILMIIVVLTFVFGANVEKLICEPYT
	SKELFRVLDTPYLLNEDWEYYLSGKLFNKSKMKLTFEQVY

561	SDCKKNRGTYGTLHLQNSFNISEHLNINEHTGSISSELESL
	KVNLNIFLLGAAGRKNLQDFAACGIDRMNYDSYLAQTGK

641	SPAGVNLLSFAYDLEAKANSLPPGNLRNSLKRDAQTIKTI
	HQQRVLPIEQSLSTLYQSVKILQRTGNGLLERVTRILASL

721	DFAQNFITNNTSSVIIEETKKYGRTIIGYFEHYLQWIEFSIS
	EKVASCKPVATALDTAVDVFLCSYIIDPLNLFWFGIGK

801	ATVFLLPALIFAVKLAKYYRRMDSEDVYDDVETIPMKNM
	ENGNNGYHKDHVYGIHNPVMTSPSQH

5.48 alpha 3 type VI collagen isoform 1 precursor [Homo sapiens]
Protein Accession gi|55743098

Mean Expression Ratio 0.756

Median Expression Ratio 0.757

Credible Interval (0.563, 1.02)

Associated Peptides 6

Associated Spectra 7

Coverage 0.0353


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.49	0.71	1.0	SEQ ID NO: 510	AAPLQGMLPGLLAPLR
1	0.51	0.75	1.1	SEQ ID NO: 511	GADQAELEEIAFDSSLVFI
					PAEFR

1	0.5	0.73	1.1	SEQ ID NO: 512	GAQGPAGPAGPPGLIGEQG
					ISGPR

1	0.51	0.75	1.1	SEQ ID NO: 513	ITEGVPQLLIVLTADR
1	0.51	0.75	1.1	SEQ ID NO: 514	LVDYLDVGFDTTR
2	0.56	0.8	1.1	SEQ ID NO: 515	MKPLDGSALYTGSALDFVR

SEQ ID NO: 516

1 MRKHRHLPLVAVFCLFLSGFPTTHAQQQQADVKNGAAADIIFL

VDSSWTIGEEHFQLVREFLYDVVKSLAVGENDFHFAL

81 VQFNGNPHTEFLLNTYRTKQEVLSHISNMSYIGGTNQTGKGLE

YIMQSHLTKAAGSRAGDGVPQVIVVLTDGHSKDGLAL

161 PSAELKSADVNVFAIGVEDADEGALKEIASEPLNMHMFNLENF

TSLHDIVGNLVSCVHSSVSPERAGDTETLKDITAQDS

241 ADIIFLIDGSNNTGSVNFAVILDFLVNLLEKLPIGTQQIRVGV

VQFSDEPRTMFSLDTYSTKAQVLGAVKALGFAGGELA

321 NIGLALDFVVENHFTRAGGSRVEEGVPQVLVLISAGPSSDEIR

YGVVALKQASVFSFGLGAQAASRAELQHIATDDNLVF

401 TVPEFRSFGDLQEKLLPYIVGVAQRHIVLKPPTIVTQVIEVNK

RDIVFLVDGSSALGLANFNAIRDFIAKVIQRLEIGQD

481 LIQVAVAQYADTVRPEFYFNTHPTKREVITAVRKMKPLDGSAL

YTGSALDFVRNNLFTSSAGYRAAEGIPKLLVLITGGK

561 SLDEISQPAQELKRSSIMAFAIGNKGADQAELEEIAFDSSLVF

IPAEFRAAPLQGMLPGLLAPLRTLSGTPEVHSNKRDI

641 IFLLDGSANVGKTNFPYVRDFVMNLVNSLDIGNDNIRVGLVQF

SDTPVTEFSLNTYQTKSDILGHLRQLQLQGGSGLNTG

721 SALSYVYANHFTEAGGSRIREHVPQLLLLLTAGQSEDSYLQAA

NALTRAGILTFCVGASQANKAELEQIAFNPSLVYLMD

801 DFSSLPALPQQLIQPLTTYVSGGVEEVPLAQPESKRDILFLFD

GSANLVGQFPVVRDFLYKIIDELNVKPEGTRIAVAQY

881 SDDVKVESRFDEHQSKPEILNLVKRMKIKTGKALNLGYALDYA

QRYIFVKSAGSRIEDGVLQFLVLLVAGRSSDRVDGPA

961 SNLKQSGVVPFIFQAKNADPAELEQIVLSPAFILAAESLPKIG

DLHPQIVNLLKSVHNGAPAPVSGEKDVVFLLDGSEGV

1041 RSGFPLLKEFVQRVVESLDVGQDRVRVAVVQYSDRTRPEFYLN

SYMNKQDVVNAVRQLTLLGGPTPNTGAALEFVLRNIL

1121 VSSAGSRITEGVPQLLIVLTADRSGDDVRNPSVVVKRGGAVPI

GIGIGNADITEMQTISFIPDFAVAIPTFRQLGTVQQV

1201 ISERVTQLTREELSRLQPVLQPLPSPGVGGKRDVVFLIDGSQS

AGPEFQYVRTLIERLVDYLDVGFDTTRVAVIQFSDDP

1281 KVEFLLNAHSSKDEVQNAVQRLRPKGGRQINVGNALEYVSRNI

FKRPLGSRIEEGVPQFLVLISSGKSDDEVDDPAVELK

1361 QFGVAPFTIARNADQEELVKISLSPEYVFSVSTFRELPSLEQK

LLTPITTLTSEQIQKLLASTRYPPPAVESDAADIVFL

1441 IDSSEGVRPDGFAHIRDFVSRIVRRLNIGPSKVRVGVVQFSND

VFPEFYLKTYRSQAPVLDAIRRLRLRGGSPLNTGKAL

1521 EFVARNLFVKSAGSRIEDGVPQHLVLVLGGKSQDDVSRFAQVI

RSSGIVSLGVGDRNIDRTELQTITNDPRLVFTVREFR

1601 ELPNIEERIMNSFGPSAATPAPPGVDTPPPSRPEKKKADIVFL

LDGSINFRRDSFQEVLRFVSEIVDTVYEDGDSIQVGL

1681 VQYNSDPTDEFFLKDFSTKRQIIDAINKVVYKGGRHANTKVGL

EHLRVNHFVPEAGSRLDQRVPQIAFVITGGKSVEDAQ

1761 DVSLALTQRGVKVFAVGVRNIDSEEVGKIASNSATAFRVGNVQ

ELSELSEQVLETLHDAMHETLCPGVTDAAKACNLDVI

1841 LGFDGSRDQNVFVAQKGFESKVDAILNRISQMHRVSCSGGRSP

TVRVSVVANTPSGPVEAFDFDEYQPEMLEKFRNMRSQ

1921 HPYVLTEDTLKVYLNKFRQSSPDSVKVVIHFTDGADGDLADLH

RASENLRQEGVRALILVGLERVVNLERLMHLEFGRGF

2001 MYDRPLRLNLLDLDYELAEQLDNIAEKACCGVPCKCSGQRGDR

GPIGSIGPKGIPGEDGYRGYPGDEGGPGERGPPGVNG

2081 TQGFQGCPGQRGVKGSRGFPGEKGEVGEIGLDGLDGEDGDKGL

PGSSGEKGNPGRRGDKGPRGEKGERGDVGIRGDPGNP

2161 GQDSQERGPKGETGDLGPMGVPGRDGVPGGPGETGKNGGFGRR

GPPGAKGNKGGPGQPGFEGEQGTRGAQGPAGPAGPPG

2241 LIGEQGISGPRGSGGAAGAPGERGRTGPLGRKGEPGEPGPKGG

IGNRGPRGETGDDGRDGVGSEGRRGKKGERGFPGYPG

2321 PKGNPGEPGLNGTTGPKGIRGRRGNSGPPGIVGQKGDPGYPGP

AGPKGNRGDSIDQCALIQSIKDKCPCCYGPLECPVFP

2401 TELAFALDTSEGVNQDTFGRMRDVVLSIVNDLTIAESNCPRGA

RVAVVTYNNEVTTEIRFADSKRKSVLLDKIKNLQVAL

2481 TSKQQSLETAMSFVARNTFKRVRNGFLMRKVAVFFSNTPTRAS

PQLREAVLKLSDAGITPLFLTRQEDRQLINALQINNT

2561 AVGHALVLPAGRDLTDFLENVLTCHVCLDICNIDPSCGFGSWR

PSFRDRRAAGSDVDIDMAFILDSAETTTLFQFNEMKK

2641 YIAYLVRQLDMSPDPKASQHFARVAVVQHAPSESVDNASMPPV

KVEFSLTDYGSKEKLVDFLSRGMTQLQGTRALGSAIE

2721 YTIENVFESAPNPRDLKIVVLMLTGEVPEQQLEEAQRVILQAK

CKGYFFVVLGIGRKVNIKEVYTFASEPNDVFFKLVDK

2801 STELNEEPLMRFGRLLPSFVSSENAFYLSPDIRKQCDWFQGDQ

PTKNLVKFGHKQVNVPNNVTSSPTSNPVTTTKPVTTT

2881 KPVTTTTKPVTTTTKPVTIINQPSVKPAAAKPAPAKPVAAKPV

ATKMATVRPPVAVKPATAAKPVAAKPAAVRPPAAAAA

2961 KPVATKPEVPRPQAAKPAATKPATTKPMVKMSREVQVFEITEN

SAKLHWERAEPPGPYFYDLTVTSAHDQSLVLKQNLTV

3041 TDRVIGGLLAGQTYHVAVVCYLRSQVRATYHGSFSTKKSQPPP

PQPARSASSSTINLMVSTEPLALTETDICKLPKDEGT

3121 CRDFILKWYYDPNTKSCARFWYGGCGGNENKFGSQKECEKVCA

PVLAKPGVISVMGT

5.49 actin, gamma 1 propeptide [Homo sapiens]; beta actin [Homo sapiens]
Protein Accession gi|4501887 gi|4501885

Mean Expression Ratio 1.31

Median Expression Ratio 1.31

Credible Interval (1.05, 1.67)

Associated Peptides 10

Associated Spectra 13

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.9	1.3	1.8	SEQ ID NO: 517	ANTVLSGGTTMYPGIADR

1	0.95	1.4	1.9	SEQ ID NO: 518	DLYANTVLSGGTTMYPGIADR

1	1	1.4	1.9	SEQ ID NO: 519	KDLYANTVLSGGTTMYPGIAD
					R


2	0.97	1.3	1.8	SEQ ID NO: 520	LCYVALDFEQEMATAASSSSL
					EK


2	0.92	1.3	1.8	SEQ ID NO: 521	TTGIVMDSGDGVTHTVPIYEG
					Y


1	0.95	1.3	1.9	SEQ ID NO: 522	TTGIVMDSGDGVTHTVPIYEG
					YALPHAILR


1	0.93	1.3	1.8	SEQ ID NO: 523	TVLSGGTTMYPGIADR

1	0.91	1.3	1.8	SEQ ID NO: 524	VALDFEQEMATAASSSSLEK

1	0.98	1.4	2.0	SEQ ID NO: 525	VAPEEHPVLLTEAPLNPK

2	0.97	1.3	1.8	SEQ ID NO: 526	YPIEHGIVTNWDDMEK

5.50 solute carrier family 5 (sodium/glucose cotransporter), member 12 [Homo sapiens]
Protein Accession gi|157671931

Mean Expression Ratio 0.762

Median Expression Ratio 0.764

Credible Interval (0.515, 1.12)

Associated Peptides 2

Associated Spectra 3

Coverage 0.0388


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.44	0.68	1	SEQ ID NO: 527	LHIFDFDVDPLR
1	0.52	0.8	1.2	SEQ ID NO: 528	QGAESVLQNGLR

SEQ ID NO: 529

1 MEVKNFAVWDYVVFAALFFISSGIGVFFAIKERKKATSREF

LVGGRQMSFGPVGLSLTASFMSAVTVLGTPSEVYRFGAS

81 FLVFFIAYLFVILLTSELFLPVFYRSGITSTYEYLQLRFNK

PVRYAATVIYIVQTILYTGVVVYAPALALNQVTGFDLWG

161 SVFATGIVCTFYCTLGGLKAVVWTDAFQMVVMIVGFLTVLI

QGSTHAGGFHNVLEQSTNGSRLHIFDFDVDPLRRHTFWT

241 ITVGGTFTWLGIYGVNQSTIQRCISCKTEKHAKLALYFNLL

GLWIILVCAVFSGLIMYSHFKDCDPWTSGIISAPDQLMP

321 YFVMEIFATMPGLPGLFVACAFSGTLSTVASSINALATVTF

EDFVKSCFPHLSDKLSTWISKGLCLLFGVMCTSMAVAAS

401 VMGGVVQASLSIHGMCGGPMLGLFSLGIVFPFVNWKGALGG

LLTGITLSFWVAIGAFIYPAPASKTWPLPLSTDQCIKSN

481 VTATGPPVLSSRPGIADTWYSISYLYYSAVGCLGCIVAGVI

ISLITGRQRGEDIQPLLIRPVCNLFCFWSKKYKTLCWCG

561 VQHDSGTEQENLENGSARKQGAESVLQNGLRRESLVHVPGY

DPKDKSYNNMAFETTHF

5.51 vacuolar protein sorting 25 [Homo sapiens]
Protein Accession gi|14150155

Mean Expression Ratio 1.31

Median Expression Ratio 1.30

Credible Interval (0.845, 2.04)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0852


A	2.5	50	97.5	Sequence ID No.	Sequence
2	0.9	1.4	2.2	SEQ ID NO: 530	KLPVESIQIVLEELR

SEQ ID NO: 531

1 MAMSFEWPWQYRFPPFFTLQPNVDTRQKQLAAWCSLVLSF

CRLHKQSSMTVMEAQESPLFNNVKLQRKLPVESIQIVLEE

81 LRKKGNLEWLDKSKSSFLIMWRRPEEWGKLIYQWVSRSGQ

NNSVFTLYELTNGEDTEDEEFHGLDEATLLRALQALQQEH

161 KAEIITVSDGRGVKFF

5.52 annexin A11 [Homo sapiens]; annexin A11 [Homo sapiens]; annexin A11 [Homo sapiens]
Protein Accession gi|4557317 gi|22165433 gi|22165431

Mean Expression Ratio 1.3

Median Expression Ratio 1.30

Credible Interval (0.93, 1.82)

Associated Peptides 4

Associated Spectra 5

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.88	1.3	2.0	SEQ ID NO: 532	AHLVAVFNEYQR

1	0.9	1.3	2	SEQ ID NO: 533	GFGTDEQAIIDCLGSR

1	0.9	1.3	2	SEQ ID NO: 534	GTITDAPGFDPLR

2	0.9	1.3	1.9	SEQ ID NO: 535	GVGTDEACLIEILASR

5.53 chromatin modifying protein 4B [Homo sapiens]
Protein Accession gi|28827795

Mean Expression Ratio 1.3

Median Expression Ratio 1.30

Credible Interval (0.882, 1.89)

Associated Peptides 3

Associated Spectra 3

Coverage 0.147


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.87	1.3	2.1	SEQ ID NO: 536	QLAQIDGTLSTIEFQR
1	0.85	1.3	2.0	SEQ ID NO: 537	KIEQELTAAK
1	0.87	1.3	2.1	SEQ ID NO: 538	KQEFLEK

SEQ ID NO: 539

1 MSVFGKLFGAGGGKAGKGGPTPQEAIQRLRDTEEMLSKKQ

EFLEKKIEQELTAAKKHGTKNKRAALQALKRKKRYEKQLA

81 QIDGTLSTIEFQREALENANTNTEVLKNMGYAAKAMKAAH

DNMDIDKVDELMQDIADQQELAEEISTAISKPVGFGEEFD

161 EDELMAELEELEQEELDKNLLEISGPETVPLPNVPSIALP

SKPAKKKEEEDDDMKELENWAGSM

5.54 fatty acid binding protein 4, adipocyte [Homo sapiens]
Protein Accession gi|4557579

Mean Expression Ratio 0.769

Median Expression Ratio 0.771

Credible Interval (0.526, 1.12)

Associated Peptides 2

Associated Spectra 4

Coverage 0.242


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.49	0.73	1.1	SEQ ID NO: 540	NTEISFILGQEFDEVTADDR
1	0.49	0.76	1.2	SEQ ID NO: 541	LVSSENFDDYMK

SEQ ID NO: 542

1 MCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISV

NGDVITIKSESTFKNTEISFILGQEFDEVTADDRK

81 VKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTS

TRVYERA

5.55 chloride intracellular channel 6 [Homo sapiens]
Protein Accession gi|27894378

Mean Expression Ratio 1.29

Median Expression Ratio 1.29

Credible Interval (0.8, 2.07)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0219


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.82	1.4	2.2	SEQ ID NO: 543	VGDGPQQEPGEDEER

SEQ ID NO: 544

1 MAEAAEPEGVAPGPQGPPEVPAPLAERPGEPGAAGGEAEGP

EGSEGAEEAPRGAAAVKEAGGGGPDRGPEAEARGTRGAH

81 GETEAEEGAPEGAEVPQGGEETSGAQQVEGASPGRGAQGEP

RGEAQREPEDSAAPERQEEAEQRPEVPEGSASGEAGDSV

161 DAEGPLGDNIEAEGPAGDSVEAEGRVGDSVDAEGPAGDSVD

AEGPLGDNIQAEGPAGDSVDAEGRVGDSVDAEGPAGDSV

241 DAEGRVGDSVEAGDPAGDGVEAGVPAGDSVEAEGPAGDSMD

AEGPAGRARRVSGEPQQSGDGSLSPQAEAIEVAAGESAG

321 RSPGELAWDAAEEAEVPGVKGSEEAAPGDARADAGEDRVGD

GPQQEPGEDEERRERSPEGPREEEAAGGEEESPDSSPHG

401 EASRGAAEPEAQLSNHLAEEGPAEGSGEAARVNGRREDGEA

SEPRALGQEHDITLFVKAGYDGESIGNCPFSQRLFMILW

481 LKGVIFNVTTVDLKRKPADLQNLAPGTNPPFMTFDGEVKTD

VNKIEEFLEEKLAPPRYPKLGTQHPESNSAGNDVFAKFS

561 AFIKNTKKDANEIHEKNLLKALRKLDNYLNSPLPDEIDAYS

TEDVTVSGRKFLDGDELTLADCNLLPKLHIIKIVAKKYR

641 DFEFPSEMTGIWRYLNNAYARDEFTNTCPADQEIEHAYSDV

AKRMK

5.56 proteasome alpha 3 subunit isoform 1 [Homo sapiens]; proteasome alpha 3 subunit isoform 2 [Homo sapiens]
Protein Accession gi|4506183 gi|23110939

Mean Expression Ratio 1.29

Median Expression Ratio 1.29

Credible Interval (0.844, 1.97)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.85 1.4 2.2 SEQ ID NO: 545 HVGMAVAGLLADAR

1 0.82 1.3 2.1 SEQ ID NO: 546 AFELELSWVGELTNGR

5.57 gelsolin isoform a precursor [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform c [Homo sapiens]; gelsolin isoform c [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens]; gelsolin isoform b [Homo sapiens]
Protein Accession gi|4504165 gi|38044288 gi|89083782 gi|89083780 gi|89083778 gi|189083776 gi|189083774

Mean Expression Ratio 0.776

Median Expression Ratio 0.777

Credible Interval (0.57, 1.05)

Associated Peptides 5

Associated Spectra 6

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.56	0.8	1.2	SEQ ID NO: 547	AAQHGMDDDGTGQK

1	0.53	0.77	1.1	SEQ ID NO: 548	AQPVQVAEGSEPDGFWEALG
					GK


1	0.53	0.78	1.1	SEQ ID NO: 549	DSQEEEKTEALTSAK

1	0.49	0.73	1.1	SEQ ID NO: 550	NWQGAQSTQDEVAASAILTA
					QLDEELGGTPVQSR


1	0.52	0.77	1.1	SEQ ID NO: 551	TAQLDEELGGTPVQSR

5.58 vacuolar protein sorting 37B [Homo sapiens]
Protein Accession gi|13375926

Mean Expression Ratio 1.29

Median Expression Ratio 1.28

Credible Interval (0.848, 1.94)

Associated Peptides 1

Associated Spectra 3

Coverage 0.0912


A	2.5	50	97.5	Sequence ID No.	Sequence

3 0.	93	1.4	2.0	SEQ ID NO: 552	LPELAPTAPLPYPAPEASG
					PPAVAPR

SEQ ID NO: 553

1 MAGAGSEARFAGLSLVQLNELLEDEGQLTEMVQKMEETQNVQLN

KEMTLASNRSLAEGNLLYQPQLDTLKARLTQKYQEL

81 QVLFEAYQIKKTKLDRQSSSASLETLLALLQAEGAKIEEDTENM

AEKFLDGELPLDSFIDVYQSKRKLAHMRRVKIEKLQ

161 EMVLKGQRLPQALAPLPPRLPELAPTAPLPYPAPEASGPPAVAP

RRIPPPPPPVPAGRLATPFTAAMSSGQAVPYPGLQC

241 PPLPPRVGLPTQQGFSSQFVSPYPPPLPQRPPPRLPPHQPGFIL

Q

5.59 programmed cell death 6 interacting protein [Homo sapiens]
Protein Accession gi|22027538

Mean Expression Ratio 1.28

Median Expression Ratio 1.28

Credible Interval (1.05, 1.57)

Associated Peptides 12

Associated Spectra 20

Coverage 0.192


A	2.5	50	97.5	Sequence ID No.	Sequence

2	1	1.3	1.8	SEQ ID NO: 554	EPSAPSIPTPAYQSSPAGGH
					APTPPTPAPR

1	0.9	1.3	1.7	SEQ ID NO: 555	FIQQTYPSGGEEQAQYCR
3	1	1.3	1.8	SEQ ID NO: 556	FLTALAQDGVINEEALSVTE
					LDR

2	0.97	1.3	1.8	SEQ ID NO: 557	FYNELTEILVR
1	0.92	1.3	1.7	SEQ ID NO: 558	HEGALETLLR
2	0.93	1.3	1.7	SEQ ID NO: 559	LQHAAELIK
1	0.93	1.3	1.8	SEQ ID NO: 560	NIQVSHQEFSK
3	0.98	1.3	1.7	SEQ ID NO: 561	NLATAYDNFVELVANLK
2	0.97	1.3	1.8	SEQ ID NO: 562	SVIEQGGIQTVDQLIK
1	0.88	1.2	1.7	SEQ ID NO: 563	FTDLFEK
1	0.95	1.3	1.8	SEQ ID NO: 564	KQEGLLK
1	0.91	1.3	1.7	SEQ ID NO: 565	YDEYVNVK

SEQ ID NO: 566

1 MATFISVQLKKTSEVDLAKPLVKFIQQTYPSGGEEQAQYCRAA

EELSKLRRAAVGRPLDKHEGALETLLRYYDQICSIEP

81 KFPFSENQICLTFTWKDAFDKGSLFGGSVKLALASLGYEKSCV

LFNCAALASQIAAEQNLDNDEGLKIAAKHYQFASGAF

161 LHIKETVLSALSREPTVDISPDTVGTLSLIMLAQAQEVFFLKA

TRDKMKDAIIAKLANQAADYFGDAFKQCQYKDTLPKE

241 VFPVLAAKHCIMQANAEYHQSILAKQQKKFGEEIARLQHAAEL

IKTVASRYDEYVNVKDFSDKINRALAAAKKDNDFIYH

321 DRVPDLKDLDPIGKATLVKSTPVNVPISQKFTDLFEKMVPVSV

QQSLAAYNQRKADLVNRSIAQMREATTLANGVLASLN

401 LPAAIEDVSGDTVPQSILTKSRSVIEQGGIQTVDQLIKELPEL

LQRNREILDESLRLLDEEEATDNDLRAKFKERWQRTP

481 SNELYKPLRAEGTNFRTVLDKAVQADGQVKECYQSHRDTIVLL

CKPEPELNAAIPSANPAKTMQGSEVVNVLKSLLSNLD

561 EVKKEREGLENDLKSVNFDMTSKFLTALAQDGVINEEALSVTE

LDRVYGGLTTKVQESLKKQEGLLKNIQVSHQEFSKMK

641 QSNNEANLREEVLKNLATAYDNFVELVANLKEGTKFYNELTEI

LVRFQNKCSDIVFARKTERDELLKDLQQSIAREPSAP

721 SIPTPAYQSSPAGGHAPTPPTPAPRTMPPTKPQPPARPPPPVL

PANRAPSATAPSPVGAGTAAPAPSQTPGSAPPPQAQG

801 PPYPTYPGYPGYCQMPMPMGYNPYAYGQYNMPYPPVYHQSPGQ

APYPGPQQPSYPFPQPPQQSYYPQQ

5.60 prosaposin isoform a preproprotein [Homo sapiens]
Protein Accession gi|11386147

Mean Expression Ratio 0.78

Median Expression Ratio 0.78

Credible Interval (0.587, 1.04)

Associated Peptides 5

Associated Spectra 8

Coverage 0.0954


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.51	0.72	1.0	SEQ ID NO: 567	EIVDSYLPVILDIIK
1	0.55	0.8	1.2	SEQ ID NO: 568	GCSFLPDPYQK
1	0.55	0.79	1.1	SEQ ID NO: 569	LVGYLDR
3	0.55	0.77	1.1	SEQ ID NO: 570	QEILAALEK
1	0.54	0.78	1.1	SEQ ID NO: 571	SLPCDICK

SEQ ID NO: 572

1 MYALFLLASLLGAALAGPVLGLKECTRGSAVWCQNVKTASD

CGAVKHCLQTVWNKPTVKSLPCDICKDVVTAAGDMLKDN

81 ATEEEILVYLEKTCDWLPKPNMSASCKEIVDSYLPVILDII

KGEMSRPGEVCSALNLCESLQKHLAELNHQKQLESNKIP

161 ELDMTEVVAPFMANIPLLLYPQDGPRSKPQPKDNGDVCQDC

IQMVTDIQTAVRTNSTFVQALVEHVKEECDRLGPGMADI

241 CKNYISQYSEIAIQMMMHMQPKEICALVGFCDEVKEMPMQT

LVPAKVASKNVIPALELVEPIKKHEVPAKSDVYCEVCEF

321 LVKEVTKLIDNNKTEKEILDAFDKMCSKLPKSLSEECQEVV

DTYGSSILSILLEEVSPELVCSMLHLCSGTRLPALTVHV

401 TQPKDGGFCEVCKKLVGYLDRNLEKNSTKQEILAALEKGCS

FLPDPYQKQCDQFVAEYEPVLIEILVEVMDPSFVCLKIG

481 ACPSAHKPLLGTEKCIWGPSYWCQNTETAAQCNAVEHCKRH

VWN

5.61 ferritin, light polypeptide [Homo sapiens]
Protein Accession gi|20149498

Mean Expression Ratio 1.28

Median Expression Ratio 1.28

Credible Interval (1.11, 1.47)

Associated Peptides 16

Associated Spectra 66

Coverage 0.634


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.97	1.3	1.7	SEQ ID NO: 573	AAMALEK
5	1.0	1.3	1.7	SEQ ID NO: 574	ALFQDIK
3	0.98	1.3	1.7	SEQ ID NO: 575	DDVALEGVSHFFR
3	0.93	1.2	1.6	SEQ ID NO: 576	DLHALGSAR
1	0.96	1.3	1.7	SEQ ID NO: 577	FDRDDVALEGVSHFFR
1	0.98	1.3	1.8	SEQ ID NO: 578	KLNQALLDLHALGSAR
3	1.0	1.3	1.7	SEQ ID NO: 579	KPAEDEWGK
4	0.92	1.2	1.5	SEQ ID NO: 580	LCDFLETHFLDEEVK
12	0.93	1.1	1.4	SEQ ID NO: 581	LGGPEAGLGEYLFER
1	1.0	1.4	1.9	SEQ ID NO: 582	LGGPEAGLGEYLFERLTLK
2	1.1	1.5	2.0	SEQ ID NO: 583	LGGPEAGLGEYLFERLTLK
					HD

12	1	1.2	1.5	SEQ ID NO: 584	LNQALLDLHALGSAR
1	0.96	1.3	1.7	SEQ ID NO: 585	MGDHLTNLHR
1	0.85	1.1	1.5	SEQ ID NO: 586	QALLDLHALGSAR
15	1.1	1.4	1.7	SEQ ID NO: 587	TDPHLCDFLETHFLDEEVK
1	0.96	1.3	1.7	SEQ ID NO: 588	ELAEEK

SEQ ID NO: 589

1 MSSQIRQNYSTDVEAAVNSLVNLYLQASYTYLSLGFYFDRDDVAL

EGVSHFFRELAEEKREGYERLLKMQNQRGGRALFQ

81 DIKKPAEDEWGKTPDAMKAAMALEKKLNQALLDLHALGSARTDPH

LCDFLETHFLDEEVKLIKKMGDHLTNLHRLGGPEA

161 GLGEYLFERLTLKHD

5.62 galectin 3 binding protein [Homo sapiens]
Protein Accession gi|5031863

Mean Expression Ratio 1.28

Median Expression Ratio 1.28

Credible Interval (1.11, 1.48)

Associated Peptides 19

Associated Spectra 57

Coverage 0.369


A	2.5	50	97.5	Sequence ID No.	Sequence

3	1.0	1.3	1.8	SEQ ID NO: 590	AAFGQGSGPIMLDEVQCTGT
					EASLADCK

2	0.93	1.2	1.6	SEQ ID NO: 591	ALMLCEGLFVADVTDFEGWK
3	1.0	1.3	1.7	SEQ ID NO: 592	ASHEEVEGLVEK
15	1.0	1.2	1.5	SEQ ID NO: 593	ELSEALGQIFDSQR
8	0.96	1.2	1.5	SEQ ID NO: 594	GQWGTVCDNLWDLTDASVVC
					R

1	0.95	1.3	1.7	SEQ ID NO: 595	IDITLSSVK
1	0.92	1.2	1.7	SEQ ID NO: 596	IYTSPTWSAFVTDSSWSAR
1	0.95	1.3	1.7	SEQ ID NO: 597	QSFQTPQHPSFL
3	1.0	1.3	1.8	SEQ ID NO: 598	QSFQTPQHPSFLFQDK
3	1	1.3	1.7	SEQ ID NO: 599	QTPQHPSFLFQDK
1	0.94	1.3	1.7	SEQ ID NO: 600	RIDITLSSVK
2	0.96	1.3	1.7	SEQ ID NO: 601	SDLAVPSELALLK
6	1.2	1.5	1.9	SEQ ID NO: 602	STSSFPCPAGHFNGFR
1	0.97	1.3	1.8	SEQ ID NO: 603	TIAYENK
1	0.97	1.3	1.7	SEQ ID NO: 604	TLQALEFHTVPF
1	0.92	1.3	1.7	SEQ ID NO: 605	VADVTDFEGWK
2	0.92	1.2	1.6	SEQ ID NO: 606	WSHEALFQK
2	0.9	1.2	1.6	SEQ ID NO: 607	YSSDYFQAPSDYR
1	0.96	1.3	1.8	SEQ ID NO: 608	VEIFYR

SEQ ID NO: 609

1 MTPPRLFWVWLLVAGTQGVNDGDMRLADGGATNQGRVEIFYRGQW

GTVCDNLWDLTDASVVCRALGFENATQALGRAAFG

81 QGSGPIMLDEVQCTGTEASLADCKSLGWLKSNCRHERDAGVVCTN

ETRSTHTLDLSRELSEALGQIFDSQRGCDLSISVN

161 VQGEDALGFCGHTVILTANLEAQALWKEPGSNVTMSVDAECVPMV

RDLLRYFYSRRIDITLSSVKCFHKLASAYGARQLQ

241 GYCASLFAILLPQDPSFQMPLDLYAYAVATGDALLEKLCLQFLAW

NFEALTQAEAWPSVPTDLLQLLLPRSDLAVPSELA

321 LLKAVDTWSWGERASHEEVEGLVEKIRFPMMLPEELFELQFNLSL

YWSHEALFQKKTLQALEFHTVPFQLLARYKGLNLT

401 EDTYKPRIYTSPTWSAFVTDSSWSARKSQLVYQSRRGPLVKYSSD

YFQAPSDYRYYPYQSFQTPQHPSFLFQDKRVSWSL

481 VYLPTIQSCWNYGFSCSSDELPVLGLTKSGGSDRTIAYENKALML

CEGLFVADVTDFEGWKAAIPSALDTNSSKSTSSFP

561 CPAGHFNGFRTVIRPFYLTNSSGVD

5.63 peptidoglycan recognition protein 1 [Homo sapiens]
Protein Accession gi|4827036

Mean Expression Ratio 0.784

Median Expression Ratio 0.786

Credible Interval (0.55, 1.12)

Associated Peptides 3

Associated Spectra 4

Coverage 0.276


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.51	0.77	1.2	SEQ ID NO: 610	AAQGLLACGVAQGALR
2	0.52	0.76	1.1	SEQ ID NO: 611	ALASECAQHLSLPLR
1	0.51	0.77	1.2	SEQ ID NO: 612	TLGWCDVGYNFLIGEDGLVY
					EGR

SEQ ID NO: 613

1 MSRRSMLLAWALPSLLRLGAAQETEDPACCSPIVPRNEWKALAS

ECAQHLSLPLRYVVVSHTAGSSCNTPASCQQQARNV

81 QHYHMKTLGWCDVGYNFLIGEDGLVYEGRGWNFTGAHSGHLWNP

MSIGISFMGNYMDRVPTPQAIRAAQGLLACGVAQGA

161 LRSNYVLKGHRDVQRTLSPGNQLYHLIQNWPHYRSP

5.64 ubiquitin and ribosomal protein S27a precursor [Homo sapiens]; ubiquitin and ribosomal protein S27a precursor [Homo sapiens]
Protein Accession gi|4506713 gi|208022622

Mean Expression Ratio 1.27

Median Expression Ratio 1.27

Credible Interval (0.99, 1.64)

Associated Peptides 5

Associated Spectra 12

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.95	1.3	1.8	SEQ ID NO: 614	ESTLHLVLR

4	1.0	1.4	1.8	SEQ ID NO: 615	TITLEVEPSDTIENVK

1	0.9	1.3	1.9	SEQ ID NO: 616	TLSDYNIQK

1	0.9	1.3	1.8	SEQ ID NO: 617	LIFAGK

3	0.89	1.2	1.7	SEQ ID NO: 618	MQIFVK

5.65 complement component 4A preproprotein [Homo sapiens]
Protein Accession gi|67190748

Mean Expression Ratio 0.787

Median Expression Ratio 0.786

Credible Interval (0.511, 1.21)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0115


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.48	0.74	1.2	SEQ ID NO: 619	LLSQQQADGSFQDPCPVLDR

SEQ ID NO: 620

1 MRLLWGLIWASSFFTLSLQKPRLLLFSPSVVHLGVPLSVGVQL

QDVPRGQVVKGSVFLRNPSRNNVPCSPKVDFTLSSER

81 DFALLSLQVPLKDAKSCGLHQLLRGPEVQLVAHSPWLKDSLSR

TTNIQGINLLFSSRRGHLFLQTDQPIYNPGQRVRYRV

161 FALDQKMRPSTDTITVMVENSHGLRVRKKEVYMPSSIFQDDFV

IPDISEPGTWKISARFSDGLESNSSTQFEVKKYVLPN

241 FEVKITPGKPYILTVPGHLDEMQLDIQARYIYGKPVQGVAYVR

FGLLDEDGKKTFFRGLESQTKLVNGQSHISLSKAEFQ

321 DALEKLNMGITDLQGLRLYVAAAIIESPGGEMEEAELTSWYFV

SSPFSLDLSKTKRHLVPGAPFLLQALVREMSGSPASG

401 IPVKVSATVSSPGSVPEVQDIQQNTDGSGQVSIPIIIPQTISE

LQLSVSAGSPHPAIARLTVAAPPSGGPGFLSIERPDS

481 RPPRVGDTLNLNLRAVGSGATFSHYYYMILSRGQIVFMNREPK

RTLTSVSVFVDHHLAPSFYFVAFYYHGDHPVANSLRV

561 DVQAGACEGKLELSVDGAKQYRNGESVKLHLETDSLALVALGA

LDTALYAAGSKSHKPLNMGKVFEAMNSYDLGCGPGGG

641 DSALQVFQAAGLAFSDGDQWTLSRKRLSCPKEKTTRKKRNVNF

QKAINEKLGQYASPTAKRCCQDGVTRLPMMRSCEQRA

721 ARVQQPDCREPFLSCCQFAESLRKKSRDKGQAGLQRALEILQE

EDLIDEDDIPVRSFFPENWLWRVETVDRFQILTLWLP

801 DSLTTWEIHGLSLSKTKGLCVATPVQLRVFREFHLHLRLPMSV

RRFEQLELRPVLYNYLDKNLTVSVHVSPVEGLCLAGG

881 GGLAQQVLVPAGSARPVAFSVVPTAAAAVSLKVVARGSFEFPV

GDAVSKVLQIEKEGAIHREELVYELNPLDHRGRTLEI

961 PGNSDPNMIPDGDFNSYVRVTASDPLDTLGSEGALSPGGVASL

LRLPRGCGEQTMIYLAPTLAASRYLDKTEQWSTLPPE

1041 TKDHAVDLIQKGYMRIQQFRKADGSYAAWLSRDSSTWLTAFVL

KVLSLAQEQVGGSPEKLQETSNWLLSQQQADGSFQDP

1121 CPVLDRSMQGGLVGNDETVALTAFVTIALHHGLAVFQDEGAEP

LKQRVEASISKANSFLGEKASAGLLGAHAAAITAYAL

1201 TLTKAPVDLLGVAHNNLMAMAQETGDNLYWGSVTGSQSNAVSP

TPAPRNPSDPMPQAPALWIETTAYALLHLLLHEGKAE

1281 MADQASAWLTRQGSFQGGFRSTQDTVIALDALSAYWIASHTTE

ERGLNVTLSSTGRNGFKSHALQLNNRQIRGLEEELQF

1361 SLGSKINVKVGGNSKGTLKVLRTYNVLDMKNTTCQDLQIEVTV

KGHVEYTMEANEDYEDYEYDELPAKDDPDAPLQPVTP

1441 LQLFEGRRNRRRREAPKVVEEQESRVHYTVCIWRNGKVGLSGM

AIADVTLLSGFHALRADLEKLTSLSDRYVSHFETEGP

1521 HVLLYFDSVPTSRECVGFEAVQEVPVGLVQPASATLYDYYNPE

RRCSVFYGAPSKSRLLATLCSAEVCQCAEGKCPRQRR

1601 ALERGLQDEDGYRMKFACYYPRVEYGFQVKVLREDSRAAFRLF

ETKITQVLHFTKDVKAAANQMRNFLVRASCRLRLEPG

1681 KEYLIMGLDGATYDLEGHPQYLLDSNSWIEEMPSERLCRSTRQ

RAACAQLNDFLQEYGTQGCQV

5.66 hypothetical protein LOC169693 [Homo sapiens]
Protein Accession gi|23397518

Mean Expression Ratio 0.788

Median Expression Ratio 0.788

Credible Interval (0.572, 1.07)

Associated Peptides 3

Associated Spectra 8

Coverage 0.282


A	2.5	50	97.5	Sequence ID No.	Sequence

6	0.56	0.75	1	SEQ ID NO: 621	ESIAGLVVTAISEDAQR
1	0.52	0.77	1.1	SEQ ID NO: 622	QHLAHGALPVATVDRPDF
					YPPAYEESLEVEK

1	0.53	0.8	1.2	SEQ ID NO: 623	QHLAHGALPVATVDRPDF

SEQ ID NO: 624

1 MQNRTGLILCALALLMGFLMVCLGAFFISWGSIFDCQGSLIAA

YLLLPLGFVILLSGIFWSNYRQVTESKGVLRHMLRQH

81 LAHGALPVATVDRPDFYPPAYEESLEVEKQSCPAEREASGIPP

PLYTETGLEFQDGNDSHPEAPPSYRESIAGLVVTAIS

161 EDAQRRGQEC

5.67 nidogen 1 precursor [Homo sapiens]
Protein Accession gi|115298674

Mean Expression Ratio 0.79

Median Expression Ratio 0.788

Credible Interval (0.513, 1.22)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0217


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.48	0.75	1.2	SEQ ID NO: 625	GPGQGDLELEDGDDFVSPALE
					LSGALR

SEQ ID NO: 626

1 MLASSSRIRAAWTRALLLPLLLAGPVGCLSRQELFPFGPGQGDL

ELEDGDDFVSPALELSGALRFYDRSDIDAVYVTTNG

81 IIATSEPPAKESHPGLFPPTFGAVAPFLADLDTTDGLGKVYYRE

DLSPSITQRAAECVHRGFPEISFQPSSAVVVTWESV

161 APYQGPSRDPDQKGKRNTFQAVLASSDSSSYAIFLYPEDGLQFH

TTFSKKENNQVPAVVAFSQGSVGFLWKSNGAYNIFA

241 NDRESVENLAKSSNSGQQGVWVFEIGSPATTNGVVPADVILGTE

DGAEYDDEDEDYDLATTRLGLEDVGTTPFSYKALRR

321 GGADTYSVPSVLSPRRAATERPLGPPTERTRSFQLAVETFHQQH

PQVIDVDEVEETGVVFSYNTDSRQTCANNRHQCSVH

401 AECRDYATGFCCSCVAGYTGNGRQCVAEGSPQRVNGKVKGRIFV

GSSQVPIVFENTDLHSYVVMNHGRSYTAISTIPETV

481 GYSLLPLAPVGGIIGWMFAVEQDGFKNGFSITGGEFTRQAEVTF

VGHPGNLVIKQRFSGIDEHGHLTIDTELEGRVPQIP

561 FGSSVHIEPYTELYHYSTSVITSSSTREYTVTEPERDGASPSRI

YTYQWRQTITFQECVHDDSRPALPSTQQLSVDSVFV

641 LYNQEEKILRYALSNSIGPVREGSPDALQNPCYIGTHGCDTNAA

CRPGPRTQFTCECSIGFRGDGRTCYDIDECSEQPSV

721 CGSHTICNNHPGTFRCECVEGYQFSDEGTCVAVVDQRPINYCET

GLHNCDIPQRAQCIYTGGSSYTCSCLPGFSGDGQAC

801 QDVDECQPSRCHPDAFCYNTPGSFTCQCKPGYQGDGFRCVPGEV

EKTRCQHEREHILGAAGATDPQRPIPPGLFVPECDA

881 HGHYAPTQCHGSTGYCWCVDRDGREVEGTRTRPGMTPPCLSTVA

PPIHQGPAVPTAVIPLPPGTHLLFAQTGKIERLPLE

961 GNTMRKTEAKAFLHVPAKVIIGLAFDCVDKMVYWTDITEPSIGR

ASLHGGEPTTIIRQDLGSPEGIAVDHLGRNIFWTDS

1041 NLDRIEVAKLDGTQRRVLFETDLVNPRGIVTDSVRGNLYWTDWN

RDNPKIETSYMDGTNRRILVQDDLGLPNGLTFDAFS

1121 SQLCWVDAGTNRAECLNPSQPSRRKALEGLQYPFAVTSYGKNLY

FTDWKMNSVVALDLAISKETDAFQPHKQTRLYGITT

1201 ALSQCPQGHNYCSVNNGGCTHLCLATPGSRTCRCPDNTLGVDCI

EQK

5.68 CD9 antigen [Homo sapiens]
Protein Accession gi|4502693

Mean Expression Ratio 1.27

Median Expression Ratio 1.27

Credible Interval (0.856, 1.88)

Associated Peptides 2

Associated Spectra 3

Coverage 0.0921


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.91	1.4	2.1	SEQ ID NO: 627	EVQEFYK
1	0.8	1.2	2.0	SEQ ID NO: 628	AGGVEQFISDICPK

SEQ ID NO: 629

1 MPVKGGTKCIKYLLFGFNFIFWLAGIAVLAIGLWLRFDSQT

KSIFEQETNNNNSSFYTGVYILIGAGALMMLVGFLGCCG

81 AVQESQCMLGLFFGFLLVIFAIEIAAAIWGYSHKDEVIKEV

QEFYKDTYNKLKTKDEPQRETLKAIHYALNCCGLAGGVE

161 QFISDICPKKDVLETFTVKSCPDAIKEVFDNKFHIIGAVGI

GIAVVMIFGMIFSMILCCAIRRNREMV

5.69 solute carrier family 5 (sodium/glucose cotransporter), member 10 isoform 2 [Homo sapiens]
Protein Accession gi|109659836

Mean Expression Ratio 0.79

Median Expression Ratio 0.79

Credible Interval (0.519, 1.22)

Associated Peptides 2

Associated Spectra 2

Coverage 0.047


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.47	0.76	1.2	SEQ ID NO: 630	ALFPDDVGCVVPSECLR
1	0.48	0.78	1.2	SEQ ID NO: 631	LVMELMPIGLR

SEQ ID NO: 632

1 MAANSTSDLHTPGTQLSVADIIVITVYFALNVAVGIWSSCR

ASRNTVNGYFLAGRDMTWWPIGASLFASSEGSGLFIGLA

81 GSGAAGGLAVAGFEWNATYVLLALAWVFVPIYISSEIVTLP

EYIQKRYGGQRIRMYLSVLSLLLSVFTKISLDLYAGALF

161 VHICLGWNFYLSTILTLGITALYTIAGGLAAVIYTDALQTL

IMVVGAVILTIKAFDQIGGYGQLEAAYAQAIPSRTIANT

241 TCHLPRTDAMHMFRDPHTGDLPWTGMTFGLTIMATWYWCTD

QVIVQRSLSARDLNHAKAGSILASYLKMLPMGLIIMPGM

321 ISRALFPDDVGCVVPSECLRACGAEVGCSNIAYPKLVMELM

PIGLRGLMIAVMLAALMSSLTSIFNSSSTLFTMDIWRRL

401 RPRSGERELLLVGRLVIVALIGVSVAWIPVLQDSNSGQLFI

YMQSVTSSLAPPVTAVFVLGVFWRRANEQGAFWGLIAGL

481 VVGATRLVLEFLNPAPPCGEPDTRPAVLGSIHYLHFAVALF

ALSGAVVVAGSLLTPPPQSVQIENLTWWTLAQDVPLGTK

561 AGDGQTPQKHAFWARVCGFNAILLMCVNIFFYAYFA

5.70 sorting nexin 18 isoform a [Homo sapiens]; sorting nexin 18 isoform b 30 [Homo sapiens]

Protein Accession gi 157057545 gi 157057543

Mean Expression Ratio 1.26

Median Expression Ratio 1.26

Credible Interval (0.82, 1.91)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.86 1.4 2.2 SEQ ID NO: 633 APEPGPAGDGGPGAPAR

1 0.78 1.2 2.0 SEQ ID NO: 634 LVPTHTQVPVHR

5.71 syntenin isoform 1 [Homo sapiens]; syntenin isoform 1 [Homo sapiens]
Protein Accession gi|56243522 gi|55749490

Mean Expression Ratio 1.26

Median Expression Ratio 1.26

Credible Interval (0.87, 1.83)

Associated Peptides 2

Associated Spectra 4

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

3 0.94 1.4 2.0 SEQ ID NO: 635 ANVAVVSGAPLQGQLVAR

1 0.82 1.2 1.9 SEQ ID NO: 636 VAVVSGAPLQGQLVAR

5.72 glutamyl aminopeptidase (aminopeptidase A) [Homo sapiens]
Protein Accession gi|132814467

Mean Expression Ratio 0.795

Median Expression Ratio 0.794

Credible Interval (0.682, 0.932)

Associated Peptides 25

Associated Spectra 39

Coverage 0.268


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.6	0.8	1.1	SEQ ID NO: 637	AQLLDYK
1	0.58	0.78	1.1	SEQ ID NO: 638	ASLIDDAFALAR
2	0.62	0.81	1.1	SEQ ID NO: 639	AVHQFDSVK
1	0.63	0.84	1.1	SEQ ID NO: 640	EESVDDKWTR
1	0.6	0.8	1.1	SEQ ID NO: 641	ETNLLYDPK
1	0.61	0.83	1.1	SEQ ID NO: 642	EYGALSNMPVAK
4	0.65	0.84	1.1	SEQ ID NO: 643	IAIPDFGTGAMENWGLI
					TYR
6	0.6	0.76	0.98	SEQ ID NO: 644	INPDHIGFYR
1	0.59	0.8	1.1	SEQ ID NO: 645	KSFPCFDEPNKK
1	0.59	0.8	1.1	SEQ ID NO: 646	LLYGLASVK
1	0.58	0.79	1.1	SEQ ID NO: 647	LPDFVNPVHY
1	0.57	0.77	1.0	SEQ ID NO: 648	NMAWNWIQLNWDYLVNR
1	0.58	0.79	1.1	SEQ ID NO: 649	NNIEWLK
1	0.61	0.83	1.1	SEQ ID NO: 650	QMGYPVLNVNGVK
1	0.57	0.77	1.1	SEQ ID NO: 651	SFPCFDEPNKK
1	0.56	0.75	1.0	SEQ ID NO: 652	SIVATDHEPTDAR
1	0.57	0.78	1.0	SEQ ID NO: 653	SSHPIIVTVTTPDEITS
					VFDGISY
3	0.57	0.75	0.99	SEQ ID NO: 654	TSDFWAALEEASR
1	0.61	0.82	1.1	SEQ ID NO: 655	TSDFWAALEEASRLPVK
2	0.62	0.82	1.1	SEQ ID NO: 656	YLWLHLR
3	0.58	0.77	1.0	SEQ ID NO: 657	YPQAGAGEKPR
1	0.58	0.8	1.1	SEQ ID NO: 658	MLEDWIKPENFQK
1	0.58	0.78	1.1	SEQ ID NO: 659	IQLNWDYLVNR
1	0.57	0.77	1.0	SEQ ID NO: 660	YLDLLK
1	0.58	0.78	1.1	SEQ ID NO: 661	QMESFFAK

SEQ ID NO: 662

1 MNFAEREGSKRYCIQTKHVAILCAVVVGVGLIVGLAVGLTRSCD

SSGDGGPGTAPAPSHLPSSTASPSGPPAQDQDICPA

81 SEDESGQWKNFRLPDFVNPVHYDLHVKPLLEEDTYTGTVSISIN

LSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRC

161 FEYKKQEYVVVEAEEELTPSSGDGLYLLTMEFAGWLNGSLVGFY

RTTYTENGQVKSIVATDHEPTDARKSFPCFDEPNKK

241 ATYTISITHPKEYGALSNMPVAKEESVDDKWTRTTFEKSVPMST

YLVCFAVHQFDSVKRISNSGKPLTIYVQPEQKHTAE

321 YAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGL

ITYRETNLLYDPKESASSNQQRVATVVAHELVHQWF

401 GNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLED

VLPVQEDDSLMSSHPIIVTVTTPDEITSVFDGISYS

481 KGSSILRMLEDWIKPENFQKGCQMYLEKYQFKNAKTSDFWAALE

EASRLPVKEVMDTWTRQMGYPVLNVNGVKNITQKRF

561 LLDPRANPSQPPSDLGYTWNIPVKWTEDNITSSVLFNRSEKEGI

TLNSSNPSGNAFLKINPDHIGFYRVNYEVATWDSIA

641 TALSLNHKTFSSADRASLIDDAFALARAQLLDYKVALNLTKYLK

REENFLPWQRVISAVTYIISMFEDDKELYPMIEEYF

721 QGQVKPIADSLGWNDAGDHVTKLLRSSVLGFACKMGDREALNNA

SSLFEQWLNGTVSLPVNLRLLVYRYGMQNSGNEISW

801 NYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNL

IKTQDVFTVIRYISYNSYGKNMAWNWIQLNWDYLVN

881 RYTLNNRNLGRIVTIAEPFNTELQLWQMESFFAKYPQAGAGEKP

REQVLETVKNNIEWLKQHRNTIREWFFNLLESG

5.73 histone cluster 2, H4b [Homo sapiens]; histone cluster 2, H4a [Homo sapiens]; histone cluster 1, H4i [Homo sapiens]; histone cluster 1, H41 [Homo sapiens]; histone cluster 1, H4e [Homo sapiens]; histone cluster 1, H4b [Homo sapiens]; histone cluster 1, H4h [Homo sapiens]; histone cluster 1, H4c [Homo sapiens]; histone cluster 1, H4k [Homo sapiens]; histone cluster 1, H4f [Homo sapiens]; histone cluster 1, H4d [Homo sapiens]; histone cluster 1, H4a [Homo sapiens]; histone cluster 4, H4 [Homo sapiens]; histone cluster 1, H4j [Homo sapiens]
Protein Accession gi|77539758 gi|4504323 gi|4504321 gi|4504317 gi|4504315 gi|4504313 gi|4504311 gi|4504309

Mean Expression Ratio 0.791

Median Expression Ratio 0.794

Credible Interval (0.489, 1.26)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.45 0.75 1.3 SEQ ID NO: 663 VFLENVIR

5.74 guanine nucleotide binding protein (G protein), q polypeptide [Homo sapiens]
Protein Accession gi|40254462

Mean Expression Ratio 1.25

Median Expression Ratio 1.26

Credible Interval (0.847, 1.88)

Associated Peptides 2

Associated Spectra 3

Coverage 0.0947


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.86	1.3	1.9	SEQ ID NO: 664	VADPAYLPTQQDVLR
1	0.83	1.3	2	SEQ ID NO: 665	VPTTGIIEYPFDLQSVIFR

SEQ ID NO: 666

1 MTLESIMACCLSEEAKEARRINDEIERQLRRDKRDARRELKL

LLLGTGESGKSTFIKQMRIIHGSGYSDEDKRGFTKLVY

81 QNIFTAMQAMIRAMDTLKIPYKYEHNKAHAQLVREVDVEKVS

AFENPYVDAIKSLWNDPGIQECYDRRREYQLSDSTKYY

161 LNDLDRVADPAYLPTQQDVLRVRVPTTGIIEYPFDLQSVIFR

MVDVGGQRSERRKWIHCFENVTSIMFLVALSEYDQVLV

241 ESDNENRMEESKALFRTIITYPWFQNSSVILFLNKKDLLEEK

IMYSHLVDYFPEYDGPQRDAQAAREFILKMFVDLNPDS

321 DKIIYSHFTCATDTENIRFVFAAVKDTILQLNLKEYNLV

5.75 syndecan 1 precursor [Homo sapiens]; syndecan 1 precursor [Homo sapiens]
Protein Accession gi|55749480 gi|29568086

Mean Expression Ratio 0.797

Median Expression Ratio 0.795

Credible Interval (0.536, 1.19)

Associated Peptides 2

Associated Spectra 3

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.49 0.74 1.1 SEQ ID NO: 667 EGEAVVLPEVEPGLTAR

1 0.52 0.8 1.3 SEQ ID NO: 668 NQSPVDQGATGASQGLLDR

5.76 copine III [Homo sapiens]
Protein Accession gi|4503015

Mean Expression Ratio 1.26

Median Expression Ratio 1.26

Credible Interval (0.877, 1.80)

Associated Peptides 3

Associated Spectra 4

Coverage 0.0782


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.9	1.3	1.9	SEQ ID NO: 669	DIVQFVPFR
1	0.83	1.3	1.9	SEQ ID NO: 670	LYGPTNFSPIINHVAR
1	0.82	1.3	1.9	SEQ ID NO: 671	VLLIITDGVITDLDETR

SEQ ID NO: 672

1 MAAQCVTKVALNVSCANLLDKDIGSKSDPLCVLFLNTSGQQ

WYEVERTERIKNCLNPQFSKTFIIDYYFEVVQKLKFGVY

81 DIDNKTIELSDDDFLGECECTLGQIVSSKKLTRPLVMKTGR

PAGKGSITISAEEIKDNRVVLFEMEARKLDNKDLFGKSD

161 PYLEFHKQTSDGNWLMVHRTEVVKNNLNPVWRPFKISLNSL

CYGDMDKTIKVECYDYDNDGSHDLIGTFQTTMTKLKEAS

241 RSSPVEFECINEKKRQKKKSYKNSGVISVKQCEITVECTFL

DYIMGGCQLNFTVGVDFTGSNGDPRSPDSLHYISPNGVN

321 EYLTALWSVGLVIQDYDADKMFPAFGFGAQIPPQWQVSHEF

PMNFNPSNPYCNGIQGIVEAYRSCLPQIKLYGPTNFSPI

401 INHVARFAAAATQQQTASQYFVLLIITDGVITDLDETRQAI

VNASRLPMSIIIVGVGGADFSAMEFLDGDGGSLRSPLGE

481 VAIRDIVQFVPFRQFQNAPKEALAQCVLAEIPQQVVGYFNT

YKLLPPKNPATKQQKQ

5.77 annexin VII isoform 2 [Homo sapiens]; annexin VII isoform 1 [Homo sapiens]
Protein Accession gi|4809279 gi|4502111

Mean Expression Ratio 1.26

Median Expression Ratio 1.26

Credible Interval (0.897, 1.79)

Associated Peptides 3

Associated Spectra 5

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

3 0.9 1.3 1.8 SEQ ID NO: 673 DENQSINHQMAQEDAQR

1 0.86 1.3 2 SEQ ID NO: 674 GFGTDEQAIVDVVANR

1 0.83 1.3 1.9 SEQ ID NO: 675 VLIEILCTR

5.78 cubilin [Homo sapiens]
Protein Accession gi|126091152

Mean Expression Ratio 0.798

Median Expression Ratio 0.798

Credible Interval (0.637, 1.01)

Associated Peptides 10

Associated Spectra 14

Coverage 0.0461


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.56	0.79	1.1	SEQ ID NO: 676	CNFDVLEIYGGPDFHSPR

4	0.56	0.75	1	SEQ ID NO: 677	DFVEILDGGHEDAPLR

1	0.58	0.81	1.1	SEQ ID NO: 678	EQLANPIVSSGNSLFLR

1	0.57	0.8	1.1	SEQ ID NO: 679	LQVLLLTDGVGR

1	0.57	0.8	1.1	SEQ ID NO: 680	NGGSPESPIIGQYCGNSNPR

2	0.58	0.78	1.1	SEQ ID NO: 681	SPENPMQVSSTGNELAIR

1	0.57	0.8	1.1	SEQ ID NO: 682	SPFFPNVYPGER

1	0.55	0.78	1.1	SEQ ID NO: 683	VPGQSGVVESIGHPTLPYR

1	0.57	0.8	1.1	SEQ ID NO: 684	LNDEDLSECLHQIQK

1	0.59	0.82	1.2	SEQ ID NO: 685	YCGNTIPDSIDTSSNTAVVR

SEQ ID NO: 686

1 M M N M S L P F L W S L L T L L I F A E V N

G E A G E L E L Q R Q K R S I N L Q Q P R M

A T E R G N L V F L T G S A Q N I E F R T G

S L G K I K L N D E D L S E

81 C L H Q I Q K N K E D I I E L K G S A I G L

P Q N I S S Q I Y Q L N S K L V D L E R K F

Q G L Q Q T V D K K V C S S N P C Q N G G T

C L N L H D S F F C I C P P

161 Q W K G P L C S A D V N E C E I Y S G T P L

S C Q N G G T C V N T M G S Y S C H C P P E

T Y G P Q C A S K Y D D C E G G S V A R C V

H G I C E D L M R E Q A G E

241 P K Y S C V C D A G W M F S P N S P A C T L

D R D E C S F Q P G P C S T L V Q C F N T Q

G S F Y C G A C P T G W Q G N G Y I C E D I

N E C E I N N G G C S V A P

321 P V E C V N T P G S S H C Q A C P P G Y Q G

D G R V C T L T D I C S V S N G G C H P D A

S C S S T L G S L P L C T C L P G Y T G N G

Y G P N G C V Q L S N I C L

401 S H P C L N G Q C I D T V S G Y F C K C D S

G W T G V N C T E N I N E C L S N P C L N G

G T C V D G V D S F S C E C T R L W T G A L

C Q V P Q Q V C G E S L S G

481 I N G S F S Y R S P D V G Y V H D V N C F W

V I K T E M G K V L R I T F T F F R L E S M

D N C P H E F L Q V Y D G D S S S A F Q L G

R F C G S S L P H E L L S S

561 D N A L Y F H L Y S E H L R N G R G F T V R

W E T Q Q P E C G G I L T G P Y G S I K S P

G Y P G N Y P P G R D C V W I V V T S P D L

L V T F T F G T L S L E H H

641 D D C N K D Y L E I R D G P L Y Q D P L L G

K F C T T F S V P P L Q T T G P F A R I H F

H S D S Q I S D Q G F H I T Y L T S P S D L

R C G G N Y T D P E G E L F

721 L P E L S G P F T H T R Q C V Y M M K Q P Q

G E Q I Q I N F T H V E L Q C Q S D S S Q N

Y I E V R D G E T L L G K V C G N G T I S H

I K S I T N S V W I R F K I

801 D A S V E K A S F R A V Y Q V A C G D E L T

G E G V I R S P F F P N V Y P G E R T C R W

T I H Q P Q S Q V I L L N F T V F E I G S S

A H C E T D Y V E I G S S S

881 I L G S P E N K K Y C G T D I P S F I T S V

Y N F L Y V T F V K S S S T E N H G F M A K

F S A E D L A C G E I L T E S T G T I Q S P

G H P N V Y P H G I N C T W

961 H I L V Q P N H L I H L M F E T F H L E F H

Y N C T N D Y L E V Y D T D S E T S L G R Y

C G K S I P P S L T S S G N S L M L V F V T

D S D L A Y E G F L I N Y E

1041 A I S A A T A C L Q D Y T D D L G T F T S P

N F P N N Y P N N W E C I Y R I T V R T G Q

L I A V H F T N F S L E E A I G N Y Y T D F

L E I R D G G Y E K S P L L

1121 G I F Y G S N L P P T I I S H S N K L W L K

F K S D Q I D T R S G F S A Y W D G S S T G

C G G N L T T S S G T F I S P N Y P M P Y Y

H S S E C Y W W L K S S H G

1201 S A F E L E F K D F H L E H H P N C T L D Y

L A V Y D G P S S N S H L L T Q L C G D E K

P P L I R S S G D S M F I K L R T D E G Q Q

G R G F K A E Y R Q T C E N

1281 V V I V N Q T Y G I L E S I G Y P N P Y S E

N Q H C N W T I R A T T G N T V N Y T F L A

F D L E H H I N C S T D Y L E L Y D G P R Q

M G R Y C G V D L P P P G S

1361 T T S S K L Q V L L L T D G V G R R E K G F

Q M Q W F V Y G C G G E L S G A T G S F S S

P G F P N R Y P P N K E C I W Y I R T D P G

S S I Q L T I H D F D V E Y

1441 H S R C N F D V L E I Y G G P D F H S P R I

A Q L C T Q R S P E N P M Q V S S T G N E L

A I R F K T D L S I N G R G F N A S W Q A V

T G G C G G I F Q A P S G E

1521 I H S P N Y P S P Y R S N T D C S W V I R V

D R N H R V L L N F T D F D L E P Q D S C I

M A Y D G L S S T M S R L A R T C G R E Q L

A N P I V S S G N S L F L R

1601 F Q S G P S R Q N R G F R A Q F R Q A C G G

H I L T S S F D T V S S P R F P A N Y P N N

Q N C S W I I Q A Q P P L N H I T L S F T H

F E L E R S T T C A R D F V

1681 E I L D G G H E D A P L R G R Y C G T D M P

H P I T S F S S A L T L R F V S D S S I S A

G G F H T T V T A S V S A C G G T F Y M A E

G I F N S P G Y P D I Y P P

1761 N V E C V W N I V S S P G N R L Q L S F I S

F Q L E D S Q D C S R D F V E I R E G N A T

G H L V G R Y C G N S F P L N Y S S I V G H

T L W V R F I S D G S G S G

1841 T G F Q A T F M K I F G N D N I V G T H G K

V A S P F W P E N Y P H N S N Y Q W T V N V

N A S H V V H G R I L E M D I E E I Q N C Y

Y D K L R I Y D G P S I H A

1921 R L I G A Y C G T Q T E S F S S T G N S L T

F H F Y S D S S I S G K G F L L E W F A V D

A P D G V L P T I A P G A C G G F L R T G D

A P V F L F S P G W P D S Y

2001 S N R V D C T W L I Q A P D S T V E L N I L

S L D I E S H R T C A Y D S L V I R D G D N

N L A Q Q L A V L C G R E I P G P I R S T G

E Y M F I R F T S D S S V T

2081 R A G F N A S F H K S C G G Y L H A D R G I

I T S P K Y P E T Y P S N L N C S W H V L V

Q S G L T I A V H F E Q P F Q I P N G D S S

C N Q G D Y L V L R N G P D

2161 I C S P P L G P P G G N G H F C G S H A S S

T L F T S D N Q M F V Q F I S D H S N E G Q

G F K I K Y E A K S L A C G G N V Y I H D A

D S A G Y V T S P N H P H N

2241 Y P P H A D C I W I L A A P P E T R I Q L Q

F E D R F D I E V T P N C T S N Y L E L R D

G V D S D A P I L S K F C G T S L P S S Q W

S S G E V M Y L R F R S D N

2321 S P T H V G F K A K Y S I A Q C G G R V P G

Q S G V V E S I G H P T L P Y R D N L F C E

W H L Q G L S G H Y L T I S F E D F N L Q N

S S G C E K D F V E I W D N

2401 H T S G N I L G R Y C G N T I P D S I D T S

S N T A V V R F V T D G S V T A S G F R L R

F E S S M E E C G G D L Q G S I G T F T S P

N Y P N P N P H G R I C E W

2481 R I T A P E G R R I T L M F N N L R L A T H

P S C N N E H V I V F N G I R S N S P Q L E

K L C S S V N V S N E I K S S G N T M K V I

F F T D G S R P Y G G F T A

2561 S Y T S S E D A V C G G S L P N T P E G N F

T S P G Y D G V R N Y S R N L N C E W T L S

N P N Q G N S S I S I H F E D F Y L E S H Q

D C Q F D V L E F R V G D A

2641 D G P L M W R L C G P S K P T L P L V I P Y

S Q V W I H F V T N E R V E H I G F H A K Y

S F T D C G G I Q I G D S G V I T S P N Y P

N A Y D S L T H C S S L L E

2721 A P Q G H T I T L T F S D F D I E P H T T C

A W D S V T V R N G G S P E S P I I G Q Y C

G N S N P R T I Q S G S N Q L V V T F N S D

H S L Q G G G F Y A T W N T

2801 Q T L G C G G I F H S D N G T I R S P H W P

Q N F P E N S R C S W T A I T H K S K H L E

I S F D N N F L I P S G D G Q C Q N S F V K

V W A G T E E V D K A L L A

2881 T G C G N V A P G P V I T P S N T F T A V F

Q S Q E A P A Q G F S A S F V S R C G S N F

T G P S G Y I I S P N Y P K Q Y D N N M N C

T Y V I E A N P L S V V L L

2961 T F V S F H L E A R S A V T G S C V N D G V

H I I R G Y S V M S T P F A T V C G D E M P

A P L T I A G P V L L N F Y S N E Q I T D F

G F K F S Y R I I S C G G V

3041 F N F S S G I I T S P A Y S Y A D Y P N D M

H C L Y T I T V S D D K V I E L K F S D F D

V V P S T S C S H D Y L A I Y D G A N T S D

P L L G K F C G S K R P P N

3121 V K S S N N S M L L V F K T D S F Q T A K G

W K M S F R Q T L G P Q Q G C G G Y L T G S

N N T F A S P D S D S N G M Y D K N L N C V

W I I I A P V N K V I H L T

3201 F N T F A L E A A S T R Q R C L Y D Y V K L

Y D G D S E N A N L A G T F C G S T V P A P

F I S S G N F L T V Q F I S D L T L E R E G

F N A T Y T I M D M P C G G

3281 T Y N A T W T P Q N I S S P N S S D P D V P

F S I C T W V I D S P P H Q Q V K I T V W A

L Q L T S Q D C T Q N Y L Q L Q D S P Q G H

G N S R F Q F C G R N A S A

3361 V P V F Y S S M S T A M V I F K S G V V N R

N S R M S F T Y Q I A D C N R D Y H K A F G

N L R S P G W P D N Y D N D K D C T V T L T

A P Q N H T I S L F F H S L

3441 G I E N S V E C R N D F L E V R N G S N S N

S P L L G K Y C G T L L P N P V F S Q N N E

L Y L R F K S D S V T S D R G Y E I I W T S

S P S G C G G T L Y G D R G

3521 S F T S P G Y P G T Y P N N T Y C E W V L V

A P A G R L V T I N F Y F I S I D D P G D C

V Q N Y L T L Y D G P N A S S P S S G P Y C

G G D T S I A P F V A S S N

3601 Q V F I K F H A D Y A R R P S A F R L T W D

S

5.79 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) [Homo sapiens]
Protein Accession gi|115511049

Mean Expression Ratio 1.25

Median Expression Ratio 1.25

Credible Interval (0.849, 1.85)

Associated Peptides 2

Associated Spectra 3

Coverage 0.0947


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.8	1.2	1.9	SEQ ID	SHLVDYFPEFDGPQR
				NO: 687

2	0.88	1.3	2	SEQ ID	VPTTGIIEYPFDLENIIFR
				NO: 688

SEQ ID NO: 689

1 M T L E S M M A C C L S D E V K E S K R I N A

E I E K Q L R R D K R D A R R E L K L L L L G

T G E S G K S T F I K Q M R I I H G A G Y S E

E D K R G F T K L V Y

81 Q N I F T A M Q A M I R A M E T L K I L Y K Y

E Q N K A N A L L I R E V D V E K V T T F E H

Q Y V S A I K T L W E D P G I Q E C Y D R R R

E Y Q L S D S A K Y Y

161 L T D V D R I A T L G Y L P T Q Q D V L R V R

V P T T G I I E Y P F D L E N I I F R M V D V

G G Q R S E R R K W I H C F E N V T S I M F L

V A L S E Y D Q V L V

241 E S D N E N R M E E S K A L F R T I I T Y P W

F Q N S S V I L F L N K K D L L E D K I L Y S

H L V D Y F P E F D G P Q R D A Q A A R E F I

L K M F V D L N P D S

321 D K I I Y S H F T C A T D T E N I R F V F A A

V K D T I L Q L N L K E Y N L V

5.80 proteasome alpha 1 subunit isoform 2 [Homo sapiens]; proteasome alpha 1 subunit isoform 1 [Homo sapiens]
Protein Accession gi|4506179 gi|23110935

Mean Expression Ratio 1.25

Median Expression Ratio 1.25

Credible Interval (0.869, 1.78)

Associated Peptides 3

Associated Spectra 4

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

2	0.9	1.3	2.0	SEQ ID	DLEFTIYDDDDVSPFLEGLEER
				NO: 690

1	0.82	1.2	1.9	SEQ ID	ILHVDNHIGISIAGLTADAR
				NO: 691

1	0.84	1.3	1.9	SEQ ID	DLEFTIYDDDDVSPFLEGLEERPQR
				NO: 692

5.81 myeloperoxidase [Homo sapiens]
Protein Accession gi|4557759

Mean Expression Ratio 0.805

Median Expression Ratio 0.805

Credible Interval (0.627, 1.04)

Associated Peptides 9

Associated Spectra 11

Coverage 0.172


				Sequence
A	2.5	50	97.5	ID No.	Sequence

2	0.55	0.78	1.1	SEQ ID	FCGLPQPETVGQLGTVLR
				NO: 693

1	0.56	0.8	1.1	SEQ ID	FPTDQLTPDQER
				NO: 694

2	0.56	0.78	1.1	SEQ ID	IGLDLPALNMQR
				NO: 695

1	0.56	0.8	1.1	SEQ ID	IVGAMVQIITYR
				NO: 696

1	0.57	0.83	1.2	SEQ ID	NIDIWMGGVSEPLK
				NO: 697

1	0.56	0.8	1.1	SEQ ID	NQINALTSFVDASMVYGSEEPLAR
				NO: 698

1	0.58	0.81	1.2	SEQ ID	QALAQISLPR
				NO: 699

1	0.55	0.79	1.1	SEQ ID	VVLEGGIDPILR
				NO: 700

1	0.57	0.81	1.2	SEQ ID	VGPLLACIIGTQFR
				NO: 701

SEQ ID NO: 702

1 M G V P F F S S L R C M V D L G P C W A G G L

T A E M K L L L A L A G L L A I L A T P Q P S

E G A A P A V L G E V D T S L V L S S M E E A

K Q L V D K A Y K E R

81 R E S I K Q R L R S G S A S P M E L L S Y F K

Q P V A A T R T A V R A A D Y L H V A L D L L

E R K L R S L W R R P F N V T D V L T P A Q L

N V L S K S S G C A Y

161 Q D V G V T C P E Q D K Y R T I T G M C N N R

R S P T L G A S N R A F V R W L P A E Y E D G

F S L P Y G W T P G V K R N G F P V A L A R A

V S N E I V R F P T D

241 Q L T P D Q E R S L M F M Q W G Q L L D H D L

D F T P E P A A R A S F V T G V N C E T S C V

Q Q P P C F P L K I P P N D P R I K N Q A D C

I P F F R S C P A C P

321 G S N I T I R N Q I N A L T S F V D A S M V Y

G S E E P L A R N L R N M S N Q L G L L A V N

Q R F Q D N G R A L L P F D N L H D D P C L L

T N R S A R I P C F L

401 A G D T R S S E M P E L T S M H T L L L R E H

N R L A T E L K S L N P R W D G E R L Y Q E A

R K I V G A M V Q I I T Y R D Y L P L V L G P

T A M R K Y L P T Y R

481 S Y N D S V D P R I A N V F T N A F R Y G H T

L I Q P F M F R L D N R Y Q P M E P N P R V P

L S R V F F A S W R V V L E G G I D P I L R G

L M A T P A K L N R Q

561 N Q I A V D E I R E R L F E Q V M R I G L D L

P A L N M Q R S R D H G L P G Y N A W R R F C

G L P Q P E T V G Q L G T V L R N L K L A R K

L M E Q Y G T P N N I

641 D I W M G G V S E P L K R K G R V G P L L A C

I I G T Q F R K L R D G D R F W W E N E G V F

S M Q Q R Q A L A Q I S L P R I I C D N T G I

T T V S K N N I F M S

721 N S Y P R D F V N C S T L P A L N L A S W R E

A S

5.82 solute carrier family 5 (iodide transporter), member 8 [Homo sapiens]
Protein Accession gi|167466278

Mean Expression Ratio 0.808

Median Expression Ratio 0.806

Credible Interval (0.554, 1.18)

Associated Peptides 2

Associated Spectra 4

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.54	0.84	1.3	SEQ ID	EDFLSNFDIFK
				NO: 703

3	0.51	0.74	1.1	SEQ ID	SHPVEDGGTDNPAFNHIELNSDQSGK
				NO: 704

5.83 ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member C precursor [Homo sapiens]; ras homolog gene family, member A [Homo sapiens]
Protein Accession gi|28395033 gi|11494251 gi|11494248 gi|0835049

Mean Expression Ratio 1.24

Median Expression Ratio 1.24

Credible Interval (0.815, 1.90)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.78 1.3 2 SEQ ID NO: 705 HFCPNVPIILVGNK

1 0.82 1.3 2.0 SEQ ID NO: 706 QVELALWDTAGQEDYDR

5.84 complement factor H isoform a precursor [Homo sapiens]
Protein Accession gi|62739186

Mean Expression Ratio 0.806

Median Expression Ratio 0.807

Credible Interval (0.627, 1.04)

Associated Peptides 8

Associated Spectra 10

Coverage 0.0812


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.56	0.8	1.1	SEQ ID NO: 707	EQVQSCGPPPELLNGNVK

2	0.55	0.76	1.0	SEQ ID NO: 708	KGEWVALNPLR

1	0.57	0.81	1.2	SEQ ID NO: 709	LIILEEHLK

1	0.55	0.78	1.1	SEQ ID NO: 710	RPYFPVAVGK

1	0.59	0.85	1.2	SEQ ID NO: 711	SCDNPYIPNGDYSPLR

2	0.57	0.79	1.1	SEQ ID NO: 712	SSNLIILEEHLK

1	0.58	0.83	1.2	SEQ ID NO: 713	TCNEGYQLLGEINYR

1	0.55	0.79	1.1	SEQ ID NO: 714	TDCLSLPSFENAIPMGEK

SEQ ID NO: 715

1 M R L L A K I I C L M L W A I C V A E D C N

E L P P R R N T E I L T G S W S D Q T Y P E

G T Q A I Y K C R P G Y R S L G N V I M V C

R K G E W V A L N P L R K C

81 Q K R P C G H P G D T P F G T F T L T G G N

V F E Y G V K A V Y T C N E G Y Q L L G E I

N Y R E C D T D G W T N D I P I C E V V K C

L P V T A P E N G K I V S S

161 A M E P D R E Y H F G Q A V R F V C N S G Y

K I E G D E E M H C S D D G F W S K E K P K

C V E I S C K S P D V I N G S P I S Q K I I

Y K E N E R F Q Y K C N M G

241 Y E Y S E R G D A V C T E S G W R P L P S C

E E K S C D N P Y I P N G D Y S P L R I K H

R T G D E I T Y Q C R N G F Y P A T R G N T

A K C T S T G W I P A P R C

321 T L K P C D Y P D I K H G G L Y H E N M R R

P Y F P V A V G K Y Y S Y Y C D E H F E T P

S G S Y W D H I H C T Q D G W S P A V P C L

R K C Y F P Y L E N G Y N Q

401 N H G R K F V Q G K S I D V A C H P G Y A L

P K A Q T T V T C M E N G W S P T P R C I R

V K T C S K S S I D I E N G F I S E S Q Y T

Y A L K E K A K Y Q C K L G

481 Y V T A D G E T S G S I T C G K D G W S A Q

P T C I K S C D I P V F M N A R T K N D F T

W F K L N D T L D Y E C H D G Y E S N T G S

T T G S I V C G Y N G W S D

561 L P I C Y E R E C E L P K I D V H L V P D R

K K D Q Y K V G E V L K F S C K P G F T I V

G P N S V Q C Y H F G L S P D L P I C K E Q

V Q S C G P P P E L L N G N

641 V K E K T K E E Y G H S E V V E Y Y C N P R

F L M K G P N K I Q C V D G E W T T L P V C

I V E E S T C G D I P E L E H G W A Q L S S

P P Y Y Y G D S V E F N C S

721 E S F T M I G H R S I T C I H G V W T Q L P

Q C V A I D K L K K C K S S N L I I L E E H

L K N K K E F D H N S N I R Y R C R G K E G

W I H T V C I N G R W D P E

801 V N C S M A Q I Q L C P P P P Q I P N S H N

M T T T L N Y R D G E K V S V L C Q E N Y L

I Q E G E E I T C K D G R W Q S I P L C V E

K I P C S Q P P Q I E H G T

881 I N S S R S S Q E S Y A H G T K L S Y T C E

G G F R I S E E N E T T C Y M G K W S S P P

Q C E G L P C K S P P E I S H G V V A H M S

D S Y Q Y G E E V T Y K C F

961 E G F G I D G P A I A K C L G E K W S H P P

S C I K T D C L S L P S F E N A I P M G E K

K D V Y K A G E Q V T Y T C A T Y Y K M D G

A S N V T C I N S R W T G R

1041 P T C R D T S C V N P P T V Q N A Y I V S R

Q M S K Y P S G E R V R Y Q C R S P Y E M F

G D E E V M C L N G N W T E P P Q C K D S T

G K C G P P P P I D N G D I

1121 T S F P L S V Y A P A S S V E Y Q C Q N L Y

Q L E G N K R I T C R N G Q W S E P P K C L

H P C V I S R E I M E N Y N I A L R W T A K

Q K L Y S R T G E S V E F V

1201 C K R G Y R L S S R S H T L R T T C W D G K

L E Y P T C A K R

5.85 flotillin 1 [Homo sapiens]
Protein Accession gi|5031699

Mean Expression Ratio 1.23

Median Expression Ratio 1.23

Credible Interval (0.95, 1.62)

Associated Peptides 7

Associated Spectra 9

Coverage 0.234


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.88	1.2	1.8	SEQ ID NO: 716	AQQVAVQEQEIAR

1	0.88	1.3	1.8	SEQ ID NO: 717	DIHDDQDYLHSLGK

1	0.85	1.2	1.8	SEQ ID NO: 718	LPQVAEEISGPLTSANK

3	0.9	1.2	1.7	SEQ ID NO: 719	TEAEIAHIALETLEGHQR

1	0.87	1.3	1.8	SEQ ID NO: 720	VTGEVLDILTR

1	0.87	1.3	1.8	SEQ ID NO: 721	LTGVSISQVNHKPLR

1	0.83	1.2	1.7	SEQ ID NO: 722	VFVLPCIQQIQR

SEQ ID NO: 723

1 M F F T C G P N E A M V V S G F C R S P P V M

V A G G R V F V L P C I Q Q I Q R I S L N T L

T L N V K S E K V Y T R H G V P I S V T G I A

Q V K I Q G Q N K E M

81 L A A A C Q M F L G K T E A E I A H I A L E T

L E G H Q R A I M A H M T V E E I Y K D R Q K

F S E Q V F K V A S S D L V N M G I S V V S Y

T L K D I H D D Q D Y

161 L H S L G K A R T A Q V Q K D A R I G E A E A

K R D A G I R E A K A K Q E K V S A Q Y L S E

I E M A K A Q R D Y E L K K A A Y D I E V N T

R R A Q A D L A Y Q L

241 Q V A K T K Q Q I E E Q R V Q V Q V V E R A Q

Q V A V Q E Q E I A R R E K E L E A R V R K P

A E A E R Y K L E R L A E A E K S Q L I M Q A

E A E A A S V R M R G

321 E A E A F A I G A R A R A E A E Q M A K K A E

A F Q L Y Q E A A Q L D M L L E K L P Q V A E

E I S G P L T S A N K I T L V S S G S G T M G

A A K V T G E V L D I

401 L T R L P E S V E R L T G V S I S Q V N H K P

L R T A

5.86 hypothetical protein LOC91894 [Homo sapiens]
Protein Accession gi|131889517

Mean Expression Ratio 1.23

Median Expression Ratio 1.23

Credible Interval (0.786, 1.91)

Associated Peptides 1

Associated Spectra 2

Coverage 0.122


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.83	1.3	2	SEQ ID NO: 724	TLKPQPQQLQQNLPK

SEQ ID NO: 725

1 M G N R V C C G G S W S C P S T F Q K K K K T

G S Q T R R T L K P Q P Q Q L Q Q N L P K G H

E T T G H T Y E R V L Q Q Q G S Q E R S P G L

M S E D S N L H Y A D

81 I Q V C S R P H A R E V K H V H L E N A T E Y

A T L R F P Q A T P R Y D S K N G T L V

5.87 ring finger protein 152 [Homo sapiens]
Protein Accession gi|27734873

Mean Expression Ratio 0.815

Median Expression Ratio 0.814

Credible Interval (0.506, 1.31)

Associated Peptides 1

Associated Spectra 1

Coverage 0.143


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.46	0.77	1.3	SEQ ID	SVTVVTIPAEQQPLQGGAPQEAVEEE
				NO: 726	QDR

SEQ ID NO: 727

1 M E T L S Q D S L L E C Q I C F N Y Y S P R R

R P K L L D C K H T C C S V C L Q Q M R T S Q

K D V R C P W C R G V T K L P P G F S V S Q L

P D D P E V L A V I A

81 I P H T S E H T P V F I K L P S N G C Y M L P

L P I S K E R A L L P G D M G C R L L P G S Q

Q K S V T V V T I P A E Q Q P L Q G G A P Q E

A V E E E Q D R R G V

161 V K S S T W S G V C T V I L V A C V L V F L L

G I V L H N M S C I S K R F T V I S C G

5.88 WIRE protein [Homo sapiens]
Protein Accession gi|18959210

Mean Expression Ratio 1.22

Median Expression Ratio 1.23

Credible Interval (0.829, 1.8)

Associated Peptides 2

Associated Spectra 3

Coverage 0.0841


				Sequence
A	2.5	50	97.5	ID No.	Sequence

2	0.83	1.3	1.9	SEQ ID	QPPGVPNGPSSPTNESAPELPQR
				NO: 728

1	0.8	1.2	1.9	SEQ ID	TPAGPPPPPPPPLR
				NO: 729

SEQ ID NO: 730

1 M P I P P P P P P P P G P P P P P T F H Q A N

T E Q P K L S R D E Q R G R G A L L Q D I C K

G T K L K K V T N I N D R S A P I L E K P K G

S S G G Y G S G G A A

81 L Q P K G G L F Q G G V L K L R P V G A K D G

S E N L A G K P A L Q I P S S R A A A P R P P

V S A A S G R P Q D D T D S S R A S L P E L P

R M Q R P S L P D L S

161 R P N T T S S T G M K H S S S A P P P P P P G

R R A N A P P T P L P M H S S K A P A Y N R E

K P L P P T P G Q R L H P G R E G P P A P P P

V K P P P S P V N I R

241 T G P S G Q S L A P P P P P Y R Q P P G V P N

G P S S P T N E S A P E L P Q R H N S L H R K

T P G P V R G L A P P P P T S A S P S L L S N

R P P P P A R D P P S

321 R G A A P P P P P P V I R N G A R D A P P P P

P P Y R M H G S E P P S R G K P P P P P S R T

P A G P P P P P P P P L R N G H R D S I T T V

R S F L D D F E S K Y

401 S F H P V E D F P A P E E Y K H F Q R I Y P S

K T N R A A R G A P P L P P I L R

5.89 putative MAPK activating protein PM28 [Homo sapiens]
Protein Accession gi|41281489

Mean Expression Ratio 1.22

Median Expression Ratio 1.22

Credible Interval (0.829, 1.77)

Associated Peptides 3

Associated Spectra 3

Coverage 0.0833


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.79	1.2	1.9	SEQ ID NO: 731	LQSEVAELK

1	0.79	1.2	1.9	SEQ ID NO: 732	YLIEIAK

1	0.81	1.3	1.9	SEQ ID NO: 733	KEIADYLAAGKDER

SEQ ID NO: 734

1	M L G S G F K A E R L R V N L R L V I N R L K L L E K K K T E L A Q K A R K E I
	A D Y L A A G K D E R A R I R V E H I I R E D Y L V E A M E I L E L Y C D L L L

81	A R F G L I Q S M K E L D S G L A E S V S T L I W A A P R L Q S E V A E L K I V A
	D Q L C A K Y S K E Y G K L C R T N Q I G T V N D R L M H K L S V E A P P K I

161	L V E R Y L I E I A K N Y N V P Y E P D S V V M A E A P P G V E T D L I D V G F
	T D D V K K G G P G R G G S G G F T A P V G G P D G T V P M P M P M P M P M P S

241	A N T P F S Y P L P K G P S D F N G L P M G T Y Q A F P N I H P P Q I P A T P P S
	Y E S M T L M L I R I S L L H R L L V L D P S Q K P L Q S F L P D L Q I T M T

321	T L S Y Q S C H L C Q T H Y Q L H L L V P A P Q H L K T L T L M I F P G G L K S

5.90 flotillin 2 [Homo sapiens]
Protein Accession gi|94538362

Mean Expression Ratio 1.22

Median Expression Ratio 1.22

Credible Interval (0.969, 1.55)

Associated Peptides 8

Associated Spectra 15

Coverage 0.238


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.87	1.2	1.7	SEQ ID NO: 735	ELLAVACEQFLGK

1	0.87	1.2	1.7	SEQ ID NO: 736	IGEAEAAVIEAMGK

7	1.0	1.3	1.7	SEQ ID NO: 737	NVVLQTLEGHLR

1	0.85	1.2	1.7	SEQ ID NO: 738	QIAVEAQEILR

1	0.89	1.2	1.7	SEQ ID NO: 739	SILGTLTVEQIYQDR

1	0.87	1.2	1.7	SEQ ID NO: 740	TAEAQLAYELQGAR

2	0.88	1.2	1.7	SEQ ID NO: 741	MALVLEALPQIAAK

1	0.84	1.2	1.7	SEQ ID NO: 742	RPAEAEAHR

SEQ ID NO: 743

1 M G N C H T V G P N E A L V V S G G C C G S D

Y K Q Y V F G G W A W A W W C I S D T Q R I S

L E I M T L Q P R C E D V E T A E G V A L T V

T G V A Q V K I M T E

81 K E L L A V A C E Q F L G K N V Q D I K N V V

L Q T L E G H L R S I L G T L T V E Q I Y Q D

R D Q F A K L V R E V A A P D V G R M G I E I

L S F T I K D V Y D K

161 V D Y L S S L G K T Q T A V V Q R D A D I G V

A E A E R D A G I R E A E C K K E M L D V K F

M A D T K I A D S K R A F E L Q K S A F S E E

V N I K T A E A Q L A

241 Y E L Q G A R E Q Q K I R Q E E I E I E V V Q

R K K Q I A V E A Q E I L R T D K E L I A T V

R R P A E A E A H R I Q Q I A E G E K V K Q V

L L A Q A E A E K I R

321 K I G E A E A A V I E A M G K A E A E R M K L

K A E A Y Q K Y G D A A K M A L V L E A L P Q

I A A K I A A P L T K V D E I V V L S G D N S

K V T S E V N R L L A

401 E L P A S V H A L T G V D L S K I P L I K K A

T G V Q V

5.91 ephrin receptor EphA1 [Homo sapiens]
Protein Accession gi|56119207

Mean Expression Ratio 0.819

Median Expression Ratio 0.821

Credible Interval (0.508, 1.33)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0184


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.46	0.78	1.3	SEQ ID NO: 744	APGEGPQVACTGPPSAPR

SEQ ID NO: 745

1 M E R R W P L G L G L V L L L C A P L P P G A

R A K E V T L M D T S K A Q G E L G W L L D P

P K D G W S E Q Q Q I L N G T P L Y M Y Q D C

P M Q G R R D T D H W

81 L R S N W I Y R G E E A S R V H V E L Q F T V

R D C K S F P G G A G P L G C K E T F N L L Y

M E S D Q D V G I Q L R R P L F Q K V T T V A

A D Q S F T I R D L A

161 S G S V K L N V E R C S L G R L T R R G L Y L

A F H N P G A C V A L V S V R V F Y Q R C P E

T L N G L A Q F P D T L P G P A G L V E V A G

T C L P H A R A S P R

241 P S G A P R M H C S P D G E W L V P V G R C H

C E P G Y E E G G S G E A C V A C P S G S Y R

M D M D T P H C L T C P Q Q S T A E S E G A T

I C T C E S G H Y R A

321 P G E G P Q V A C T G P P S A P R N L S F S A

S G T Q L S L R W E P P A D T G G R Q D V R Y

S V R C S Q C Q G T A Q D G G P C Q P C G V G

V H F S P G A R G L T

401 T P A V H V N G L E P Y A N Y T F N V E A Q N

G V S G L G S S G H A S T S V S I S M G H A E

S L S G L S L R L V K K E P R Q L E L T W A G

S R P R S P G A N L T

481 Y E L H V L N Q D E E R Y Q M V L E P R V L L

T E L Q P D T T Y I V R V R M L T P L G P G P

F S P D H E F R T S P P V S R G L T G G E I V

A V I F G L L L G A A

561 L L L G I L V F R S R R A Q R Q R Q Q R Q R D

R A T D V D R E D K L W L K P Y V D L Q A Y E

D P A Q G A L D F T R E L D P A W L M V D T V

I G E G E F G E V Y R

641 G T L R L P S Q D C K T V A I K T L K D T S P

G G Q W W N F L R E A T I M G Q F S H P H I L

H L E G V V T K R K P I M I I T E F M E N G A

L D A F L R E R E D Q

721 L V P G Q L V A M L Q G I A S G M N Y L S N H

N Y V H R D L A A R N I L V N Q N L C C K V S

D F G L T R L L D D F D G T Y E T Q G G K I P

I R W T A P E A I A H

801 R I F T T A S D V W S F G I V M W E V L S F G

D K P Y G E M S N Q E V M K S I E D G Y R L P

P P V D C P A P L Y E L M K N C W A Y D R A R

R P H F Q K L Q A H L

881 E Q L L A N P H S L R T I A N F D P R M T L R

L P S L S G S D G I P Y R T V S E W L E S I R

M K R Y I L H F H S A G L D T M E C V L E L T

A E D L T Q M G I T L

961 P G H Q K R I L C S I Q G F K D

5.92 proteasome beta 3 subunit [Homo sapiens]
Protein Accession gi|22538465

Mean Expression Ratio 1.22

Median Expression Ratio 1.22

Credible Interval (0.756, 1.98)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0878


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.77	1.3	2.2	SEQ ID NO: 746	LYIGLAGLATDVQTVAQR

SEQ ID NO: 747

1 M S I M S Y N G G A V M A M K G K N C V A I A

A D R R F G I Q A Q M V T T D F Q K I F P M G

D R L Y I G L A G L A T D V Q T V A Q R L K F

R L N L Y E L K E G R

81 Q I K P Y T L M S M V A N L L Y E K R F G P Y

Y T E P V I A G L D P K T F K P F I C S L D L

I G C P M V T D D F V V S G T C A E Q M Y G M

C E S L W E P N M D P

161 D H L F E T I S Q A M L N A V D R D A V S G M

G V I V H I I E K D K I T T R T L K A R M D

5.93 cathepsin D preproprotein [Homo sapiens]
Protein Accession gi|4503143

Mean Expression Ratio 0.826

Median Expression Ratio 0.824

Credible Interval (0.69, 0.984)

Associated Peptides 15

Associated Spectra 29

Coverage 0.456


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.61	0.83	1.1	SEQ ID	AIGAVPLIQGEYMIPCEK
				NO: 748

1	0.61	0.83	1.1	SEQ ID	AYWQVHLDQVEVASGL
				NO: 749

4	0.63	0.82	1.1	SEQ ID	DPDAQPGGELMLGGTDSK
				NO: 750

5	0.6	0.78	1	SEQ ID	EGCEAIVDTGTSLMVGPVDEVR
				NO: 751

4	0.63	0.83	1.1	SEQ ID	ISVNNVLPVFDNLMQQK
				NO: 752

1	0.62	0.85	1.2	SEQ ID	LLDIACWIHHK
				NO: 753

1	0.6	0.82	1.1	SEQ ID	MVGPVDEVR
				NO: 754

1	0.61	0.84	1.2	SEQ ID	QVFGEATK
				NO: 755

2	0.65	0.87	1.2	SEQ ID	TVVFDTGSSNLWVPSIHCK
				NO: 756

1	0.6	0.83	1.1	SEQ ID	VSTLPAITLK
				NO: 757

2	0.6	0.8	1.1	SEQ ID	WILGDVFIGR
				NO: 758

3	0.6	0.8	1.1	SEQ ID	FDGILGMAYPR
				NO: 759

1	0.6	0.82	1.1	SEQ ID	AYWQVHLDQVEVASGLTLCK
				NO: 760

1	0.6	0.82	1.1	SEQ ID	VSQAGK
				NO: 761

1	0.6	0.83	1.1	SEQ ID	YSQAVPAVTEGPIPEVLK
				NO: 762

SEQ ID NO: 763

1 M Q P S S L L P L A L C L L A A P A S A L V R

I P L H K F T S I R R T M S E V G G S V E D L

I A K G P V S K Y S Q A V P A V T E G P I P E

V L K N Y M D A Q Y Y

81 G E I G I G T P P Q C F T V V F D T G S S N L

W V P S I H C K L L D I A C W I H H K Y N S D

K S S T Y V K N G T S F D I H Y G S G S L S G

Y L S Q D T V S V P C

161 Q S A S S A S A L G G V K V E R Q V F G E A T

K Q P G I T F I A A K F D G I L G M A Y P R I

S V N N V L P V F D N L M Q Q K L V D Q N I F

S F Y L S R D P D A Q

241 P G G E L M L G G T D S K Y Y K G S L S Y L N

V T R K A Y W Q V H L D Q V E V A S G L T L C

K E G C E A I V D T G T S L M V G P V D E V R

E L Q K A I G A V P L

321 I Q G E Y M I P C E K V S T L P A I T L K L G

G K G Y K L S P E D Y T L K V S Q A G K T L C

L S G F M G M D I P P P S G P L W I L G D V F

I G R Y Y T V F D R D

401 N N R V G F A E A A R L

5.94 hypothetical protein LOC58527 [Homo sapiens]
Protein Accession gi|24308273

Mean Expression Ratio 0.824

Median Expression Ratio 0.827

Credible Interval (0.557, 1.22)

Associated Peptides 2

Associated Spectra 3

Coverage 0.358


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.53	0.82	1.3	SEQ ID NO: 764	CANLFEALVGTLK

2	0.52	0.78	1.2	SEQ ID NO: 765	MNVDHEVNLLVEEIHR

SEQ ID NO: 766

1 M N V D H E V N L L V E E I H R L G S K N A D G

K L S V K F G V L F R D D K C A N L F E A L V G

T L K A A K R R K I V T Y P G E L L L Q G V H D

D V D I I L L Q

81 D

5.95 annexin 5 [Homo sapiens]
Protein Accession gi|4502107

Mean Expression Ratio 1.21

Median Expression Ratio 1.21

Credible Interval (0.82, 1.80)

Associated Peptides 3

Associated Spectra 3

Coverage 0.141


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.78	1.2	1.8	SEQ ID	GTVTDFPGFDER
				NO: 767

1	0.78	1.2	1.9	SEQ ID	QEISAAFK
				NO: 768

1	0.83	1.3	2	SEQ ID	QVYEEEYGSSLEDDVVGDTSGYYQR
				NO: 769

SEQ ID NO: 770

1 M A Q V L R G T V T D F P G F D E R A D A E T

L R K A M K G L G T D E E S I L T L L T S R S

N A Q R Q E I S A A F K T L F G R D L L D D L

K S E L T G K F E K L

81 I V A L M K P S R L Y D A Y E L K H A L K G A

G T N E K V L T E I I A S R T P E E L R A I K

Q V Y E E E Y G S S L E D D V V G D T S G Y Y

Q R M L V V L L Q A N

161 R D P D A G I D E A Q V E Q D A Q A L F Q A G

E L K W G T D E E K F I T I F G T R S V S H L

R K V F D K Y M T I S G F Q I E E T I D R E T

S G N L E Q L L L A V

241 V K S I R S I P A Y L A E T L Y Y A M K G A G

T D D H T L I R V M V S R S E I D L F N I R K

E F R K N F A T S L Y S M I K G D T S G D Y K

K A L L L L C G E D D

5.96 carboxypeptidase M precursor [Homo sapiens]; carboxypeptidase M precursor [Homo sapiens]; carboxypeptidase M precursor [Homo sapiens]
Protein Accession gi|6631081 gi|53832021 gi|38327526

Mean Expression Ratio 0.83

Median Expression Ratio 0.829

Credible Interval (0.535, 1.28)

Associated Peptides 1

Associated Spectra 2

Coverage NaN

Sequence

A 2.5 50 97.5 ID No. Sequence

2 0.51 0.79 1.2 SEQ ID GQVFDQNGNPLPNVIVEVQDR

NO: 771

5.97 profilin 1 [Homo sapiens]
Protein Accession gi|4826898

Mean Expression Ratio 0.829

Median Expression Ratio 0.83

Credible Interval (0.563, 1.23)

Associated Peptides 3

Associated Spectra 3

Coverage 0.293


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.52	0.8	1.2	SEQ ID NO: 772	DSLLQDGEFSMDLR

1	0.52	0.83	1.3	SEQ ID NO: 773	EGVHGGLINKK

1	0.53	0.82	1.3	SEQ ID NO: 774	TFVNITPAEVGVLVGK

SEQ ID NO: 775

1 M A G W N A Y I D N L M A D G T C Q D A A I V G

Y K D S P S V W A A V P G K T F V N I T P A E V

G V L V G K D R S S F Y V N G L T L G G Q K C S

V I R D S L L Q

81 D G E F S M D L R T K S T G G A P T F N V T V T

K T D K T L V L L M G K E G V H G G L I N K K C

Y E M A S H L R R S Q Y

5.98 cortactin isoform b [Homo sapiens]; cortactin isoform a [Homo sapiens]
Protein Accession gi|20357556 gi|20357552

Mean Expression Ratio 1.2

Median Expression Ratio 1.20

Credible Interval (0.78, 1.81)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.76 1.2 1.9 SEQ ID NO: 776 GPVSGTEPEPVYSMEAADYR

1 0.77 1.2 2.0 SEQ ID NO: 777 TQTPPVSPAPQPTEER

5.99 solute carrier family 3, member 1 [Homo sapiens]
Protein Accession gi|187423904

Mean Expression Ratio 0.833

Median Expression Ratio 0.832

Credible Interval (0.642, 1.09)

Associated Peptides 8

Associated Spectra 10

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.56	0.8	1.1	SEQ ID	CLDWWQEGPMYQIYPR
				NO: 778

3	0.63	0.84	1.1	SEQ ID	EVDPIFGTMEDFENLVAAIHDK
				NO: 779

1	0.6	0.85	1.2	SEQ ID	FMGTEAYAESIDR
				NO: 780

1	0.58	0.82	1.2	SEQ ID	LIIDFIPNHTSDK
				NO: 781

1	0.59	0.84	1.2	SEQ ID	LYQDLSLLHANELLLNR
				NO: 782

1	0.57	0.81	1.2	SEQ ID	TQIPDTVTQYSELYHDFTTTQVGMHD
				NO: 783	IVR

1	0.58	0.82	1.2	SEQ ID	WPNWMIGGPDSSR
				NO: 784

1	0.59	0.84	1.2	SEQ ID	FLLEAK
				NO: 785

5.100 cell division cycle 42 isoform 1 [Homo sapiens]; cell division cycle 42 isoform 1 [Homo sapiens]
Protein Accession gi|89903012 gi|4757952

Mean Expression Ratio 1.20

Median Expression Ratio 1.20

Credible Interval (0.894, 1.62)

Associated Peptides 5

Associated Spectra 7

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.8	1.2	1.7	SEQ ID NO: 786	NVFDEAILAALEPPEPK

3	0.95	1.3	1.8	SEQ ID NO: 787	QKPITPETAEK

1	0.8	1.2	1.7	SEQ ID NO: 788	TLGLFDTAGQEDYDR

1	0.79	1.2	1.7	SEQ ID NO: 789	PYTLGLFDTAGQEDYDR

1	0.85	1.2	1.8	SEQ ID NO: 790	TPFLLVGTQIDLR

5.101 CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein 15 [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]; CD59 antigen preproprotein [Homo sapiens]
Protein Accession gi|42761474 gi|42716302 gi|42716299 gi|187829185 gi|187829183 gi|187829070 gi|187828910

Mean Expression Ratio 1.20

Median Expression Ratio 1.2

Credible Interval (0.832, 1.72)

Associated Peptides 1

Associated Spectra 5

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

5 0.9 1.3 1.7 SEQ ID NO: 791 FEHCNFNDVTTR

5.102 amnionless protein precursor [Homo sapiens]
Protein Accession gi|110611172

Mean Expression Ratio 1.2

Median Expression Ratio 1.20

Credible Interval (0.807, 1.81)

Associated Peptides 1

Associated Spectra 3

Coverage 0.0353


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.85	1.3	1.8	SEQ ID NO: 792	NPVFDVTASEELPLPR

SEQ ID NO: 793

1 M G V L G R V L L W L Q L C A L T Q A V S K L

W V P N T D F D V A A N W S Q N R T P C A G G

A V E F P A D K M V S V L V Q E G H A V S D M

L L P L D G E L V L A

81 S G A G F G V S D V G S H L D C G A G E P A V

F R D S D R F S W H D P H L W R S G D E A P G

L F F V D A E R V P C R H D D V F F P P S A S

F R V G L G P G A S P

161 V R V R S I S A L G R T F T R D E D L A V F L

A S R A G R L R F H G P G A L S V G P E D C A

D P S G C V C G N A E A Q P W I C A A L L Q P

L G G R C P Q A A C H

241 S A L R P Q G Q C C D L C G A V V L L T H G P

A F D L E R Y R A R I L D T F L G L P Q Y H G

L Q V A V S K V P R S S R L R E A D T E I Q V

V L V E N G P E T G G

321 A G R L A R A L L A D V A E N G E A L G V L E

A T M R E S G A H V W G S S A A G L A G G V A

A A V L L A L L V L L V A P P L L R R A G R L

R W R R H E A A A P A

401 G A P L G F R N P V F D V T A S E E L P L P R

R L S L V P K A A A D S T S H S Y F V N P L F

A G A E A E A

5.103 von Willebrand factor A domain containing 1 isoform 1 [Homo sapiens]
Protein Accession gi|40068485

Mean Expression Ratio 0.834

Median Expression Ratio 0.836

Credible Interval (0.511, 1.35)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0404


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.48	0.8	1.3	SEQ ID NO: 794	EFVGQLVAPLPLGTGALR

SEQ ID NO: 795

1 M L P W T A L G L A L S L R L A L A R S G A E

R G P P A S A P R G D L M F L L D S S A S V S

H Y E F S R V R E F V G Q L V A P L P L G T G

A L R A S L V H V G S

81 R P Y T E F P F G Q H S S G E A A Q D A V R A

S A Q R M G D T H T G L A L V Y A K E Q L F A

E A S G A R P G V P K V L V W V T D G G S S D

P V G P P M Q E L K D

161 L G V T V F I V S T G R G N F L E L S A A A S

A P A E K H L H F V D V D D L H I I V Q E L R

G S I L D A M R P Q Q L H A T E I T S S G F R

L A W P P L L T A D S

241 G Y Y V L E L V P S A Q P G A A R R Q Q L P G

N A T D W I W A G L D P D T D Y D V A L V P E

S N V R L L R P Q I L R V R T R P G E A G P G

A S G P E S G A G P A

321 P T Q L A A L P A P E E A G P E R I V I S H A

R P R S L R V S W A P A L G S A A A L G Y H V

Q F G P L R G G E A Q R V E V P A G R N C T T

L Q G L A P G T A Y L

401 V T V T A A F R S G R E S A L S A K A C T P D

G P R P R P R P V P R A P T P G T A S R E P

5.104 vacuolar protein sorting 28 isoform 1 [Homo sapiens]
Protein Accession gi|7705885

Mean Expression Ratio 1.20

Median Expression Ratio 1.19

Credible Interval (0.815, 1.77)

Associated Peptides 3

Associated Spectra 3

Coverage 0.249


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.79	1.2	1.9	SEQ ID	QMLFDLESAYNAFNR
				NO: 796

1	0.82	1.3	2.0	SEQ ID	QTVSQWLQTLSGMSASDELDDSQVR
				NO: 797

1	0.76	1.2	1.8	SEQ ID	QVQGSEISSIDEFCR
				NO: 798

SEQ ID NO: 799

1 M F H G I P A T P G I G A P G N K P E L Y E E

V K L Y K N A R E R E K Y D N M A E L F A V V

K T M Q A L E K A Y I K D C V S P S E Y T A A

C S R L L V Q Y K A A

81 F R Q V Q G S E I S S I D E F C R K F R L D C

P L A M E R I K E D R P I T I K D D K G N L N

R C I A D V V S L F I T V M D K L R L E I R A

M D E I Q P D L R E L

161 M E T M H R M S H L P P D F E G R Q T V S Q W

L Q T L S G M S A S D E L D D S Q V R Q M L F

D L E S A Y N A F N R F L H A

5.105 mannosidase, alpha, class 2B, member 1 precursor [Homo sapiens]
Protein Accession gi|51873064

Mean Expression Ratio 1.19

Median Expression Ratio 1.19

Credible Interval (0.812, 1.76)

Associated Peptides 3

Associated Spectra 3

Coverage 0.0415


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.79	1.2	1.9	SEQ ID NO: 800	ELVDYFLNVATAQGR

1	0.78	1.2	1.9	SEQ ID NO: 801	FQVIVYNPLGR

1	0.76	1.2	1.9	SEQ ID NO: 802	HLVLLDTAQAAAAGHR

SEQ ID NO: 803

1 M G A Y A R A S G V C A R G C L D S A G P W T

M S R A L R P P L P P L C F F L L L L A A A G

A R A G G Y E T C P T V Q P N M L N V H L L P

H T H D D V G W L K T

81 V D Q Y F Y G I K N D I Q H A G V Q V I L D S

V I S A L L A D P T R R F I Y V E I A F F S R

W W H Q Q T N A T Q E V V R D L V R Q G R L E

F A N G G W V M N D E

161 A A T H Y G A I V D Q M T L G L R F L E D T F

G N D G R P R V A W H I D P F G H S R E Q A S

L F A Q M G F D G F F F G R L D Y Q D K W V R

M Q K L E M E Q V W R

241 A S T S L K P P T A D L F T G V L P N G Y N P

P R N L C W D V L C V D Q P L V E D P R S P E

Y N A K E L V D Y F L N V A T A Q G R Y Y R T

N H T V M T M G S D F

321 Q Y E N A N M W F K N L D K L I R L V N A Q Q

A K G S S V H V L Y S T P A C Y L W E L N K A

N L T W S V K H D D F F P Y A D G P H Q F W T

G Y F S S R P A L K R

401 Y E R L S Y N F L Q V C N Q L E A L V G L A A

N V G P Y G S G D S A P L N E A M A V L Q H H

D A V S G T S R Q H V A N D Y A R Q L A A G W

G P C E V L L S N A L

481 A R L R G F K D H F T F C Q Q L N I S I C P L

S Q T A A R F Q V I V Y N P L G R K V N W M V

R L P V S E G V F V V K D P N G R T V P S D V

V I F P S S D S Q A H

561 P P E L L F S A S L P A L G F S T Y S V A Q V

P R W K P Q A R A P Q P I P R R S W S P A L T

I E N E H I R A T F D P D T G L L M E I M N M

N Q Q L L L P V R Q T

641 F F W Y N A S I G D N E S D Q A S G A Y I F R

P N Q Q K P L P V S R W A Q I H L V K T P L V

Q E V H Q N F S A W C S Q V V R L Y P G Q R H

L E L E W S V G P I P

721 V G D T W G K E V I S R F D T P L E T K G R F

Y T D S N G R E I L E R R R D Y R P T W K L N

Q T E P V A G N Y Y P V N T R I Y I T D G N M

Q L T V L T D R S Q G

801 G S S L R D G S L E L M V H R R L L K D D G R

G V S E P L M E N G S G A W V R G R H L V L L

D T A Q A A A A G H R L L A E Q E V L A P Q V

V L A P G G G A A Y N

881 L G A P P R T Q F S G L R R D L P P S V H L L

T L A S W G P E M V L L R L E H Q F A V G E D

S G R N L S A P V T L N L R D L F S T F T I T

R L Q E T T L V A N Q

961 L R E A A S R L K W T T N T G P T P H Q T P Y

Q L D P A N I T L E P M E I R T F L A S V Q W

K E V D G

5.106 chloride intracellular channel 1 [Homo sapiens]
Protein Accession gi|14251209

Mean Expression Ratio 1.19

Median Expression Ratio 1.19

Credible Interval (0.876, 1.62)

Associated Peptides 4

Associated Spectra 7

Coverage 0.224


				Se-
				quence
A	2.5	50	97.5	ID No.	Sequence

1	0.82	1.2	1.8	SEQ	LAALNPESNTAGLDIFAK
				ID
				NO:
				804

2	0.83	1.2	1.7	SEQ	LHIVQVVCK
				ID
				NO:
				805

1	0.8	1.2	1.7	SEQ	LTSPLPEEVDETSAEDEGVSQR
				ID
				NO:
				806

3	0.9	1.3	1.8	SEQ	VLDNYLTSPLPEEVDETSAEDEGVSQ
				ID	R
				NO:
				807

SEQ ID NO: 808

1 M A E E Q P Q V E L F V K A G S D G A K I G N

C P F S Q R L F M V L W L K G V T F N V T T V

D T K R R T E T V Q K L C P G G Q L P F L L Y

G T E V H T D T N K I

81 E E F L E A V L C P P R Y P K L A A L N P E S

N T A G L D I F A K F S A Y I K N S N P A L N

D N L E K G L L K A L K V L D N Y L T S P L P

E E V D E T S A E D E

161 G V S Q R K F L D G N E L T L A D C N L L P K

L H I V Q V V C K K Y R G F T I P E A F R G V

H R Y L S N A Y A R E E F A S T C P D D E E I

E L A Y E Q V A K A L

241 K

5.107 complement factor D preproprotein [Homo sapiens]
Protein Accession gi|42544239

Mean Expression Ratio 0.84

Median Expression Ratio 0.84

Credible Interval (0.568, 1.24)

Associated Peptides 3

Associated Spectra 3

Coverage 0.241


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.54	0.85	1.3	SEQ ID	AVPHPDSQPDTIDHDLLLLQLSEK
				NO: 809

1	0.53	0.83	1.3	SEQ ID	RPDSLQHVLLPVLDR
				NO: 810

1	0.51	0.81	1.3	SEQ ID	GDSGGPLVCGGVLEGVVTSGSR
				NO: 811

SEQ ID NO: 812

1 M H S W E R L A V L V L L G A A A C A A P P R

G R I L G G R E A E A H A R P Y M A S V Q L N

G A H L C G G V L V A E Q W V L S A A H C L E

D A A D G K V Q V L L

81 G A H S L S Q P E P S K R L Y D V L R A V P H

P D S Q P D T I D H D L L L L Q L S E K A T L

G P A V R P L P W Q R V D R D V A P G T L C D

V A G W G I V N H A G

161 R R P D S L Q H V L L P V L D R A T C N R R T

H H D G A I T E R L M C A E S N R R D S C K G

D S G G P L V C G G V L E G V V T S G S R V C

G N R K K P G I Y T R

241 V A S Y A A W I D S V L A

5.108 scavenger receptor class B, member 2 [Homo sapiens]
Protein Accession gi|5031631

Mean Expression Ratio 0.842

Median Expression Ratio 0.841

Credible Interval (0.677, 1.04)

Associated Peptides 11

Associated Spectra 17

Coverage 0.247


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.64	0.89	1.2	SEQ ID	DEVLYVFPSDFCR
				NO: 813

1	0.59	0.83	1.2	SEQ ID	EIIEAMLK
				NO: 814

1	0.58	0.81	1.1	SEQ ID	FVSAIEGMHPNQEDHETFVDIN
				NO: 815	PLTGIILK

2	0.6	0.82	1.1	SEQ ID	ITFSDYESVQGLPAFR
				NO: 816

1	0.58	0.8	1.1	SEQ ID	IVEWNGK
				NO: 817

3	0.59	0.79	1.1	SEQ ID	KLDDFVETGDIR
				NO: 818

1	0.62	0.86	1.2	SEQ ID	LDDFVETGDIR
				NO: 819

1	0.6	0.83	1.2	SEQ ID	SDYESVQGLPAFR
				NO: 820

4	0.69	0.91	1.2	SEQ ID	SVYITFSDYESVQGLPAFR
				NO: 821

1	0.61	0.85	1.2	SEQ ID	TLNIPVLTVIEWSQVHFLR
				NO: 822

1	0.61	0.84	1.2	SEQ ID	TSLDWWITDK
				NO: 823

SEQ ID NO: 824

1 M G R C C F Y T A G T L S L L L L V T S V T L

L V A R V F Q K A V D Q S I E K K I V L R N G

T E A F D S W E K P P L P V Y T Q F Y F F N V

T N P E E I L R G E T

81 P R V E E V G P Y T Y R E L R N K A N I Q F G

D N G T T I S A V S N K A Y V F E R D Q S V G

D P K I D L I R T L N I P V L T V I E W S Q V

H F L R E I I E A M L

161 K A Y Q Q K L F V T H T V D E L L W G Y K D E

I L S L I H V F R P D I S P Y F G L F Y E K N

G T N D G D Y V F L T G E D S Y L N F T K I V

E W N G K T S L D W W

241 I T D K C N M I N G T D G D S F H P L I T K D

E V L Y V F P S D F C R S V Y I T F S D Y E S

V Q G L P A F R Y K V P A E I L A N T S D N A

G F C I P E G N C L G

321 S G V L N V S I C K N G A P I I M S F P H F Y

Q A D E R F V S A I E G M H P N Q E D H E T F

V D I N P L T G I I L K A A K R F Q I N I Y V

K K L D D F V E T G D

401 I R T M V F P V M Y L N E S V H I D K E T A S

R L K S M I N T T L I I T N I P Y I I M A L G

V F F G L V F T W L A C K G Q G S M D E G T A

D E R A P L I R T

5.109 plasminogen [Homo sapiens]
Protein Accession gi|4505881

Mean Expression Ratio 0.845

Median Expression Ratio 0.844

Credible Interval (0.519, 1.39)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0272


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.49	0.81	1.4	SEQ ID NO: 825	VILGAHQEVNLEPHVQEIEVSR

SEQ ID NO: 826

1	M E H K E V V L L L L L F L K S G Q G E P L D D Y V N T Q G A S L F S V T K K Q
	L G A G S I E E C A A K C E E D E E F T C R A F Q Y H S K E Q Q C V I M A E N R

81	K S S I I I R M R D V V L F E K K V Y L S E C K T G N G K N Y R G T M S K T K N
	G I T C Q K W S S T S P H R P R F S P A T H P S E G L E E N Y C R N P D N D P Q

161	G P W C Y T T D P E K R Y D Y C D I L E C E E E C M H C S G E N Y D G K I S K
	T M S G L E C Q A W D S Q S P H A H G Y I P S K F P N K N L K K N Y C R N P D R E

241	L R P W C F T T D P N K R W E L C D I P R C T T P P P S S G P T Y Q C L K G T G
	E N Y R G N V A V T V S G H T C Q H W S A Q T P H T H N R T P E N F P C K N L D

321	E N Y C R N P D G K R A P W C H T T N S Q V R W E Y C K I P S C D S S P V S T
	E Q L A P T A P P E L T P V V Q D C Y H G D G Q S Y R G T S S T T T T G K K C Q S

401	W S S M T P H R H Q K T P E N Y P N A G L T M N Y C R N P D A D K G P W C F
	T T D P S V R W E Y C N L K K C S G T E A S V V A P P P V V L L P D V E T P S E E D

481	C M F G N G K G Y R G K R A T T V T G T P C Q D W A A Q E P H R H S I F T P E
	T N P R A G L E K N Y C R N P D G D V G G P W C Y T T N P R K L Y D Y C D V P Q C

561	A A P S F D C G K P Q V E P K K C P G R V V G G C V A H P H S W P W Q V S L
	R T R F G M H F C G G T L I S P E W V L T A A H C L E K S P R P S S Y K V I L G A H

641	Q E V N L E P H V Q E I E V S R L F L E P T R K D I A L L K L S S P A V I T D K V
	I P A C L P S P N Y V V A D R T E C F I T G W G E T Q G T F G A G L L K E A Q

721	L P V I E N K V C N R Y E F L N G R V Q S T E L C A G H L A G G T D S C Q G D
	S G G P L V C F E K D K Y I L Q G V T S W G L G C A R P N K P G V Y V R V S R F V

801	T W I E G V M R N N

5.110 ficolin 2 isoform a precursor [Homo sapiens]
Protein Accession gi|61744445

Mean Expression Ratio 0.842

Median Expression Ratio 0.844

Credible Interval (0.539, 1.31)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0671


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.52	0.81	1.2	SEQ ID NO: 827	AGPPGPNGAPGEPQPCLTGPR

SEQ ID NO: 828

1	M E L D R A V G V L G A A T L L L S F L G M A W A L Q A A D T C P E V K M V G
	L E G S D K L T I L R G C P G L P G A P G P K G E A G T N G K R G E R G P P G P P

81	G K A G P P G P N G A P G E P Q P C L T G P R T C K D L L D R G H F L S G W H T
	I Y L P D C R P L T V L C D M D T D G G G W T V F Q R R V D G S V D F Y R D W A

161	T Y K Q G F G S R L G E F W L G N D N I H A L T A Q G T S E L R V D L V D F E
	D N Y Q F A K Y R S F K V A D E A E K Y N L V L G A F V E G S A G D S L T F H N N

241	Q S F S T K D Q D N D L N T G N C A V M F Q G A W W Y K N C H V S N L N G R
	Y L R G T H G S F A N G I N W K S G K G Y N Y S Y K V S E M K V R P A

5.111 glycophorin C isoform 2 [Homo sapiens]; glycophorin C isoform 1 [Homo sapiens]
Protein Accession gi|8051605 gi|4504229

Mean Expression Ratio 1.18

Median Expression Ratio 1.18

Credible Interval (0.727, 1.93)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.72 1.2 2.1 SEQ ID NO: 829 GTEFAESADAALQGDPALQ

DAGDSSR

5.112 prolylcarboxypeptidase isoform 1 preproprotein [Homo sapiens]; prolylcarboxypeptidase isoform 2 preproprotein [Homo sapiens]
Protein Accession gi|4826940 gi|117306169

Mean Expression Ratio 0.846

Median Expression Ratio 0.847

Credible Interval (0.677, 1.06)

Associated Peptides 9

Associated Spectra 15

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.6	0.84	1.2	SEQ ID NO: 830	AMLVFAEHR

1	0.59	0.83	1.2	SEQ ID NO: 831	DITDTLVAVTISEGAH

1	0.59	0.83	1.2	SEQ ID NO: 832	DITDTLVAVTISEGAHHL

4	0.65	0.86	1.1	SEQ ID NO: 833	DITDTLVAVTISEGAHH
					LDLR


2	0.61	0.84	1.2	SEQ ID NO: 834	FLTSEQALADFAELIK

3	0.63	0.84	1.1	SEQ ID NO: 835	HLNFLTSEQALADFA
					ELIK


1	0.6	0.83	1.2	SEQ ID NO: 836	VDHFGFNTVK

1	0.59	0.82	1.2	SEQ ID NO: 837	YYGESLPFGDNSFK

1	0.62	0.87	1.2	SEQ ID NO: 838	NALDPMSVLLAR

5.113 collagen, type VI, alpha 1 precursor [Homo sapiens]
Protein Accession gi|87196339

Mean Expression Ratio 0.85

Median Expression Ratio 0.848

Credible Interval (0.525, 1.37)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0175


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.5	0.82	1.3	SEQ ID NO: 839	DAEEAISQTIDTIVDMIK

SEQ ID NO: 840

1	M R A A R A L L P L L L Q A C W T A A Q D E P E T P R A V A F Q D C P V D L F F
	V L D T S E S V A L R L K P Y G A L V D K V K S F T K R F I D N L R D R Y Y R C

81	D R N L V W N A G A L H Y S D E V E I I Q G L T R M P G G R D A L K S S V D A
	V K Y F G K G T Y T D C A I K K G L E Q L L V G G S H L K E N K Y L I V V T D G H

161	P L E G Y K E P C G G L E D A V N E A K H L G V K V F S V A I T P D H L E P R
	L S I I A T D H T Y R R N F T A A D W G Q S R D A E E A I S Q T I D T I V D M I K

241	N N V E Q V C C S F E C Q P A R G P P G L R G D P G F E G E R G K P G L P G E
	K G E A G D P G R P G D L G P V G Y Q G M K G E K G S R G E K G S R G P K G Y K G

321	E K G K R G I D G V D G V K G E M G Y P G L P G C K G S P G F D G I Q G P P G
	P K G D P G A F G L K G E K G E P G A D G E A G R P G S S G P S G D E G Q P G E P

401	G P P G E K G E A G D E G N P G P D G A P G E R G G P G E R G P R G T P G T R
	G P R G D P G E A G P Q G D Q G R E G P V G V P G D P G E A G P I G P K G Y R G D

481	E G P P G S E G A R G A P G P A G P P G D P G L M G E R G E D G P A G N G T E
	G F P G F P G Y P G N R G A P G I N G T K G Y P G L K G D E G E A G D P G D D N N

561	D I A P R G V K G A K G Y R G P E G P Q G P P G H Q G P P G P D E C E I L D I I
	M K M C S C C E C K C G P I D L L F V L D S S E S I G L Q N F E I A K D F V V K

641	V I D R L S R D E L V K F E P G Q S Y A G V V Q Y S H S Q M Q E H V S L R S P
	S I R N V Q E L K E A I K S L Q W M A G G T F T G E A L Q Y T R D Q L L P P S P N

721	N R I A L V I T D G R S D T Q R D T T P L N V L C S P G I Q V V S V G I K D V F
	D F I P G S D Q L N V I S C Q G L A P S Q G R P G L S L V K E N Y A E L L E D A

801	F L K N V T A Q I C I D K K C P D Y T C P I T F S S P A D I T I L L D G S A S V G
	S H N F D T T K R F A K R L A E R F L T A G R T D P A H D V R V A V V Q Y S G

881	T G Q Q R P E R A S L Q F L Q N Y T A L A S A V D A M D F I N D A T D V N D A
	L G Y V T R F Y R E A S S G A A K K R L L L F S D G N S Q G A T P A A I E K A V Q

961	E A Q R A G I E I F V V V V G R Q V N E P H I R V L V T G K T A E Y D V A Y G
	E S H L F R V P S Y Q A L L R G V F H Q T V S R K V A L G

5.114 calmodulin 1 [Homo sapiens]; calmodulin 3 [Homo sapiens]; calmodulin 2 [Homo sapiens]
Protein Accession gi|5901912 gi|58218968 gi|4502549

Mean Expression Ratio 1.18

Median Expression Ratio 1.18

Credible Interval (0.728, 1.92)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.74 1.2 2.1 SEQ ID NO: 841 VFDKDGNGYISAAELR

5.115 annexin I [Homo sapiens]
Protein Accession gi|4502101

Mean Expression Ratio 1.17

Median Expression Ratio 1.17

Credible Interval (0.795, 1.74)

Associated Peptides 2

Associated Spectra 3

Coverage 0.078


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.8	1.2	1.8	SEQ ID NO: 842	GLGTDEDTLIEILASR

1	0.76	1.2	1.8	SEQ ID NO: 843	TPAQFDADELR

SEQ ID NO: 844

1	M A M V S E F L K Q A W F I E N E E Q E Y V Q T V K S S K G G P G S A V S P Y P
	T F N P S S D V A A L H K A I M V K G V D E A T I I D I L T K R N N A Q R Q Q I

81	K A A Y L Q E T G K P L D E T L K K A L T G H L E E V V L A L L K T P A Q F D A
	D E L R A A M K G L G T D E D T L I E I L A S R T N K E I R D I N R V Y R E E L

161	K R D L A K D I T S D T S G D F R N A L L S L A K G D R S E D F G V N E D L A
	D S D A R A L Y E A G E R R K G T D V N V F N T I L T T R S Y P Q L R R V F Q K Y

241	T K Y S K H D M N K V L D L E L K G D I E K C L T A I V K C A T S K P A F F A
	E K L H Q A M K G V G T R H K A L I R I M V S R S E I D M N D I K A F Y Q K M Y G

321	I S L C Q A I L D E T K G D Y E K I L V A L C G G N

5.116 ras homolog gene family, member G [Homo sapiens]
Protein Accession gi|46249393

Mean Expression Ratio 1.17

Median Expression Ratio 1.17

Credible Interval (0.723, 1.92)

Associated Peptides 1

Associated Spectra 1

Coverage 0.089


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.73	1.2	2	SEQ ID NO: 845	TVNLNLWDTAGQEEYDR

SEQ ID NO: 846

1	M Q S I K C V V V G D G A V G K T C L L I C Y T T N A F P K E Y I P T V F D N Y S
	A Q S A V D G R T V N L N L W D T A G Q E E Y D R L R T L S Y P Q T N V F V I

81	C F S I A S P P S Y E N V R H K W H P E V C H H C P D V P I L L V G T K K D L R
	A Q P D T L R R L K E Q G Q A P I T P Q Q G Q A L A K Q I H A V R Y L E C S A L

161	Q Q D G V K E V F A E A V R A V L N P T P I K R G R S C I L L

5.117 immunoglobulin superfamily, member 8 [Homo sapiens]

Protein Accession gi 16445029

Mean Expression Ratio 0.849

Median Expression Ratio 0.853

Credible Interval (0.548, 1.29)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0440


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.52	0.84	1.3	SEQ ID NO: 847	VLPDVLQVSAAPPGPR

1	0.52	0.83	1.3	SEQ ID NO: 848	EVLVPEGPLYR

SEQ ID NO: 849

1	M G A L R P T L L P P S L P L L L L L M L G M G C W A R E V L V P E G P L Y R V
	A G T A V S I S C N V T G Y E G P A Q Q N F E W F L Y R P E A P D T A L G I V S

81	T K D T Q F S Y A V F K S R V V A G E V Q V Q R L Q G D A V V L K I A R L Q A
	Q D A G I Y E C H T P S T D T R Y L G S Y S G K V E L R V L P D V L Q V S A A P P

161	G P R G R Q A P T S P P R M T V H E G Q E L A L G C L A R T S T Q K H T H L A
	V S F G R S V P E A P V G R S T L Q E V V G I R S D L A V E A G A P Y A E R L A A

241	G E L R L G K E G T D R Y R M V V G G A Q A G D A G T Y H C T A A E W I Q D
	P D G S W A Q I A E K R A V L A H V D V Q T L S S Q L A V T V G P G E R R I G P G E

321	P L E L L C N V S G A L P P A G R H A A Y S V G W E M A P A G A P G P G R L V
	A Q L D T E G V G S L G P G Y E G R H I A M E K V A S R T Y R L R L E A A R P G D

401	A G T Y R C L A K A Y V R G S G T R L R E A A S A R S R P L P V H V R E E G V
	V L E A V A W L A G G T V Y R G E T A S L L C N I S V R G G P P G L R L A A S W W

481	V E R P E D G E L S S V P A Q L V G G V G Q D G V A E L G V R P G G G P V S V
	E L V G P R S H R L R L H S L G P E D E G V Y H C A P S A W V Q H A D Y S W Y Q A

561	G S A R S G P V T V Y P Y M H A L D T L F V P L L V G T G V A L V T G A T V L
	G T I T C C F M K R L R K R

5.118 Fc fragment of IgG binding protein [Homo sapiens]
Protein Accession gi|154146262

Mean Expression Ratio 1.17

Median Expression Ratio 1.17

Credible Interval (0.839, 1.62)

Associated Peptides 3

Associated Spectra 6

Coverage 0.00833


A	2.5	50	97.5	Sequence ID No.	Sequence

4	0.84	1.2	1.6	SEQ ID NO: 850	VNGVLTALPVSVADGR

1	0.8	1.2	1.8	SEQ ID NO: 851	YYPLGEVFYPGPECER

1	0.8	1.2	1.8	SEQ ID NO: 852	APGWDPLCWDECR

SEQ ID NO: 853

1	M G A L W S W W I L W A G A T L L W G L T Q E A S V D L K N T G R E E F L T A
	F L Q N Y Q L A Y S K A Y P R L L I S S L S E S P A S V S I L S Q A D N T S K K V

81	T V R P G E S V M V N I S A K A E M I G S K I F Q H A V V I H S D Y A I S V Q A L
	N A K P D T A E L T L L R P I Q A L G T E Y F V L T P P G T S A R N V K E F A

161	V V A G A A G A S V S V T L K G S V T F N G K F Y P A G D V L R V T L Q P Y N
	V A Q L Q S S V D L S G S K V T A S S P V A V L S G H S C A Q K H T T C N H V V E

241	Q L L P T S A W G T H Y V V P T L A S Q S R Y D L A F V V A S Q A T K L T Y N
	H G G I T G S R G L Q A G D V V E F E V R P S W P L Y L S A N V G I Q V L L F G T

321	G A I R N E V T Y D P Y L V L I P D V A A Y C P A Y V V K S V P G C E G V A L
	V V A Q T K A I S G L T I D G H A V G A K L T W E A V P G S E F S Y A E V E L G T

401	A D M I H T A E A T T N L G L L T F G L A K A I G Y A T A A D C G R T V L S P
	V E P S C E G M Q C A A G Q R C Q V V G G K A G C V A E S T A V C R A Q G D P H Y

481	T T F D G R R Y D M M G T C S Y T M V E L C S E D D T L P A F S V E A K N E H
	R G S R R V S Y V G L V T V R A Y S H S V S L T R G E V G F V L V D N Q R S R L P

561	V S L S E G R L R V Y Q S G P R A V V E L V F G L V V T Y D W D C Q L A L S L
	P A R F Q D Q V C G L C G N Y N G D P A D D F L T P D G A L A P D A V E F A S S W

641	K L D D G D Y L C E D G C Q N N C P A C T P G Q A Q H Y E G D R L C G M L T
	K L D G P F A V C H D T L D P R P F L E Q C V Y D L C V V G G E R L S L C R G L S A

721	Y A Q A C L E L G I S V G D W R S P A N C P L S C P A N S R Y E L C G P A C P T
	S C N G A A A P S N C S G R P C V E G C V C L P G F V A S G G A C V P A S S C G

801	C T F Q G L Q L A P G Q E V W A D E L C Q R R C T C N G A T H Q V T C R D K
	Q S C P A G E R C S V Q N G L L G C Y P D R F G T C Q G S G D P H Y V S F D G R R F

881	D F M G T C T Y L L V G S C G Q N A A L P A F R V L V E N E H R G S Q T V S Y
	T R A V R V E A R G V K V A V R R E Y P G Q V L V D D V L Q Y L P F Q A A D G Q V

961	Q V F R Q G R D A V V R T D F G L T V T Y D W N A R V T A K V P S S Y A E A
	L C G L C G N F N G D P A D D L A L R G G G Q A A N A L A F G N S W Q E E T R P
	G C

1041	G A T E P G D C P K L D S L V A Q Q L Q S K N E C G I L A D P K G P F R E C H
	S K L D P Q G A V R D C V Y D R C L L P G Q S G P L C D A L A T Y A A A C Q A A G

1121	A T V H P W R S E E L C P L S C P P H S H Y E A C S Y G C P L S C G D L P V P
	G G C G S E C H E G C V C D E G F A L S G E S C L P L A S C G C V H Q G T Y H P P

1201	G Q T F Y P G P G C D S L C H C Q E G G L V S C E S S S C G P H E A C Q P S G
	G S L G C V A V G S S T C Q A S G D P H Y T T F D G R R F D F M G T C V Y V L A Q

1281	T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A N F
	T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V V I
	E T

1361	D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q Q M C G L C G N Y N G D P
	K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P T P C P P G S
	E D

1441	C I P S H K C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V D P
	Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G H V E

1521	P W R T E T F C P M E C P P N S H Y E L C A D T C S L G C S A L S A P P Q C Q
	D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G V Y Y E P E Q T V

1601	L I D N C R Q Q C T C H A G K G M V C Q E H S C K P G Q V C Q P S G G I L S C
	V T K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D P H

1681	Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V T T
	K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G V L

1761	T A L P V S V A D G R I S V T Q G A S K A L L V A D F G L Q V S Y D W N W R
	V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P I W

1841	G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G F C
	G P L A P G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I L C

1921	K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y E V
	C G S P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D R C

2001	V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G P G
	G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G D P
	H Y

2081	V T L D G H R F N F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A N E
	H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V T L

2161	P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L R V
	P A A Y A G S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G A Q
	G C

2241	G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P C H
	G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q A A

2321	G A Q L R E W R R P D F C P F Q C P A H S H Y E L C G D S C P G S C P S L S A
	P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D D R Y Y P

2401	L G Q T F Y P G P G C D S L C R C R E G G E V S C E P S S C G P H E T C R P S
	G G S L G C V A V G S T T C Q A S G D P H Y T T F D G R R F D F M G T C V Y V L A

2481	Q T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A N
	F T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V V I E

2561	T D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q L M C G L C G N Y N G D
	P K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P P T C P P G
	S E

2641	G C I P S E E C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V D
	P Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G Q V

2721	E P W R N E T F C P M E C P Q N S H Y E L C A D T C S L G C S A L S A P L Q C
	P D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G A Y Y E P E Q T

2801	V L I D N C R Q Q C T C H V G K V V V C Q E H S C K P G Q V C Q P S G G I L S
	C V N K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D P

2881	H Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V T
	T K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G V

2961	L T A L P V S V A D G R I S V T Q G A S K A L L V A D F G L Q V S Y D W N W
	R V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P I

3041	W G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G F
	C G P L A P G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I L

3121	C K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y E
	V C G P P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D R

3201	C V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G P
	G G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G D
	P H

3281	Y V T L D G H R F D F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A N
	E H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V T

3361	L P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L R
	V P A A Y A G S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G A
	Q G

3441	C G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P C
	H G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q A

3521	A G A Q L R E W R R P D F C P F Q C P A H S H Y E L C G D S C P G S C P S L S
	A P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D D R Y Y

3601	P L G Q T F Y P G P G C D S L C R C R E G G E V S C E P S S C G P H E T C R P S
	G G S L G C V A V G S T T C Q A S G D P H Y T T F D G H R F D F M G T C V Y V L

3681	A Q T C G T R P G L H R F A V L Q E N V A W G N G R V S V T R V I T V Q V A
	N F T L R L E Q R Q W K V T V N G V D M K L P V V L A N G Q I R A S Q H G S D V
	V I

3761	E T D F G L R V A Y D L V Y Y V R V T V P G N Y Y Q L M C G L C G N Y N G
	D P K D D F Q K P N G S Q A G N A N E F G N S W E E V V P D S P C L P P P T C P P
	G S

3841	A G C I P S D K C P P E L E K K Y Q K E E F C G L L S S P T G P L S S C H K L V
	D P Q G P L K D C I F D L C L G G G N L S I L C S N I H A Y V S A C Q A A G G H

3921	V E P W R N E T F C P M E C P Q N S H Y E L C A D T C S L G C S A L S A P L Q
	C P D G C A E G C Q C D S G F L Y N G Q A C V P I Q Q C G C Y H N G V Y Y E P E Q

4001	T V L I D N C R Q Q C T C H V G K V V V C Q E H S C K P G Q V C Q P S G G I L
	S C V T K D P C H G V T C R P Q E T C K E Q G G Q G V C L P N Y E A T C W L W G D

4081	P H Y H S F D G R K F D F Q G T C N Y V L A T T G C P G V S T Q G L T P F T V
	T T K N Q N R G N P A V S Y V R V V T V A A L G T N I S I H K D E I G K V R V N G

4161	V L T A L P V S V A D G R I S V A Q G A S K A L L V A D F G L Q V S Y D W N
	W R V D V T L P S S Y H G A V C G L C G N M D R N P N N D Q V F P N G T L A P S I P

4241	I W G G S W R A P G W D P L C W D E C R G S C P T C P E D R L E Q Y E G P G
	F C G P L S S G T G G P F T T C H A H V P P E S F F K G C V L D V C M G G G D R D I

4321	L C K A L A S Y V A A C Q A A G V V I E D W R A Q V G C E I T C P E N S H Y
	E V C G P P C P A S C P S P A P L T T P A V C E G P C V E G C Q C D A G F V L S A D

4401	R C V P L N N G C G C W A N G T Y H E A G S E F W A D G T C S Q W C R C G
	P G G G S L V C T P A S C G L G E V C G L L P S G Q H G C Q P V S T A E C Q A W G
	D P

4481	H Y V T L D G H R F D F Q G T C E Y L L S A P C H G P P L G A E N F T V T V A
	N E H R G S Q A V S Y T R S V T L Q I Y N H S L T L S A R W P R K L Q V D G V F V

4561	A L P F Q L D S L L H A H L S G A D V V V T T T S G L S L A F D G D S F V R L
	R V P A A Y A A S L C G L C G N Y N Q D P A D D L K A V G G K P A G W Q V G G
	A Q

4641	G C G E C V S K P C P S P C T P E Q Q E S F G G P D A C G V I S A T D G P L A P
	C H G L V P P A Q Y F Q G C L L D A C Q V Q G H P G G L C P A V A T Y V A A C Q

4721	A A G A Q L G E W R R P D F C P L Q C P A H S H Y E L C G D S C P V S C P S L
	S A P E G C E S A C R E G C V C D A G F V L S G D T C V P V G Q C G C L H D G R Y

4801	Y P L G E V F Y P G P E C E R R C E C G P G G H V T C Q E G A A C G P H E E C
	R L E D G V Q A C H A T G C G R C L A N G G I H Y I T L D G R V Y D L H G S C S Y

4881	V L A Q V C H P K P G D E D F S I V L E K N A A G D L Q R L L V T V A G Q V
	V S L A Q G Q Q V T V D G E A V A L P V A V G R V R V T A E G R N M V L Q T T K
	G L

4961	R L L F D G D A H L L M S I P S P F R G R L C G L C G N F N G N W S D D F V L
	P N G S A A S S V E T F G A A W R A P G S S K G C G E G C G P Q G C P V C L A E E

5041	T A P Y E S N E A C G Q L R N P Q G P F A T C Q A V L S P S E Y F R Q C V Y D
	L C A Q K G D K A F L C R S L A A Y T A A C Q A A G V A V K P W R T D S F C P L H

5121	C P A H S H Y S I C T R T C Q G S C A A L S G L T G C T T R C F E G C E C D D
	R F L L S Q G V C I P V Q D C G C T H N G R Y L P V N S S L L T S D C S E R C S C

5201	S S S S G L T C Q A A G C P P G R V C E V K A E A R N C W A T R G L C V L S
	V G A N L T T F D G A R G A T T S P G V Y E L S S R C P G L Q N T I P W Y R V V A E

5281	V Q I C H G K T E A V G Q V H I F F Q D G M V T L T P N K G V W V N G L R V
	D L P A E K L A S V S V S R T P D G S L L V R Q K A G V Q V W L G A N G K V A V I V

5361	S N D H A G K L C G A C G N F D G D Q T N D W H D S Q E K P A M E K W R A
	Q D F S P C Y G

5.119 hypothetical protein LOC284422 [Homo sapiens]
Protein Accession gi|211059425

Mean Expression Ratio 1.17

Median Expression Ratio 1.17

Credible Interval (0.796, 1.74)

Associated Peptides 2

Associated Spectra 3

Coverage NaN

Sequence

A 2.5 50 97.5 ID No. Sequence

2 0.8 1.2 1.8 SEQ ID NO: 854 EGESNLGLDLEEKEPGDHER

1 0.78 1.2 1.9 SEQ ID NO: 855 MESNLYQDQSEDKR

5.120 vacuolar protein sorting 37D [Homo sapiens]
Protein Accession gi|117938318

Mean Expression Ratio 1.17

Median Expression Ratio 1.17

Credible Interval (0.732, 1.91)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0558


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.73	1.2	2.0	SEQ ID NO: 856	SFPAAAVLPTGAAR

SEQ ID NO: 857

1	M Y R A R A A R A G P E P G S P G R F G I L S T G Q L R D L L Q D E P K L D R I V
	R L S R K F Q G L Q L E R E A C L A S N Y A L A K E N L A L R P R L E M G R A

81	A L A I K Y Q E L R E V A E N C A D K L Q R L E E S M H R W S P H C A L G W L
	Q A E L E E A E Q E A E E Q M E Q L L L G E Q S L E A F L P A F Q R G R A L A H L

161	R R T Q A E K L Q E L L R R R E R S A Q P A P T S A A D P P K S F P A A A V L P
	T G A A R G P P A V P R S L P P L D S R P V P P L K G S P G C P L G P A P L L S

241	P R P S Q P E P P H R

5.121 protease, serine, 1 preproprotein [Homo sapiens]
Protein Accession gi|4506145

Mean Expression Ratio 1.17

Median Expression Ratio 1.17

Credible Interval (0.811, 1.68)

Associated Peptides 1

Associated Spectra 5

Coverage 0.0324


A	2.5	50	97.5	Sequence ID No.	Sequence

5	0.88	1.2	1.7	SEQ ID NO: 858	NKPGVYTK

SEQ ID NO: 859

1	M N P L L I L T F V A A A L A A P F D D D D K I V G G Y N C E E N S V P Y Q V S
	L N S G Y H F C G G S L I N E Q W V V S A G H C Y K S R I Q V R L G E H N I E V

81	L E G N E Q F I N A A K I I R H P Q Y D R K T L N N D I M L I K L S S R A V I N A
	R V S T I S L P T A P P A T G T K C L I S G W G N T A S S G A D Y P D E L Q C

161	L D A P V L S Q A K C E A S Y P G K I T S N M F C V G F L E G G K D S C Q G D
	S G G P V V C N G Q L Q G V V S W G D G C A Q K N K P G V Y T K V Y N Y V K W
	I K

241	N T I A A N S

5.122 prominin 2 [Homo sapiens]
Protein Accession gi|21389623

Mean Expression Ratio 1.17

Median Expression Ratio 1.17

Credible Interval (0.766, 1.82)

Associated Peptides 1

Associated Spectra 2

Coverage 0.03


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.79	1.2	1.9	SEQ ID NO: 860	TSMEQLAQELQGLAQAQDNSVLGQR

SEQ ID NO: 861

1	M K H T L A L L A P L L G L G L G L A L S Q L A A G A T D C K F L G P A E H L T
	F T P A A R A R W L A P R V R A P G L L D S L Y G T V R R F L S V V Q L N P F P

81	S E L V K A L L N E L A S V K V N E V V R Y E A G Y V V C A V I A G L Y L L L
	V P T A G L C F C C C R C H R R C G G R V K T E H K A L A C E R A A L M V F L L L

161	T T L L L L I G V V C A F V T N Q R T H E Q M G P S I E A M P E T L L S L W G L
	V S D V P Q E L Q A V A Q Q F S L P Q E Q V S E E L D G V G V S I G S A I H T Q

241	L R S S V Y P L L A A V G S L G Q V L Q V S V H H L Q T L N A T V V E L Q A G
	Q Q D L E P A I R E H R D R L L E L L Q E A R C Q G D C A G A L S W A R T L E L G

321	A D F S Q V P S V D H V L H Q L K G V P E A N F S S M V Q E E N S T F N A L P
	A L A A M Q T S S V V Q E L K K A V A Q Q P E G V R T L A E G F P G L E A A S R W

401	A Q A L Q E V E E S S R P Y L Q E V Q R Y E T Y R W I V G C V L C S V V L F V
	V L C N L L G L N L G I W G L S A R D D P S H P E A K G E A G A R F L M A G V G L

481	S F L F A A P L I L L V F A T F L V G G N V Q T L V C R S W E N G E L F E F A D
	T P G N L P P S M N L S Q L L G L R K N I S I H Q A Y Q Q C K E G A A L W T V L

561	Q L N D S Y D L E E H L D I N Q Y T N K L R Q E L Q S L K V D T Q S L D L L S S
	A A R R D L E A L Q S S G L Q R I H Y P D F L V Q I Q R P V V K T S M E Q L A Q

641	E L Q G L A Q A Q D N S V L G Q R L Q E E A Q G L R N L H Q E K V V P Q Q S L
	V A K L N L S V R A L E S S A P N L Q L E T S D V L A N V T Y L K G E L P A W A A

721	R I L R N V S E C F L A R E M G Y F S Q Y V A W V R E E V T Q R I A T C Q P L S
	G A L D N S R V I L C D M M A D P W N A F W F C L A W C T F F L I P S I I F A V

801	K T S K Y F R P I R K R L S S T S S E E T Q L F H I P R V T S L K L

5.123 cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]; cathepsin B preproprotein [Homo sapiens]
Protein Accession gi|4503139 gi|22538437 gi|22538435 gi|22538433 gi|22538431

Mean Expression Ratio 0.858

Median Expression Ratio 0.856

Credible Interval (0.556, 1.32)

Associated Peptides 1

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.54 0.83 1.3 SEQ ID NO: 862 GQDHCGIESEVVAGIPR

5.124 radixin [Homo sapiens]
Protein Accession gi|4506467

Mean Expression Ratio 1.16

Median Expression Ratio 1.16

Credible Interval (0.77, 1.75)

Associated Peptides 1

Associated Spectra 3

Coverage 0.0292


SEQ ID NO: 863

SEQ ID NO: 864

1	M P K P I N V R V T T M D A E L E F A I Q P N T T G K Q L F D Q V V K T V G L R
	E V W F F G L Q Y V D S K G Y S T W L K L N K K V T Q Q D V K K E N P L Q F K F

81	R A K F F P E D V S E E L I Q E I T Q R L F F L Q V K E A I L N D E I Y C P P E T A
	V L L A S Y A V Q A K Y G D Y N K E I H K P G Y L A N D R L L P Q R V L E Q

161	H K L T K E Q W E E R I Q N W H E E H R G M L R E D S M M E Y L K I A Q D L
	E M Y G V N Y F E I K N K K G T E L W L G V D A L G L N I Y E H D D K L T P K I G F

241	P W S E I R N I S F N D K K F V I K P I D K K A P D F V F Y A P R L R I N K R I L
	A L C M G N H E L Y M R R R K P D T I E V Q Q M K A Q A R E E K H Q K Q L E R

321	A Q L E N E K K K R E I A E K E K E R I E R E K E E L M E R L K Q I E E Q T I K
	A Q K E L E E Q T R K A L E L D Q E R K R A K E E A E R L E K E R R A A E E A K

401	S A I A K Q A A D Q M K N Q E Q L A A E L A E F T A K I A L L E E A K K K K E
	E E A T E W Q H K A F A A Q E D L E K T K E E L K T V M S A P P P P P P P P V I P

481	P T E N E H D E H D E N N A E A S A E L S N E G V M N H R S E E E R V T E T Q
	K N E R V K K Q L Q A L S S E L A Q A R D E T K K T Q N D V L H A E N V K A G R D

561	K Y K T L R Q I R Q G N T K Q R I D E F E A M

5.125 annexin VI isoform 2 [Homo sapiens]; annexin VI isoform 1 [Homo sapiens]
Protein Accession gi|71773415 gi|71773329

Mean Expression Ratio 1.16

Median Expression Ratio 1.16

Credible Interval (0.832, 1.60)

Associated Peptides 3

Associated Spectra 6

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.77	1.1	1.7	SEQ ID NO: 865	EAILDIITSR

4	0.89	1.2	1.7	SEQ ID NO: 866	GLGTDEDTIIDIITHR

1	0.78	1.2	1.7	SEQ ID NO: 867	GSIHDFPGFDPNQDAEALY

5.126 cystatin C precursor [Homo sapiens]
Protein Accession gi|4503107

Mean Expression Ratio 0.859

Median Expression Ratio 0.86

Credible Interval (0.716, 1.03)

Associated Peptides 9

Associated Spectra 37

Coverage 0.425


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	0.88	1.2	SEQ ID NO: 868	ALDFAVGEYNK

3	0.63	0.83	1.1	SEQ ID NO: 869	KQIVAGVNYFLDVELGR

1	0.64	0.87	1.2	SEQ ID NO: 870	LDNCPFHDQPHLK

8	0.66	0.83	1.0	SEQ ID NO: 871	LVGGPMDASVEEEGVR

3	0.61	0.81	1.1	SEQ ID NO: 872	LVGGPMDASVEEEGVRR

15	0.72	0.87	1.1	SEQ ID NO: 873	QIVAGVNYFLDVELGR

4	0.65	0.84	1.1	SEQ ID NO: 874	TQPNLDNCPFHDQPHLK

1	0.66	0.9	1.2	SEQ ID NO: 875	VGGPMDASVEEEGVR

1	0.63	0.86	1.2	SEQ ID NO: 876	FLDVELGR

SEQ ID NO: 877

1	M A G P L R A P L L L L A I L A V A L A V S P A A G S S P G K P P R L V G G P M
	D A S V E E E G V R R A L D F A V G E Y N K A S N D M Y H S R A L Q V V R A R K

81	Q I V A G V N Y F L D V E L G R T T C T K T Q P N L D N C P F H D Q P H L K R K
	A F C S F Q I Y A V P W Q G T M T L S K S T C Q D A

5.127 tweety 3 [Homo sapiens]
Protein Accession gi|51100978

Mean Expression Ratio 0.86

Median Expression Ratio 0.86

Credible Interval (0.702, 1.06)

Associated Peptides 8

Associated Spectra 21

Coverage 0.222


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	0.86	1.2	SEQ ID NO: 878	AANPFQQK

4	0.66	0.87	1.1	SEQ ID NO: 879	AAPWWVSLLHR

7	0.64	0.82	1.0	SEQ ID NO: 880	ALVEMQDVVAELLR

2	0.65	0.9	1.2	SEQ ID NO: 881	GPDEDGEEEAAPGPR

1	0.64	0.9	1.2	SEQ ID NO: 882	MVEEYSVLSGDILQYYLACSPR

3	0.57	0.77	1.0	SEQ ID NO: 883	QLAGRPEPLR

2	0.63	0.85	1.2	SEQ ID NO: 884	TVSNAPVTEYMSQNANFQNPR

1	0.65	0.9	1.3	SEQ ID NO: 885	TVPWEQPATKDPLLR

SEQ ID NO: 886

1	M A G V S Y A A P W W V S L L H R L P H F D L S W E A T S S Q F R P E D T D Y Q
	Q A L L L L G A A A L A C L A L D L L F L L F Y S F W L C C R R R K S E E H L D

81	A D C C C T A W C V I I A T L V C S A G I A V G F Y G N G E T S D G I H R A T Y
	S L R H A N R T V A G V Q D R V W D T A V G L N H T A E P S L Q T L E R Q L A G

161	R P E P L R A V Q R L Q G L L E T L L G Y T A A I P F W R N T A V S L E V L A E
	Q V D L Y D W Y R W L G Y L G L L L L D V I I C L L V L V G L I R S S K G I L V

241	G V C L L G V L A L V I S W G A L G L E L A V S V G S S D F C V D P D A Y V T
	K M V E E Y S V L S G D I L Q Y Y L A C S P R A A N P F Q Q K L S G S H K A L V E

321	M Q D V V A E L L R T V P W E Q P A T K D P L L R V Q E V L N G T E V N L Q
	H L T A L V D C R S L H L D Y V Q A L T G F C Y D G V E G L I Y L A L F S F V T A L

401	M F S S I V C S V P H T W Q Q K R G P D E D G E E E A A P G P R Q A H D S L Y
	R V H M P S L Y S C G S S Y G S E T S I P A A A H T V S N A P V T E Y M S Q N A N

481	F Q N P R C E N T P L I G R E S P P P S Y T S S M R A K Y L A T S Q P R P D S S G
	S H

5.128 hypothetical protein LOC84418 [Homo sapiens]
Protein Accession gi|14165278

Mean Expression Ratio 1.16

Median Expression Ratio 1.16

Credible Interval (0.761, 1.78)

Associated Peptides 2

Associated Spectra 2

Coverage 0.278


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.74	1.2	1.9	SEQ ID NO: 887	QGYPQYGWQGGPQEPPK

1	0.74	1.2	1.9	SEQ ID NO: 888	TTVYVVEDQR

SEQ ID NO: 889

1	M N Q E N P P P Y P G P G P T A P Y P P Y P P Q P M G P G P M G G P Y P P P Q G
	Y P Y Q G Y P Q Y G W Q G G P Q E P P K T T V Y V V E D Q R R D E L G P S T C L

81	T A C W T A L C C C C L W D M L T

5.129 CD82 antigen isoform 2 [Homo sapiens]; CD82 antigen isoform 1 [Homo sapiens]
Protein Accession gi|67782354 gi|4504813

Mean Expression Ratio 1.16

Median Expression Ratio 1.16

Credible Interval (0.755, 1.79)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.74 1.2 1.8 SEQ ID NO: 890 EDSLQDAWDYVQAQVK

1 0.75 1.2 1.9 SEQ ID NO: 891 QEMGGIVTELIR

5.130 napsin A preproprotein [Homo sapiens]
Protein Accession gi|4758754

Mean Expression Ratio 0.862

Median Expression Ratio 0.864

Credible Interval (0.674, 1.09)

Associated Peptides 6

Associated Spectra 13

Coverage 0.207


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.59	0.83	1.1	SEQ ID NO: 892	DPEEPDGGELVLGGSDPAH

5	0.57	0.76	1	SEQ ID NO: 893	GCAAILDTGTSLITGPTEEIR

2	0.61	0.85	1.2	SEQ ID NO: 894	ILDTGTSLITGPTEEIR

1	0.65	0.92	1.3	SEQ ID NO: 895	SPGDKPIFVPLSNYR

1	0.6	0.85	1.2	SEQ ID NO: 896	TVAFDTGSSNLWVPSR

2	0.68	0.95	1.3	SEQ ID NO: 897	VDGILSEDKLTIGGIK

SEQ ID NO: 898

1	M S P P P L L Q P L L L L L P L L N V E P S G A T L I R I P L H R V Q P G R R I L N
	L L R G W R E P A E L P K L G A P S P G D K P I F V P L S N Y R D V Q Y F G

81	E I G L G T P P Q N F T V A F D T G S S N L W V P S R R C H F F S V P C W L H H
	R F D P K A S S S F Q A N G T K F A I Q Y G T G R V D G I L S E D K L T I G G I

161	K G A S V I F G E A L W E P S L V F A F A H F D G I L G L G F P I L S V E G V R
	P P M D V L V E Q G L L D K P V F S F Y L N R D P E E P D G G E L V L G G S D P

241	A H Y I P P L T F V P V T V P A Y W Q I H M E R V K V G P G L T L C A K G C A
	A I L D T G T S L I T G P T E E I R A L H A A I G G I P L L A G E Y I I L C S E I

321	P K L P A V S F L L G G V W F N L T A H D Y V I Q T T R N G V R L C L S G F Q
	A L D V P P P A G P F W I L G D V F L G T Y V A V F D R G D M K S S A R V G L A R

401	A R T R G A D L G W G E T A Q A Q F P G

5.131 acid phosphatase 2, lysosomal isoform 1 precursor [Homo sapiens]
Protein Accession gi|4557010

Mean Expression Ratio 0.864

Median Expression Ratio 0.864

Credible Interval (0.64, 1.17)

Associated Peptides 4

Associated Spectra 7

Coverage 0.132


A	2.5	50	97.5	Sequence ID No.	Sequence

4	0.6	0.83	1.1	SEQ ID NO: 899	EGMLQHWELGQALR

1	0.6	0.87	1.3	SEQ ID NO: 900	FVTLLYR

1	0.59	0.87	1.3	SEQ ID NO: 901	NVYDTLFCEQTHGLR

1	0.58	0.85	1.3	SEQ ID NO: 902	TLMSAEANLAGLFPPNGMQR

SEQ ID NO: 903

1	M A G K R S G W S R A A L L Q L L L G V N L V V M P P T R A R S L R F V T L L Y
	R H G D R S P V K T Y P K D P Y Q E E E W P Q G F G Q L T K E G M L Q H W E L G

81	Q A L R Q R Y H G F L N T S Y H R Q E V Y V R S T D F D R T L M S A E A N L A
	G L F P P N G M Q R F N P N I S W Q P I P V H T V P I T E D R L L K F P L G P C P

161	R Y E Q L Q N E T R Q T P E Y Q N E S S R N A Q F L D M V A N E T G L T D L T
	L E T V W N V Y D T L F C E Q T H G L R L P P W A S P Q T M Q R L S R L K D F S F

241	R F L F G I Y Q Q A E K A R L Q G G V L L A Q I R K N L T L M A T T S Q L P K L
	L V Y S A H D T T L V A L Q M A L D V Y N G E Q A P Y A S C H I F E L Y Q E D S

321	G N F S V E M Y F R N E S D K A P W P L S L P G C P H R C P L Q D F L R L T E P
	V V P K D W Q Q E C Q L A S G P A D T E V I V A L A V C G S I L F L L I V L L L

401	T V L F R M Q A Q P P G Y R H V A D G E D H A

5.132 apolipoprotein E precursor [Homo sapiens]
Protein Accession gi|4557325

Mean Expression Ratio 0.863

Median Expression Ratio 0.864

Credible Interval (0.56, 1.32)

Associated Peptides 2

Associated Spectra 2

Coverage 0.110


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.55	0.87	1.4	SEQ ID NO: 904	SWFEPLVEDMQR

1	0.52	0.83	1.3	SEQ ID NO: 905	WVQTLSEQVQEELLSSQVTQELR

SEQ ID NO: 906

1	M K V L W A A L L V T F L A G C Q A K V E Q A V E T E P E P E L R Q Q T E W Q
	S G Q R W E L A L G R F W D Y L R W V Q T L S E Q V Q E E L L S S Q V T Q E L R A

81	L M D E T M K E L K A Y K S E L E E Q L T P V A E E T R A R L S K E L Q A A Q
	A R L G A D M E D V C G R L V Q Y R G E V Q A M L G Q S T E E L R V R L A S H L R

161	K L R K R L L R D A D D L Q K R L A V Y Q A G A R E G A E R G L S A I R E R L
	G P L V E Q G R V R A A T V G S L A G Q P L Q E R A Q A W G E R L R A R M E E M G

241	S R T R D R L D E V K E Q V A E V R A K L E E Q A Q Q I R L Q A E A F Q A R L
	K S W F E P L V E D M Q R Q W A G L V E K V Q A A V G T S A A P V P S D N H

5.133 transmembrane protein 176B isoform b [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]; transmembrane protein 176B isoform a [Homo sapiens]
Protein Accession gi|156416022 gi|56416020 gi|156416018 gi|156416016 gi|156416014

Mean Expression Ratio 0.864

Median Expression Ratio 0.865

Credible Interval (0.64, 1.17)

Associated Peptides 3

Associated Spectra 8

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

5 0.6 0.82 1.1 SEQ ID NO: 907 FLFHPGDTVPSTAR

1 0.58 0.85 1.2 SEQ ID NO: 908 LFHPGDTVPSTAR

2 0.62 0.89 1.3 SEQ ID NO: 909 LLGENSVPPSPSR

5.134 GM2 ganglioside activator precursor [Homo sapiens]
Protein Accession gi|39995109

Mean Expression Ratio 1.15

Median Expression Ratio 1.16

Credible Interval (0.703, 1.88)

Associated Peptides 1

Associated Spectra 1

Coverage 0.104


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.71	1.2	2	SEQ ID NO: 910	SEFVVPDLELPSWLTTGNYR

SEQ ID NO: 911

1	M Q S L M Q A P L L I A L G L L L A A P A Q A H L K K P S Q L S S F S W D N C D
	E G K D P A V I R S L T L E P D P I I V P G N V T L S V M G S T S V P L S S P L

81	K V D L V L E K E V A G L W I K I P C T D Y I G S C T F E H F C D V L D M L I P T
	G E P C P E P L R T Y G L P C H C P F K E G T Y S L P K S E F V V P D L E L P

161	S W L T T G N Y R I E S V L S S S G K R L G C I K I A A S L K G I

5.135 mercaptopyruvate sulfurtransferase isoform 2 [Homo sapiens]; mercaptopyruvate sulfurtransferase isoform 2 [Homo sapiens]; mercaptopyruvate sulfurtransferase isoform 1 [Homo sapiens]
Protein Accession gi|61835204 gi|194473681 gi|194473668

Mean Expression Ratio 0.865

Median Expression Ratio 0.866

Credible Interval (0.564, 1.33)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.53 0.85 1.4 SEQ ID NO: 912 ALVSAQWVAEALR

1 0.53 0.85 1.4 SEQ ID NO: 913 HIPGAAFFDIDQCSDR

5.136 mannosidase, alpha, class 1A, member 1 [Homo sapiens]
Protein Accession gi|24497519

Mean Expression Ratio 0.866

Median Expression Ratio 0.867

Credible Interval (0.556, 1.32)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0475


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.53	0.86	1.4	SEQ ID NO: 914	GLPPVDFVPPIGVESR

1	0.53	0.85	1.3	SEQ ID NO: 915	MYFDAVQAIETHLIR

SEQ ID NO: 916

1	M P V G G L L P L F S S P A G G V L G G G L G G G G G R K G S G P A A L R L T E
	K F V L L L V F S A F I T L C F G A I F F L P D S S K L LS G V L F H S S P A L

81	Q P A A D H K P G P G A R A E D A A E G R A R R R E E G A P G D P E A A L E D
	N L A R I R E N H E R A L R E A K E T L Q K L P E E I Q R D I L L E K K K V A Q D

161	Q L R D K A P F R G L P P V D F V P P I G V E S R E P A D A A I R E K R A K I K
	E M M K H A W N N Y K G Y A W G L N E L K P I S K G G H S S S L F G N I K G A T

241	I V D A L D T L F I M E M K H E F E E A K S W V E E N L D F N V N A E I S V F E
	V N I R F V G G L L S A Y Y L S G E E I F R K K A V E L G V K L L P A F H T P S

321	G I P W A L L N M K S G I G R N W P W A S G G S S I L A E F G T L H L E F M H
	L S H L S G N P I F A E K V M N I R T V L N K L E K P Q G L Y P N Y L N P S S G Q

401	W G Q H H V S V G G L G D S F Y E Y L L K A W L M S D K T D L E A K K M Y F
	D A V Q A I E T H L I R K S S S G L T Y I A E W K G G L L E H K M G H L T C F A G G

481	M F A L G A D A A P E G M A Q H Y L E L G A E I A R T C H E S Y N R T F M K L
	G P E A F R F D G G V E A I A T R Q N E K Y Y I L R P E V M E T Y M Y M W R L T H

561	D P K Y R K W A W E A V E A L E N H C R V N G G Y S G L R D V Y L L H E S Y
	D D V Q Q S F F L A E T L K Y L Y L I F S D D D L L P L E H W I F N S E A H L L P I

641	L P K D K K E V E I R E E

5.137 integral membrane protein 2B [Homo sapiens]
Protein Accession gi|11527402

Mean Expression Ratio 0.87

Median Expression Ratio 0.868

Credible Interval (0.571, 1.35)

Associated Peptides 2

Associated Spectra 2

Coverage 0.109


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.53	0.85	1.4	SEQ ID NO: 917	SGEEALIIPPDAVAVDCK

1	0.54	0.86	1.4	SEQ ID NO: 918	DPDDVVPVGQR

SEQ ID NO: 919

1	M V K V T F N S A L A Q K E A K K D E P K S G E E A L I I P P D A V A V D C K D
	P D D V V P V G Q R R A W C W C M C F G L A F M L A G V I L G G A Y L Y K Y F A

81	L Q P D D V Y Y C G I K Y I K D D V I L N E P S A D A P A A L Y Q T I E E N I K I
	F E E E E V E F I S V P V P E F A D S D P A N I V H D F N K K L T A Y L D L N

161	L D K C Y V I P L N T S I V M P P R N L L E L L I N I K A G T Y L P Q S Y L I H E
	H M V I T D R I E N I D H L G F F I Y R L C H D K E T Y K L Q R R E T I K G I

241	Q K R E A S N C F A I R H F E N K F A V E T L I C S

5.138 tetraspan 1 [Homo sapiens]
Protein Accession gi|21264578

Mean Expression Ratio 1.16

Median Expression Ratio 1.15

Credible Interval (0.857, 1.57)

Associated Peptides 4

Associated Spectra 8

Coverage 0.112


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.8	1.2	1.7	SEQ ID NO: 920	AHDQKVEGCFNQLLYDIR

1	0.77	1.1	1.7	SEQ ID NO: 921	QKAHDQK

5	0.92	1.2	1.7	SEQ ID NO: 922	VEGCFNQLLYDIR

1	0.77	1.1	1.7	SEQ ID NO: 923	LVVPAIK

SEQ ID NO: 924

1	M Q C F S F I K T M M I L F N L L I F L C G A A L L A V G I W V S I D G A S F L K I
	F G P L S S S A M Q F V N V G Y F L I A A G V V V F A L G F L G C Y G A K T

81	E S K C A L V T F F F I L L L I F I A E V A A A V V A L V Y T T M A E H F L T L L
	V V P A I K K D Y G S Q E D F T Q V W N T T M K G L K C C G F T N Y T D F E D

161	S P Y F K E N S A F P P F C C N D N V T N T A N E T C T K Q K A H D Q K V E G
	C F N Q L L Y D I R T N A V T V G G V A A G I G G L E L A A M I V S M Y L Y C N L

241 Q

5.139 apolipoprotein D precursor [Homo sapiens]
Protein Accession gi|4502163

Mean Expression Ratio 0.869

Median Expression Ratio 0.868

Credible Interval (0.709, 1.06)

Associated Peptides 9

Associated Spectra 23

Coverage 0.344


A	2.5	50	97.5	Sequence ID No.	Sequence

5	0.65	0.85	1.1	SEQ ID NO: 925	CPNPPVQENFDVNK

1	0.61	0.84	1.2	SEQ ID NO: 926	IPTTFENGR

4	0.73	0.97	1.3	SEQ ID NO: 927	KMTVTDQVNCPK

2	0.63	0.86	1.2	SEQ ID NO: 928	MTVTDQVNCPK

3	0.65	0.87	1.2	SEQ ID NO: 929	NILTSNNIDVK

2	0.62	0.83	1.1	SEQ ID NO: 930	NPNLPPETVDSLK

1	0.63	0.87	1.2	SEQ ID NO: 931	NPPVQENFDVNK

3	0.64	0.85	1.1	SEQ ID NO: 932	WYEIEK

2	0.64	0.86	1.2	SEQ ID NO: 933	WYEIEKIPTTFENGR

SEQ ID NO: 934

1	M V M L L L L L S A L A G L F G A A E G Q A F H L G K C P N P P V Q E N F D V N
	K Y L G R W Y E I E K I P T T F E N G R C I Q A N Y S L M E N G K I K V L N Q E

81	L R A D G T V N Q I E G E A T P V N L T E P A K L E V K F S W F M P S A P Y W I
	L A T D Y E N Y A L V Y S C T C I I Q L F H V D F A W I L A R N P N L P P E T V

161	D S L K N I L T S N N I D V K K M T V T D Q V N C P K L S

5.140 stomatin isoform a [Homo sapiens]
Protein Accession gi|38016911

Mean Expression Ratio 0.87

Median Expression Ratio 0.869

Credible Interval (0.7, 1.07)

Associated Peptides 9

Associated Spectra 18

Coverage 0.417


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.67	0.92	1.3	SEQ ID NO: 935	EASMVITESPAALQLR

4	0.66	0.87	1.2	SEQ ID NO: 936	EEIAHNMQSTLDDATDAWGIK

1	0.62	0.87	1.2	SEQ ID NO: 937	FILPCTDSFIK

2	0.6	0.83	1.1	SEQ ID NO: 938	TISFDIPPQEILTK

1	0.63	0.88	1.2	SEQ ID NO: 939	VIAAEGEMNASR

4	0.6	0.8	1.1	SEQ ID NO: 940	VQNATLAVANITNADSATR

1	0.62	0.88	1.2	SEQ ID NO: 941	YLQTLTTIAAEK

2	0.65	0.89	1.2	SEQ ID NO: 942	LPVQLQR

1	0.61	0.87	1.2	SEQ ID NO: 943	LLAQTTLR

SEQ ID NO: 944

1	M A E K R H T R D S E A Q R L P D S F K D S P S K G L G P C G W I L V A F S F L F
	T V I T F P I S I W M C I K I I K E Y E R A I I F R L G R I L Q G G A K G P G

81	L F F I L P C T D S F I K V D M R T I S F D I P P Q E I L T K D S V T I S V D G V V
	Y Y R V Q N A T L A V A N I T N A D S A T R L L A Q T T L R N V L G T K N L

161	S Q I L S D R E E I A H N M Q S T L D D A T D A W G I K V E R V E I K D V K L P
	V Q L Q R A M A A E A E A S R E A R A K V I A A E G E M N A S R A L K E A S M V

241	I T E S P A A L Q L R Y L Q T L T T I A A E K N S T I V F P L P I D M L Q G I I G
	A K H S H L G

5.141 eukaryotic translation initiation factor 6 isoform c [Homo sapiens]
Protein Accession gi|31563374

Mean Expression Ratio 0.867

Median Expression Ratio 0.869

Credible Interval (0.534, 1.41)

Associated Peptides 1

Associated Spectra 1

Coverage 0.106


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.5	0.84	1.4	SEQ ID NO: 945	TSIEDQDELSSLLQVPLVAGTVNR

SEQ ID NO: 946

1	M A V R A S F E N N C E I G C F A K L T N T Y C L V A I G G S E N F Y R C G G S P
	G A Y G G G E A C A G V K S S G S G R V P A P L P R H H R V H V P T V C S R A

81	S S P I P S P W C T R L S P A A A S S G A C V W E T E E I L A D V L K V E V F R Q
	T V A D Q V L V G S Y C V F S N Q G G L V H P K T S I E D Q D E L S S L L Q V

161	P L V A G T V N R G S E V I A A G M V V N D W C A F C G L D T T S T E L S V V
	E S V F K L N E A Q P S T I A T S M R D S L I D S L T

5.142 kininogen 1 isoform 2 [Homo sapiens]
Protein Accession gi|4504893

Mean Expression Ratio 0.876

Median Expression Ratio 0.869

Credible Interval (0.603, 1.30)

Associated Peptides 3

Associated Spectra 3

Coverage 0.0937


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.55	0.84	1.3	SEQ ID NO: 947	DIPTNSPELEETLTHTITK

1	0.55	0.86	1.3	SEQ ID NO: 948	YFIDFVAR

1	0.58	0.89	1.4	SEQ ID NO: 949	IGEIKEETTSHLR

SEQ ID NO: 950

1	M K L I T I L F L C S R L L L S L T Q E S Q S E E I D C N D K D L F K A V D A A L K
	K Y N S Q N Q S N N Q F V L Y R I T E A T K T V G S D T F Y S F K Y E I K E

81	G D C P V Q S G K T W Q D C E Y K D A A K A A T G E C T A T V G K R S S T K F
	S V A T Q T C Q I T P A E G P V V T A Q Y D C L G C V H P I S T Q S P D L E P I L

161	R H G I Q Y F N N N T Q H S S L F M L N E V K R A Q R Q V V A G L N F R I T Y
	S I V Q T N C S K E N F L F L T P D C K S L W N G D T G E C T D N A Y I D I Q L R

241	I A S F S Q N C D I Y P G K D F V Q P P T K I C V G C P R D I P T N S P E L E E T
	L T H T I T K L N A E N N A T F Y F K I D N V K K A R V Q V V A G K K Y F I D

321	F V A R E T T C S K E S N E E L T E S C E T K K L G Q S L D C N A E V Y V V P
	W E K K I Y P T V N C Q P L G M I S L M K R P P G F S P F R S S R I G E I K E E T

401	T S H L R S C E Y K G R P P K A G A E P A S E R E V S

5.143 syntenin isoform 3 [Homo sapiens]; syntenin isoform 3 [Homo sapiens]
Protein Accession gi|55749523 gi|55749515

Mean Expression Ratio 1.15

Median Expression Ratio 1.15

Credible Interval (0.747, 1.77)

Associated Peptides 1

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.77 1.2 1.8 SEQ ID NO: 951 ANVAVVSGAPLQGLVAR

5.144 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 [Homo sapiens]
Protein Accession gi|4504041

Mean Expression Ratio 1.15

Median Expression Ratio 1.15

Credible Interval (0.8, 1.64)

Associated Peptides 3

Associated Spectra 4

Coverage 0.101


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.77	1.2	1.8	SEQ ID NO: 952	ALSCTAEEQGVLPDDLSGVIR

1	0.78	1.2	1.8	SEQ ID NO: 953	IAQSDYIPTQQDVLR

2	0.77	1.1	1.7	SEQ ID NO: 954	SCTAEEQGVLPDDLSGVIR

SEQ ID NO: 955

1	M G C T V S A E D K A A A E R S K M I D K N L R E D G E K A A R E V K L L L L G
	A G E S G K S T I V K Q M K I I H E D G Y S E E E C R Q Y R A V V Y S N T I Q S

81	I M A I V K A M G N L Q I D F A D P S R A D D A R Q L F A L S C T A E E Q G V L
	P D D L S G V I R R L W A D H G V Q A C F G R S R E Y Q L N D S A A Y Y L N D L

161	E R I A Q S D Y I P T Q Q D V L R T R V K T T G I V E T H F T F K D L H F K M F
	D V G G Q R S E R K K W I H C F E G V T A I I F C V A L S A Y D L V L A E D E E

241	M N R M H E S M K L F D S I C N N K W F T D T S I I L F L N K K D L F E E K I T
	H S P L T I C F P E Y T G A N K Y D E A A S Y I Q S K F E D L N K R K D T K E I

321	Y T H F T C A T D T K N V Q F V F D A V T D V I I K N N L K D C G L F

5.145 guanine nucleotide binding protein, alpha z polypeptide [Homo sapiens]
Protein Accession gi|4504051

Mean Expression Ratio 1.15

Median Expression Ratio 1.15

Credible Interval (0.708, 1.89)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0423


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.72	1.2	2	SEQ ID NO: 956	IAAADYIPTVEDILR

SEQ ID NO: 957

1	M G C R Q S S E E K E A A R R S R R I D R H L R S E S Q R Q R R E I K L L L L G T
	S N S G K S T I V K Q M K I I H S G G F N L E A C K E Y K P L I I Y N A I D S

81	L T R I I R A L A A L R I D F H N P D R A Y D A V Q L F A L T G P A E S K G E I T
	P E L L G V M R R L W A D P G A Q A C F S R S S E Y H L E D N A A Y Y L N D L

161	E R I A A A D Y I P T V E D I L R S R D M T T G I V E N K F T F K E L T F K M V
	D V G G Q R S E R K K W I H C F E G V T A I I F C V E L S G Y D L K L Y E D N Q

241	T S R M A E S L R L F D S I C N N N W F I N T S L I L F L N K K D L L A E K I R R
	I P L T I C F P E Y K G Q N T Y E E A A V Y I Q R Q F E D L N R N K E T K E I

321	Y S H F T C A T D T S N I Q F V F D A V T D V I I Q N N L K Y I G L C

5.146 cytochrome P450, family 4, subfamily A, polypeptide 11 [Homo sapiens]
Protein Accession gi|158937242

Mean Expression Ratio 0.875

Median Expression Ratio 0.873

Credible Interval (0.54, 1.41)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0231


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.51	0.84	1.4	SEQ ID NO: 958	VWPNPEVFDPFR

SEQ ID NO: 959

1	M S V S V L S P S R L L G D V S G I L Q A A S L L I L L L L L I K A V Q L Y L H R Q
	W L L K A L Q Q F P C P P S H W L F G H I Q E L Q Q D Q E L Q R I Q K W V E

81	T F P S A C P H W L W G G K V R V Q L Y D P D Y M K V I L G R S D P K S H G S
	Y R F L A P W I G Y G L L L L N G Q T W F Q H R R M L T P A F H Y D I L K P Y V G

161	L M A D S V R V M L D K W E E L L G Q D S P L E V F Q H V S L M T L D T I M
	K C A F S H Q G S I Q V D R N S Q S Y I Q A I S D L N N L V F S R V R N A F H Q N D

241	T I Y S L T S A G R W T H R A C Q L A H Q H T D Q V I Q L R K A Q L Q K E G E
	L E K I K R K R H L D F L D I L L L A K M E N G S I L S D K D L R A E V D T F M F

321	E G H D T T A S G I S W I L Y A L A T H P K H Q E R C R E E I H S L L G D G A S
	I T W N H L D Q M P Y T T M C I K E A L R L Y P P V P G I G R E L S T P V T F P

401	D G R S L P K G I M V L L S I Y G L H H N P K V W P N P E V F D P F R F A P G S
	A Q H S H A F L P F S G G S R N C I G K Q F A M N E L K V A T A L T L L R F E L

481	L P D P T R I P I P I A R L V L K S K N G I H L R L R R L P N P C E D K D Q L

5.147 olfactomedin 4 precursor [Homo sapiens]
Protein Accession gi|32313593

Mean Expression Ratio 0.876

Median Expression Ratio 0.876

Credible Interval (0.784, 0.983)

Associated Peptides 39

Associated Spectra 112

Coverage 0.657


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	0.84	1.1	SEQ ID NO: 960	DLGDVGPPIPSPGFSSFPGVDSSSSFSSS
					SR

1	0.64	0.86	1.1	SEQ ID NO: 961	DLSVLQKPQ

1	0.66	0.88	1.2	SEQ ID NO: 962	DQNTPVVHPPPTPGSC

1	0.67	0.89	1.2	SEQ ID NO: 963	DQNTPVVHPPPTPGSCGH

3	0.68	0.9	1.2	SEQ ID NO: 964	DTISYTELDFELIK

3	0.67	0.87	1.1	SEQ ID NO: 965	DYSPQHPNK

40	0.7	0.8	0.91	SEQ ID NO: 966	ESFGGSSEIVDQLEVEIR

1	0.65	0.87	1.2	SEQ ID NO: 967	EYVQLISVYEK

1	0.69	0.92	1.2	SEQ ID NO: 968	GFSYLYGAWGR

1	0.68	0.9	1.2	SEQ ID NO: 969	GLYWVAPLNTDGR

2	0.61	0.8	1.1	SEQ ID NO: 970	GTCQCSVSLPDTTFPVDR

1	0.65	0.86	1.1	SEQ ID NO: 971	ITYGQGSGTAVYNNNMYVNMYNTGN
					IAR

6	0.7	0.88	1.1	SEQ ID NO: 972	LDIVMHK

1	0.64	0.85	1.1	SEQ ID NO: 973	LEFTAHVL

4	0.72	0.92	1.2	SEQ ID NO: 974	LEFTAHVLSQK

1	0.67	0.89	1.2	SEQ ID NO: 975	LEFTAHVLSQKFEK

4	0.68	0.88	1.1	SEQ ID NO: 976	LETLDKNNVLAIR

2	0.67	0.88	1.1	SEQ ID NO: 977	LLEYYR

4	0.72	0.94	1.2	SEQ ID NO: 978	LYNTLDDLLLYINAR

3	0.68	0.9	1.2	SEQ ID NO: 979	LYVYNDGYLLNYDLSVLQKPQ

1	0.66	0.88	1.2	SEQ ID NO: 980	QCSVSLPDTTFPVDR

1	0.66	0.87	1.2	SEQ ID NO: 981	QYKPSASNAF

4	0.65	0.83	1.1	SEQ ID NO: 982	QYKPSASNAFMVCGVLYATR

2	0.67	0.89	1.2	SEQ ID NO: 983	SVSLPDTTFPVDR

1	0.64	0.85	1.1	SEQ ID NO: 984	TIAVTQTLPNAAYNNR

3	0.67	0.87	1.1	SEQ ID NO: 985	WVAPLNTDGR

2	0.66	0.87	1.1	SEQ ID NO: 986	TEEIFYYYDTNTGK

5	0.72	0.91	1.2	SEQ ID NO: 987	VQSINYNPFDQK

1	0.64	0.86	1.1	SEQ ID NO: 988	YYDTNTGK

1	0.67	0.9	1.2	SEQ ID NO: 989	LLNYDLSVLQKPQ

1	0.66	0.88	1.2	SEQ ID NO: 990	YYYDTNTGK

2	0.66	0.87	1.1	SEQ ID NO: 991	LKECEASK

1	0.67	0.9	1.2	SEQ ID NO: 992	EIVALK

1	0.66	0.89	1.2	SEQ ID NO: 993	IDIMEK

1	0.67	0.9	1.2	SEQ ID NO: 994	LETLDK

1	0.67	0.9	1.2	SEQ ID NO: 995	VYNDGYLLNYDLSVLQKPQ

1	0.67	0.9	1.2	SEQ ID NO: 996	YNPFDQK

1	0.66	0.87	1.2	SEQ ID NO: 997	LYNTLDDLLLY

1	0.63	0.83	1.1	SEQ ID NO: 998	VNMYNTGNIARVNLTTNTIAVTQTLP
					NAAYNNR

SEQ ID NO: 999

1	M R P G L S F L L A L L F F L G Q A A G D L G D V G P P I P S P G F S S F P G V D S
	S S S F S S S S R S G S S S S R S L G S G G S V S Q L F S N F T G S V D D R

81	G T C Q C S V S L P D T T F P V D R V E R L E F T A H V L S Q K F E K E L S K V
	R E Y V Q L I S V Y E K K L L N L T V R I D I M E K D T I S Y T E L D F E L I K

161	V E V K E M E K L V I Q L K E S F G G S S E I V D Q L E V E I R N M T L L V E K
	L E T L D K N N V L A I R R E I V A L K T K L K E C E A S K D Q N T P V V H P P

241	P T P G S C G H G G V V N I S K P S V V Q L N W R G F S Y L Y G A W G R D Y S
	P Q H P N K G L Y W V A P L N T D G R L L E Y Y R L Y N T L D D L L L Y I N A R E

321	L R I T Y G Q G S G T A V Y N N N M Y V N M Y N T G N I A R V N L T T N T I A
	V T Q T L P N A A Y N N R F S Y A N V A W Q D I D F A V D E N G L W V I Y S T E A

401	S T G N M V I S K L N D T T L Q V L N T W Y T K Q Y K P S A S N A F M V C G
	V L Y A T R T M N T R T E E I F Y Y Y D T N T G K E G K L D I V M H K M Q E K V
	Q S

481	I N Y N P F D Q K L Y V Y N D G Y L L N Y D L S V L Q K P Q

5.148 peptidoglycan recognition protein 2 precursor [Homo sapiens]
Protein Accession gi|56616294

Mean Expression Ratio 0.877

Median Expression Ratio 0.876

Credible Interval (0.542, 1.41)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0226


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.52	0.85	1.4	SEQ ID NO: 1000	TDCPGDALFDLLR

SEQ ID NO: 1001

1	M A Q G V L W I L L G L L L W S D P G T A S L P L L M D S V I Q A L A E L E Q K
	V P A A K T R H T A S A W L M S A P N S G P H N R L Y H F L L G A W S L N A T E

81	L D P C P L S P E L L G L T K E V A R H D V R E G K E Y G V V L A P D G S T V A
	V E P L L A G L E A G L Q G R R V I N L P L D S M A A P W E T G D T F P D V V A

161	I A P D V R A T S S P G L R D G S P D V T T A D I G A N T P D A T K G C P D V Q
	A S L P D A K A K S P P T M V D S L L A V T L A G N L G L T F L R G S Q T Q S H

241	P D L G T E G C W D Q L S A P R T F T L L D P K A S L L T M A F L N G A L D G
	V I L G D Y L S R T P E P R P S L S H L L S Q Y Y G A G V A R D P G F R S N F R R

321	Q N G A A L T S A S I L A Q Q V W G T L V L L Q R L E P V H L Q L Q C M S Q E
	Q L A Q V A A N A T K E F T E A F L G C P A I H P R C R W G A A P Y R G R P K L L

401	Q L P L G F L Y V H H T Y V P A P P C T D F T R C A A N M R S M Q R Y H Q D
	T Q G W G D I G Y S F V V G S D G Y V Y E G R G W H W V G A H T L G H N S R G F
	G V

481	A I V G N Y T A A L P T E A A L R T V R D T L P S C A V R A G L L R P D Y A L
	L G H R Q L V R T D C P G D A L F D L L R T W P H F T A T V K P R P A R S V S K R

561	S R R E P P P R T L P A T D L Q

5.149 SMAD family member 9 isoform b [Homo sapiens]; SMAD family member 9 isoform a [Homo sapiens]
Protein Accession gi|5174519 gi 187828357

Mean Expression Ratio 1.14

Median Expression Ratio 1.14

Credible Interval (0.696, 1.84)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.71 1.2 1.9 SEQ ID NO: 1002 VETPVLPPVLVPR

5.150 brain creatine kinase [Homo sapiens]
Protein Accession gi|21536286

Mean Expression Ratio 1.14

Median Expression Ratio 1.14

Credible Interval (0.776, 1.69)

Associated Peptides 3

Associated Spectra 3

Coverage 0.150


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.75	1.2	1.8	SEQ ID NO: 1003	GTGGVDTAAVGGVFDVSNADR

1	0.76	1.2	1.8	SEQ ID NO: 1004	TDLNPDNLQGGDDLDPNYVLSSR

1	0.74	1.1	1.8	SEQ ID NO: 1005	TFLVWVNEEDHLR

SEQ ID NO: 1006

1	M P F S N S H N A L K L R F P A E D E F P D L S A H N N H M A K V L T P E L Y A
	E L R A K S T P S G F T L D D V I Q T G V D N P G H P Y I M T V G C V A G D E E

81	S Y E V F K D L F D P I I E D R H G G Y K P S D E H K T D L N P D N L Q G G D D
	L D P N Y V L S S R V R T G R S I R G F C L P P H C S R G E R R A I E K L A V E

161	A L S S L D G D L A G R Y Y A L K S M T E A E Q Q Q L I D D H F L F D K P V S
	P L L L A S G M A R D W P D A R G I W H N D N K T F L V W V N E E D H L R V I S M

241	Q K G G N M K E V F T R F C T G L T Q I E T L F K S K D Y E F M W N P H L G Y
	I L T C P S N L G T G L R A G V H I K L P N L G K H E K F S E V L K R L R L Q K R

321	G T G G V D T A A V G G V F D V S N A D R L G F S E V E L V Q M V V D G V K
	L L I E M E Q R L E Q G Q A I D D L M P A Q K

5.151 chromatin modifying protein 2A [Homo sapiens]; chromatin modifying protein 2A [Homo sapiens]
Protein Accession gi|7656922 gi|38372933

Mean Expression Ratio 1.14

Median Expression Ratio 1.14

Credible Interval (0.798, 1.62)

Associated Peptides 3

Associated Spectra 4

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.76 1.2 1.8 SEQ ID NO: 1007 AEAAASALADADADLEER

2 0.8 1.2 1.8 SEQ ID NO: 1008 KAEAAASALADADADLEER

1 0.73 1.1 1.6 SEQ ID NO: 1009 KIIADIK

5.152 solute carrier family 4, sodium bicarbonate cotransporter, member 4 isoform 2 [Homo sapiens]
Protein Accession gi|4507025

Mean Expression Ratio 0.88

Median Expression Ratio 0.878

Credible Interval (0.573, 1.34)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0329


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.53	0.84	1.3	SEQ ID NO: 1010	LQQAVMLGALTEVPVPTR

1	0.55	0.9	1.4	SEQ ID NO: 1011	ILVATDASFLVQYFTR

SEQ ID NO: 1012

1	M S T E N V E G K P S N L G E R G R A R S S T F L R V V Q P M F N H S I F T S A V
	S P A A E R I R F I L G E E D D S P A P P Q L F T E L D E L L A V D G Q E M E

81	W K E T A R W I K F E E K V E Q G G E R W S K P H V A T L S L H S L F E L R T C
	M E K G S I M L D R E A S S L P Q L V E M I V D H Q I E T G L L K P E L K D K V

161	T Y T L L R K H R H Q T K K S N L R S L A D I G K T V S S A S R M F T N P D N
	G S P A M T H R N L T S S S L N D I S D K P E K D Q L K N K F M K K L P R D A E A

241	S N V L V G E V D F L D T P F I A F V R L Q Q A V M L G A L T E V P V P T R F L
	F I L L G P K G K A K S Y H E I G R A I A T L M S D E V F H D I A Y K A K D R H

321	D L I A G I D E F L D E V I V L P P G E W D P A I R I E P P K S L P S S D K R K N
	M Y S G G E N V Q M N G D T P H D G G H G G G G H G D C E E L Q R T G R F C G

401	G L I K D I K R K A P F F A S D F Y D A L N I Q A L S A I L F I Y L A T V T N A I
	T F G G L L G D A T D N M Q G V L E S F L G T A V S G A I F C L F A G Q P L T

481	I L S S T G P V L V F E R L L F N F S K D N N F D Y L E F R L W I G L W S A F L
	C L I L V A T D A S F L V Q Y F T R F T E E G F S S L I S F I F I Y D A F K K M

561	I K L A D Y Y P I N S N F K V G Y N T L F S C T C V P P D P A N I S I S N D T T L
	A P E Y L P T M S S T D M Y H N T T F D W A F L S K K E C S K Y G G N L V G N

641	N C N F V P D I T L M S F I L F L G T Y T S S M A L K K F K T S P Y F P T T A R
	K L I S D F A I I L S I L I F C V I D A L V G V D T P K L I V P S E F K P T S P

721	N R G W F V P P F G E N P W W V C L A A A I P A L L V T I L I F M D Q Q I T A V
	I V N R K E H K L K K G A G Y H L D L F W V A I L M V I C S L M A L P W Y V A A

801	T V I S I A H I D S L K M E T E T S A P G E Q P K F L G V R E Q R V T G T L V F I
	L T G L S V F M A P I L K F I P M P V L Y G V F L Y M G V A S L N G V Q F M D

881	R L K L L L M P L K H Q P D F I Y L R H V P L R R V H L F T F L Q V L C L A L L
	W I L K S T V A A I I F P V M I L A L V A V R K G M D Y L F S Q H D L S F L D D

961	V I P E K D K K K K E D E K K K K K K K G S L D S D N D D S D C P Y S E K V P
	S I K I P M D I M E Q Q P F L S D S K P S D R E R S P T F L E R H T S C

5.153 phospholipid transfer protein isoform a precursor [Homo sapiens]
Protein Accession gi|5453914

Mean Expression Ratio 0.875

Median Expression Ratio 0.878

Credible Interval (0.563, 1.35)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0304


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.54	0.84	1.3	SEQ ID NO: 1013	FLEQELETITIPDLR

SEQ ID NO: 1014

1	M A L F G A L F L A L L A G A H A E F P G C K I R V T S K A L E L V K Q E G L R
	F L E Q E L E T I T I P D L R G K E G H F Y Y N I S E V K V T E L Q L T S S E L

81	D F Q P Q Q E L M L Q I T N A S L G L R F R R Q L L Y W F F Y D G G Y I N A S A
	E G V S I R T G L E L S R D P A G R M K V S N V S C Q A S V S R M H A A F G G T

161	F K K V Y D F L S T F I T S G M R F L L N Q Q I C P V L Y H A G T V L L N S L L
	D T V P V R S S V D E L V G I D Y S L M K D P V A S T S N L D M D F R G A F F P

241	L T E R N W S L P N R A V E P Q L Q E E E R M V Y V A F S E F F F D S A M E S
	Y F R A G A L Q L L L V G D K V P H D L D M L L R A T Y F G S I V L L S P A V I D

321	S P L K L E L R V L A P P R C T I K P S G T T I S V T A S V T I A L V P P D Q P E
	V Q L S S M T M D A R L S A K M A L R G K A L R T Q L D L R R F R I Y S N H S

401	A L E S L A L I P L Q A P L K T M L Q I G V M P M L N E R T W R G V Q I P L P E
	G I N F V H E V V T N H A G F L T I G A D L H F A K G L R E V I E K N R P A D V

481	R A S T A P T P S T A A V

5.154 ceruloplasmin precursor [Homo sapiens]
Protein Accession gi|4557485

Mean Expression Ratio 0.879

Median Expression Ratio 0.878

Credible Interval (0.737, 1.05)

Associated Peptides 20

Associated Spectra 27

Coverage 0.232


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.65	0.86	1.2	SEQ ID NO: 1015	AEEEHLGILGPQLHADVGDK

2	0.6	0.82	1.1	SEQ ID NO: 1016	ALYLQYTDETFR

1	0.65	0.9	1.2	SEQ ID NO: 1017	DIFTGLIGPMK

2	0.65	0.87	1.2	SEQ ID NO: 1018	DLYSGLIGPLIVCR

1	0.63	0.86	1.2	SEQ ID NO: 1019	DVDKEFYLFPTVFDENESLLLEDNIR

2	0.66	0.89	1.2	SEQ ID NO: 1020	EFYLFPTVFDENESLLLEDNIR

1	0.63	0.87	1.2	SEQ ID NO: 1021	GAYPLSIEPIGVR

2	0.65	0.86	1.2	SEQ ID NO: 1022	GPEEEHLGILGPVIWAEVGDTIR

1	0.62	0.86	1.2	SEQ ID NO: 1023	GVYSSDVFDIFPGTYQTLEMFPR

1	0.63	0.86	1.2	SEQ ID NO: 1024	IYHSHIDAPK

1	0.65	0.88	1.2	SEQ ID NO: 1025	KAEEEHLGILGPQLHADVGDK

1	0.65	0.88	1.2	SEQ ID NO: 1026	LFPTVFDENESLLLEDNIR

1	0.63	0.86	1.2	SEQ ID NO: 1027	MFTTAPDQVDKEDEDFQESNK

1	0.67	0.9	1.2	SEQ ID NO: 1028	MLLATEEQSPGEGDGNCVTR

1	0.64	0.87	1.2	SEQ ID NO: 1029	SVPPSASHVAPTETFTY

1	0.66	0.9	1.2	SEQ ID NO: 1030	TTIEKPVWLGFLGPIIK

3	0.69	0.9	1.2	SEQ ID NO: 1031	VNKDDEEFIESNK

1	0.64	0.88	1.2	SEQ ID NO: 1032	YLFPTVFDENESLLLEDNIR

1	0.64	0.88	1.2	SEQ ID NO: 1033	VTFHNK

1	0.69	0.93	1.3	SEQ ID NO: 1034	GPEEEHLGILGPVIW

SEQ ID NO: 1035

1	M K I L I L G I F L F L C S T P A W A K E K H Y Y I G I I E T T W D Y A S D H G E K
	K L I S V D T E H S N I Y L Q N G P D R I G R L Y K K A L Y L Q Y T D E T F

81	R T T I E K P V W L G F L G P I I K A E T G D K V Y V H L K N L A S R P Y T F H S
	H G I T Y Y K E H E G A I Y P D N T T D F Q R A D D K V Y P G E Q Y T Y M L L

161	A T E E Q S P G E G D G N C V T R I Y H S H I D A P K D I A S G L I G P L I I C K
	K D S L D K E K E K H I D R E F V V M F S V V D E N F S W Y L E D N I K T Y C

241	S E P E K V D K D N E D F Q E S N R M Y S V N G Y T F G S L P G L S M C A E D
	R V K W Y L F G M G N E V D V H A A F F H G Q A L T N K N Y R I D T I N L F P A T

321	L F D A Y M V A Q N P G E W M L S C Q N L N H L K A G L Q A F F Q V Q E C N
	K S S S K D N I R G K H V R H Y Y I A A E E I I W N Y A P S G I D I F T K E N L T A

401	P G S D S A V F F E Q G T T R I G G S Y K K L V Y R E Y T D A S F T N R K E R G
	P E E E H L G I L G P V I W A E V G D T I R V T F H N K G A Y P L S I E P I G V

481	R F N K N N E G T Y Y S P N Y N P Q S R S V P P S A S H V A P T E T F T Y E W T
	V P K E V G P T N A D P V C L A K M Y Y S A V D P T K D I F T G L I G P M K I C

561	K K G S L H A N G R Q K D V D K E F Y L F P T V F D E N E S L L L E D N I R M
	F T T A P D Q V D K E D E D F Q E S N K M H S M N G F M Y G N Q P G L T M C K G D

641	S V V W Y L F S A G N E A D V H G I Y F S G N T Y L W R G E R R D T A N L F P
	Q T S L T L H M W P D T E G T F N V E C L T T D H Y T G G M K Q K Y T V N Q C R R

721	Q S E D S T F Y L G E R T Y Y I A A V E V E W D Y S P Q R E W E K E L H H L Q
	E Q N V S N A F L D K G E F Y I G S K Y K K V V Y R Q Y T D S T F R V P V E R K A

801	E E E H L G I L G P Q L H A D V G D K V K I I F K N M A T R P Y S I H A H G V Q
	T E S S T V T P T L P G E T L T Y V W K I P E R S G A G T E D S A C I P W A Y Y

881	S T V D Q V K D L Y S G L I G P L I V C R R P Y L K V F N P R R K L E F A L L F
	L V F D E N E S W Y L D D N I K T Y S D H P E K V N K D D E E F I E S N K M H A

961	I N G R M F G N L Q G L T M H V G D E V N W Y L M G M G N E I D L H T V H F
	H G H S F Q Y K H R G V Y S S D V F D I F P G T Y Q T L E M F P R T P G I W L L H C

1041	H V T D H I H A G M E T T Y T V L Q N E D T K S G

5.155 glycerophosphodiester phosphodiesterase domain containing 3 [Homo sapiens]
Protein Accession gi|146198640

Mean Expression Ratio 0.88

Median Expression Ratio 0.88

Credible Interval (0.617, 1.25)

Associated Peptides 4

Associated Spectra 4

Coverage 0.186


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.56	0.85	1.3	SEQ ID NO: 1036	GGSGELLENTMEAMENSMAQR

1	0.58	0.88	1.3	SEQ ID NO: 1037	SDLLELDCQLTR

1	0.57	0.87	1.3	SEQ ID NO: 1038	DVGSLDFEDLPLYK

1	0.58	0.9	1.4	SEQ ID NO: 1039	VVVVSHDENLCR

SEQ ID NO: 1040

1	M S L L L Y Y A L P A L G S Y A M L S I F F L R R P H L L H T P R A P T F R I R L G
	A H R G G S G E L L E N T M E A M E N S M A Q R S D L L E L D C Q L T R D R

81	V V V V S H D E N L C R Q S G L N R D V G S L D F E D L P L Y K E K L E V Y F S
	P G H F A H G S D R R M V R L E D L F Q R F P R T P M S V E I K G K N E E L I R

161	E I A G L V R R Y D R N E I T I W A S E K S S V M K K C K A A N P E M P L S F T
	I S R G F W V L L S Y Y L G L L P F I P I P E K F F F C F L P N I I N R T Y F P

241	F S C S C L N Q L L A V V S K W L I M R K S L I R H L E E R G V Q V V F W C L
	N E E S D F E A A F S V G A T G V I T D Y P T A L R H Y L D N H G P A A R T S

5.156 glucuronidase, beta [Homo sapiens]
Protein Accession gi|4504223

Mean Expression Ratio 1.14

Median Expression Ratio 1.14

Credible Interval (0.797, 1.61)

Associated Peptides 4

Associated Spectra 4

Coverage 0.0707


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.74	1.1	1.7	SEQ ID NO: 1041	GFDWPLLVK

1	0.76	1.1	1.7	SEQ ID NO: 1042	NFADFMTEQSPTR

1	0.76	1.2	1.7	SEQ ID NO: 1043	YVVGELIWNFADFMTEQSPTR

1	0.75	1.1	1.7	SEQ ID NO: 1044	TSHYPYAEEVMQMCDR

SEQ ID NO: 1045

1	M A R G S A V A W A A L G P L L W G C A L G L Q G G M L Y P Q E S P S R E C K
	E L D G L W S F R A D F S D N R R R G F E E Q W Y R R P L W E S G P T V D M P V P

81	S S F N D I S Q D W R L R H F V G W V W Y E R E V I L P E R W T Q D L R T R V
	V L R I G S A H S Y A I V W V N G V D T L E H E G G Y L P F E A D I S N L V Q V G

161	P L P S R L R I T I A I N N T L T P T T L P P G T I Q Y L T D T S K Y P K G Y F V
	Q N T Y F D F F N Y A G L Q R S V L L Y T T P T T Y I D D I T V T T S V E Q D

241	S G L V N Y Q I S V K G S N L F K L E V R L L D A E N K V V A N G T G T Q G Q
	L K V P G V S L W W P Y L M H E R P A Y L Y S L E V Q L T A Q T S L G P V S D F Y

321	T L P V G I R T V A V T K S Q F L I N G K P F Y F H G V N K H E D A D I R G K G
	F D W P L L V K D F N L L R W L G A N A F R T S H Y P Y A E E V M Q M C D R Y G

401	I V V I D E C P G V G L A L P Q F F N N V S L H H H M Q V M E E V V R R D K N
	H P A V V M W S V A N E P A S H L E S A G Y Y L K M V I A H T K S L D P S R P V T

481	F V S N S N Y A A D K G A P Y V D V I C L N S Y Y S W Y H D Y G H L E L I Q L
	Q L A T Q F E N W Y K K Y Q K P I I Q S E Y G A E T I A G F H Q D P P L M F T E E

561	Y Q K S L L E Q Y H L G L D Q K R R K Y V V G E L I W N F A D F M T E Q S P T
	R V L G N K K G I F T R Q R Q P K S A A F L L R E R Y W K I A N E T R Y P H S V A

641	K S Q C L E N S P F T

5.157 solute carrier family 4, anion exchanger, member 1 [Homo sapiens]
Protein Accession gi|4507021

Mean Expression Ratio 1.13

Median Expression Ratio 1.14

Credible Interval (0.734, 1.73)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0329


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.72	1.1	1.8	SEQ ID NO: 1046	ADFLEQPVLGFVR

1	0.73	1.2	1.8	SEQ ID NO: 1047	LQEAAELEAVELPVPIR

SEQ ID NO: 1048

1	M E E L Q D D Y E D M M E E N L E Q E E Y E D P D I P E S Q M E E P A A H D T E
	A T A T D Y H T T S H P G T H K V Y V E L Q E L V M D E K N Q E L R W M E A A R

81	W V Q L E E N L G E N G A W G R P H L S H L T F W S L L E L R R V F T K G T V
	L L D L Q E T S L A G V A N Q L L D R F I F E D Q I R P Q D R E E L L R A L L L K

161	H S H A G E L E A L G G V K P A V L T R S G D P S Q P L L P Q H S S L E T Q L F
	C E Q G D G G T E G H S P S G I L E K I P P D S E A T L V L V G R A D F L E Q P

241	V L G F V R L Q E A A E L E A V E L P V P I R F L F V L L G P E A P H I D Y T Q
	L G R A A A T L M S E R V F R I D A Y M A Q S R G E L L H S L E G F L D C S L V

321	L P P T D A P S E Q A L L S L V P V Q R E L L R R R Y Q S S P A K P D S S F Y K
	G L D L N G G P D D P L Q Q T G Q L F G G L V R D I R R R Y P Y Y L S D I T D A

401	F S P Q V L A A V I F I Y F A A L S P A I T F G G L L G E K T R N Q M G V S E L
	L I S T A V Q G I L F A L L G A Q P L L V V G F S G P L L V F E E A F F S F C E

481	T N G L E Y I V G R V W I G F W L I L L V V L V V A F E G S F L V R F I S R Y T
	Q E I F S F L I S L I F I Y E T F S K L I K I F Q D H P L Q K T Y N Y N V L M V

561	P K P Q G P L P N T A L L S L V L M A G T F F F A M M L R K F K N S S Y F P G
	K L R R V I G D F G V P I S I L I M V L V D F F I Q D T Y T Q K L S V P D G F K V

641	S N S S A R G W V I H P L G L R S E F P I W M M F A S A L P A L L V F I L I F L E
	S Q I T T L I V S K P E R K M V K G S G F H L D L L L V V G M G G V A A L F G

721	M P W L S A T T V R S V T H A N A L T V M G K A S T P G A A A Q I Q E V K E
	Q R I S G L L V A V L V G L S I L M E P I L S R I P L A V L F G I F L Y M G V T S L

801	S G I Q L F D R I L L L F K P P K Y H P D V P Y V K R V K T W R M H L F T G I Q
	I I C L A V L W V V K S T P A S L A L P F V L I L T V P L R R V L L P L I F R N

881	V E L Q C L D A D D A K A T F D E E E G R D E Y D E V A M P V

5.158 arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens]; arylsulfatase A isoform b [Homo sapiens]; arylsulfatase A isoform a precursor [Homo sapiens]
Protein Accession gi|6005990 gi|146229331 gi|146229329 gi|146229327 gi|146229324

Mean Expression Ratio 1.14

Median Expression Ratio 1.14

Credible Interval (0.749, 1.77)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.72 1.1 1.8 SEQ ID NO: 1049 GGLPLEEVTVAEVLAAR

1 0.73 1.2 1.9 SEQ ID NO: 1050 YMAFAHDLMADAQR

5.159 guanine nucleotide binding protein (G protein) alpha 12 [Homo sapiens]
Protein Accession gi|42476111

Mean Expression Ratio 1.14

Median Expression Ratio 1.14

Credible Interval (0.701, 1.86)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0341


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.7	1.2	2	SEQ ID NO: 1051	ATKGIVEHDFVIK

SEQ ID NO: 1052

1	M S G V V R T L S R C L L P A E A G G A R E R R A G S G A R D A E R E A R R R S
	R D I D A L L A R E R R A V R R L V K I L L L G A G E S G K S T F L K Q M R I I

81	H G R E F D Q K A L L E F R D T I F D N I L K G S R V L V D A R D K L G I P W Q
	Y S E N E K H G M F L M A F E N K A G L P V E P A T F Q L Y V P A L S A L W R D

161	S G I R E A F S R R S E F Q L G E S V K Y F L D N L D R I G Q L N Y F P S K Q D I
	L L A R K A T K G I V E H D F V I K K I P F K M V D V G G Q R S Q R Q K W F Q

241	C F D G I T S I L F M V S S S E Y D Q V L M E D R R T N R L V E S M N I F E T I
	V N N K L F F N V S I I L F L N K M D L L V E K V K T V S I K K H F P D F R G D

321	P H R L E D V Q R Y L V Q C F D R K R R N R S K P L F H H F T T A I D T E N V
	R F V F H A V K D T I L Q E N L K D I M L Q

5.160 solute carrier family 1, member 1 [Homo sapiens]
Protein Accession gi|66773030

Mean Expression Ratio 0.882

Median Expression Ratio 0.881

Credible Interval (0.541, 1.44)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0344


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.51	0.86	1.4	SEQ ID NO: 1053	TGSTPEVSTVDAMLDLIR

SEQ ID NO: 1054

1	M G K P A R K G C E W K R F L K N N W V L L S T V A A V V L G I T T G V L V R
	E H S N L S T L E K F Y F A F P G E I L M R M L K L I I L P L I I S S M I T G V A

81	A L D S N V S G K I G L R A V V Y Y F C T T L I A V I L G I V L V V S I K P G V T
	Q K V G E I A R T G S T P E V S T V D A M L D L I R N M F P E N L V Q A C F Q

161	Q Y K T K R E E V K P P S D P E M N M T E E S F T A V M T T A I S K N K T K E
	Y K I V G M Y S D G I N V L G L I V F C L V F G L V I G K M G E K G Q I L V D F F

241	N A L S D A T M K I V Q I I M C Y M P L G I L F L I A G K I I E V E D W E I F R K
	L G L Y M A T V L T G L A I H S I V I L P L I Y F I V V R K N P F R F A M G M

321	A Q A L L T A L M I S S S S A T L P V T F R C A E E N N Q V D K R I T R F V L P
	V G A T I N M D G T A L Y E A V A A V F I A Q L N D L D L G I G Q I I T I S I T

401	A T S A S I G A A G V P Q A G L V T M V I V L S A V G L P A E D V T L I I A V D
	W L L D R F R T M V N V L G D A F G T G I V E K L S K K E L E Q M D V S S E V N

481	I V N P F A L E S T I L D N E D S D T K K S Y V N G G F A V D K S D T I S F T Q
	T S Q F

5.161 keratin 9 [Homo sapiens]
Protein Accession gi|55956899

Mean Expression Ratio 0.881

Median Expression Ratio 0.882

Credible Interval (0.578, 1.34)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0642


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.54	0.86	1.4	SEQ ID NO: 1055	HGVQELEIELQSQLSK

1	0.55	0.87	1.4	SEQ ID NO: 1056	SYGGGSGGGFSASSLGGGFGGGSR

SEQ ID NO: 1057

1	M S C R Q F S S S Y L S R S G G G G G G G L G S G G S I R S S Y S R F S S S G G G
	G G G G R F S S S S G Y G G G S S R V C G R G G G G S F G Y S Y G G G S G G G

81	F S A S S L G G G F G G G S R G F G G A S G G G Y S S S G G F G G G F G G G S G
	G G F G G G Y G S G F G G F G G F G G G A G G G D G G I L T A N E K S T M Q E L

161	N S R L A S Y L D K V Q A L E E A N N D L E N K I Q D W Y D K K G P A A I Q K
	N Y S P Y Y N T I D D L K D Q I V D L T V G N N K T L L D I D N T R M T L D D F R

241	I K F E M E Q N L R Q G V D A D I N G L R Q V L D N L T M E K S D L E M Q Y E
	T L Q E E L M A L K K N H K E E M S Q L T G Q N S G D V N V E I N V A P G K D L T

321	K T L N D M R Q E Y E Q L I A K N R K D I E N Q Y E T Q I T Q I E H E V S S S G
	Q E V Q S S A K E V T Q L R H G V Q E L E I E L Q S Q L S K K A A L E K S L E D

401	T K N R Y C G Q L Q M I Q E Q I S N L E A Q I T D V R Q E I E C Q N Q E Y S L L
	L S I K M R L E K E I E T Y H N L L E G G Q E D F E S S G A G K I G L G G R G G

481	S G G S Y G R G S R G G S G G S Y G G G G S G G G Y G G G S G S R G G S G G S
	Y G G G S G S G G G S G G G Y G G G S G G G H S G G S G G G H S G G S G G N Y G G

561	G S G S G G G S G G G Y G G G S G S R G G S G G S H G G G S G F G G E S G G S
	Y G G G E E A S G S G G G Y G G G S G K S S H S

5.162 pyruvate kinase, muscle isoform M2 [Homo sapiens]
Protein Accession gi|33286418

Mean Expression Ratio 1.13

Median Expression Ratio 1.13

Credible Interval (0.83, 1.57)

Associated Peptides 4

Associated Spectra 6

Coverage 0.0923


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.78	1.1	1.7	SEQ ID NO: 1058	DPVQEAWAEDVDLR

1	0.78	1.2	1.7	SEQ ID NO: 1059	FDEILEASDGIMVAR

3	0.8	1.1	1.6	SEQ ID NO: 1060	HLQLFEELR

1	0.76	1.1	1.7	SEQ ID NO: 1061	LDIDSPPITAR

SEQ ID NO: 1062

1	M S K P H S E A G T A F I Q T Q Q L H A A M A D T F L E H M C R L D I D S P P I T
	A R N T G I I C T I G P A S R S V E T L K E M I K S G M N V A R L N F S H G T

81	H E Y H A E T I K N V R T A T E S F A S D P I L Y R P V A V A L D T K G P E I R T
	G L I K G S G T A E V E L K K G A T L K I T L D N A Y M E K C D E N I L W L D

161	Y K N I C K V V E V G S K I Y V D D G L I S L Q V K Q K G A D F L V T E V E N
	G G S L G S K K G V N L P G A A V D L P A V S E K D I Q D L K F G V E Q D V D M V

241	F A S F I R K A S D V H E V R K V L G E K G K N I K I I S K I E N H E G V R R F
	D E I L E A S D G I M V A R G D L G I E I P A E K V F L A Q K M M I G R C N R A

321	G K P V I C A T Q M L E S M I K K P R P T R A E G S D V A N A V L D G A D C I
	M L S G E T A K G D Y P L E A V R M Q H L I A R E A E A A I Y H L Q L F E E L R R

401	L A P I T S D P T E A T A V G A V E A S F K C C S G A I I V L T K S G R S A H Q
	V A R Y R P R A P I I A V T R N P Q T A R Q A H L Y R G I F P V L C K D P V Q E

481	A W A E D V D L R V N F A M N V G K A R G F F K K G D V V I V L T G W R P G
	S G F T N T M R V V P V P

5.163 solute carrier family 13 member 3 isoform b [Homo sapiens]; solute carrier family 13 member 3 isoform a [Homo sapiens]
Protein Accession gi|58761541 gi|31377715

Mean Expression Ratio 0.884

Median Expression Ratio 0.883

Credible Interval (0.572, 1.37)

Associated Peptides 1

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.55 0.86 1.3 SEQ ID NO: 1063 DHPGETEVPLDLPADSR

5.164 GTPase Rab14 [Homo sapiens]
Protein Accession gi|19923483

Mean Expression Ratio 0.887

Median Expression Ratio 0.883

Credible Interval (0.541, 1.46)

Associated Peptides 1

Associated Spectra 1

Coverage 0.140


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.51	0.86	1.5	SEQ ID NO: 1064	IYQNIQDGSLDLNAAESGVQHKPSAPQG
					GR

SEQ ID NO: 1065

1	M A T A P Y N Y S Y I F K Y I I I G D M G V G K S C L L H Q F T E K K F M A D C P
	H T I G V E F G T R I I E V S G Q K I K L Q I W D T A G Q E R F R A V T R S Y

81	Y R G A A G A L M V Y D I T R R S T Y N H L S S W L T D A R N L T N P N T V I I
	L I G N K A D L E A Q R D V T Y E E A K Q F A E E N G L L F L E A S A K T G E N

161	V E D A F L E A A K K I Y Q N I Q D G S L D L N A A E S G V Q H K P S A P Q G
	G R L T S E P Q P Q R E G C G C

5.165 coagulation factor II preproprotein [Homo sapiens]
Protein Accession gi|4503635

Mean Expression Ratio 0.887

Median Expression Ratio 0.885

Credible Interval (0.613, 1.30)

Associated Peptides 3

Associated Spectra 3

Coverage 0.0836


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.88	1.4	SEQ ID NO: 1066	HQDFNSAVQLVENFCR

1	0.57	0.87	1.3	SEQ ID NO: 1067	SEGSSVNLSPPLEQCVPDR

1	0.58	0.88	1.4	SEQ ID NO: 1068	TFGSGEADCGLRPLFEK

SEQ ID NO: 1069

1	M A H V R G L Q L P G C L A L A A L C S L V H S Q H V F L A P Q Q A R S L L Q R
	V R R A N T F L E E V R K G N L E R E C V E E T C S Y E E A F E A L E S S T A T

81	D V F W A K Y T A C E T A R T P R D K L A A C L E G N C A E G L G T N Y R G H
	V N I T R S G I E C Q L W R S R Y P H K P E I N S T T H P G A D L Q E N F C R N P

161	D S S T T G P W C Y T T D P T V R R Q E C S I P V C G Q D Q V T V A M T P R S
	E G S S V N L S P P L E Q C V P D R G Q Q Y Q G R L A V T T H G L P C L A W A S A

241	Q A K A L S K H Q D F N S A V Q L V E N F C R N P D G D E E G V W C Y V A G
	K P G D F G Y C D L N Y C E E A V E E E T G D G L D E D S D R A I E G R T A T S E Y

321	Q T F F N P R T F G S G E A D C G L R P L F E K K S L E D K T E R E L L E S Y I
	D G R I V E G S D A E I G M S P W Q V M L F R K S P Q E L L C G A S L I S D R W

401	V L T A A H C L L Y P P W D K N F T E N D L L V R I G K H S R T R Y E R N I E
	K I S M L E K I Y I H P R Y N W R E N L D R D I A L M K L K K P V A F S D Y I H P

481	V C L P D R E T A A S L L Q A G Y K G R V T G W G N L K E T W T A N V G K G
	Q P S V L Q V V N L P I V E R P V C K D S T R I R I T D N M F C A G Y K P D E G K R

561	G D A C E G D S G G P F V M K S P F N N R W Y Q M G I V S W G E G C D R D G
	K Y G F Y T H V F R L K K W I Q K V I D Q F G E

5.166 proteasome alpha 6 subunit [Homo sapiens]
Protein Accession gi|23110944

Mean Expression Ratio 1.13

Median Expression Ratio 1.13

Credible Interval (0.738, 1.76)

Associated Peptides 2

Associated Spectra 2

Coverage 0.122


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.72	1.2	1.9	SEQ ID NO: 1070	AINQGGLTSVAVR

1	0.71	1.1	1.8	SEQ ID NO: 1071	ILTEAEIDAHLVALAER

SEQ ID NO: 1072

1	M S R G S S A G F D R H I T I F S P E G R L Y Q V E Y A F K A I N Q G G L T S V A
	V R G K D C A V I V T Q K K V P D K L L D S S T V T H L F K I T E N I G C V M

81	T G M T A D S R S Q V Q R A R Y E A A N W K Y K Y G Y E I P V D M L C K R I A
	D I S Q V Y T Q N A E M R P L G C C M I L I G I D E E Q G P Q V Y K C D P A G Y Y

161	C G F K A T A A G V K Q T E S T S F L E K K V K K K F D W T F E Q T V E T A I
	T C L S T V L S I D F K P S E I E V G V V T V E N P K F R I L T E A E I D A H L V

241	A L A E R D

5.167 tubulin, beta, 2 [Homo sapiens]
Protein Accession gi|5174735

Mean Expression Ratio 1.13

Median Expression Ratio 1.13

Credible Interval (0.767, 1.67)

Associated Peptides 2

Associated Spectra 3

Coverage 0.0742


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.78	1.2	1.8	SEQ ID NO: 1073	GHYTEGAELVDSVLDVVR

1	0.72	1.1	1.7	SEQ ID NO: 1074	AVLVDLEPGTMDSVR

SEQ ID NO: 1075

1	M R E I V H L Q A G Q C G N Q I G A K F W E V I S D E H G I D P T G T Y H G D S
	D L Q L E R I N V Y Y N E A T G G K Y V P R A V L V D L E P G T M D S V R S G P

81	F G Q I F R P D N F V F G Q S G A G N N W A K G H Y T E G A E L V D S V L D V
	V R K E A E S C D C L Q G F Q L T H S L G G G T G S G M G T L L I S K I R E E Y P

161	D R I M N T F S V V P S P K V S D T V V E P Y N A T L S V H Q L V E N T D E T
	Y C I D N E A L Y D I C F R T L K L T T P T Y G D L N H L V S A T M S G V T T C L

241	R F P G Q L N A D L R K L A V N M V P F P R L H F F M P G F A P L T S R G S Q
	Q Y R A L T V P E L T Q Q M F D A K N M M A A C D P R H G R Y L T V A A V F R G R

321	M S M K E V D E Q M L N V Q N K N S S Y F V E W I P N N V K T A V C D I P P R
	G L K M S A T F I G N S T A I Q E L F K R I S E Q F T A M F R R K A F L H W Y T G

401	E G M D E M E F T E A E S N M N D L V S E Y Q Q Y Q D A T A E E E G E F E E E
	A E E E V A

5.168 solute carrier family 6, member 19 [Homo sapiens]
Protein Accession gi|51468073

Mean Expression Ratio 0.887

Median Expression Ratio 0.887

Credible Interval (0.638, 1.24)

Associated Peptides 4

Associated Spectra 5

Coverage 0.0489


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.58	0.87	1.3	SEQ ID NO: 1076	IPSLAELETIEQEEASSR

2	0.62	0.9	1.3	SEQ ID NO: 1077	IPSLAELETIEQEEASSRPK

1	0.6	0.9	1.4	SEQ ID NO: 1078	LVLPNPGLDAR

1	0.57	0.85	1.3	SEQ ID NO: 1079	VLPNPGLDAR

SEQ ID NO: 1080

1	M V R L V L P N P G L D A R I P S L A E L E T I E Q E E A S S R P K W D N K A Q Y
	M L T C L G F C V G L G N V W R F P Y L C Q S H G G G A F M I P F L I L L V L

81	E G I P L L Y L E F A I G Q R L R R G S L G V W S S I H P A L K G L G L A S M L T
	S F M V G L Y Y N T I I S W I M W Y L F N S F Q E P L P W S D C P L N E N Q T

161	G Y V D E C A R S S P V D Y F W Y R E T L N I S T S I S D S G S I Q W W M L L C
	L A C A W S V L Y M C T I R G I E T T G K A V Y I T S T L P Y V V L T I F L I R

241	G L T L K G A T N G I V F L F T P N V T E L A Q P D T W L D A G A Q V F F S F S
	L A F G G L I S F S S Y N S V H N N C E K D S V I V S I I N G F T S V Y V A I V

321	V Y S V I G F R A T Q R Y D D C F S T N I L T L I N G F D L P E G N V T Q E N F
	V D M Q Q R C N A S D P A A Y A Q L V F Q T C D I N A F L S E A V E G T G L A F

401	I V F T E A I T K M P L S P L W S V L F F I M L F C L G L S S M F G N M E G V V
	V P L Q D L R V I P P K W P K E V L T G L I C L G T F L I G F I F T L N S G Q Y

481	W L S L L D S Y A G S I P L L I I A F C E M F S V V Y V Y G V D R F N K D I E F
	M I G H K P N I F W Q V T W R V V S P L L M L I I F L F F F V V E V S Q E L T Y

561	S I W D P G Y E E F P K S Q K I S Y P N W V Y V V V V I V A G V P S L T I P G Y
	A I Y K L I R N H C Q K P G D H Q G L V S T L S T A S M N G D L K Y

5.169 decay accelerating factor for complement isoform 2 precursor [Homo sapiens]
Protein Accession gi|168693643

Mean Expression Ratio 1.13

Median Expression Ratio 1.13

Credible Interval (0.736, 1.71)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.7 1.2 1.8 SEQ ID NO: 1081 EIYCPAPPQIDNGIIQGER

1 0.72 1.1 1.8 SEQ ID NO: 1082 DCGLPPDVPNAQPALEGR

5.170 membrane alanine aminopeptidase precursor [Homo sapiens]
Protein Accession gi|157266300

Mean Expression Ratio 1.13

Median Expression Ratio 1.13

Credible Interval (1.02, 1.25)

Associated Peptides 54

Associated Spectra 111

Coverage 0.483


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.87	1.1	1.5	SEQ ID NO: 1083	AIAQGGEEEWDFAWEQFR

8	1.0	1.3	1.6	SEQ ID NO: 1084	AQIINDAFNLASAHK

1	0.81	1.1	1.4	SEQ ID NO: 1085	ASSHPLSTPASEINTPAQISELFDAISY

5	0.88	1.1	1.4	SEQ ID NO: 1086	CNAIAQGGEEEWDFAWEQFR

1	0.85	1.1	1.5	SEQ ID NO: 1087	DFAWEQFR

1	0.82	1.1	1.4	SEQ ID NO: 1088	DFVQSNWK

3	0.87	1.1	1.5	SEQ ID NO: 1089	DHSAIPVINR

2	0.87	1.2	1.5	SEQ ID NO: 1090	DLMVLNDVYR

1	0.86	1.1	1.5	SEQ ID NO: 1091	DLTALSNMLPK

1	0.82	1.1	1.5	SEQ ID NO: 1092	ELQQLEQFK

1	0.83	1.1	1.5	SEQ ID NO: 1093	ELWILNR

1	0.86	1.1	1.5	SEQ ID NO: 1094	ENSLLFDPLSSSSSNK

2	0.88	1.2	1.5	SEQ ID NO: 1095	EVVLQWFTENSK

2	0.82	1.1	1.4	SEQ ID NO: 1096	FFAGHYDTPYPLPK

1	0.86	1.1	1.5	SEQ ID NO: 1097	FSTEYELQQLEQFK

2	0.84	1.1	1.5	SEQ ID NO: 1098	FSTEYELQQLEQFKK

1	0.84	1.1	1.5	SEQ ID NO: 1099	GVGGSQPPDIDKTELVEPTEY

1	0.88	1.2	1.6	SEQ ID NO: 1100	GVGGSQPPDIDKTELVEPTEYLVVHLK

1	0.84	1.1	1.5	SEQ ID NO: 1101	IVSEFDYVEK

1	0.86	1.2	1.6	SEQ ID NO: 1102	KIQTQLQR

1	0.86	1.2	1.5	SEQ ID NO: 1103	KLFNDYGGGSFSFSNLIQAVTR

1	0.84	1.1	1.5	SEQ ID NO: 1104	KQVTPLFIHFR

5	0.9	1.1	1.4	SEQ ID NO: 1105	KVVATTQMQAADAR

4	0.87	1.1	1.4	SEQ ID NO: 1106	LFNDYGGGSFSFSNLIQAVTR

1	0.86	1.1	1.5	SEQ ID NO: 1107	LLAFIVSEFDYVEK

1	0.85	1.1	1.5	SEQ ID NO: 1108	LPNTLKPDSYR

2	0.86	1.1	1.5	SEQ ID NO: 1109	MLSSFLSEDVFK

1	0.85	1.1	1.5	SEQ ID NO: 1110	NAIAQGGEEEWDFAWEQFR

2	0.84	1.1	1.5	SEQ ID NO: 1111	NYVWIVPITSIR

2	0.88	1.2	1.5	SEQ ID NO: 1112	PSEFNYVWIVPITSIR

2	0.89	1.2	1.5	SEQ ID NO: 1113	QQQDYWLIDVR

2	0.79	1.0	1.4	SEQ ID NO: 1114	QVTPLFIHFR

1	0.83	1.1	1.5	SEQ ID NO: 1115	QWMENPNNNPIHPN

10	0.82	1	1.2	SEQ ID NO: 1116	QWMENPNNNPIHPNLR

4	0.96	1.2	1.6	SEQ ID NO: 1117	QYMPWEAALSSLSYFK

2	0.85	1.1	1.5	SEQ ID NO: 1118	RFSTEYELQQLEQFK

4	1.0	1.3	1.7	SEQ ID NO: 1119	SDQIGLPDFNAGAMENWGLVTYR

1	0.86	1.1	1.5	SEQ ID NO: 1120	SFPCFDEPAMK

2	0.81	1.1	1.4	SEQ ID NO: 1121	SFSNLIQAVTR

1	0.84	1.1	1.5	SEQ ID NO: 1122	SIQLPTTVR

3	0.82	1.1	1.4	SEQ ID NO: 1123	STVYCNAIAQGGEEEWDFAWEQFR

1	0.85	1.1	1.5	SEQ ID NO: 1124	VKDSQYEMDSEFEGELADDLAGFYR

1	0.85	1.1	1.5	SEQ ID NO: 1125	VNYDEENWR

1	0.85	1.1	1.5	SEQ ID NO: 1126	VVATTQMQAADAR

1	0.81	1.1	1.4	SEQ ID NO: 1127	VWIVPITSIR

1	0.85	1.1	1.5	SEQ ID NO: 1128	YLSYTLNPDLIR

8	0.91	1.1	1.4	SEQ ID NO: 1129	DSQYEMDSEFEGELADDLAGFYR

1	0.85	1.1	1.5	SEQ ID NO: 1130	AGHYDTPYPLPK

1	0.84	1.1	1.5	SEQ ID NO: 1131	EATDVIIIHSK

3	0.87	1.1	1.5	SEQ ID NO: 1132	LVVHLK

1	0.86	1.1	1.5	SEQ ID NO: 1134	RFSTEYELQQLEQFKK

1	0.84	1.1	1.5	SEQ ID NO: 1135	YVWIVPITSIR

1	0.85	1.1	1.5	SEQ ID NO: 1136	GFYISK

1	0.87	1.2	1.5	SEQ ID NO: 1137	KDNEETGFGSGTR

SEQ ID NO: 1138

1	M A K G F Y I S K S L G I L G I L L G V A A V C T I I A L S V V Y S Q E K N K N A
	N S S P V A S T T P S A S A T T N P A S A T T L D Q S K A W N R Y R L P N T L

81	K P D S Y R V T L R P Y L T P N D R G L Y V F K G S S T V R F T C K E A T D V I I
	I H S K K L N Y T L S Q G H R V V L R G V G G S Q P P D I D K T E L V E P T E

161	Y L V V H L K G S L V K D S Q Y E M D S E F E G E L A D D L A G F Y R S E Y M
	E G N V R K V V A T T Q M Q A A D A R K S F P C F D E P A M K A E F N I T L I H P

241	K D L T A L S N M L P K G P S T P L P E D P N W N V T E F H T T P K M S T Y L
	L A F I V S E F D Y V E K Q A S N G V L I R I W A R P S A I A A G H G D Y A L N V

321	T G P I L N F F A G H Y D T P Y P L P K S D Q I G L P D F N A G A M E N W G L
	V T Y R E N S L L F D P L S S S S S N K E R V V T V I A H E L A H Q W F G N L V T

401	I E W W N D L W L N E G F A S Y V E Y L G A D Y A E P T W N L K D L M V L N
	D V Y R V M A V D A L A S S H P L S T P A S E I N T P A Q I S E L F D A I S Y S K G

481	A S V L R M L S S F L S E D V F K Q G L A S Y L H T F A Y Q N T I Y L N L W D
	H L Q E A V N N R S I Q L P T T V R D I M N R W T L Q M G F P V I T V D T S T G T

561	L S Q E H F L L D P D S N V T R P S E F N Y V W I V P I T S I R D G R Q Q Q D Y
	W L I D V R A Q N D L F S T S G N E W V L L N L N V T G Y Y R V N Y D E E N W R

641	K I Q T Q L Q R D H S A I P V I N R A Q I I N D A F N L A S A H K V P V T L A L
	N N T L F L I E E R Q Y M P W E A A L S S L S Y F K L M F D R S E V Y G P M K N

721	Y L K K Q V T P L F I H F R N N T N N W R E I P E N L M D Q Y S E V N A I S T A
	C S N G V P E C E E M V S G L F K Q W M E N P N N N P I H P N L R S T V Y C N A

801	I A Q G G E E E W D F A W E Q F R N A T L V N E A D K L R A A L A C S K E L
	W I L N R Y L S Y T L N P D L I R K Q D A T S T I I S I T N N V I G Q G L V W D F V

881	Q S N W K K L F N D Y G G G S F S F S N L I Q A V T R R F S T E Y E L Q Q L E Q
	F K K D N E E T G F G S G T R A L E Q A L E K T K A N I K W V K E N K E V V L Q

961	W F T E N S K

5.171 transmembrane protein 9 [Homo sapiens]
Protein Accession gi|7705999

Mean Expression Ratio 0.888

Median Expression Ratio 0.888

Credible Interval (0.541, 1.42)

Associated Peptides 1

Associated Spectra 1

Coverage 0.104


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.52	0.87	1.4	SEQ ID NO: 1139	KPDAYTEQLHNEEENEDAR

SEQ ID NO: 1140

1	M K L L S L V A V V G C L L V P P A E A N K S S E D I R C K C I C P P Y R N I S G
	H I Y N Q N V S Q K D C N C L H V V E P M P V P G H D V E A Y C L L C E C R Y

81	E E R S T T T I K V I I V I Y L S V V G A L L L Y M A F L M L V D P L I R K P D A
	Y T E Q L H N E E E N E D A R S M A A A A A S L G G P R A N T V L E R V E G A

161	Q Q R W K L Q V Q E Q R K T V F D R H K M L S

5.172 toll interacting protein [Homo sapiens]
Protein Accession gi|21361619

Mean Expression Ratio 1.13

Median Expression Ratio 1.12

Credible Interval (0.772, 1.68)

Associated Peptides 3

Associated Spectra 3

Coverage 0.106


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.72	1.1	1.7	SEQ ID NO: 1141	AIQDMFPNMDQEVIR

1	0.78	1.2	1.9	SEQ ID NO: 1142	GPVYIGELPQDFLR

1	0.72	1.1	1.7	SEQ ID NO: 1143	IGELPQDFLR

SEQ ID NO: 1144

1	M A T T V S T Q R G P V Y I G E L P Q D F L R I T P T Q Q Q R Q V Q L D A Q A A
	Q Q L Q Y G G A V G T V G R L N I T V V Q A K L A K N Y G M T R M D P Y C R L R

81	L G Y A V Y E T P T A H N G A K N P R W N K V I H C T V P P G V D S F Y L E I F
	D E R A F S M D D R I A W T H I T I P E S L R Q G K V E D K W Y S L S G R Q G D

161	D K E G M I N L V M S Y A L L P A A M V M P P Q P V V L M P T V Y Q Q G V G
	Y V P I T G M P A V C S P G M V P V A L P P A A V N A Q P R C S E E D L K A I Q D M

241	F P N M D Q E V I R S V L E A Q R G N K D A A I N S L L Q M G E E P

5.173 arylsulfatase F precursor [Homo sapiens]
Protein Accession gi|31742482

Mean Expression Ratio 0.893

Median Expression Ratio 0.89

Credible Interval (0.584, 1.38)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0593


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.9	1.5	SEQ ID NO: 1145	ILDAIDDFGLR

1	0.53	0.85	1.4	SEQ ID NO: 1146	EPTSLMDILPTVASVSGGSLPQDR

SEQ ID NO: 1147

1	M R P R R P L V F M S L V C A L L N T C Q A H R V H D D K P N I V L I M V D D L
	G I G D L G C Y G N D T M R T P H I D R L A R E G V R L T Q H I S A A S L C S P

81	S R S A F L T G R Y P I R S G M V S S G N R R V I Q N L A V P A G L P L N E T T L
	A A L L K K Q G Y S T G L I G K W H Q G L N C D S R S D Q C H H P Y N Y G F D

161	Y Y Y G M P F T L V D S C W P D P S R N T E L A F E S Q L W L C V Q L V A I A
	I L T L T F G K L S G W V S V P W L L I F S M I L F I F L L G Y A W F S S H T S P

241	L Y W D C L L M R G H E I T E Q P M K A E R A G S I M V K E A I S F L E R H S
	K E T F L L F F S F L H V H T P L P T T D D F T G T S K H G L Y G D N V E E M D S

321	M V G K I L D A I D D F G L R N N T L V Y F T S D H G G H L E A R R G H A Q L
	G G W N G I Y K G G K G M G G W E G G I R V P G I V R W P G K V P A G R L I K E P

401	T S L M D I L P T V A S V S G G S L P Q D R V I D G R D L M P L L Q G N V R H S
	E H E F L F H Y C G S Y L H A V R W I P K D D S G S V W K A H Y V T P V F Q P P

481	A S G G C Y V T S L C R C F G E Q V T Y H N P P L L F D L S R D P S E S T P L T
	P A T E P L H D F V I K K V A N A L K E H Q E T I V P V T Y Q L S E L N Q G R T

561	W L K P C C G V F P F C L C D K E E E V S Q P R G P N E K R

5.174 calcium binding protein 39 [Homo sapiens]; calcium binding protein 39 [Homo sapiens]; calcium binding protein 39 [Homo sapiens]
Protein Accession gi|7706481 gi|195927022 gi|195927020

Mean Expression Ratio 1.12

Median Expression Ratio 1.12

Credible Interval (0.693, 1.81)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.69 1.2 1.9 SEQ ID NO: 1148 LLSAEFLEQHYDR

5.175 hemicentin 1 [Homo sapiens]
Protein Accession gi|118572606

Mean Expression Ratio 0.889

Median Expression Ratio 0.89

Credible Interval (0.544, 1.45)

Associated Peptides 1

Associated Spectra 1

Coverage 0.00284


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.51	0.86	1.4	SEQ ID NO: 1149	LVSLPFGIATNQDLIR

SEQ ID NO: 1150

1	M I S W E V V H T V F L F A L L Y S S L A Q D A S P Q S E I R A E E I P E G A S T L
	A F V F D V T G S M Y D D L V Q V I E G A S K I L E T S L K R P K R P L F N

81	F A L V P F H D P E I G P V T I T T D P K K F Q Y E L R E L Y V Q G G G D C P E
	M S I G A I K I A L E I S L P G S F I Y V F T D A R S K D Y R L T H E V L Q L I

161	Q Q K Q S Q V V F V L T G D C D D R T H I G Y K V Y E E I A S T S S G Q V F H
	L D K K Q V N E V L K W V E E A V Q A S K V H L L S T D H L E Q A V N T W R I P F

241	D P S L K E V T V S L S G P S P M I E I R N P L G K L I K K G F G L H E L L N I H
	N S A K V V N V K E P E A G M W T V K T S S S G R H S V R I T G L S T I D F R

321	A G F S R K P T L D F K K T V S R P V Q G I P T Y V L L N T S G I S T P A R I D L
	L E L L S I S G S S L K T I P V K Y Y P H R K P Y G I W N I S D F V P P N E A

401	F F L K V T G Y D K D D Y L F Q R V S S V S F S S I V P D A P K V T M P E K T P
	G Y Y L Q P G Q I P C S V D S L L P F T L S F V R N G V T L G V D Q Y L K E S A

481	S V N L D I A K V T L S D E G F Y E C I A V S S A G T G R A Q T F F D V S E P P
	P V I Q V P N N V T V T P G E R A V L T C L I I S A V D Y N L T W Q R N D R D V

561	R L A E P A R I R T L A N L S L E L K S V K F N D A G E Y H C M V S S E G G S S
	A A S V F L T V Q E P P K V T V M P K N Q S F T G G S E V S I M C S A T G Y P K

641	P K I A W T V N D M F I V G S H R Y R M T S D G T L F I K N A A P K D A G I Y
	G C L A S N S A G T D K Q N S T L R Y I E A P K L M V V Q S E L L V A L G D I T V

721	M E C K T S G I P P P Q V K W F K G D L E L R P S T F L I I D P L L G L L K I Q E
	T Q D L D A G D Y T C V A I N E A G R A T G K I T L D V G S P P V F I Q E P A

801	D V S M E I G S N V T L P C Y V Q G Y P E P T I K W R R L D N M P I F S R P F S
	V S S I S Q L R T G A L F I L N L W A S D K G T Y I C E A E N Q F G K I Q S E T

881	T V T V T G L V A P L I G I S P S V A N V I E G Q Q L T L P C T L L A G N P I P E
	R R W I K N S A M L L Q N P Y I T V R S D G S L H I E R V Q L Q D G G E Y T C

961	V A S N V A G T N N K T T S V V V H V L P T I Q H G Q Q I L S T I E G I P V T L
	P C K A S G N P K P S V I W S K K G E L I S T S S A K F S A G A D G S L Y V V S

1041	P G G E E S G E Y V C T A T N T A G Y A K R K V Q L T V Y V R P R V F G D Q
	R G L S Q D K P V E I S V L A G E E V T L P C E V K S L P P P I I T W A K E T Q L I

1121	S P F S P R H T F L P S G S M K I T E T R T S D S G M Y L C V A T N I A G N V T
	Q A V K L N V H V P P K I Q R G P K H L K V Q V G Q R V D I P C N A Q G T P L P

1201	V I T W S K G G S T M L V D G E H H V S N P D G T L S I D Q A T P S D A G I Y
	T C V A T N I A G T D E T E I T L H V Q E P P T V E D L E P P Y N T T F Q E R V A

1281	N Q R I E F P C P A K G T P K P T I K W L H N G R E L T G R E P G I S I L E D G
	T L L V I A S V T P Y D N G E Y I C V A V N E A G T T E R K Y N L K V H V P P V

1361	I K D K E Q V T N V S V L L N Q L T N L F C E V E G T P S P I I M W Y K D N V
	Q V T E S S T I Q T V N N G K I L K L F R A T P E D A G R Y S C K A I N I A G T S

1441	Q K Y F N I D V L V P P T I I G T N F P N E V S V V L N R D V A L E C Q V K G
	T P F P D I H W F K D G K P L F L G D P N V E L L D R G Q V L H L K N A R R N D K

1521	G R Y Q C T V S N A A G K Q A K D I K L T I Y I P P S I K G G N V T T D I S V L
	I N S L I K L E C E T R G L P M P A I T W Y K D G Q P I M S S S Q A L Y I D K G

1601	Q Y L H I P R A Q V S D S A T Y T C H V A N V A G T A E K S F H V D V Y V P
	P M I E G N L A T P L N K Q V V I A H S L T L E C K A A G N P S P I L T W L K D G V

1681	P V K A N D N I R I E A G G K K L E I M S A Q E I D R G Q Y I C V A T S V A G
	E K E I K Y E V D V L V P P A I E G G D E T S Y F I V M V N N L L E L D C H V T G

1761	5 P P P T I M W L K D G Q L I D E R D G F K I L L N G R K L V I A Q A Q V S N
	T G L Y R C M A A N T A G D H K K E F E V T V H V P P T I K S S G L S E R V V V K

1841	Y K P V A L Q C I A N G I P N P S I T W L K D D Q P V N T A Q G N L K I Q S S
	G R V L Q I A K T L L E D A G R Y T C V A T N A A G E T Q Q H I Q L H V H E P P S

1921	L E D A G K M L N E T V L V S N P V Q L E C K A A G N P V P V I T W Y K D N
	R L L S G S T S M T F L N R G Q I I D I E S A Q I S D A G I Y K C V A I N S A G A T

2001	E L F Y S L Q V H V A P S I S G S N N M V A V V V N N P V R L E C E A R G I P
	A P S L T W L K D G S P V S S F S N G L Q V L S G G R I L A L T S A Q I S D T G R

2081	Y T C V A V N A A G E K Q R D I D L R V Y V P P N I M G E E Q N V S V L I S Q
	A V E L L C Q S D A I P P P T L T W L K D G H P L L K K P G L S I S E N R S V L K

2161	I E D A Q V Q D T G R Y T C E A T N V A G K T E K N Y N V N I W V P P N I G
	G S D E L T Q L T V I E G N L I S L L C E S S G I P P P N L I W K K K G S P V L T D

2241	S M G R V R I L S G G R Q L Q I S I A E K S D A A L Y S C V A S N V A G T A K
	K E Y N L Q V Y I R P T I T N S G S H P T E I I V T R G K S I S L E C E V Q G I P

2321	P P T V T W M K D G H P L I K A K G V E I L D E G H I L Q L K N I H V S D T G
	R Y V C V A V N V A G M T D K K Y D L S V H A P P S I I G N H R S P E N I S V V E

2401	K N S V S L T C E A S P S I S I T W F K D G W P V S L S N S V R I L S G G R
	M L R L M Q T T M E D A G Q Y T C V V R N A A G E E R K I F G L S V L V P P H I

2481	V G E N T L E D V K V K E K Q S V T L T C E V T G N P V P E I T W H K D G Q
	P L Q E D E A H H I I S G G R F L Q I T N V Q V P H T G R Y T C L A S S P A G H K S

2561	R S F S L N V F V S P T I A G V G S D G N P E D V T V I L N S P T S L V C E A Y
	S Y P P A T I T W F K D G T P L E S N R N I R I L P G G R T L Q I L N A Q E D N

2641	A G R Y S C V A T N E A G E M I K H Y E V K V Y I P P I I N K G D L W G P G L
	S P K E V K I K V N N T L T L E C E A Y A I P S A S L S W Y K D G Q P L K S D D H

2721	V N I A A N G H T L Q I K E A Q I S D T G R Y T C V A S N I A G E D E L D F D
	V N I Q V P P S F Q K L W E I G N M L D T G R N G E A K D V I I N N P I S L Y C E

2801	T N A A P P P T L T W Y K D G H P L T S S D K V L I L P G G R V L Q I P R A K
	V E D A G R Y T C V A V N E A G E D S L Q Y D V R V L V P P I I K G A N S D L P E

2881	E V T V L V N K S A L I E C L S S G S P A P R N S W Q K D G Q P L L E D D H H
	K F L S N G R I L Q I L N T Q I T D I G R Y V C V A E N T A G S A K K Y F N L N V

2961	H V P P S V I G P K S E N L T V V V N N F I S L T C E V S G F P P P D L S W L K
	N E Q P I K L N T N T L I V P G G R T L Q I I R A K V S D G G E Y T C I A I N Q

3041	A G E S K K K F S L T V Y V P P S I K D H D S E S L S V V N V R E G T S V S L E
	C E S N A V P P P V I T W Y K N G R M I T E S T H V E I L A D G Q M L H I K K A

3121	E V S D T G Q Y V C R A I N V A G R D D K N F H L N V Y V P P S I E G P E R E
	V I V E T I S N P V T L T C D A T G I P P P T I A W L K N H K R I E N S D S L E V

3201	R I L S G G S K L Q I A R S Q H S D S G N Y T C I A S N M E G K A Q K Y Y F L
	S I Q V P P S V A G A E I P S D V S V L L G E N V E L V C N A N G I P T P L I Q W

3281	L K D G K P I A S G E T E R I R V S A N G S T L N I Y G A L T S D T G K Y T C V
	A T N P A G E E D R I F N L N V Y V T P T I R G N K D E A E K L M T L V D T S I

3361	N I E C R A T G T P P P Q I N W L K N G L P L P L S S H I R L L A A G Q V I R I
	V R A Q V S D V A V Y T C V A S N R A G V D N K H Y N L Q V F A P P N M D N S M

3441	G T E E I T V L K G S S T S M A C I T D G T P A P S M A W L R D G Q P L G L D
	A H L T V S T H G M V L Q L L K A E T E D S G K Y T C I A S N E A G E V S K H F I

3521	L K V L E P P H I N G S E E H E E I S V I V N N P L E L T C I A S G I P A P K M T
	W M K D G R P L P Q T D Q V Q T L G G G E V L R I S T A Q V E D T G R Y T C L

3601	A S S P A G D D D K E Y L V R V H V P P N I A G T D E P R D I T V L R N R Q V
	T L E C K S D A V P P P V I T W L R N G E R L Q A T P R V R I L S G G R Y L Q I N

3681	N A D L G D T A N Y T C V A S N I A G K T T R E F I L T V N V P P N I K G G P
	Q S L V I L L N K S T V L E C I A E G V P T P R I T W R K D G A V L A G N H A R Y

3761	S I L E N G F L H I Q S A H V T D T G R Y L C M A T N A A G T D R R R I D L Q
	V H V P P S I A P G P T N M T V I V N V Q T T L A C E A T G I P K P S I N W R K N

3841	G H L L N V D Q N Q N S Y R L L S S G S L V I I S P S V D D T A T Y E C T V T
	N G A G D D K R T V D L T V Q V P P S I A D E P T D F L V T K H A P A V I T C T A

3921	S G V P F P S I H W T K N G I R L L P R G D G Y R I L S S G A I E I L A T Q L N
	H A G R Y T C V A R N A A G S A H R H V T L H V H E P P V I Q P Q P S E L H V I

4001	L N N P I L L P C E A T G T P S P F I T W Q K E G I N V N T S G R N H A V L P S
	G G L Q I S R A V R E D A G T Y M C V A Q N P A G T A L G K I K L N V Q V P P V

4081	I S P H L K E Y V I A V D K P I T L S C E A D G L P P P D I T W H K D G R A I V
	E S I R Q R V L S S G S L Q I A F V Q P G D A G H Y T C M A A N V A G S S S T S

4161	T K L T V H V P P R I R S T E G H Y T V N E N S Q A I L P C V A D G I P T P A I
	N W K K D N V L L A N L L G K Y T A E P Y G E L I L E N V V L E D S G F Y T C V

4241	A N N A A G E D T H T V S L T V H V L P T F T E L P G D V S L N K G E Q L R L
	S C K A T G I P L P K L T W T F N N N I I P A H F D S V N G H S E L V I E R V S K

4321	E D S G T Y V C T A E N S V G F V K A I G F V Y V K E P P V F K G D Y P S N
	W I E P L G G N A I L N C E V K G D P T P T I Q W N R K G V D I E I S H R I R Q L G

4401	N G S L A I Y G T V N E D A G D Y T C V A T N E A G V V E R S M S L T L Q S
	P P I I T L E P V E T V I N A G G K I I L N C Q A T G E P Q P T I T W S R Q G H S I

4481	S W D D R V N V L S N N S L Y I A D A Q K E D T S E F E C V A R N L M G S V
	L V R V P V I V Q V H G G F S Q W S A W R A C S V T C G K G I Q K R S R L C N Q P L

4561	P A N G G K P C Q G S D L E M R N C Q N K P C P V D G S W S E W S L W E E C
	T R S C G R G N Q T R T R T C N N P S V Q H G G R P C E G N A V E I I M C N I R P C

4641	P V H G A W S A W Q P W G T C S E S C G K G T Q T R A R L C N N P P P A F G
	G S Y C D G A E T Q M Q V C N E R N C P I H G K W A T W A S W S A C S V S C G G
	G A

4721	R Q R T R G C S D P V P Q Y G G R K C E G S D V Q S D F C N S D P C P T H G
	N W S P W S G W G T C S R T C N G G Q M R R Y R T C D N P P P S N G G R A C G G
	P D

4801	S Q I Q R C N T D M C P V D G S W G S W H S W S Q C S A S C G G G E K T R K
	R L C D H P V P V K G G R P C P G D T T Q V T R C N V Q A C P G G P Q R A R G S V I

4881	G N I N D V E F G I A F L N A T I T D S P N S D T R I I R A K I T N V P R S L G S
	A M R K I V S I L N P I Y W T T A K E I G E A V N G F T L T N A V F K R E T Q

4961	V E F A T G E I L Q M S H I A R G L D S D G S L L L D I V V S G Y V L Q L Q S P
	A E V T V K D Y T E D Y I Q T G P G Q L Y A Y S T R L F T I D G I S I P Y T W N

5041	H T V F Y D Q A Q G R M P F L V E T L H A S S V E S D Y N Q I E E T L G F K I
	H A S I S K G D R S N Q C P S G F T L D S V G P F C A D E D E C A A G N P C S H S

5121	C H N A M G T Y Y C S C P K G L T I A A D G R T C Q D I D E C A L G R H T C
	H A G Q D C D N T I G S Y R C V V R C G S G F R R T S D G L S C Q D I N E C Q E S S

5201	P C H Q R C F N A I G S F H C G C E P G Y Q L K G R K C M D V N E C R Q N V
	C R P D Q H C K N T R G G Y K C I D L C P N G M T K A E N G T C I D I D E C K D G T

5281	H Q C R Y N Q I C E N T R G S Y R C V C P R G Y R S Q G V G R P C M D I N E
	C E Q V P K P C A H Q C S N T P G S F K C I C P P G Q H L L G D G K S C A G L E R L

5361	P N Y G T Q Y S S Y N L A R F S P V R N N Y Q P Q Q H Y R Q Y S H L Y S S Y S
	E Y R N S R T S L S R T R R T I R K T C P E G S E A S H D T C V D I D E C E N T D

5441	A C Q H E C K N T F G S Y Q C I C P P G Y Q L T H N G K T C Q D I D E C L E Q
	N V H C G P N R M C F N M R G S Y Q C I D T P C P P N Y Q R D P V S G F C L K N C

5521	P P N D L E C A L S P Y A L E Y K L V S L P F G I A T N Q D L I R L V A Y T Q D
	G V M H P R T T F L M V D E E Q T V P F A L R D E N L K G V V Y T T R P L R E A

5601	E T Y R M R V R A S S Y S A N G T I E Y Q T T F I V Y I A V S A Y P Y

5.176 prostate stem cell antigen preproprotein [Homo sapiens]
Protein Accession gi|5031995

Mean Expression Ratio 1.12

Median Expression Ratio 1.12

Credible Interval (0.692, 1.81)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0813


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.7	1.2	1.9	SEQ ID NO: 1151	AVGLLTVISK

SEQ ID NO: 1152

1	M K A V L L A L L M A G L A L Q P G T A L L C Y S C K A Q V S N E D C L Q V E
	N C T Q L G E Q C W T A R I R A V G L L T V I S K G C S L N C V D D S Q D Y Y V G

81	K K N I T C C D T D L C N A S G A H A L Q P A A A I L A L L P A L G L L L W G P
	G Q L

5.177 solute carrier family 47, member 1 [Homo sapiens]
Protein Accession gi|22907060

Mean Expression Ratio 1.12

Median Expression Ratio 1.12

Credible Interval (0.725, 1.74)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0246


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.74	1.2	1.8	SEQ ID NO: 1153	QEEPLPEHPQDGAK

SEQ ID NO: 1154

1	M E A P E E P A P V R G G P E A T L E V R G S R C L R L S A F R E E L R A L L V L
	A G P A F L V Q L M V F L I S F I S S V F C G H L G K L E L D A V T L A I A V

81	I N V T G V S V G F G L S S A C D T L I S Q T Y G S Q N L K H V G V I L Q R S A L
	V L L L C C F P C W A L F L N T Q H I L L L F R Q D P D V S R L T Q T Y V T I

161	F I P A L P A T F L Y M L Q V K Y L L N Q G I V L P Q I V T G V A A N L V N A L
	A N Y L F L H Q L H L G V I G S A L A N L I S Q Y T L A L L L F L Y I L G K K L

241	H Q A T W G G W S L E C L Q D W A S F L R L A I P S M L M L C M E W W A Y E
	V G S F L S G I L G M V E L G A Q S I V Y E L A I I V Y M V P A G F S V A A S V R V

321	G N A L G A G D M E Q A R K S S T V S L L I T V L F A V A F S V L L L S C K D
	H V G Y I F T T D R D I I N L V A Q V V P I Y A V S H L F E A L A C T S G G V L R

401	G S G N Q K V G A I V N T I G Y Y V V G L P I G I A L M F A T T L G V M G L W
	S G I I I C T V F Q A V C F L G F I I Q L N W K K A C Q Q A Q V H A N L K V N N V

481	P R S G N S A L P Q D P L H P G C P E N L E G I L T N D V G K T G E P Q S D Q Q
	M R Q E E P L P E H P Q D G A K L S R K Q L V L R R G L L L L G V F L I L L V G

561	I L V R F Y V R I Q

5.178 polymeric immunoglobulin receptor [Homo sapiens]
Protein Accession gi|31377806

Mean Expression Ratio 1.12

Median Expression Ratio 1.12

Credible Interval (0.926, 1.35)

Associated Peptides 16

Associated Spectra 25

Coverage 0.234


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.83	1.1	1.6	SEQ ID NO: 1155	DGSFSVVITGLR

2	0.78	1.0	1.4	SEQ ID NO: 1156	ILLNPQDKDGSFSVVITGLR

1	0.83	1.1	1.6	SEQ ID NO: 1157	LDIQGTGQLLFSVVINQLR

1	0.8	1.1	1.5	SEQ ID NO: 1158	LVSLTLNLVTR

9	0.9	1.1	1.4	SEQ ID NO: 1159	NADLQVLKPEPELVYEDLR

1	0.83	1.2	1.6	SEQ ID NO: 1160	QLFVNEESTIPR

1	0.8	1.1	1.5	SEQ ID NO: 1161	QSSGENCDVVVNTLGK

1	0.85	1.2	1.6	SEQ ID NO: 1162	TVTINCPFK

1	0.81	1.1	1.5	SEQ ID NO: 1163	VVNIAQLSQDDSGR

1	0.78	1.1	1.5	SEQ ID NO: 1164	YLCGAHSDGQLQEGSPIQAW

1	0.8	1.1	1.5	SEQ ID NO: 1165	YWCLWEGAQNGR

1	0.82	1.1	1.6	SEQ ID NO: 1166	SVVINQLR

1	0.83	1.1	1.6	SEQ ID NO: 1167	KTENAQK

1	0.79	1.1	1.5	SEQ ID NO: 1168	HCALGPEVANVAK

1	0.82	1.1	1.5	SEQ ID NO: 1169	ILLNPQDK

1	0.8	1.1	1.5	SEQ ID NO: 1170	ADAAPDEK

SEQ ID NO: 1171

1	M L L F V L T C L L A V F P A I S T K S P I F G P E E V N S V E G N S V S I T C Y Y
	P P T S V N R H T R K Y W C R Q G A R G G C I T L I S S E G Y V S S K Y A G

81	R A N L T N F P E N G T F V V N I A Q L S Q D D S G R Y K C G L G I N S R G L S
	F D V S L E V S Q G P G L L N D T K V Y T V D L G R T V T I N C P F K T E N A Q

161	K R K S L Y K Q I G L Y P V L V I D S S G Y V N P N Y T G R I R L D I Q G T G Q
	L L F S V V I N Q L R L S D A G Q Y L C Q A G D D S N S N K K N A D L Q V L K P

241	E P E L V Y E D L R G S V T F H C A L G P E V A N V A K F L C R Q S S G E N C
	D V V V N T L G K R A P A F E G R I L L N P Q D K D G S F S V V I T G L R K E D A

321	G R Y L C G A H S D G Q L Q E G S P I Q A W Q L F V N E E S T I P R S P T V V K
	G V A G G S V A V L C P Y N R K E S K S I K Y W C L W E G A Q N G R C P L L V D

401	S E G W V K A Q Y E G R L S L L E E P G N G T F T V I L N Q L T S R D A G F Y
	W C L T N G D T L W R T T V E I K I I E G E P N L K V P G N V T A V L G E T L K V

481	P C H F P C K F S S Y E K Y W C K W N N T G C Q A L P S Q D E G P S K A F V N
	C D E N S R L V S L T L N L V T R A D E G W Y W C G V K Q G H F Y G E T A A V Y V

561	A V E E R K A A G S R D V S L A K A D A A P D E K V L D S G F R E I E N K A I
	Q D P R L F A E E K A V A D T R D Q A D G S R A S V D S G S S E E Q G G S S R A L

641	V S T L V P L G L V L A V G A V A V G V A R A R H R K N V D R V S I R S Y R T
	D I S M S D F E N S R E F G A N D N M G A S S I T Q E T S L G G K E E F V A T T E

721	S T T E T K E P K K A K R S S K E E A E M A Y K D F L L Q S S T V A A E A Q D
	G P Q E A

5.179 cathepsin C isoform a preproprotein [Homo sapiens]
Protein Accession gi|189083844

Mean Expression Ratio 1.12

Median Expression Ratio 1.12

Credible Interval (0.874, 1.43)

Associated Peptides 6

Associated Spectra 13

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

4	0.83	1.1	1.5	SEQ ID NO: 1172	AVAFEVYDDFLHYK

2	0.78	1.1	1.5	SEQ ID NO: 1173	EVYDDFLHYK

1	0.79	1.1	1.6	SEQ ID NO: 1174	GTDECAIESIAVAATPIPK

3	0.83	1.1	1.6	SEQ ID NO: 1175	NVHGINFVSPVR

1	0.8	1.1	1.6	SEQ ID NO: 1176	WFAFFK

2	0.84	1.1	1.6	SEQ ID NO: 1177	LELVHHGPMAVAF

5.180 biliverdin reductase B (flavin reductase (NADPH)) [Homo sapiens]
Protein Accession gi|4502419

Mean Expression Ratio 0.897

Median Expression Ratio 0.896

Credible Interval (0.551, 1.46)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0728


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.52	0.87	1.5	SEQ ID NO: 1178	TVAGQDAVIVLLGTR

SEQ ID NO: 1179

1	M A V K K I A I F G A T G Q T G L T T L A Q A V Q A G Y E V T V L V R D S S R L
	P S E G P R P A H V V V G D V L Q A A D V D K T V A G Q D A V I V L L G T R N D

81	L S P T T V M S E G A R N I V A A M K A H G V D K V V A C T S A F L L W D P T
	K V P P R L Q A V T D D H I R M H K V L R E S G L K Y V A V M P P H I G D Q P L T

161	G A Y T V T L D G R G P S R V I S K H D L G H F M L R C L T T D E Y D G H S T
	Y P S H Q Y Q

5.181 prostatic binding protein [Homo sapiens]
Protein Accession gi|4505621

Mean Expression Ratio 1.12

Median Expression Ratio 1.12

Credible Interval (0.79, 1.59)

Associated Peptides 2

Associated Spectra 5

Coverage 0.144


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.78	1.1	1.7	SEQ ID NO: 1180	LYTLVLTDPDAPSR

3	0.78	1.1	1.6	SEQ ID NO: 1181	YVWLVYEQDRPLK

SEQ ID NO: 1182

1	M P V D L S K W S G P L S L Q E V D E Q P Q H P L H V T Y A G A A V D E L G K V
	L T P T Q V K N R P T S I S W D G L D S G K L Y T L V L T D P D A P S R K D P K

81	Y R E W H H F L V V N M K G N D I S S G T V L S D Y V G S G P P K G T G L H R
	Y V W L V Y E Q D R P L K C D E P I L S N R S G D H R G K F K V A S F R K K Y E L

161	R A P V A G T C Y Q A E W D D Y V P K L Y E Q L S G K

5.182 proteasome alpha 4 subunit isoform 1 [Homo sapiens]; proteasome alpha 4 subunit isoform 1 [Homo sapiens]
Protein Accession gi|4506185 gi|156713442

Mean Expression Ratio 1.12

Median Expression Ratio 1.12

Credible Interval (0.696, 1.82)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.69 1.2 1.9 SEQ ID NO: 1183 LLDEVFFSEK

5.183 palate, lung and nasal epithelium associated precursor [Homo sapiens]; palate, lung and nasal epithelium associated precursor [Homo sapiens]
Protein Accession gi|7706119 gi|18765705

Mean Expression Ratio 0.896

Median Expression Ratio 0.897

Credible Interval (0.552, 1.44)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.52 0.87 1.5 SEQ ID NO: 1184 LQVNTPLVGASLLR

5.184 vacuolar protein sorting factor 4A [Homo sapiens]
Protein Accession gi|7019569

Mean Expression Ratio 1.12

Median Expression Ratio 1.12

Credible Interval (0.773, 1.59)

Associated Peptides 4

Associated Spectra 4

Coverage 0.144


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.74	1.1	1.7	SEQ ID NO: 1185	IYIPLPEEAAR

1	0.74	1.1	1.7	SEQ ID NO: 1186	LHLGSTPHNLTDANIHELAR

1	0.75	1.1	1.7	SEQ ID NO: 1187	QHKPSIIFIDEVDSLCGSR

1	0.73	1.1	1.7	SEQ ID NO: 1188	LLEPVVCMSDMLR

SEQ ID NO: 1189

1	M T T S T L Q K A I D L V T K A T E E D K A K N Y E E A L R L Y Q H A V E Y F L
	H A I K Y E A H S D K A K E S I R A K C V Q Y L D R A E K L K D Y L R S K E K H

81	G K K P V K E N Q S E G K G S D S D S E G D N P E K K K L Q E Q L M G A V V M
	E K P N I R W N D V A G L E G A K E A L K E A V I L P I K F P H L F T G K R T P W

161	R G I L L F G P P G T G K S Y L A K A V A T E A N N S T F F S V S S S D L M S K
	W L G E S E K L V K N L F E L A R Q H K P S I I F I D E V D S L C G S R N E N E

241	S E A A R R I K T E F L V Q M Q G V G N N N D G T L V L G A T N I P W V L D S
	A I R R R F E K R I Y I P L P E E A A R A Q M F R L H L G S T P H N L T D A N I H

321	E L A R K T E G Y S G A D I S I I V R D S L M Q P V R K V Q S A T H F K K V C G
	P S R T N P S M M I D D L L T P C S P G D P G A M E M T W M D V P G D K L L E P

401	V V C M S D M L R S L A T T R P T V N A D D L L K V K K F S E D F G Q E S

5.185 transmembrane protein 192 [Homo sapiens]
Protein Accession gi|154240704

Mean Expression Ratio 0.899

Median Expression Ratio 0.899

Credible Interval (0.586, 1.35)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0996


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.9	1.4	SEQ ID NO: 1190	IYAYPSNITSETGFR

1	0.55	0.88	1.4	SEQ ID NO: 1191	AKPEPDILEEEK

SEQ ID NO: 1192

1	M A A G G R M E D G S L D I T Q S I E D D P L L D A Q L L P H H S L Q A H F R P R
	F H P L P T V I I V N L L W F I H L V F V V L A F L T G V L C S Y P N P N E D

81	K C P G N Y T N P L K V Q T V I I L G K V I L W I L H L L L E C Y I Q Y H H S K I
	R N R G Y N L I Y R S T R H L K R L A L M I Q S S G N T V L L L I L C M Q H S

161	F P E P G R L Y L D L I L A I L A L E L I C S L I C L L I Y T V K I R R F N K A K P
	E P D I L E E E K I Y A Y P S N I T S E T G F R T I S S L E E I V E K Q G D

241	T I E Y L K R H N A L L S K R L L A L T S S D L G C Q P S R T

5.186 vitronectin precursor [Homo sapiens]
Protein Accession gi|88853069

Mean Expression Ratio 0.901

Median Expression Ratio 0.9

Credible Interval (0.619, 1.31)

Associated Peptides 3

Associated Spectra 3

Coverage 0.09


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.87	1.3	SEQ ID NO: 1193	DVWGIEGPIDAAFTR

1	0.58	0.9	1.4	SEQ ID NO: 1194	DWHGVPGQVDAAMAGR

1	0.59	0.91	1.4	SEQ ID NO: 1195	FEDGVLDPDYPR

SEQ ID NO: 1196

1	M A P L R P L L I L A L L A W V A L A D Q E S C K G R C T E G F N V D K K C Q C
	D E L C S Y Y Q S C C T D Y T A E C K P Q V T R G D V F T M P E D E Y T V Y D D

81	G E E K N N A T V H E Q V G G P S L T S D L Q A Q S K G N P E Q T P V L K P E E
	E A P A P E V G A S K P E G I D S R P E T L H P G R P Q P P A E E E L C S G K P

161	F D A F T D L K N G S L F A F R G Q Y C Y E L D E K A V R P G Y P K L I R D V
	W G I E G P I D A A F T R I N C Q G K T Y L F K G S Q Y W R F E D G V L D P D Y P

241	R N I S D G F D G I P D N V D A A L A L P A H S Y S G R E R V Y F F K G K Q Y
	W E Y Q F Q H Q P S Q E E C E G S S L S A V F E H F A M M Q R D S W E D I F E L L

321	F W G R T S A G T R Q P Q F I S R D W H G V P G Q V D A A M A G R I Y I S G M
	A P R P S L A K K Q R F R H R N R K G Y R S Q R G H S R G R N Q N S R R P S R A T

401	W L5 L F5 S E E S N L G A N N Y D D Y R M D W L V P A T C E P I Q S V F F F S
	G D K Y Y R V N L R T R R V D T V D P P Y P R S I A Q Y W L G C P A P G H L

5.187 von Willebrand factor preproprotein [Homo sapiens]
Protein Accession gi|89191868

Mean Expression Ratio 1.11

Median Expression Ratio 1.11

Credible Interval (0.866, 1.41)

Associated Peptides 7

Associated Spectra 13

Coverage 0.0387


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.81	1.1	1.6	SEQ ID NO: 1197	AFVLSSVDELEQQR

2	0.8	1.1	1.5	SEQ ID NO: 1198	APILIQDFETLPR

4	0.8	1.1	1.4	SEQ ID NO: 1199	AVVILVTDVSVDSVDAAADAAR

1	0.78	1.1	1.6	SEQ ID NO: 1200	LLDLVFLLDGSSR

3	0.81	1.1	1.5	SEQ ID NO: 1201	LP GDIQVVPIGVGPNANVQELER

1	0.81	1.1	1.6	SEQ ID NO: 1202	VIVIPVGIGPHANLK

1	0.81	1.1	1.6	SEQ ID NO: 1203	EAPDLVLQR

SEQ ID NO: 1204

1	M I P A R F A G V L L A L A L I L P G T L C A E G T R G R S S T A R C S L F G S D
	F V N T F D G S M Y S F A G Y C S Y L L A G G C Q K R S F S I I G D F Q N G K

81	R V S L S V Y L G E F F D I H L F V N G T V T Q G D Q R V S M P Y A S K G L Y L
	E T E A G Y Y K L S G E A Y G F V A R I D G S G N F Q V L L S D R Y F N K T C G

161	L C G N F N I F A E D D F M T Q E G T L T S D P Y D F A N S W A L S S G E Q W
	C E R A S P P S S S C N I S S G E M Q K G L W E Q C Q L L K S T S V F A R C H P L

241	V D P E P F V A L C E K T L C E C A G G L E C A C P A L L E Y A R T C A Q E G
	M V L Y G W T D H S A C S P V C P A G M E Y R Q C V S P C A R T C Q S L H I N E M

321	C Q E R C V D G C S C P E G Q L L D E G L C V E S T E C P C V H S G K R Y P P
	G T S L S R D C N T C I C R N S Q W I C S N E E C P G E C L V T G Q S H F K S F D

401	N R Y F T F S G I C Q Y L L A R D C Q D H S F S I V I E T V Q C A D D R D A V C
	T R S V T V R L P G L H N S L V K L K H G A G V A M D G Q D V Q L P L L K G D L

481	R I Q H T V T A S V R L S Y G E D L Q M D W D G R G R L L V K L S P V Y A G
	K T C G L C G N Y N G N Q G D D F L T P S G L A E P R V E D F G N A W K L H G D
	C Q

561	D L Q K Q H S D P C A L N P R M T R F S E E A C A V L T S P T F E A C H R A V
	S P L P Y L R N C R Y D V C S C S D G R E C L C G A L A S Y A A A C A G R G V R V

641	A W R E P G R C E L N C P K G Q V Y L Q C G T P C N L T C R S L S Y P D E E C
	N E A C L E G C F C P P G L Y M D E R G D C V P K A Q C P C Y Y D G E I F Q P E D

721	I F S D H H T M C Y C E D G F M H C T M S G V P G S L L P D A V L S S P L S H
	R S K R S L S C R P P M V K L V C P A D N L R A E G L E C T K T C Q N Y D L E C M

801	S M G C V S G C L C P P G M V R H E N R C V A L E R C P C F H Q G K E Y A P G
	E T V K I G C N T C V C R D R K W N C T D H V C D A T C S T I G M A H Y L T F D G

881	L K Y L F P G E C Q Y V L V Q D Y C G S N P G T F R I L V G N K G C S H P S V
	K C K K R V T I L V E G G E I E L F D G E V N V K R P M K D E T H F E V V E S G R

961	Y I I L L L G K A L S V V W D R H L S I S V V L K Q T Y Q E K V C G L C G N F D
	G I Q N N D L T S S N L Q V E E D P V D F G N S W K V S S Q C A D T R K V P L D

1041	S S P A T C H N N I M K Q T M V D S S C R I L T S D V F Q D C N K L V D P E P
	Y L D V C I Y D T C S C E S I G D C A C F C D T I A A Y A H V C A Q H G K V V T W

1121	R T A T L C P Q S C E E R N L R E N G Y E C E W R Y N S C A P A C Q V T C Q
	H P E P L A C P V Q C V E G C H A H C P P G K I L D E L L Q T C V D P E D C P V C E

1201	V A G R R F A S G K K V T L N P S D P E H C Q I C H C D V V N L T C E A C Q E
	P G G L V V P P T D A P V S P T T L Y V E D I S E P P L H D F Y C S R L L D L V F

1281	L L D G S S R L S E A E F E V L K A F V V D M M E R L R I S Q K W V R V A V
	V E Y H D G S H A Y I G L K D R K R P S E L R R I A S Q V K Y A G S Q V A S T S E V

1361	L K Y T L F Q I F S K I D R P E A S R I T L L L M A S Q E P Q R M S R N F V R Y
	V Q G L K K K K V I V I P V G I G P H A N L K Q I R L I E K Q A P E N K A F V L

1441	S S V D E L E Q Q R D E I V S Y L C D L A P E A P P P T L P P D M A Q V T V G
	P G L L G V S T L G P K R N S M V L D V A F V L E G S D K I G E A D F N R S K E F

1521	M E E V I Q R M D V G Q D S I H V T V L Q Y S Y M V T V E Y P F S E A Q S K
	G D I L Q R V R E I R Y Q G G N R T N T G L A L R Y L S D H S F L V S Q G D R E Q A

1601	P N L V Y M V T G N P A S D E I K R L P G D I Q V V P I G V G P N A N V Q E L
	E R I G W P N A P I L I Q D F E T L P R E A P D L V L Q R C C S G E G L Q I P T L

1681	S P A P D C S Q P L D V I L L L D G S S S F P A S Y F D E M K S F A K A F I S K
	A N I G P R L T Q V S V L Q Y G S I T T I D V P W N V V P E K A H L L S L V D V

1761	M Q R E G G P S Q I G D A L G F A V R Y L T S E M H G A R P G A S K A V V I
	L V T D V S V D S V D A A A D A A R S N R V T V F P I G I G D R Y D A A Q L R I L A

1841	G P A G D S N V V K L Q R I E D L P T M V T L G N S F L H K L C S G F V R I C
	M D E D G N E K R P G D V W T L P D Q C H T V T C Q P D G Q T L L K S H R V N C D

1921	R G L R P S C P N S Q S P V K V E E T C G C R W T C P C V C T G S S T R H I V
	T F D G Q N F K L T G S C S Y V L F Q N K E Q D L E V I L H N G A C S P G A R Q G

2001	C M K S I E V K H S A L S V E L H S D M E V T V N G R L V S V P Y V G G N M
	E V N V Y G A I M H E V R F N H L G H I F T F T P Q N N E F Q L Q L S P K T F A S K

2081	T Y G L C G I C D E N G A N D F M L R D G T V T T D W K T L V Q E W T V Q R
	P G Q T C Q P I L E E Q C L V P D S S H C Q V L L L P L F A E C H K V L A P A T F Y

2161	A I C Q Q D S C H Q E Q V C E V I A S Y A H L C R T N G V C V D W R T P D F
	C A M S C P P S L V Y N H C E H G C P R H C D G N V S S C G D H P S E G C F C P P D

2241	K V M L E G S C V P E E A C T Q C I G E D G V Q H Q F L E A W V P D H Q P C
	Q I C T C L S G R K V N C T T Q P C P T A K A P T C G L C E V A R L R Q N A D Q C C

2321	P E Y E C V C D P V S C D L P P V P H C E R G L Q P T L T N P G E C R P N F T
	C A C R K E E C K R V S P P S C P P H R L P T L R K T Q C C D E Y E C A C N C V N

2401	S T V S C P L G Y L A S T A T N D C G C T T T T C L P D K V C V H R S T I Y P
	V G Q F W E E G C D V C T C T D M E D A V M G L R V A Q C S Q K P C E D S C R S G

2481	F T Y V L H E G E C C G R C L P S A C E V V T G S P R G D S Q S S W K S V G S
	Q W A S P E N P C L I N E C V R V K E E V F I Q Q R N V S C P Q L E V P V C P S G

2561	F Q L S C K T S A C C P S C R C E R M E A C M L N G T V I G P G K T V M I D V
	C T T C R C M V Q V G V I S G F K L E C R K T T C N P C P L G Y K E E N N T G E C

2641	C G R C L P T A C T I Q L R G G Q I M T L K R D E T L Q D G C D T H F C K V N
	E R G E Y F W E K R V T G C P P F D E H K C L A E G G K I M K I P G T C C D T C E

2721	E P E C N D I T A R L Q Y V K V G S C K S E V E V D I H Y C Q G K C A S K A
	M Y S I D I N D V Q D Q C S C C S P T R T E P M Q V A L H C T N G S V V Y H E V L N

2801	A M E C K C S P R K C S K

5.188 tripartite motif protein TRIM14 isoform alpha [Homo sapiens]; tripartite motif protein TRIM14 isoform alpha [Homo sapiens]; tripartite motif protein TRIM14 isoform alpha [Homo sapiens]
Protein Accession gi|15208667 gi|15208665 gi|15208663

Mean Expression Ratio 0.9

Median Expression Ratio 0.9

Credible Interval (0.61, 1.35)

Associated Peptides 2

Associated Spectra 3

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.61 0.9 1.4 SEQ ID NO: 1205 GLVEAVESTLQTPLDIR

1 0.57 0.88 1.4 SEQ ID NO: 1206 ATFQEPLYPALR

5.189 PREDICTED: similar to hCG1642538 [Homo sapiens]; PREDICTED: similar to hCG1642538 [Homo sapiens]
Protein Accession gi|169216113 gi|169215489

Mean Expression Ratio 1.11

Median Expression Ratio 1.11

Credible Interval (0.773, 1.61)

Associated Peptides 1

Associated Spectra 5

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

5 0.82 1.1 1.6 SEQ ID NO: 1207 DIQMTQSPSSLSASVGDR

5.190 actin, alpha 1, skeletal muscle [Homo sapiens]
Protein Accession gi|4501881

Mean Expression Ratio 1.11

Median Expression Ratio 1.11

Credible Interval (0.691, 1.82)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0424


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.69	1.1	1.9	SEQ ID NO: 1208	YPIEHGIITNWDDMEK

SEQ ID NO: 1209

1	M C D E D E T T A L V C D N G S G L V K A G F A G D D A P R A V F P S I V G R P
	R H Q G V M V G M G Q K D S Y V G D E A Q S K R G I L T L K Y P I E H G I I T N

81	W D D M E K I W H H T F Y N E L R V A P E E H P T L L T E A P L N P K A N R E
	K M T Q I M F E T F N V P A M Y V A I Q A V L S L Y A S G R T T G I V L D S G D G

161	V T H N V P I Y E G Y A L P H A I M R L D L A G R D L T D Y L M K I L T E R G
	Y S F V T T A E R E I V R D I K E K L C Y V A L D F E N E M A T A A S S S S L E K

241	S Y E L P D G Q V I T I G N E R F R C P E T L F Q P S F I G M E S A G I H E T T Y
	N S I M K C D I D I R K D L Y A N N V M S G G T T M Y P G I A D R M Q K E I T

321	A L A P S T M K I K I I A P P E R K Y S V W I G G S I L A S L S T F Q Q M W I T K
	Q E Y D E A G P S I V H R K C F

5.191 RAP2B, member of RAS oncogene family [Homo sapiens]
Protein Accession gi|38201690

Mean Expression Ratio 1.11

Median Expression Ratio 1.11

Credible Interval (0.688, 1.78)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0656


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.68	1.1	1.9	SEQ ID NO: 1210	ASVDELFAEIVR

SEQ ID NO: 1211

1	M R E Y K V V V L G S G G V G K S A L T V Q F V T G S F I E K Y D P T I E D F Y R
	K E I E V D S S P S V L E I L D T A G T E Q F A S M R D L Y I K N G Q G F I L

81	V Y S L V N Q Q S F Q D I K P M R D Q I I R V K R Y E R V P M I L V G N K V D L
	E G E R E V S Y G E G K A L A E E W S C P F M E T S A K N K A S V D E L F A E I

161	V R Q M N Y A A Q P N G D E G C C S A C V I L

5.192 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative function) [Homo sapiens]
Protein Accession gi|7662358

Mean Expression Ratio 0.907

Median Expression Ratio 0.905

Credible Interval (0.622, 1.33)

Associated Peptides 3

Associated Spectra 3

Coverage 0.0486


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.58	0.9	1.4	SEQ ID NO: 1212	IDDLIGDLVQR

1	0.58	0.9	1.4	SEQ ID NO: 1213	LLLVSFDGFR

1	0.58	0.9	1.4	SEQ ID NO: 1214	KIDDLIGDLVQR

SEQ ID NO: 1215

1	M K L L V I L L F S G L I T G F R S D S S S S L P P K L L L V S F D G F R A D Y L K
	N Y E F P H L Q N F I K E G V L V E H V K N V F I T K T F P N H Y S I V T G

81	L Y E E S H G I V A N S M Y D A V T K K H F S D S N D K D P F W W N E A V P I
	W V T N Q L Q E N R S S A A A M W P G T D V P I H D T I S S Y F M N Y N S S V S F

161	E E R L N N I T M W L N N S N P P V T F A T L Y W E E P D A S G H K Y G P E D
	K E N M S R V L K K I D D L I G D L V Q R L K M L G L W E N L N V I I T S D H G M

241	T Q C S Q D R L I N L D S C I D H S Y Y T L I D L S P V A A I L P K I N R T E V Y
	N K L K N C S P H M N V Y L K E D I P N R F Y Y Q H N D R I Q P I I L V A D E

321	G W T I V L N E S S Q K L G D H G Y D N S L P S M H P F L A A H G P A F H K G
	Y K H S T I N I V D I Y P M M C H I L G L K P H P N N G T F G H T K C L L V D Q W

401	C I N L P E A I A I V I G S L L V L T M L T C L I I I M Q N R L S V P R P F S R L Q
	L Q E D D D D P L I G

5.193 transmembrane BAX inhibitor motif containing 1 [Homo sapiens]
Protein Accession gi|50593008

Mean Expression Ratio 0.905

Median Expression Ratio 0.906

Credible Interval (0.645, 1.27)

Associated Peptides 1

Associated Spectra 8

Coverage 0.045


A	2.5	50	97.5	Sequence ID No.	Sequence

8	0.67	0.88	1.2	SEQ ID NO: 1216	AVSDSFGPGEWDDR

SEQ ID NO: 1217

1	M S N P S A P P P Y E D R N P L Y P G P P P P G G Y G Q P S V L P G G Y P A Y P G
	Y P Q P G Y G H P A G Y P Q P M P P T H P M P M N Y G P G H G Y D G E E R A V

81	S D S F G P G E W D D R K V R H T F I R K V Y S I I S V Q L L I T V A I I A I F T F
	V E P V S A F V R R N V A V Y Y V S Y A V F V V T Y L I L A C C Q G P R R R

161	F P W N I I L L T L F T F A M G F M T G T I S S M Y Q T K A V I I A M I I T A V V
	S I S V T I F C F Q T K V D F T S C T G L F C V L G I V L L V T G I V T S I V

241	L Y F Q Y V Y W L H M L Y A A L G A I C F T L F L A Y D T Q L V L G N R K H T
	I S P E D Y I T G A L Q I Y T D I I Y I F T F V L Q L M G D R N

5.194 mucolipin 1 [Homo sapiens]
Protein Accession gi|10092597

Mean Expression Ratio 1.1

Median Expression Ratio 1.10

Credible Interval (0.676, 1.79)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0483


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.67	1.1	1.9	SEQ ID NO: 1218	LLTPNPGYGTQAGPSPAPPTPPEEEDLR

SEQ ID NO: 1219

1	M T A P A G P R G S E T E R L L T P N P G Y G T Q A G P S P A P P T P P E E E D L
	R R R L K Y F F M S P C D K F R A K G R K P C K L M L Q V V K I L V V T V Q L

81	I L F G L S N Q L A V T F R E E N T I A F R H L F L L G Y S D G A D D T F A A Y T
	R R E Q L Y Q A I F H A V D Q Y L A L P D V S L G R Y A Y V R G G G D P W T N G

161	S G L A L C Q R Y Y H R G H V D P A N D T F D I D P M V V T D C I Q V D P P E
	R P P P P P S D D L T L L E S S S S Y K N L T L K F H K L V N V T I H F R L K T I

241	N L Q S L I N N E I P D C Y T F S V L I T F D N K A H S G R I P I S L E T Q A H I Q
	E C K H P S V F Q H G D N S F R L L F D V V V I L T C S L S F L L C A R S L

321	L R G F L L Q N E F V G F M W R Q R G R V I S L W E R L E F V N G W Y I L L V
	T S D V L T I S G T I M K I G I E A K N L A S Y D V C S I L L G T S T L L V W V G

401	V I R Y L T F F H N Y N I L I A T L R V A L P S V M R F C C C V A V I Y L G Y C
	F C G W I V L G P Y H V K F R S L S M V S E C L F S L I N G D D M F V T F A A M

481	Q A Q Q G R S S L V W L F S Q L Y L Y S F I S L F I Y M V L S L F I A L I T G A Y
	D T I K H P G G A G A E E S E L Q A Y I A Q C Q D S P T S G K F R R G S G S A

561	C S L L C C C G R D P S E E H S L L V N

5.195 annexin IV [Homo sapiens]
Protein Accession gi|4502105

Mean Expression Ratio 1.10

Median Expression Ratio 1.10

Credible Interval (0.674, 1.81)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0343


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.67	1.1	1.9	SEQ ID NO: 1220	NHLLHVFDEYK

SEQ ID NO: 1221

1	M A M A T K G G T V K A A S G F N A M E D A Q T L R K A M K G L G T D E D A I
	I S V L A Y R N T A Q R Q E I R T A Y K S T I G R D L I D D L K S E L S G N F E Q

81	V I V G M M T P T V L Y D V Q E L R R A M K G A G T D E G C L I E I L A S R T P
	E E I R R I S Q T Y Q Q Q Y G R S L E D D I R S D T S F M F Q R V L V S L S A G

161	G R D E G N Y L D D A L V R Q D A Q D L Y E A G E K K W G T D E V K F L T V
	L C S R N R N H L L H V F D E Y K R I S Q K D I E Q S I K S E T S G S F E D A L L A

241	I V K C M R N K S A Y F A E K L Y K S M K G L G T D D N T L I R V M V S R A E
	I D M L D I R A H F K R L Y G K S L Y S F I K G D T S G D Y R K V L L V L C G G D

321	D

5.196 PREDICTED: similar to kappa immunoglobulin (subgroup V kappa I) [Homo sapiens]
Protein Accession gi|169218204

Mean Expression Ratio 0.907

Median Expression Ratio 0.908

Credible Interval (0.615, 1.35)

Associated Peptides 2

Associated Spectra 3

Coverage NaN

Sequence

A 2.5 50 97.5 ID No. Sequence

1 0.57 0.89 1.4 SEQ ID NO: DIQLTQSPSFLSASVGDR

1222

2 0.6 0.9 1.3 SEQ ID NO: LLIYAASTLQSGVPSR

1223

5.197 diazepam binding inhibitor isoform 2 [Homo sapiens]; diazepam binding inhibitor isoform 3 [Homo sapiens]; diazepam binding inhibitor isoform 1 [Homo sapiens]
Protein Accession gi|120433593 gi|120433590 gi|10140853

Mean Expression Ratio 1.1

Median Expression Ratio 1.10

Credible Interval (0.677, 1.80)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

Sequence ID

A 2.5 50 97.5 No. Sequence

1 0.67 1.1 1.9 SEQ ID NO: QATVGDINTERPGMLDFTGK

1224

5.198 CD63 antigen isoform B [Homo sapiens]; CD63 antigen isoform A [Homo sapiens]
Protein Accession gi|91199546 gi|4502679

Mean Expression Ratio 1.10

Median Expression Ratio 1.10

Credible Interval (0.871, 1.40)

Associated Peptides 8

Associated Spectra 15

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.78	1.1	1.6	SEQ ID NO: 1225	DKVMSEFNNNFR

7	0.83	1.1	1.4	SEQ ID NO: 1226	VMSEFNNNFR

2	0.84	1.2	1.6	SEQ ID NO: 1227	QQMENYPK

1	0.8	1.1	1.6	SEQ ID NO: 1228	MQADFK

1	0.78	1.1	1.5	SEQ ID NO: 1229	GINFNEK

1	0.78	1.1	1.5	SEQ ID NO: 1230	EGCVEK

1	0.78	1.1	1.6	SEQ ID NO: 1231	IGGWLR

1	0.77	1.1	1.5	SEQ ID NO: 1232	AIHKEGCVEK

5.199 tubulin, alpha 4a [Homo sapiens]
Protein Accession gi|17921989

Mean Expression Ratio 1.10

Median Expression Ratio 1.1

Credible Interval (0.715, 1.69)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0335


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.71	1.1	1.7	SEQ ID NO: 1233	AVFVDLEPTVIDEIR

SEQ ID NO: 1234

1	M R E C I S V H V G Q A G V Q M G N A C W E L Y C L E H G I Q P D G Q M P S D
	K T I G G G D D S F T T F F C E T G A G K H V P R A V F V D L E P T V I D E I R N

81	G P Y R Q L F H P E Q L I T G K E D A A N N Y A R G H Y T I G K E I I D P V L D R
	I R K L S D Q C T G L Q G F L V F H S F G G G T G S G F T S L L M E R L S V D

161	Y G K K S K L E F S I Y P A P Q V S T A V V E P Y N S I L T T H T T L E H S D C
	A F M V D N E A I Y D I C R R N L D I E R P T Y T N L N R L I S Q I V S S I T A

241	S L R F D G A L N V D L T E F Q T N L V P Y P R I H F P L A T Y A P V I S A E K
	A Y H E Q L S V A E I T N A C F E P A N Q M V K C D P R H G K Y M A C C L L Y R

321	G D V V P K D V N A A I A A I K T K R S I Q F V D W C P T G F K V G I N Y Q P P
	T V V P G G D L A K V Q R A V C M L S N T T A I A E A W A R L D H K F D L M Y A

401	K R A F V H W Y V G E G M E E G E F S E A R E D M A A L E K D Y E E V G I D
	S Y E D E D E G E E

5.200 MARVEL domain containing 3 isoform 1 [Homo sapiens]
Protein Accession gi|65301122

Mean Expression Ratio 1.10

Median Expression Ratio 1.1

Credible Interval (0.737, 1.62)

Associated Peptides 2

Associated Spectra 3

Coverage 0.061


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.69	1.1	1.7	SEQ ID NO: 1235	EAPEPPQPQR

2	0.75	1.1	1.7	SEQ ID NO: 1236	GLTWDAAAPPGPAPWEAPEPPQPQR

SEQ ID NO: 1237

1	M E D P S G A R E P R A R P R E R D P G R R P H P D Q G R T H D R P R D R P G D
	P R R K R S S D G N R R R D G D R D P E R D Q E R D G N R D R N R D R E R E R E

81	R E R D P D R G P R R D T H R D A G P R A G E H G V W E K P R Q S R T R D G A
	R G L T W D A A A P P G P A P W E A P E P P Q P Q R K G D P G R R R P E S E P P S

161	E R Y L P S T P R P G R E E V E Y Y Q S E A E G L L E C H K C K Y L C T G R G
	V V Q I V E V V L N G M V L I C I V A S Y F V L A G F S A S F S S G G G F G N N Y

241	Y S P F E G T E L E Q V R Q L D Q Q Y T I L R S P L I Y G G V A V S L G L G V L
	T M G V L L Q G A K S R T M L S G K W L L T E A A F S L L A A V G Y C T G I G V

321	Y L H V A L Q I N S T D T C K T R E R L Y A R K G L T W M D C Q L A G T D G
	A A A T F A C L L V I M Y G A S V V L A L R S Y R E Q K R Y K G S R E Q P G S Y S D

401	A P E Y L W S G T L

5.201 sialin [Homo sapiens]
Protein Accession gi|6912666

Mean Expression Ratio 0.91

Median Expression Ratio 0.91

Credible Interval (0.65, 1.25)

Associated Peptides 4

Associated Spectra 5

Coverage 0.0848


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.64	0.94	1.4	SEQ ID NO: 1238	ACPEHSAPIK

1	0.6	0.91	1.4	SEQ ID NO: 1239	ALEGLGEGVTFPAMH

1	0.58	0.87	1.3	SEQ ID NO: 1240	EYILSSLR

1	0.6	0.9	1.4	SEQ ID NO: 1241	TPLLPGAPR

SEQ ID NO: 1242

1	M R S P V R D L A R N D G E E S T D R T P L L P G A P R A E A A P V C C S A R Y
	N L A I L A F F G F F I V Y A L R V N L S V A L V D M V D S N T T L E D N R T S

81	K A C P E H S A P I K V H H N Q T G K K Y Q W D A E T Q G W I L G S F F Y G Y I
	I T Q I P G G Y V A S K I G G K M L L G F G I L G T A V L T L F T P I A A D L G

161	V G P L I V L R A L E G L G E G V T F P A M H A M W S S W A P P L E R S K L L
	S I S Y A G A Q L G T V I S L P L S G I I C Y Y M N W T Y V F Y F F G T I G I F W

241	F L L W I W L V S D T P Q K H K R I S H Y E K E Y I L S S L R N Q L S S Q K S V
	P W V P I L K S L P L W A I V V A H F S Y N W T F Y T L L T L L P T Y M K E I L

321	R F N V Q E N G F L S S L P Y L G S W L C M I L S G Q A A D N L R A K W N F S
	T L C V R R I F S L I G M I G P A V F L V A A G F I G C D Y S L A V A F L T I S T

401	T L G G F C S S G F S I N H L D I A P S Y A G I L L G I T N T F A T I P G M V G P
	V I A K S L T P D N T V G E W Q T V F Y I A A A I N V F G A I F F T L F A K G

481	E V Q N W A L N D H H G H R H

5.202 solute carrier family 1 (neutral amino acid transporter), member 5 [Homo sapiens]
Protein Accession gi|5032093

Mean Expression Ratio 0.912

Median Expression Ratio 0.91

Credible Interval (0.561, 1.48)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0203


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.54	0.89	1.5	SEQ ID NO: 1243	EVLDSFLDLAR

SEQ ID NO: 1244

1	M V A D P P R D S K G L A A A E P T A N G G L A L A S I E D Q G A A A G G Y C G
	S R D Q V R R C L R A N L L V L L T V V A V V A G V A L G L G V S G A G G A L A

81	L G P E R L S A F V F P G E L L L R L L R M I I L P L V V C S L I G G A A S L D P
	G A L G R L G A W A L L F F L V T T L L A S A L G V G L A L A L Q P G A A S A

161	A I N A S V G A A G S A E N A P S K E V L D S F L D L A R N I F P S N L V S A A
	F R S Y S T T Y E E R N I T G T R V K V P V G Q E V E G M N I L G L V V F A I V

241	F G V A L R K L G P E G E L L I R F F N S F N E A T M V L V S W I M W Y A P V
	G I M F L V A G K I V E M E D V G L L F A R L G K Y I L C C L L G H A I H G L L V

321	L P L I Y F L F T R K N P Y R F L W G I V T P L A T A F G T S S S S A T L P L M
	M K C V E E N N G V A K H I S R F I L P I G A T V N M D G A A L F Q C V A A V F

401	I A Q L S Q Q S L D F V K I I T I L V T A T A S S V G A A G I P A G G V L T L A I I
	L E A V N L P V D H I S L I L A V D W L V D R S C T V L N V E G D A L G A G

481	L L Q N Y V D R T E S R S T E P E L I Q V K S E L P L D P L P V P T E E G N P L L
	K H Y R G P A G D A T V A S E K E S V M

5.203 claudin 2 [Homo sapiens]
Protein Accession gi|9966781

Mean Expression Ratio 1.10

Median Expression Ratio 1.10

Credible Interval (0.686, 1.79)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0652


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.68	1.1	1.9	SEQ ID NO: 1245	SNYYDAYQAQPLATR

SEQ ID NO: 1246

1	M A S L G L Q L V G Y I L G L L G L L G T L V A M L L P S W K T S S Y V G A S I
	V T A V G F S K G L W M E C A T H S T G I T Q C D I Y S T L L G L P A D I Q A A

81	Q A M M V T S S A I S S L A C I I S V V G M R C T V F C Q E S R A K D R V A V A
	G G V F F I L G G L L G F I P V A W N L H G I L R D F Y S P L V P D S M K F E I

161	G E A L Y L G I I S S L F S L I A G I I L C F S C S S Q R N R S N Y Y D A Y Q A Q
	P L A T R S S P R P G Q P P K V K S E F N S Y S L T G Y V

5.204 myoferlin isoform a [Homo sapiens]; myoferlin isoform b [Homo sapiens]
Protein Accession gi|7305053 gi|9718759

Mean Expression Ratio 1.10

Median Expression Ratio 1.10

Credible Interval (0.677, 1.78)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.66 1.1 1.9 SEQ ID NO: 1247 IYPLPDDPSVPAPPR

5.205 tubulin, alpha 1a [Homo sapiens]
Protein Accession gi|17986283

Mean Expression Ratio 1.10

Median Expression Ratio 1.10

Credible Interval (0.708, 1.68)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0532


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.7	1.1	1.8	SEQ ID NO: 1248	AVFVDLEPTVIDEVR

1	0.67	1.1	1.7	SEQ ID NO: 1249	EIIDLVLDR

SEQ ID NO: 1250

1	M R E C I S I H V G Q A G V Q I G N A C W E L Y C L E H G I Q P D G Q M P S D K
	T I G G G D D S F N T F F S E T G A G K H V P R A V F V D L E P T V I D E V R T

81	G T Y R Q L F H P E Q L I T G K E D A A N N Y A R G H Y T I G K E I I D L V L D
	R I R K L A D Q C T G L Q G F L V F H S F G G G T G S G F T S L L M E R L S V D

161	Y G K K S K L E F S I Y P A P Q V S T A V V E P Y N S I L T T H T T L E H S D C
	A F M V D N E A I Y D I C R R N L D I E R P T Y T N L N R L I G Q I V S S I T A

241	S L R F D G A L N V D L T E F Q T N L V P Y P R I H F P L A T Y A P V I S A E K
	A Y H E Q L S V A E I T N A C F E P A N Q M V K C D P R H G K Y M A C C L L Y R

321	G D V V P K D V N A A I A T I K T K R T I Q F V D W C P T G F K V G I N Y Q P P
	T V V P G G D L A K V Q R A V C M L S N T T A I A E A W A R L D H K F D L M Y A

401	K R A F V H W Y V G E G M E E G E F S E A R E D M A A L E K D Y E E V G V D
	S V E G E G E E E G E E Y

5.206 PDZ domain containing 1 [Homo sapiens]
Protein Accession gi|21361142

Mean Expression Ratio 0.913

Median Expression Ratio 0.915

Credible Interval (0.722, 1.15)

Associated Peptides 8

Associated Spectra 14

Coverage 0.212


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.66	0.9	1.2	SEQ ID NO: 1251	AGVLADDHLIEVNGENVEDASHEEVVEK

2	0.63	0.87	1.2	SEQ ID NO: 1252	EAPAPTPTSLEVSSPPDTTEEVDHKPK

5	0.66	0.87	1.2	SEQ ID NO: 1253	INGVFVDKEEHMQVVDLVR

1	0.66	0.93	1.3	SEQ ID NO: 1254	GVYMTDITPQGVAMR

1	0.66	0.93	1.3	SEQ ID NO: 1255	MTDITPQGVAMR

1	0.63	0.89	1.3	SEQ ID NO: 1256	VMFLLVDK

1	0.66	0.94	1.3	SEQ ID NO: 1257	VMFLLVDKETDKR

1	0.67	0.95	1.3	SEQ ID NO: 1258	AYDYFQAK

SEQ ID NO: 1259

1	M T S T F N P R E C K L S K Q E G Q N Y G F F L R I E K D T E G H L V R V V E K
	C S P A E K A G L Q D G D R V L R I N G V F V D K E E H M Q V V D L V R K S G N

81	S V T L L V L D G D S Y E K A V K T R V D L K E L G Q S Q K E Q G L S D N I L S
	P V M N G G V Q T W T Q P R L C Y L V K E G G S Y G F S L K T V Q G K K G V Y M

161	T D I T P Q G V A M R A G V L A D D H L I E V N G E N V E D A S H E E V V E K
	V K K S G S R V M F L L V D K E T D K R H V E Q K I Q F K R E T A S L K L L P H Q

241	P R I V E M K K G S N G Y G F Y L R A G S E Q K G Q I I K D I D S G S P A E E A
	G L K N N D L V V A V N G E S V E T L D H D S V V E M I R K G G D Q T S L L V V

321	D K E T D N M Y R L A H F S P F L Y Y Q S Q E L P N G S V K E A P A P T P T S L
	E V S S P P D T T E E V D H K P K L C R L A K G E N G Y G F H L N A I R G L P G

401	S F I K E V Q K G G P A D L A G L E D E D V I I E V N G V N V L D E P Y E K V V
	D R I Q S S G K N V T L L V C G K K A Y D Y F Q A K K I P I V S S L A D P L D T

481	P P D S K E G I V V E S N H D S H M A K E R A H S T A S H S S S N S E D T E M

5.207 deleted in malignant brain tumors 1 isoform c precursor [Homo sapiens]; deleted in malignant brain tumors 1 isoform b precursor [Homo sapiens]
Protein Accession gi|148539844 gi|148539842

Mean Expression Ratio 1.09

Median Expression Ratio 1.09

Credible Interval (0.668, 1.80)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.67 1.1 1.9 SEQ ID NO: 1260 FGQGSGPIVLDDVR

5.208 galactosylceramidase isoform a precursor [Homo sapiens]
Protein Accession gi|83281450

Mean Expression Ratio 0.915

Median Expression Ratio 0.916

Credible Interval (0.556, 1.50)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0234


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.53	0.9	1.5	SEQ ID NO: 1261	EFDGIGAVSGGGATSR

SEQ ID NO: 1262

1	M A E W L L S A S W Q R R A K A M T A A A G S A G R A A V P L L L C A L L A P
	G G A Y V L D D S D G L G R E F D G I G A V S G G G A T S R L L V N Y P E P Y R S

81	Q I L D Y L F K P N F G A S L H I L K V E I G G D G Q T T D G T E P S H M H Y A
	L D E N Y F R G Y E W W L M K E A K K R N P N I T L I G L P W S F P G W L G K G

161	F D W P Y V N L Q L T A Y Y V V T W I V G A K R Y H D L D I D Y I G I W N E R
	S Y N A N Y I K I L R K M L N Y Q G L Q R V K I I A S D N L W E S I S A S M L L D

241	A E L F K V V D V I G A H Y P G T H S A K D A K L T G K K L W S S E D F S T L
	N S D M G A G C W G R I L N Q N Y I N G Y M T S T I A W N L V A S Y Y E Q L P Y G

321	R C G L M T A Q E P W S G H Y V V E S P V W V S A H T T Q F T Q P G W Y Y L
	K T V G H L E K G G S Y V A L T D G L G N L T I I I E T M S H K H S K C I R P F L P

401	Y F N V S Q Q F A T F V L K G S F S E I P E L Q V W Y T K L G K T S E R F L F K
	Q L D S L W L L D S D G S F T L S L H E D E L F T L T T L T T G R K G S Y P L P

481	P K S Q P F P S T Y K D D F N V D Y P F F S E A P N F A D Q T G V F E Y F T N I
	E D P G E H H F T L R Q V L N Q R P I T W A A D A S N T I S I I G D Y N W T N L

561	T I K C D V Y I E T P D T G G V F I A G R V N K G G I L I R S A R G I F F W I F A
	N G S Y R V T G D L A G W I I Y A L G R V E V T A K K W Y T L T L T I K G H F

641	T S G M L N D K S L W T D I P V N F P K N G W A A I G T H S F E F A Q F D N F
	L V E A T R

5.209 target of myb1 isoform 1 [Homo sapiens]; target of myb1 isoform 2 [Homo sapiens]
Protein Accession gi|4885637 gi|209180457

Mean Expression Ratio 0.916

Median Expression Ratio 0.917

Credible Interval (0.615, 1.34)

Associated Peptides 2

Associated Spectra 3

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.58 0.89 1.3 SEQ ID NO: 1263 LPNLSSPSAEGPPGPPSG

PAPR

1 0.6 0.93 1.5 SEQ ID NO: 1264 SSPDLTGVVTIYEDLR

5.210 hypothetical protein LOC55194 [Homo sapiens]; PREDICTED: hypothetical protein [Homo sapiens]
Protein Accession gi|8922567 gi|169160626

Mean Expression Ratio 1.09

Median Expression Ratio 1.09

Credible Interval (0.666, 1.81)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.67 1.1 1.9 SEQ ID NO: 1265 TGQPDLLGTGTLGPSPTAT

GTLGR

5.211 cystin 1 [Homo sapiens]
Protein Accession gi|81158080

Mean Expression Ratio 1.09

Median Expression Ratio 1.09

Credible Interval (0.737, 1.62)

Associated Peptides 2

Associated Spectra 3

Coverage 0.241


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.71	1.1	1.7	SEQ ID NO: 1266	SPESLPAGPGAAALEGGTR

2	0.73	1.1	1.7	SEQ ID NO: 1267	VPVAAAEVPGAAAEEAPGR

SEQ ID NO: 1268

1	M G S G S S R S S R T L R R R R S P E S L P A G P G A A A L E G G T R R R V P V A
	A A E V P G A A A E E A P G R D P S P V A P P D G R D E T L R L L D E L L A E

81	S A A W G P P E P A P R R P A R L R P T A V A G S A V C A E Q S T E G H P G S G
	N V S E A P G S G R K K P E R P A A I S Y D H S E E G L M A S I E R E Y C R

5.212 CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens]; CD151 antigen [Homo sapiens]
Protein Accession gi|87159824 gi|87159822 gi|21237751 gi|21237748

Mean Expression Ratio 1.09

Median Expression Ratio 1.09

Credible Interval (0.733, 1.62)

Associated Peptides 1

Associated Spectra 3

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

3 0.76 1.1 1.6 SEQ ID NO: 1269 LETFIQEHLR

5.213 RAB2A, member RAS oncogene family [Homo sapiens]
Protein Accession gi|4506365

Mean Expression Ratio 0.921

Median Expression Ratio 0.921

Credible Interval (0.596, 1.43)

Associated Peptides 1

Associated Spectra 2

Coverage 0.066


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.58	0.9	1.4	SEQ ID NO: 1270	DTFNHLTTWLEDAR

SEQ ID NO: 1271

1	M A Y A Y L F K Y I I I G D T G V G K S C L L L Q F T D K R F Q P V H D L T I G V
	E F G A R M I T I D G K Q I K L Q I W D T A G Q E S F R S I T R S Y Y R G A A

81	G A L L V Y D I T R R D T F N H L T T W L E D A R Q H S N S N M V I M L I G N K
	S D L E S R R E V K K E E G E A F A R E H G L I F M E T S A K T A S N V E E A F

161	I N T A K E I Y E K I Q E G V F D I N N E A N G I K I G P Q H A A T N A T H A G
	N Q G G Q Q A G G G C C

5.214 CNDP dipeptidase 2 [Homo sapiens]
Protein Accession gi|8922699

Mean Expression Ratio 1.08

Median Expression Ratio 1.09

Credible Interval (0.811, 1.46)

Associated Peptides 5

Associated Spectra 8

Coverage 0.135


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.75	1.1	1.6	SEQ ID NO: 1272	GNILIPGINEAVAAVTEEEHK

3	0.77	1.1	1.5	SEQ ID NO: 1273	LPDGSEIPLPPILLGR

1	0.74	1.1	1.6	SEQ ID NO: 1274	LYDDIDFDIEEFAK

2	0.77	1.1	1.6	SEQ ID NO: 1275	QKLPDGSEIPLPPILLGR

1	0.76	1.1	1.6	SEQ ID NO: 1276	TVFGVEPDLTR

SEQ ID NO: 1277

1	M A A L T T L F K Y I D E N Q D R Y I K K L A K W V A I Q S V S A W P E K R G E
	I R R M M E V A A A D V K Q L G G S V E L V D I G K Q K L P D G S E I P L P P I

81	L L G R L G S D P Q K K T V C I Y G H L D V Q P A A L E D G W D S E P F T L V E
	R D G K L Y G G G S T D D K G P V A G W I N A L E A Y Q K T G Q E I P V N V R F

161	C L E G M E E S G S E G L D E L I F A R K D T F F K D V D Y V C I S D N Y W L
	G K K K P C I T Y G L R G I C Y F F I E V E C S N K D L H S G V Y G G S V H E A M

241	T D L I L L M G S L V D K R G N I L I P G I N E A V A A V T E E E H K L Y D D I
	D F D I E E F A K D V G A Q I L L H S H K K D I L M H R W R Y P S L S L H G I E

321	G A F S G S G A K T V I P R K V V G K F S I R L V P N M T P E V V G E Q V T S Y
	L T K K F A E L R S P N E F K V Y M G H G G K P W V S D F S H P H Y L A G R R A

401	M K T V F G V E P D L T R E G G S I P V T L T F Q E A T G K N V M L L P V G S
	A D D G A H S Q N E K L N R Y N Y I E G T K M L A A Y L Y E V S Q L K D

5.215 syntaxin binding protein 2 isoform b [Homo sapiens]; syntaxin binding protein 2 isoform a [Homo sapiens]
Protein Accession gi|188528901 gi|188528689

Mean Expression Ratio 1.09

Median Expression Ratio 1.09

Credible Interval (0.709, 1.67)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.7 1.1 1.8 SEQ ID NO: 1278 NLEQLGGTVTNPGGSGT

SSR

1 0.67 1.1 1.7 SEQ ID NO: 1279 VLLLYILLR

5.216 actinin, alpha 4 [Homo sapiens]
Protein Accession gi|12025678

Mean Expression Ratio 1.09

Median Expression Ratio 1.08

Credible Interval (0.672, 1.74)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0132


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.1	1.8	SEQ ID NO: 1280	VGWEQLLTTIAR

SEQ ID NO: 1281

1	M V D Y H A A N Q S Y Q Y G P S S A G N G A G G G G S M G D Y M A Q E D D W
	D R D L L L D P A W E K Q Q R K T F T A W C N S H L R K A G T Q I E N I D E D F R D

81	G L K L M L L L E V I S G E R L P K P E R G K M R V H K I N N V N K A L D F I A
	S K G V K L V S I G A E E I V D G N A K M T L G M I W T I I L R F A I Q D I S V

161	E E T S A K E G L L L W C Q R K T A P Y K N V N V Q N F H I S W K D G L A F N
	A L I H R H R P E L I E Y D K L R K D D P V T N L N N A F E V A E K Y L D I P K M

241	L D A E D I V N T A R P D E K A I M T Y V S S F Y H A F S G A Q K A E T A A N
	R I C K V L A V N Q E N E H L M E D Y E K L A S D L L E W I R R T I P W L E D R V

321	P Q K T I Q E M Q Q K L E D F R D Y R R V H K P P K V Q E K C Q L E I N F N T
	L Q T K L R L S N R P A F M P S E G K M V S D I N N G W Q H L E Q A E K G Y E E W

401	L L N E I R R L E R L D H L A E K F R Q K A S I H E A W T D G K E A M L K H R
	D Y E T A T L S D I K A L I R K H E A F E S D L A A H Q D R V E Q I A A I A Q E L

481	N E L D Y Y D S H N V N T R C Q K I C D Q W D A L G S L T H S R R E A L E K T
	E K Q L E A I D Q L H L E Y A K R A A P F N N W M E S A M E D L Q D M F I V H T I

561	E E I E G L I S A H D Q F K S T L P D A D R E R E A I L A I H K E A Q R I A E S N
	H I K L S G S N P Y T T V T P Q I I N S K W E K V Q Q L V P K R D H A L L E E

641	Q S K Q Q S N E H L R R Q F A S Q A N V V G P W I Q T K M E E I G R I S I E M N
	G T L E D Q L S H L K Q Y E R S I V D Y K P N L D L L E Q Q H Q L I Q E A L I F

721	D N K H T N Y T M E H I R V G W E Q L L T T I A R T I N E V E N Q I L T R D A K
	G I S Q E Q M Q E F R A S F N H F D K D H G G A L G P E E F K A C L I S L G Y D

801	V E N D R Q G E A E F N R I M S L V D P N H S G L V T F Q A F I D F M S R E T T
	D T D T A D Q V I A S F K V L A G D K N F I T A E E L R R E L P P D Q A E Y C I

881	A R M A P Y Q G P D A V P G A L D Y K S F S T A L Y G E S D L

5.217 matrix metalloproteinase 7 preproprotein [Homo sapiens]
Protein Accession gi|4505219

Mean Expression Ratio 0.919

Median Expression Ratio 0.923

Credible Interval (0.603, 1.41)

Associated Peptides 2

Associated Spectra 2

Coverage 0.120


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.9	1.4	SEQ ID NO: 1282	AFAPGTGLGGDAHFDEDER

1	0.57	0.91	1.5	SEQ ID NO: 1283	FFGLPITGMLNSR

SEQ ID NO: 1284

1	M R L T V L C A V C L L P G S L A L P L P Q E A G G M S E L Q W E Q A Q D Y L K
	R F Y L Y D S E T K N A N S L E A K L K E M Q K F F G L P I T G M L N S R V I E

81	I M Q K P R C G V P D V A E Y S L F P N S P K W T S K V V T Y R I V S Y T R D L
	P H I T V D R L V S K A L N M W G K E I P L H F R K V V W G T A D I M I G F A R

161	G A H G D S Y P F D G P G N T L A H A F A P G T G L G G D A H F D E D E R W
	T D G S S L G I N F L Y A A T H E L G H S L G M G H S S D P N A V M Y P T Y G N G D

241	P Q N F K L S Q D D I K G I Q K L Y G K R S N S R K K

5.218 keratin 1 [Homo sapiens]
Protein Accession gi|119395750

Mean Expression Ratio 0.923

Median Expression Ratio 0.923

Credible Interval (0.668, 1.28)

Associated Peptides 3

Associated Spectra 6

Coverage 0.0637


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.6	0.9	1.3	SEQ ID NO: 1285	QISNLQQSISDAEQR

4	0.68	0.94	1.3	SEQ ID NO: 1286	THNLEPYFESFINNLR

1	0.62	0.91	1.4	SEQ ID NO: 1287	NKYEDEINKR

SEQ ID NO: 1288

1	M S R Q F S S R S G Y R S G G G F S S G S A G I I N Y Q R R T T S S S T R R S G G
	G G G R F S S C G G G G G S F G A G G G F G S R S L V N L G G S K S I S I S V

81	A R G G G R G S G F G G G Y G G G G F G G G G F G G G G F G G G G I G G G G F
	G G F G S G G G G F G G G G F G G G G Y G G G Y G P V C P P G G I Q E V T I N Q S

161	L L Q P L N V E I D P E I Q K V K S R E R E Q I K S L N N Q F A S F I D K V R F L
	E Q Q N Q V L Q T K W E L L Q Q V D T S T R T H N L E P Y F E S F I N N L R R

241	R V D Q L K S D Q S R L D S E L K N M Q D M V E D Y R N K Y E D E I N K R T
	N A E N E F V T I K K D V D G A Y M T K V D L Q A K L D N L Q Q E I D F L T A L Y Q

321	A E L S Q M Q T Q I S E T N V I L S M D N N R S L D L D S I I A E V K A Q Y E D
	I A Q K S K A E A E S L Y Q S K Y E E L Q I T A G R H G D S V R N S K I E I S E

401	L N R V I Q R L R S E I D N V K K Q I S N L Q Q S I S D A E Q R G E N A L K D A
	K N K L N D L E D A L Q Q A K E D L A R L L R D Y Q E L M N T K L A L D L E I A

481	T Y R T L L E G E E S R M S G E C A P N V S V S V S T S H T T I S G G G S R G G
	G G G G Y G S G G S S Y G S G G G S Y G S G G G G G G G R G S Y G S G G S S Y G

561	S G G G S Y G S G G G G G G H G S Y G S G S S S G G Y R G G S G G G G G G S S
	G G R G S G G G S S G G S I G G R G S S S G G V K S S G G S S S V K F V S T T Y S

641	G V T R

5.219 lactotransferrin precursor [Homo sapiens]
Protein Accession gi|54607120

Mean Expression Ratio 0.925

Median Expression Ratio 0.924

Credible Interval (0.744, 1.15)

Associated Peptides 12

Associated Spectra 16

Coverage 0.217


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.66	0.9	1.2	SEQ ID NO: 1289	CSTSPLLEACEFLR

2	0.69	0.94	1.3	SEQ ID NO: 1290	DEYELLCPDNTR

1	0.67	0.94	1.3	SEQ ID NO: 1291	DSPIQCIQAIAENR

1	0.65	0.92	1.3	SEQ ID NO: 1292	DVTVLQNTDGNNNEAWAK

1	0.68	0.95	1.3	SEQ ID NO: 1293	ESTVFEDLSDEAER

2	0.63	0.85	1.2	SEQ ID NO: 1294	ESTVFEDLSDEAERDEYELLCPDNTR

1	0.66	0.93	1.3	SEQ ID NO: 1295	FDEYFSQSCAPGSDPR

1	0.68	0.95	1.3	SEQ ID NO: 1296	FQLFGSPSGQK

1	0.66	0.93	1.3	SEQ ID NO: 1297	GGSFQLNELQGLK

1	0.65	0.91	1.3	SEQ ID NO: 1298	IDSGLYLGSGYFTAIQNLR

2	0.69	0.94	1.3	SEQ ID NO: 1299	QVLLHQQAK

1	0.67	0.93	1.3	SEQ ID NO: 1300	YLGPQYVAGITNLK

SEQ ID NO: 1301

1	M K L V F L V L L F L G A L G L C L A G R R R S V Q W C A V S Q P E A T K C F Q
	W Q R N M R K V R G P P V S C I K R D S P I Q C I Q A I A E N R A D A V T L D G

81	G F I Y E A G L A P Y K L R P V A A E V Y G T E R Q P R T H Y Y A V A V V K K
	G G S F Q L N E L Q G L K S C H T G L R R T A G W N V P I G T L R P F L N W T G P

161	P E P I E A A V A R F F S A S C V P G A D K G Q F P N L C R L C A G T G E N K C
	A F S S Q E P Y F S Y S G A F K C L R D G A G D V A F I R E S T V F E D L S D E

241	A E R D E Y E L L C P D N T R K P V D K F K D C H L A R V P S H A V V A R S V
	N G K E D A I W N L L R Q A Q E K F G K D K S P K F Q L F G S P S G Q K D L L F K

321	D S A I G F S R V P P R I D S G L Y L G S G Y F T A I Q N L R K S E E E V A A R
	R A R V V W C A V G E Q E L R K C N Q W S G L S E G S V T C S S A S T T E D C I

401	A L V L K G E A D A M S L D G G Y V Y T A G K C G L V P V L A E N Y K S Q Q
	S S D P D P N C V D R P V E G Y L A V A V V R R S D T S L T W N S V K G K K S C H T

481	A V D R T A G W N I P M G L L F N Q T G S C K F D E Y F S Q S C A P G S D P R
	S N L C A L C I G D E Q G E N K C V P N S N E R Y Y G Y T G A F R C L A E N A G D

561	V A F V K D V T V L Q N T D G N N N E A W A K D L K L A D F A L L C L D G K
	R K P V T E A R S C H L A M A P N H A V V S R M D K V E R L K Q V L L H Q Q A K
	F G

641	R N G S D C P D K F C L F Q S E T K N L L F N D N T E C L A R L H G K T T Y E
	K Y L G P Q Y V A G I T N L K K C S T S P L L E A C E F L R K

5.220 tumor differentially expressed protein 1 [Homo sapiens]; tumor differentially expressed protein 1 [Homo sapiens]
Protein Accession gi|5803193 gi|39812106

Mean Expression Ratio 0.926

Median Expression Ratio 0.926

Credible Interval (0.567, 1.51)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.54 0.9 1.5 SEQ ID NO: 1302 LTLSGSDSVILGDTTTSG

ASDEEDGQPR

5.221 phosphodiesterase 8A isoform 2 [Homo sapiens]; phosphodiesterase 8A isoform 1 [Homo sapiens]
Protein Accession gi|47132537 gi|27734721

Mean Expression Ratio 1.08

Median Expression Ratio 1.08

Credible Interval (0.667, 1.74)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.66 1.1 1.8 SEQ ID NO: 1303 LVAEDAPSPAAPPLSSGG

PR

5.222 SH3 domain and tetratricopeptide repeats 1 [Homo sapiens]
Protein Accession gi|1145386551

Mean Expression Ratio 0.928

Median Expression Ratio 0.927

Credible Interval (0.572, 1.50)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0112


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.54	0.9	1.5	SEQ ID NO: 1304	QALASLTPGTGQALR

SEQ ID NO: 1305

1	M E N L P A V T T E E P T P M G R G P V G P S G G G S T R D Q V R T V V M R P S
	V S W E K A G P E E A K A P V R G D E A P P A R V A G P A A G T P P C Q M G V Y

81	P T D L T L Q L L A V R R K S R L R D P G L Q Q T L R G Q L R L L E N D S R E M
	A R V L G E L S A R L L S I H S D Q D R I V V T F K T F E E I W K F S T Y H A L

161	G F T H H C L A N L L M D Q A F W L L L P S E E E E T A I Q V H V D E N A L R
	L T H E S L L I Q E G P F F V L C P D H H V R V M T G P R D A G N G P Q A L R Q A

241	S G A P Q G E A A P E T D S S P P S P S V S S E E V A V A A A P E P L I P F H Q
	W A L R I P Q D P I D D A M G G P V M P G N P L M A V G L A S A L A D F Q G S G

321	P E E M T F R G G D L I E I L G A Q V P S L P W C V G R H A A S G R V G F V R S
	S L I S M Q G P V S E L E S A I F L N E E E K S F F S E G C F S E E D A R Q L L

401	R R M S G T D V C S V Y S L D S V E E A E T E Q P Q E K E I P P P C L S P E P Q
	E T L Q K V K N V L E Q C K T C P G C P Q E P A S W G L C A A S S D V S L Q D P

481	E E P S F C L E A E D D W E D P E A L S S L L L F L N A P G Y K A S F R G L Y D
	V A L P W L S S V F R S F S D E E E L T G R L A Q A R G A A K K A G L L M A L A

561	R L C F L L G R L C S R R L K L S Q A R V Y F E E A L G A L E G S F G D L F L V
	V A V Y A N L A S I Y R K Q K N R E K C A Q V V P K A M A L L L G T P D H I C S

641	T E A E G E L L Q L A L R R A V G G Q S L Q A E A R A C F L L A R H H V H L K
	Q P E E A L P F L E R L L L L H R D S G A P E A A W L S D C Y L L L A D I Y S R K

721	C L P H L V L S C V K V A S L R T R G S L A G S L R S V N L V L Q N A P Q P H S
	L P A Q T S H Y L R Q A L A S L T P G T G Q A L R G P L Y T S L A Q L Y S H H G

801	C H G P A I T F M T Q A V E A S A I A G V R A I V D H L V A L A W L H V L H G
	Q S P V A L D I L Q S V R D A V V A S E D Q E G V I A N M V A V A L K R T G R T R

881	Q A A E S Y Y R A L R V A R D L G Q Q R N Q A V G L A N F G A L C L H A G A
	S R L A Q H Y L L E A V R L F S R L P L G E C G R D F T H V L L Q L G H L C T R Q G

961	P A Q Q G K G Y Y E W A L L V A V E M G H V E S Q L R A V Q R L C H F Y S A
	V M P S E A Q C V I Y H E L Q L S L A C K V A D K V L E G Q L L E T I S Q L Y L S L

1041	G T E R A Y K S A L D Y T K R S L G I F I D L Q K K E K E A H A W L Q A G K I
	Y Y I L R Q S E L V D L Y I Q V A Q N V A L Y T G D P N L G L E L F E A A G D I F

1121	F D G A W E R E K A V S F Y R D R A L P L A V T T G N R K A E L R L C N K L
	V A L L A T L E E P Q E G L E F A H M A L A L S I T L G D R L N E R V A Y H R L A A

1201	L Q H R L G H G E L A E H F Y L K A L S L C N S P L E F D E E T L Y Y V K V Y
	L V L G D I I F Y D L K D P F D A A G Y Y Q L A L A A A V D L G N K K A Q L K I Y

1281	T R L A T I Y H N F L L D R E K S L F F Y Q K A R T F A T E L N V R R V N L P
	P L P L C G W A P W L A P S H P R

5.223 aminoacylase 1 [Homo sapiens]
Protein Accession gi|4501901

Mean Expression Ratio 0.926

Median Expression Ratio 0.927

Credible Interval (0.649, 1.32)

Associated Peptides 3

Associated Spectra 4

Coverage 0.125


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.59	0.91	1.4	SEQ ID NO: 1306	DMNLTLEPEIMPAATDNR

1	0.61	0.92	1.4	SEQ ID NO: 1307	GPEEEHPSVTLFR

2	0.63	0.93	1.4	SEQ ID NO: 1308	TVQPKPDYGAAVAFFEETAR

SEQ ID NO: 1309

1	M T S K G P E E E H P S V T L F R Q Y L R I R T V Q P K P D Y G A A V A F F E E T
	A R Q L G L G C Q K V E V A P G Y V V T V L T W P G T N P T L S S I L L N S H

81	T D V V P V F K E H W S H D P F E A F K D S E G Y I Y A R G A Q D M K C V S I Q
	Y L E A V R R L K V E G H R F P R T I H M T F V P D E E V G G H Q G M E L F V Q

161	R P E F H A L R A G F A L D E G I A N P T D A F T V F Y S E R S P W W V R V T
	S T G R P G H A S R F M E D T A A E K L H K V V N S I L A F R E K E W Q R L Q S N

241	P H L K E G S V T S V N L T K L E G G V A Y N V I P A T M S A S F D F R V A P
	D V D F K A F E E Q L Q S W C Q A A G E G V T L E F A Q K W M H P Q V T P T D D S

321	N P W W A A F S R V C K D M N L T L E P E I M P A A T D N R Y I R A V G V P A
	L G F S P M N R T P V L L H D H D E R L H E A V F L R G V D I Y T R L L P A L A S

401	V P A L P S D S

5.224 cathepsin A isoform a precursor [Homo sapiens]
Protein Accession gi|119395729

Mean Expression Ratio 0.928

Median Expression Ratio 0.928

Credible Interval (0.708, 1.21)

Associated Peptides 9

Associated Spectra 9

Coverage 0.207


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.66	0.94	1.3	SEQ ID NO: 1310	CNFYDNK

1	0.65	0.94	1.3	SEQ ID NO: 1311	DLECVTNLQEVAR

1	0.67	0.96	1.4	SEQ ID NO: 1312	HLHYWFVESQK

1	0.64	0.91	1.3	SEQ ID NO: 1313	NFLVNLQYR

1	0.66	0.93	1.3	SEQ ID NO: 1314	QYSGYLK

1	0.65	0.94	1.3	SEQ ID NO: 1315	YGDSGEQIAGFVK

1	0.61	0.88	1.3	SEQ ID NO: 1316	YATNDTEVAQSNFEALQDFFR

1	0.64	0.91	1.3	SEQ ID NO: 1317	ALNIPEQLPQWDMCNFLVNLQYR

1	0.63	0.9	1.3	SEQ ID NO: 1318	EFSHIAFL

SEQ ID NO: 1319

1	M T S S P R A P P G E Q G R G G A E M I R A A P P P L F L L L L L L L L L V S W A
	S R G E A A P D Q D E I Q R L P G L A K Q P S F R Q Y S G Y L K G S G S K H L

81	H Y W F V E S Q K D P E N S P V V L W L N G G P G C S S L D G L L T E H G P F L
	V Q P D G V T L E Y N P Y S W N L I A N V L Y L E S P A G V G F S Y S D D K F Y

161	A T N D T E V A Q S N F E A L Q D F F R L F P E Y K N N K L F L T G E S Y A G I
	Y I P T L A V L V M Q D P S M N L Q G L A V G N G L S S Y E Q N D N S L V Y F A

241	Y Y H G L L G N R L W S S L Q T H C C S Q N K C N F Y D N K D L E C V T N L
	Q E V A R I V G N S G L N I Y N L Y A P C A G G V P S H F R Y E K D T V V V Q D L G

321	N I F T R L P L K R M W H Q A L L R S G D K V R M D P P C T N T T A A S T Y L
	N N P Y V R K A L N I P E Q L P Q W D M C N F L V N L Q Y R R L Y R S M N S Q Y L

401	K L L S S Q K Y Q I L L Y N G D V D M A C N F M G D E W F V D S L N Q K M E
	V Q R R P W L V K Y G D S G E Q I A G F V K E F S H I A F L T I K G A G H M V P T D

481	K P L A A F T M F S R F L N K Q P Y

5.225 pleckstrin homology domain containing, family B (evectins) member 2 isoform 3 [Homo sapiens]; pleckstrin homology domain containing, family B (evectins) member 2 isoform 2 [Homo sapiens]
Protein Accession gi 154800478 gi|54800476

Mean Expression Ratio 0.93

Median Expression Ratio 0.929

Credible Interval (0.652, 1.32)

Associated Peptides 4

Associated Spectra 4

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	0.93	1.4	SEQ ID NO: 1320	AGLYGQQPANQVIIR

1	0.61	0.93	1.4	SEQ ID NO: 1321	GQQPANQVIIR

1	0.6	0.91	1.4	SEQ ID NO: 1322	NWFDLWSDGHLIYYD
					DQTR


1	0.61	0.93	1.4	SEQ ID NO: 1323	VHMPMDCINIR

5.226 BH3 interacting domain death agonist isoform 2 [Homo sapiens]; BH3 interacting domain death agonist isoform 3 [Homo sapiens]; BH3 interacting domain death agonist isoform 1 [Homo sapiens]
Protein Accession gi|4557361 gi|37574728 gi|37574726

Mean Expression Ratio 0.929

Median Expression Ratio 0.93

Credible Interval (0.572, 1.52)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.54 0.9 1.5 SEQ ID NO: 1324 DLATALEQLLQAYPR

5.227 enolase 1 [Homo sapiens]
Protein Accession gi|4503571

Mean Expression Ratio 1.08

Median Expression Ratio 1.08

Credible Interval (0.799, 1.44)

Associated Peptides 5

Associated Spectra 7

Coverage 0.184


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.75	1.1	1.5	SEQ ID NO: 1325	AAVPSGASTGIYEALELR

2	0.75	1.1	1.5	SEQ ID NO: 1326	HIADLAGNSEVILPVPAFNVINGGSHAGNK

1	0.76	1.1	1.6	SEQ ID NO: 1327	YISPDQLADLYK

1	0.73	1.1	1.5	SEQ ID NO: 1328	VVIGMDVAASEFFR

1	0.74	1.1	1.6	SEQ ID NO: 1329	YDLDFK

SEQ ID NO: 1330

1	M S I L K I H A R E I F D S R G N P T V E V D L F T S K G L F R A A V P S G A S T G
	I Y E A L E L R D N D K T R Y M G K G V S K A V E H I N K T I A P A L V S K

81	K L N V T E Q E K I D K L M I E M D G T E N K S K F G A N A I L G V S L A V C K
	A G A V E K G V P L Y R H I A D L A G N S E V I L P V P A F N V I N G G S H A G

161	N K L A M Q E F M I L P V G A A N F R E A M R I G A E V Y H N L K N V I K E K
	Y G K D A T N V G D E G G F A P N I L E N K E G L E L L K T A I G K A G Y T D K V

241	V I G M D V A A S E F F R S G K Y D L D F K S P D D P S R Y I S P D Q L A D L Y
	K S F I K D Y P V V S I E D P F D Q D D W G A W Q K F T A S A G I Q V V G D D L

321	T V T N P K R I A K A V N E K S C N C L L L K V N Q I G S V T E S L Q A C K L A
	Q A N G W G V M V S H R S G E T E D T F I A D L V V G L C T G Q I K T G A P C R

401	S E R L A K Y N Q L L R I E E E L G S K A K F A G R N F R N P L A K

5.228 hypothetical protein LOC64855 isoform 2 [Homo sapiens]; hypothetical protein LOC64855 isoform 1 [Homo sapiens]
Protein Accession gi|79750824 gi|51093863

Mean Expression Ratio 1.08

Median Expression Ratio 1.08

Credible Interval (0.708, 1.64)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.68 1.1 1.7 SEQ ID NO: 1331 FQELIFEDFAR

1 0.68 1.1 1.7 SEQ ID NO: 1332 EASPESPPPASPDGVTE

IR

5.229 ribophorin II isoform 2 precursor [Homo sapiens]
Protein Accession gi|209413738

Mean Expression Ratio 0.93

Median Expression Ratio 0.93

Credible Interval (0.573, 1.5)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.56 0.91 1.5 SEQ ID NO: 1333 SIVEEIEDLVAR

5.230 urate anion exchanger 1 isoform a [Homo sapiens]
Protein Accession gi|24497485

Mean Expression Ratio 0.93

Median Expression Ratio 0.932

Credible Interval (0.608, 1.41)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0561


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.92	1.5	SEQ ID NO: 1334	AFSELLDLVGGLGR

1	0.59	0.93	1.5	SEQ ID NO: 1335	GAVQDTLTPEVLLSAMR

SEQ ID NO: 1336

1	M A F S E L L D L V G G L G R F Q V L Q T M A L M V S I M W L C T Q S M L E N F
	S A A V P S H R C W A P L L D N S T A Q A S I L G S L S P E A L L A I S I P P G

81	P N Q R P H Q C R R F R Q P Q W Q L L D P N A T A T S W S E A D T E P C V D G
	W V Y D R S I F T S T I V A K W N L V C D S H A L K P M A Q S I Y L A G I L V G A

161	A A C G P A S D R F G R R L V L T W S Y L Q M A V M G T A A A F A P A F P V
	Y C L F R F L L A F A V A G V M M N T G T L L M E W T A A R A R P L V M T L N S
	L G

241	F S F G H G L T A A V A Y G V R D W T L L Q L V V S V P F F L C F L Y S W W L
	A E S A R W L L T T G R L D W G L Q E L W R V A A I N G K G A V Q D T L T P E V L

321	L S A M R E E L S M G Q P P A S L G T L L R M P G L R F R T C I S T L C W F A F
	G F T F F G L A L D L Q A L G S N I F L L Q M F I G V V D I P A K M G A L L L L

401	S H L G R R P T L A A S L L L A G L C I L A N T L V P H E M G A L R S A L A V L
	G L G G V G A A F T C I T I Y S S E L F P T V L R M T A V G L G Q M A A R G G A

481	I L G P L V R L L G V H G P W L P L L V Y G T V P V L S G L A A L L L P E T Q S
	L P L P D T I Q D V Q N Q A V K K A T H G T L G N S V L K S T Q F

5.231 chromatin modifying protein 4C [Homo sapiens]
Protein Accession gi|22748643

Mean Expression Ratio 1.07

Median Expression Ratio 1.07

Credible Interval (0.65, 1.75)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0687


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.66	1.1	1.8	SEQ ID NO: 1337	QLTQIDGTLSTIEFQR

SEQ ID NO: 1338

1	M S K L G K F F K G G G S S K S R A A P S P Q E A L V R L R E T E E M L G K K Q
	E Y L E N R I Q R E I A L A K K H G T Q N K R A A L Q A L K R K K R F E K Q L T

81	Q I D G T L S T I E F Q R E A L E N S H T N T E V L R N M G F A A K A M K S V H
	E N M D L N K I D D L M Q E I T E Q Q D I A Q E I S E A F S Q R V G F G D D F D

161	E D E L M A E L E E L E Q E E L N K K M T N I R L P N V P S S S L P A Q P N R K
	P G M S S T A R R S R A A S S Q R A E E E D D D I K Q L A A W A T

5.232 sacsin [Homo sapiens]
Protein Accession gi|163659918

Mean Expression Ratio 0.932

Median Expression Ratio 0.932

Credible Interval (0.577, 1.52)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.55 0.91 1.5 SEQ ID NO: 1339 NHPSVSWLK

5.233 lumican precursor [Homo sapiens]
Protein Accession gi|4505047

Mean Expression Ratio 0.936

Median Expression Ratio 0.932

Credible Interval (0.577, 1.53)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0444


SEQ ID NO: 1340

SEQ ID NO: 1341

1	M S L S A F T L F L A L I G G T S G Q Y Y D Y D F P L S I Y G Q S S P N C A P E C
	N C P E S Y P S A M Y C D E L K L K S V P M V P P G I K Y L Y L R N N Q I D H
81	I D E K A F E N V T D L Q W L I L D H N L L E N S K I K G R V F S K L K Q L K K
	L H I N H N N L T E S V G P L P K S L E D L Q L T H N K I T K L G S F E G L V N

161	L T F I H L Q H N R L K E D A V S A A F K G L K S L E Y L D L S F N Q I A R L P
	S G L P V S L L T L Y L D N N K I S N I P D E Y F K R F N A L Q Y L R L S H N E

241	L A D S G I P G N S F N V S S L V E L D L S Y N K L K N I P T V N E N L E N Y Y
	L E V N Q L E K F D I K S F C K I L G P L S Y S K I K H L R L D G N R I S E T S

321	L P P D M Y E C L R V A N E V T L N

5.234 chromatin modifying protein 1B [Homo sapiens]
Protein Accession gi|31542306

Mean Expression Ratio 1.07

Median Expression Ratio 1.07

Credible Interval (0.662, 1.73)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0302


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.1	1.8	SEQ ID NO: 1342	HLFNLK

SEQ ID NO: 1343

1	M S N M E K H L F N L K F A A K E L S R S A K K C D K E E K A E K A K I K K A I
	Q K G N M E V A R I H A E N A I R Q K N Q A V N F L R M S A R V D A V A A R V Q

81	T A V T M G K V T K S M A G V V K S M D A T L K T M N L E K I S A L M D K F E
	H Q F E T L D V Q T Q Q M E D T M S S T T T L T T P Q N Q V D M L L Q E M A D E A

161	G L D L N M E L P Q G Q T G S V G T S V A S A E Q D E L S Q R L A R L R D Q V

5.235 SHC (Src homology 2 domain containing) transforming protein 1 isoform 2 [Homo sapiens]; SHC (Src homology 2 domain containing) transforming protein 1 isoform 3 [Homo sapiens]
Protein Accession gi|32261324 gi|194239664

Mean Expression Ratio 0.933

Median Expression Ratio 0.936

Credible Interval (0.571, 1.50)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.55 0.92 1.5 SEQ ID NO: 1344 QAVGGAGPPNPAINGSA

PR

5.236 hypothetical protein LOC28970 [Homo sapiens]
Protein Accession gi|21361495

Mean Expression Ratio 1.07

Median Expression Ratio 1.07

Credible Interval (0.755, 1.53)

Associated Peptides 3

Associated Spectra 4

Coverage 0.109


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.7	1.0	1.5	SEQ ID NO: 1345	APLVCLPVFVSR

1	0.73	1.1	1.7	SEQ ID NO: 1346	FLPAEFLYR

1	0.71	1.1	1.6	SEQ ID NO: 1347	WLHFYEMK

SEQ ID NO: 1348

1	M A C A E F S F H V P S L E E L A G V M Q K G L K D N F A D V Q V S V V D C P D
	L T K E P F T F P V K G I C G K T R I A E V G G V P Y L L P L V N Q K K V Y D L

81	N K I A K E I K L P G A F I L G A G A G P F Q T L G F N S E F M P V I Q T E S E H
	K P P V N G S Y F A H V N P A D G G C L L E K Y S E K C H D F Q C A L L A N L

161	F A S E G Q P G K P A E F S S C P L N S D E E V N K W L H F Y E M K A P L V C
	L P V F V S R D P G F D L R L E H T H F F S R H G E G G H Y H Y D T T P D I V E Y

241	L G Y F L P A E F L Y R I D Q P K E T H S I G R D

5.237 ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit a4 [Homo sapiens]
Protein Accession gi|85386547 gi|85386056 gi|85386053

Mean Expression Ratio 1.07

Median Expression Ratio 1.07

Credible Interval (0.659, 1.76)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.65 1.1 1.8 SEQ ID NO: 1349 LEDLITVITQTESHR

5.238 chloride channel 7 isoform b [Homo sapiens]; chloride channel 7 isoform a [Homo sapiens]
Protein Accession gi|167466160 gi|14149607

Mean Expression Ratio 0.934

Median Expression Ratio 0.937

Credible Interval (0.616, 1.43)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.59 0.93 1.5 SEQ ID NO: 1350 IFEYFR

1 0.58 0.92 1.4 SEQ ID NO: 1351 YESLDYDNSENQLFLEE

ER

5.239 solute carrier family 34 (sodium phosphate), member 2 [Homo sapiens]
Protein Accession gi|110611906

Mean Expression Ratio 1.07

Median Expression Ratio 1.07

Credible Interval (0.785, 1.44)

Associated Peptides 5

Associated Spectra 7

Coverage 0.058


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.72	1.1	1.5	SEQ ID NO: 1352	APETFDNITISR

3	0.86	1.2	1.7	SEQ ID NO: 1353	KLQNWNFLPLWMR

1	0.71	1.0	1.5	SEQ ID NO: 1354	YLEGAAGQQPTAPDK

1	0.72	1.1	1.5	SEQ ID NO: 1355	LQNWNFLPLWMR

1	0.7	1	1.5	SEQ ID NO: 1356	NFLPLWMR

SEQ ID NO: 1357

1	M A P W P E L G D A Q P N P D K Y L E G A A G Q Q P T A P D K S K E T N K T D
	N T E A P V T K I E L L P S Y S T A T L I D E P T E V D D P W N L P T L Q D S G I

81	K W S E R D T K G K I L C F F Q G I G R L I L L L G F L Y F F V C S L D I L S S A F
	Q L V G G K M A G Q F F S N S S I M S N P L L G L V I G V L V T V L V Q S S

161	S T S T S I V V S M V S S S L L T V R A A I P I I M G A N I G T S I T N T I V A L M
	Q V G D R S E F R R A F A G A T V H D F F N W L S V L V L L P V E V A T H Y

241	L E I I T Q L I V E S F H F K N G E D A P D L L K V I T K P F T K L I V Q L D K K
	V I S Q I A M N D E K A K N K S L V K I W C K T F T N K T Q I N V T V P S T A

321	N C T S P S L C W T D G I Q N W T M K N V T Y K E N I A K C Q H I F V N F H L
	P D L A V G T I L L I L S L L V L C G C L I M I V K I L G S V L K G Q V A T V I K

401	K T I N T D F P F P F A W L T G Y L A I L V G A G M T F I V Q S S S V F T S A L
	T P L I G I G V I T I E R A Y P L T L G S N I G T T T T A I L A A L A S P G N A

481	L R S S L Q I A L C H F F F N I S G I L L W Y P I P F T R L P I R M A K G L G N I S
	A K Y R W F A V F Y L I I F F F L I P L T V F G L S L A G W R V L V G V G V

561	P V V F I I I L V L C L R L L Q S R C P R V L P K K L Q N W N F L P L W M R S L
	K P W D A V V S K F T G C F Q M R C C C C C R V C C R A C C L L C G C P K C C R

641	C S K C C E D L E E A Q E G Q D V P V K A P E T F D N I T I S R E A Q G E V P A
	S D S K T E C T A L

5.240 UBX domain protein 6 [Homo sapiens]
Protein Accession gi|13376854

Mean Expression Ratio 1.07

Median Expression Ratio 1.07

Credible Interval (0.666, 1.74)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0544


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.66	1.1	1.8	SEQ ID NO: 1358	ELQAEATVSGSPEAPGTNVVSEPR

SEQ ID NO: 1359

1	M K K F F Q E F K A D I K F K S A G P G Q K L K E S V G E K A H K E K P N Q P A
	P R P P R Q G P T N E A Q M A A A A A L A R L E Q K Q S R A W G P T S Q D T I R

81	N Q V R K E L Q A E A T V S G S P E A P G T N V V S E P R E E G S A H L A V P G
	V Y F T C P L T G A T L R K D Q R D A C I K E A I L L H F S T D P V A A S I M K

161	I Y T F N K D Q D R V K L G V D T I A K Y L D N I H L H P E E E K Y R K I K L Q
	N K V F Q E R I N C L E G T H E F F E A I G F Q K V L L P A Q D Q E D P E E F Y

241	V L S E T T L A Q P Q S L E R H K E Q L L A A E P V R A K L D R Q R R V F Q P S
	P L A S Q F E L P G D F F N L T A E E I K R E Q R L R S E A V E R L S V L R T K

321	A M R E K E E Q R G L R K Y N Y T L L R V R L P D G C L L Q G T F Y A R E R L
	G A V Y G F V R E A L Q S D W L P F E L L A S G G Q K L S E D E N L A L N E C G L

401	V P S A L L T F S W D M A V L E D I K A A G A E P D S I L K P E L L S A I E K L L

5.241 tetratricopeptide repeat domain 38 [Homo sapiens]

Protein Accession gi 116812608

Mean Expression Ratio 0.935

Median Expression Ratio 0.938

Credible Interval (0.577, 1.50)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0192


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.55	0.92	1.5	SEQ ID NO: 1360	VLELLLPIR

SEQ ID NO: 1361

1	M A A A S P L R D C Q A W K D A R L P L S T T S N E A C K L F D A T L T Q Y V K
	W T N D K S L G G I E G C L S K L K A A D P T F V M G H A M A T G L V L I G T G

81	S S V K L D K E L D L A V K T M V E I S R T Q P L T R R E Q L H V S A V E T F A
	N G N F P K A C E L W E Q I L Q D H P T D M L A L K F S H D A Y F Y L G Y Q E Q

161	M R D S V A R I Y P F W T P D I P L S S Y V K G I Y S F G L M E T N F Y D Q A E
	K L A K E A L S I N P T D A W S V H T V A H I H E M K A E I K D G L E F M Q H S

241	E T L W K D S D M L A C H N Y W H W A L Y L I E K G E Y E A A L T I Y D T H I
	L P S L Q A N D A M L D V V D S C S M L Y R L Q M E G V S V G Q R W Q D V L P V A

321	R K H S R D H I L L F N D A H F L M A S L G A H D P Q T T Q E L L T T L R D A
	S E S P G E N C Q H L L A R D V G L P L C Q A L V E A E D G N P D R V L E L L L P

5.242 crystallin, alpha B [Homo sapiens]
Protein Accession gi|4503057

Mean Expression Ratio 1.06

Median Expression Ratio 1.07

Credible Interval (0.686, 1.63)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0629


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.69	1.1	1.7	SEQ ID NO: 1362	VLGDVIEVHGK

SEQ ID NO: 1363

1	M D I A I H H P W I R R P F F P F H S P S R L F D Q F F G E H L L E S D L F P T S T
	S L S P F Y L R P P S F L R A P S W F D T G L S E M R L E K D R F S V N L D

81	V K H F S P E E L K V K V L G D V I E V H G K H E E R Q D E H G F I S R E F H R
	K Y R I P A D V D P L T I T S S L S S D G V L T V N G P R K Q V S G P E R T I P

161	I T R E E K P A V T A A P K K

5.243 dual oxidase 2 precursor [Homo sapiens]
Protein Accession gi|132566532

Mean Expression Ratio 1.07

Median Expression Ratio 1.07

Credible Interval (0.658, 1.73)

Associated Peptides 1

Associated Spectra 1

Coverage 0.00775


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.1	1.8	SEQ ID NO: 1364	AQLAEVVESMFR

SEQ ID NO: 1365

1	M L R A R P E A L M L L G A L L T G S L G P S G N Q D A L S L P W E V Q R Y D G
	W F N N L R H H E R G A V G C R L Q R R V P A N Y A D G V Y Q A L E E P Q L P N

81	P R R L S N A A T R G I A G L P S L H N R T V L G V F F G Y H V L S D V V S V E
	T P G C P A E F L N I R I P P G D P V F D P D Q R G D V V L P F Q R S R W D P E

161	T G R S P S N P R D L A N Q V T G W L D G S A I Y G S S H S W S D A L R S F S
	G G Q L A S G P D P A F P R D S Q N P L L M W A A P D P A T G Q N G P R G L Y A F

241	G A E R G N R E P F L Q A L G L L W F R Y H N L W A Q R L A R Q H P D W E D
	E E L F Q H A R K R V I A T Y Q N I A V Y E W L P S F L Q K T L P E Y T G Y R P F L

321	D P S I S P E F V V A S E Q F F S T M V P P G V Y M R N A S C H F R K V L N K G
	F Q S S Q A L R V C N N Y W I R E N P N L N S T Q E V N E L L L G M A S Q I S E

401	L E D N I V V E D L R D Y W P G P G K F S R T D Y V A S S I Q R G R D M G L P
	S Y S Q A L L A F G L D I P R N W S D L N P N V D P Q V L E A T A A L Y N Q D L S

481	Q L E L L L G G L L E S H G D P G P L F S A I V L D Q F V R L R D G D R Y W F E
	N T R N G L F S K K E I E D I R N T T L R D V L V A V I N I D P S A L Q P N V F

561	V W H K G A P C P Q P K Q L T T D G L P Q C A P L T V L D F F E G S S P G F A I
	T I I A L C C L P L V S L L L S G V V A Y F R G R E H K K L Q K K L K E S V K K

641	E A A K D G V P A M E W P G P K E R S S P I I I Q L L S D R C L Q V L N R H L T
	V L R V V Q L Q P L Q Q V N L I L S N N R G C R T L L L K I P K E Y D L V L L F

721	S S E E E R G A F V Q Q L W D F C V R W A L G L H V A E M S E K E L F R K A
	V T K Q Q R E R I L E I F F R H L F A Q V L D I N Q A D A G T L P L D S S Q K V R E

801	A L T C E L S R A E F A E S L G L K P Q D M F V E S M F S L A D K D G N G Y L
	S F R E F L D I L V V F M K G S P E D K S R L M F T M Y D L D E N G F L S K D E F

881	F T M M R S F I E I S N N C L S K A Q L A E V V E S M F R E S G F Q D K E E L T
	W E D F H F M L R D H D S E L R F T Q L C V K G G G G G G N G I R D I F K Q N I

961	S C R V S F I T R T P G E R S H P Q G L G P P A P E A P E L G G P G L K K R F G
	K K A A V P T P R L Y T E A L Q E K M Q R G F L A Q K L Q Q Y K R F V E N Y R R

1041	H I V C V A I F S A I C V G V F A D R A Y Y Y G F A S P P S D I A Q T T L V G I
	I L S R G T A A S V S F M F S Y I L L T M C R N L I T F L R E T F L N R Y V P F

1121	D A A V D F H R W I A M A A V V L A I L H S A G H A V N V Y I F S V S P L S L
	L A C I F P N V F V N D G S K L P Q K F Y W W F F Q T V P G M T G V L L L L V L A

1201	I M Y V F A S H H F R R R S F R G F W L T H H L Y I L L Y A L L I I H G S Y A L
	I Q L P T F H I Y F L V P A I I Y G G D K L V S L S R K K V E I S V V K A E L L

1281	P S G V T Y L Q F Q R P Q G F E Y K S G Q W V R I A C L A L G T T E Y H P F T
	L T S A P H E D T L S L H I R A V G P W T T R L R E I Y S S P K G N G C A G Y P K

1361	L Y L D G P F G E G H Q E W H K F E V S V L V G G G I G V T P F A S I L K D L
	V F K S S L G S Q M L C K K I Y F I W V T R T Q R Q F E W L A D I I Q E V E E N D

1441	H Q D L V S V H I Y V T Q L A E K F D L R T T M L Y I C E R H F Q K V L N R S
	L F T G L R S I T H F G R P P F E P F F N S L Q E V H P Q V R K I G V F S C G P P

5.244 DnaJ (Hsp40) homolog, subfamily C, member 5 [Homo sapiens]
Protein Accession gi|45504382

Mean Expression Ratio 0.938

Median Expression Ratio 0.938

Credible Interval (0.626, 1.41)

Associated Peptides 1

Associated Spectra 3

Coverage 0.126


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.62	0.92	1.4	SEQ ID NO: 1366	APEGEETEFYVSPEDLEAQLQSDER

SEQ ID NO: 1367

1	M A D Q R Q R S L S T S G E S L Y H V L G L D K N A T S D D I K K S Y R K L A L
	K Y H P D K N P D N P E A A D K F K E I N N A H A I L T D A T K R N I Y D K Y G

81	S L G L Y V A E Q F G E E N V N T Y F V L S S W W A K A L F V F C G L L T C C
	Y C C C C L C C C F N C C C G K C K P K A P E G E E T E F Y V S P E D L E A Q L Q

161	S D E R E A T D T P I V I Q P A S A T E T T Q L T A D S H P S Y H T D G F N

5.245 vacuolar H+ATPase B2 [Homo sapiens]
Protein Accession gi|19913428

Mean Expression Ratio 0.939

Median Expression Ratio 0.939

Credible Interval (0.652, 1.36)

Associated Peptides 3

Associated Spectra 4

Coverage 0.110


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.62	0.9	1.3	SEQ ID NO: 1368	GIVNGAAPELPVPTGGPAVGAR

1	0.63	0.95	1.5	SEQ ID NO: 1369	IPIFSAAGLPHNEIAAQICR

1	0.61	0.94	1.4	SEQ ID NO: 1370	QIYPPINVLPSLSR

SEQ ID NO: 1371

1	M A L R A M R G I V N G A A P E L P V P T G G P A V G A R E Q A L A V S R N Y L
	S Q P R L T Y K T V S G V N G P L V I L D H V K F P R Y A E I V H L T L P D G T

81	K R S G Q V L E V S G S K A V V Q V F E G T S G I D A K K T S C E F T G D I L R
	T P V S E D M L G R V F N G S G K P I D R G P V V L A E D F L D I M G Q P I N P

161	Q C R I Y P E E M I Q T G I S A I D G M N S I A R G Q K I P I F S A A G L P H N E
	I A A Q I C R Q A G L V K K S K D V V D Y S E E N F A I V F A A M G V N M E T

241	A R F F K S D F E E N G S M D N V C L F L N L A N D P T I E R I I T P R L A L T T
	A E F L A Y Q C E K H V L V I L T D M S S Y A E A L R E V S A A R E E V P G R

321	R G F P G Y M Y T D L A T I Y E R A G R V E G R N G S I T Q I P I L T M P N D D
	I T H P I P D L T G Y I T E G Q I Y V D R Q L H N R Q I Y P P I N V L P S L S R

401	L M K S A I G E G M T R K D H A D V S N Q L Y A C Y A I G K D V Q A M K A V
	V G E E A L T S D D L L Y L E F L Q K F E R N F I A Q G P Y E N R T V F E T L D I G

481	W Q L L R I F P K E M L K R I P Q S T L S E F Y P R D S A K H

5.246 angiotensin I converting enzyme 2 precursor [Homo sapiens]
Protein Accession gi|11225609

Mean Expression Ratio 0.939

Median Expression Ratio 0.939

Credible Interval (0.697, 1.27)

Associated Peptides 5

Associated Spectra 7

Coverage 0.0745


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	0.92	1.3	SEQ ID NO: 1372	GQKPNIDVTDAMVDQAWDAQR

2	0.66	0.93	1.3	SEQ ID NO: 1373	LWAWESWR

1	0.66	0.97	1.4	SEQ ID NO: 1374	NQMILFGEEDVR

2	0.68	0.98	1.4	SEQ ID NO: 1375	QLRPLYEEYVVLK

1	0.6	0.88	1.3	SEQ ID NO: 1376	WSAFLK

SEQ ID NO: 1377

1	M S S S S W L L L S L V A V T A A Q S T I E E Q A K T F L D K F N H E A E D L F Y
	Q S S L A S W N Y N T N I T E E N V Q N M N N A G D K W S A F L K E Q S T L A

81	Q M Y P L Q E I Q N L T V K L Q L Q A L Q Q N G S S V L S E D K S K R L N T I L
	N T M S T I Y S T G K V C N P D N P Q E C L L L E P G L N E I M A N S L D Y N E

161	R L W A W E S W R S E V G K Q L R P L Y E E Y V V L K N E M A R A N H Y E D
	Y G D Y W R G D Y E V N G V D G Y D Y S R G Q L I E D V E H T F E E I K P L Y E H L

241	H A Y V R A K L M N A Y P S Y I S P I G C L P A H L L G D M W G R F W T N L Y
	S L T V P F G Q K P N I D V T D A M V D Q A W D A Q R I F K E A E K F F V S V G L

321	P N M T Q G F W E N S M L T D P G N V Q K A V C H P T A W D L G K G D F R I
	L M C T K V T M D D F L T A H H E M G H I Q Y D M A Y A A Q P F L L R N G A N E
	G F

401	H E A V G E I M S L S A A T P K H L K S I G L L S P D F Q E D N E T E I N F L L K
	Q A L T I V G T L P F T Y M L E K W R W M V F K G E I P K D Q W M K K W W E M

481	K R E I V G V V E P V P H D E T Y C D P A S L F H V S N D Y S F I R Y Y T R T L
	Y Q F Q F Q E A L C Q A A K H E G P L H K C D I S N S T E A G Q K L F N M L R L

561	G K S E P W T L A L E N V V G A K N M N V R P L L N Y F E P L F T W L K D Q
	N K N S F V G W S T D W S P Y A D Q S I K V R I S L K S A L G D K A Y E W N D N E M

641	Y L F R S S V A Y A M R Q Y F L K V K N Q M I L F G E E D V R V A N L K P R I
	S F N F F V T A P K N V S D I I P R T E V E K A I R M S R S R I N D A F R L N D N

721	S L E F L G I Q P T L G P P N Q P P V S I W L I V F G V V M G V I V V G I V I L I F
	T G I R D R K K K N K A R S G E N P Y A S I D I S K G E N N P G F Q N T D D

801	V Q T S F

5.247 aquaporin 1 [Homo sapiens]
Protein Accession gi|37694062

Mean Expression Ratio 1.07

Median Expression Ratio 1.07

Credible Interval (0.791, 1.44)

Associated Peptides 3

Associated Spectra 10

Coverage 0.145


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.75	1.1	1.6	SEQ ID NO: 1378	DLGGSAPLAIGLSVALGHL

1	0.71	1.1	1.5	SEQ ID NO: 1379	TSGQVEEYDLDADDINSR

8	0.83	1.1	1.4	SEQ ID NO: 1380	VWTSGQVEEYDLDADDINSR

SEQ ID NO: 1381

1	M A S E F K K K L F W R A V V A E F L A T T L F V F I S I G S A L G F K Y P V G N
	N Q T A V Q D N V K V S L A F G L S I A T L A Q S V G H I S G A H L N P A V T

81	L G L L L S C Q I S I F R A L M V I I A Q C V G A I V A T A I L S G I T S S L T G N
	S L G R N D L A D G V N S G Q G L G I E I I G T L Q L V L C V L A T T D R R

161	R R D L G G S A P L A I G L S V A L G H L L A I D Y T G C G I N P A R S F G S A
	V I T H N F S N H W I F W V G P F I G G A L A V L I Y D F I L A P R S S D L T D

241	R V K V W T S G Q V E E Y D L D A D D I N S R V E M K P K

5.248 secretoglobin, family 1A, member 1 (uteroglobin) [Homo sapiens]
Protein Accession gi|4507809

Mean Expression Ratio 0.938

Median Expression Ratio 0.939

Credible Interval (0.586, 1.51)

Associated Peptides 1

Associated Spectra 1

Coverage 0.11


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.56	0.92	1.5	SEQ ID NO: 1382	LVDTLPQKPR

SEQ ID NO: 1383

1	M K L A V T L T L V T L A L C C S S A S A E I C P S F Q R V I E T L L M D T P S S Y
	E A A M E L F S P D Q D M R E A G A Q L K K L V D T L P Q K P R E S I I K L

81	M E K I A Q S S L C N

5.249 structural maintenance of chromosomes 2 [Homo sapiens]; structural maintenance of chromosomes 2 [Homo sapiens]; structural maintenance of chromosomes 2 [Homo sapiens]
Protein Accession gi 110347425 gi 110347420 gi|110347418

Mean Expression Ratio 1.06

Median Expression Ratio 1.06

Credible Interval (0.654, 1.72)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.64 1.1 1.8 SEQ ID NO: 1384 LGRNVNMRAMNVLTEAEER

5.250 superoxide dismutase 1, soluble [Homo sapiens]
Protein Accession gi|4507149

Mean Expression Ratio 1.07

Median Expression Ratio 1.06

Credible Interval (0.661, 1.73)

Associated Peptides 1

Associated Spectra 1

Coverage 0.091


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.1	1.8	SEQ ID NO: 1385	GDGPVQGIINFEQK

SEQ ID NO: 1386

1	M A T K A V C V L K G D G P V Q G I I N F E Q K E S N G P V K V W G S I K G L T
	E G L H G F H V H E F G D N T A G C T S A G P H F N P L S R K H G G P K D E E R

81	H V G D L G N V T A D K D G V A D V S I E D S V I S L S G D H C I I G R T L V V
	H E K A D D L G K G G N E E S T K T G N A G S R L A C G V I G I A Q

5.251 phospholipid scramblase 1 [Homo sapiens]
Protein Accession gi|10863877

Mean Expression Ratio 1.06

Median Expression Ratio 1.06

Credible Interval (0.774, 1.46)

Associated Peptides 4

Associated Spectra 6

Coverage 0.170


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.72	1.1	1.6	SEQ ID NO: 1387	EAFTDADNFGIQFPLDLDVK

3	0.76	1.1	1.5	SEQ ID NO: 1388	IIDNMGQEVITLER

1	0.71	1.0	1.5	SEQ ID NO: 1389	SGYPGPQVSYPPPPAGH

1	0.74	1.1	1.6	SEQ ID NO: 1390	IIDNMGQEVITLERPLR

SEQ ID NO: 1391

1	M D K Q N S Q M N A S H P E T N L P V G Y P P Q Y P P T A F Q G P P G Y S G Y P
	G P Q V S Y P P P P A G H S G P G P A G F P V P N Q P V Y N Q P V Y N Q P V G A

81	A G V P W M P A P Q P P L N C P P G L E Y L S Q I D Q I L I H Q Q I E L L E V L T
	G F E T N N K Y E I K N S F G Q R V Y F A A E D T D C C T R N C C G P S R P F

161	T L R I I D N M G Q E V I T L E R P L R C S S C C C P C C L Q E I E I Q A P P G V
	P I G Y V I Q T W H P C L P K F T I Q N E K R E D V L K I S G P C V V C S C C

241	G D V D F E I K S L D E Q C V V G K I S K H W T G I L R E A F T D A D N F G I Q
	F P L D L D V K M K A V M I G A C F L I D F M F F E S T G S Q E Q K S G V W

5.252 ATPase, H+ transporting, lysosomal V0 subunit al isoform c [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit al isoform b [Homo sapiens]; ATPase, H+ transporting, lysosomal V0 subunit al isoform a [Homo sapiens]
Protein Accession gi|19913418 gi|194097403 gi|194097401

Mean Expression Ratio 0.94

Median Expression Ratio 0.94

Credible Interval (0.663, 1.34)

Associated Peptides 4

Associated Spectra 4

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.62	0.94	1.4	SEQ ID	ANIPIMDTGENPEVPFPR
				NO: 1392

1	0.62	0.94	1.4	SEQ ID	ASLYPCPETPQER
				NO: 1393

1	0.61	0.92	1.4	SEQ ID	IDDLQMVLNQTEDHR
				NO: 1394

1	0.63	0.95	1.5	SEQ ID	KANIPIMDTGENPEVPFPR
				NO: 1395

5.253 solute carrier family 44, member 2 [Homo sapiens]
Protein Accession gi|31377727

Mean Expression Ratio 1.06

Median Expression Ratio 1.06

Credible Interval (0.646, 1.73)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0227


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.1	1.8	SEQ ID NO: 1396	DGDCPAVLIPSKPLAR

SEQ ID NO: 1397

1	M G D E R P H Y Y G K H G T P Q K Y D P T F K G P I Y N R G C T D I I C C V F L L
	L A I V G Y V A V G I I A W T H G D P R K V I Y P T D S R G E F C G Q K G T K

81	N E N K P Y L F V F N I V K C A S P L V L L E F Q C P T P Q I C V E K C P D R Y L
	T Y L N A R S S R D F E Y Y K Q F C V P G F K N N K G V A E V L R D G D C P A

161	V L I P S K P L A R R C F P A I H A Y K G V L M V G N E T T Y E D G H G S R K
	N I T D L V E G A K K A N G V L E A R Q L A M R I F E D Y T V S W Y W I I I G L V

241	I A M A M S L L F I I L L R F L A G I M V W V M I I M V I L V L G Y G I F H C Y
	M E Y S R L R G E A G S D V S L V D L G F Q T D F R V Y L H L R Q T W L A F M I

321	I L S I L E V I I I L L L I F L R K R I L I A I A L I K E A S R A V G Y V M C S L L Y
	P L V T F F L L C L C I A Y W A S T A V F L S T S N E A V Y K I F D D S P

401	C P F T A K T C N P E T F P S S N E S R Q C P N A R C Q F A F Y G G E S G Y H R
	A L L G L Q I F N A F M F F W L A N F V L A L G Q V T L A G A F A S Y Y W A L R

481	K P D D L P A F P L F S A F G R A L R Y H T G S L A F G A L I L A I V Q I I R V I
	L E Y L D Q R L K A A E N K F A K C L M T C L K C C F W C L E K F I K F L N R

561	N A Y I M I A I Y G T N F C T S A R N A F F L L M R N I I R V A V L D K V T D F
	L F L L G K L L I V G S V G I L A F F F F T H R I R I V Q D T A P P L N Y Y W V

641	P I L T V I V G S Y L I A H G F F S V Y G M C V D T L F L C F L E D L E R N D G
	S A E R P Y F M S S T L K K P L N K T N K K A A E S

5.254 guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 [Homo sapiens]
Protein Accession gi|5729850

Mean Expression Ratio 1.07

Median Expression Ratio 1.06

Credible Interval (0.702, 1.63)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0763


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.66	1.1	1.7	SEQ ID NO: 1398	ISQSNYIPTQQDVLR

1	0.68	1.1	1.7	SEQ ID NO: 1399	SNTIQSIIAIIR

SEQ ID NO: 1400

1	M G C T L S A E D K A A V E R S K M I D R N L R E D G E K A A K E V K L L L L G
	A G E S G K S T I V K Q M K I I H E D G Y S E D E C K Q Y K V V V Y S N T I Q S

81	I I A I I R A M G R L K I D F G E A A R A D D A R Q L F V L A G S A E E G V M T P
	E L A G V I K R L W R D G G V Q A C F S R S R E Y Q L N D S A S Y Y L N D L D

161	R I S Q S N Y I P T Q Q D V L R T R V K T T G I V E T H F T F K D L Y F K M F D
	V G G Q R S E R K K W I H C F E G V T A I I F C V A L S D Y D L V L A E D E E M

241	N R M H E S M K L F D S I C N N K W F T E T S I I L F L N K K D L F E E K I K R
	S P L T I C Y P E Y T G S N T Y E E A A A Y I Q C Q F E D L N R R K D T K E I Y

321	T H F T C A T D T K N V Q F V F D A V T D V I I K N N L K E C G L Y

5.255 PREDICTED: hypothetical protein [Homo sapiens]
Protein Accession gi|1169217813

Mean Expression Ratio 1.06

Median Expression Ratio 1.06

Credible Interval (0.685, 1.62)

Associated Peptides 1

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.69 1.1 1.7 SEQ ID NO: 1401 YNRITLNNDIMLIK

5.256 dipeptidyl peptidase 7 preproprotein [Homo sapiens]
Protein Accession gi|62420888

Mean Expression Ratio 0.94

Median Expression Ratio 0.943

Credible Interval (0.655, 1.34)

Associated Peptides 2

Associated Spectra 4

Coverage 0.065


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.63	0.92	1.3	SEQ ID NO: 1402	GHTELLTVEQALADFAELLR

1	0.62	0.95	1.4	SEQ ID NO: 1403	DLFLQGAYDTVR

SEQ ID NO: 1404

1	M G S A P W A P V L L L A L G L R G L Q A G A R R A P D P G F Q E R F F Q Q R L
	D H F N F E R F G N K T F P Q R F L V S D R F W V R G E G P I F F Y T G N E G D

81	V W A F A N N S A F V A E L A A E R G A L L V F A E H R Y Y G K S L P F G A Q
	S T Q R G H T E L L T V E Q A L A D F A E L L R A L R R D L G A Q D A P A I A F G

161	G S Y G G M L S A Y L R M K Y P H L V A G A L A A S A P V L A V A G L G D S
	N Q F F R D V T A D F E G Q S P K C T Q G V R E A F R Q I K D L F L Q G A Y D T V R

241	W E F G T C Q P L S D E K D L T Q L F M F A R N A F T V L A M M D Y P Y P T D
	F L G P L P A N P V K V G C D R L L S E A Q R I T G L R A L A G L V Y N A S G S E

321	H C Y D I Y R L Y H S C A D P T G C G T G P D A R A W D Y Q A C T E I N L T F
	A S N N V T D M F P D L P F T D E L R Q R Y C L D T W G V W P R P D W L L T S F W

401	G G D L R A A S N I I F S N G N L D P W A G G G I R R N L S A S V I A V T I Q G
	G A H H L D L R A S H P E D P A S V V E A R K L E A T I I G E W V K A A R R E Q

481	Q P A L R G G P R L S L

5.257 tropomyosin 4 [Homo sapiens]
Protein Accession gi|4507651

Mean Expression Ratio 1.06

Median Expression Ratio 1.06

Credible Interval (0.66, 1.71)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0403


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.1	1.8	SEQ ID NO: 1405	IQLVEEELDR

SEQ ID NO: 1406

1	M A G L N S L E A V K R K I Q A L Q Q Q A D E A E D R A Q G L Q R E L D G E R E
	R R E K A E G D V A A L N R R I Q L V E E E L D R A Q E R L A T A L Q K L E E A

81	E K A A D E S E R G M K V I E N R A M K D E E K M E I Q E M Q L K E A K H I A
	E E A D R K Y E E V A R K L V I L E G E L E R A E E R A E V S E L K C G D L E E E

161	L K N V T N N L K S L E A A S E K Y S E K E D K Y E E E I K L L S D K L K E A E
	T R A E F A E R T V A K L E K T I D D L E E K L A Q A K E E N V G L H Q T L D Q

241	T L N E L N C I

5.258 keratin 10 [Homo sapiens]
Protein Accession gi|195972866

Mean Expression Ratio 0.945

Median Expression Ratio 0.944

Credible Interval (0.663, 1.35)

Associated Peptides 3

Associated Spectra 4

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

2	0.65	0.95	1.4	SEQ ID	NQILNLTTDNANILLQIDNAR
				NO: 1407

1	0.61	0.92	1.4	SEQ ID	SQYEQLAEQNRK
				NO: 1408

1	0.63	0.95	1.4	SEQ ID	SQYEQLAEQNR
				NO: 1409

5.259 myosin VI [Homo sapiens]
Protein Accession gi|92859701

Mean Expression Ratio 1.05

Median Expression Ratio 1.06

Credible Interval (0.647, 1.72)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0101


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.64	1.1	1.8	SEQ ID NO: 1410	LVGILDILDEENR

SEQ ID NO: 1411

1	M E D G K P V W A P H P T D G F Q M G N I V D I G P D S L T I E P L N Q K G K T
	F L A L I N Q V F P A E E D S K K D V E D N C S L M Y L N E A T L L H N I K V R

81	Y S K D R I Y T Y V A N I L I A V N P Y F D I P K I Y S S E A I K S Y Q G K S L G T
	R P P H V F A I A D K A F R D M K V L K M S Q S I I V S G E S G A G K T E N

161	T K F V L R Y L T E S Y G T G Q D I D D R I V E A N P L L E A F G N A K T V R N
	N N S S R F G K F V E I H F N E K S S V V G G F V S H Y L L E K S R I C V Q G K

241	E E R N Y H I F Y R L C A G A S E D I R E K L H L S S P D N F R Y L N R G C T R
	Y F A N K E T D K Q I L Q N R K S P E Y L K A G S M K D P L L D D H G D F I R M

321	C T A M K K I G L D D E E K L D L F R V V A G V L H L G N I D F E E A G S T S
	G G C N L K N K S A Q S L E Y C A E L L G L D Q D D L R V S L T T R V M L T T A G

401	G T K G T V I K V P L K V E Q A N N A R D A L A K T V Y S H L F D H V V N R
	V N Q C F P F E T S S Y F I G V L D I A G F E Y F E H N S F E Q F C I N Y C N E K L

481	Q Q F F N E R I L K E E Q E L Y Q K E G L G V N E V H Y V D N Q D C I D L I E A
	K L V G I L D I L D E E N R L P Q P S D Q H F T S A V H Q K H K D H F R L T I P

561	R K S K L A V H R N I R D D E G F I I R H F A G A V C Y E T T Q F V E K N N D A
	L H M S L E S L I C E S R D K F I R E L F E S S T N N N K D T K Q K A G K L S F

641	I S V G N K F K T Q L N L L L D K L R S T G A S F I R C I K P N L K M T S H H F
	E G A Q I L S Q L Q C S G M V S V L D L M Q G G Y P S R A S F H E L Y N M Y K K

721	Y M P D K L A R L D P R L F C K A L F K A L G L N E N D Y K F G L T K V F F R
	P G K F A E F D Q I M K S D P D H L A E L V K R V N H W L T C S R W K K V Q W C S

801	L S V I K L K N K I K Y R A E A C I K M Q K T I R M W L C K R R H K P R I D G L
	V K V G T L K K R L D K F N E V V S V L K D G K P E M N K Q I K N L E I S I D T

881	L M A K I K S T M M T Q E Q I Q K E Y D A L V K S S E E L L S A L Q K K K Q Q
	E E E A E R L R R I Q E E M E K E R K R R E E D E K R R R K E E E E R R M K L E M

961	E A K R K Q E E E E R K K R E D D E K R I Q A E V E A Q L A R Q K E E E S Q Q
	Q A V L E Q E R R D R E L A L R I A Q S E A E L I S D E A Q A D L A L R R N D G T

1041	R P K M T P E Q M A K E M S E F L S R G P A V L A T K A A A G T K K Y D L S
	K W K Y A E L R D T I N T S C D I E L L A A C R E E F H R R L K V Y H A W K S K N K

1121	K R N T E T E Q R A P K S V T D Y D F A P F L N N S P Q Q N P A A Q I P A R Q
	R E I E M N R Q Q R F F R I P F I R P A D Q Y K D P Q S K K K G W W Y A H F D G P

1201	W I A R Q M E L H P D K P P I L L V A G K D D M E M C E L N L E E T G L T R
	K R G A E I L P R Q F E E I W E R C G G I Q Y L Q N A I E S R Q A R P T Y A T A M L

1281	Q S L L K

5.260 heat shock protein 90 kDa alpha (cytosolic), class A member 1 isoform 1 [Homo sapiens]
Protein Accession gi|153792590

Mean Expression Ratio 1.06

Median Expression Ratio 1.06

Credible Interval (0.65, 1.72)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0176


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.1	1.8	SEQ ID NO: 1412	HLEINPDHSIIETLR

SEQ ID NO: 1413

1	M P P C S G G D G S T P P G P S L R D R D C P A Q S A E Y P R D R L D P R P G S P
	S E A S S P P F L R S R A P V N W Y Q E K A Q V F L W H L M V S G S T T L L C

81	L W K Q P F H V S A F P V T A S L A F R Q S Q G A G Q H L Y K D L Q P F I L L R
	L L M P E E T Q T Q D Q P M E E E E V E T F A F Q A E I A Q L M S L I I N T F Y

161	S N K E I F L R E L I S N S S D A L D K I R Y E S L T D P S K L D S G K E L H I N
	L I P N K Q D R T L T I V D T G I G M T K A D L I N N L G T I A K S G T K A F

241	M E A L Q A G A D I S M I G Q F G V G F Y S A Y L V A E K V T V I T K H N D D
	E Q Y A W E S S A G G S F T V R T D T G E P M G R G T K V I L H L K E D Q T E Y L

321	E E R R I K E I V K K H S Q F I G Y P I T L F V E K E R D K E V S D D E A E E K E
	D K E E E K E K E E K E S E D K P E I E D V G S D E E E E K K D G D K K K K K

401	K I K E K V I D Q E E L N K T K P I W T R N P D D I T N E E Y G E F Y K S L T N
	D W E D H L A V K H F S V E G Q L E F R A L L F V P R R A P F D L F E N R K K K

481	N N I K L Y V R R V F I M D N C E E L I P E Y L N F I R G V V D S E D L P L N I S
	R E M L Q Q S K I L K V I R K N L V K K C L E L F T E L A E D K E N Y K K F Y

561	E Q F S K N I K L G I H E D S Q N R K K L S E L L R Y Y T S A S G D E M V S L K
	D Y C T R M K E N Q K H I Y Y I T G E T K D Q V A N S A F V E R L R K H G L E V

641	I Y M I E P I D E Y C V Q Q L K E F E G K T L V S V T K E G L E L P E D E E E K
	K K Q E E K K T K F E N L C K I M K D I L E K K V E K V V V S N R L V T S P C C

721	I V T S T Y G W T A N M E R I M K A Q A L R D N S T M G Y M A A K K H L E I
	N P D H S I I E T L R Q K A E A D K N D K S V K D L V I L L Y E T A L L S S G F S L

801	E D P Q T H A N R I Y R M I K L G L G I D E D D P T A D D T S A A V T E E M P P
	L E G D D D T S R M E E V D

5.261 RAB1A, member RAS oncogene family isoform 1 [Homo sapiens]; RAB1B, member RAS oncogene family [Homo sapiens]
Protein Accession gi|4758988 gi 13569962

Mean Expression Ratio 1.06

Median Expression Ratio 1.06

Credible Interval (0.65, 1.70)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.64 1.1 1.8 SEQ ID NO: 1414 EFADSLGIPFLETSAK

5.262 villin 1 [Homo sapiens]
Protein Accession gi|194394237

Mean Expression Ratio 1.05

Median Expression Ratio 1.05

Credible Interval (0.685, 1.62)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.65 1.0 1.7 SEQ ID NO: 1415 LMEVMNHVLGK

1 0.66 1.1 1.7 SEQ ID NO: 1416 LQEENLVITPR

5.263 PREDICTED: similar to hCG1992647, partial [Homo sapiens]
Protein Accession gi|169217452

Mean Expression Ratio 0.95

Median Expression Ratio 0.95

Credible Interval (0.604, 1.47)

Associated Peptides 1

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.6 0.94 1.5 SEQ ID NO: 1417 AVTELGRPDAEYWNSQK

5.264 aldehyde dehydrogenase 1A1 [Homo sapiens]
Protein Accession gi|21361176

Mean Expression Ratio 1.05

Median Expression Ratio 1.05

Credible Interval (0.723, 1.55)

Associated Peptides 2

Associated Spectra 3

Coverage 0.0439


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.7	1.0	1.6	SEQ ID NO: 1418	IFVEESIYDEFVR

1	0.69	1.1	1.7	SEQ ID NO: 1419	ILDLIESGK

SEQ ID NO: 1420

1	M S S S G T P D L P V L L T D L K I Q Y T K I F I N N E W H D S V S G K K F P V F
	N P A T E E E L C Q V E E G D K E D V D K A V K A A R Q A F Q I G S P W R T M

81	D A S E R G R L L Y K L A D L I E R D R L L L A T M E S M N G G K L Y S N A Y
	L N D L A G C I K T L R Y C A G W A D K I Q G R T I P I D G N F F T Y T R H E P I

161	G V C G Q I I P W N F P L V M L I W K I G P A L S C G N T V V V K P A E Q T P L
	T A L H V A S L I K E A G F P P G V V N I V P G Y G P T A G A A I S S H M D I D

241	K V A F T G S T E V G K L I K E A A G K S N L K R V T L E L G G K S P C I V L A
	D A D L D N A V E F A H H G V F Y H Q G Q C C I A A S R I F V E E S I Y D E F V

321	R R S V E R A K K Y I L G N P L T P G V T Q G P Q I D K E Q Y D K I L D L I E S
	G K K E G A K L E C G G G P W G N K G Y F V Q P T V F S N V T D E M R I A K E E

401	I F G P V Q Q I M K F K S L D D V I K R A N N T F Y G L S A G V F T K D I D K A
	I T I S S A L Q A G T V W V N C Y G V V S A Q C P F G G F K M S G N G R E L G E

481	Y G F H E Y T E V K T V T V K I S Q K N S

5.265 phosphoglycerate kinase 1 [Homo sapiens]
Protein Accession gi|4505763

Mean Expression Ratio 1.05

Median Expression Ratio 1.05

Credible Interval (0.758, 1.47)

Associated Peptides 4

Associated Spectra 5

Coverage 0.161


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.72	1.0	1.5	SEQ ID NO: 1421	ACANPAAGSVILLENLR

1	0.72	1.1	1.6	SEQ ID NO: 1422	ALESPERPFLAILGGAK

1	0.74	1.1	1.6	SEQ ID NO: 1423	ITLPVDFVTADKFDENAK

1	0.68	1.0	1.5	SEQ ID NO: 1424	LGDVYVNDAFGTAHR

SEQ ID NO: 1425

1	M S L S N K L T L D K L D V K G K R V V M R V D F N V P M K N N Q I T N N Q R I
	K A A V P S I K F C L D N G A K S V V L M S H L G R P D G V P M P D K Y S L E P

81	V A V E L K S L L G K D V L F L K D C V G P E V E K A C A N P A A G S V I L L E
	N L R F H V E E E G K G K D A S G N K V K A E P A K I E A F R A S L S K L G D V

161	Y V N D A F G T A H R A H S S M V G V N L P Q K A G G F L M K K E L N Y F A
	K A L E S P E R P F L A I L G G A K V A D K I Q L I N N M L D K V N E M I I G G G M

241	A F T F L K V L N N M E I G T S L F D E E G A K I V K D L M S K A E K N G V K I
	T L P V D F V T A D K F D E N A K T G Q A T V A S G I P A G W M G L D C G P E S

321	S K K Y A E A V T R A K Q I V W N G P V G V F E W E A F A R G T K A L M D E
	V V K A T S R G C I T I I G G G D T A T C C A K W N T E D K V S H V S T G G G A S L

401	E L L E G K V L P G V D A L S N I

5.266 eukaryotic translation initiation factor 5A isoform A [Homo sapiens]
Protein Accession gi|219555707

Mean Expression Ratio 1.05

Median Expression Ratio 1.05

Credible Interval (0.636, 1.73)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

Sequence

A 2.5 50 97.5 ID No. Sequence

1 0.65 1.1 1.8 SEQ ID NO: NDFQLIGIQDGYLSLLQDSGEVR

1426

5.267 heat shock 70 kDa protein 1A [Homo sapiens]; heat shock 70 kDa protein 1B [Homo sapiens]
Protein Accession gi 194248072 gi|167466173

Mean Expression Ratio 1.05

Median Expression Ratio 1.05

Credible Interval (0.861, 1.29)

Associated Peptides 12

Associated Spectra 21

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.74	1.0	1.4	SEQ ID NO: 1427	AQIHDLVLVGGSTR

2	0.77	1.1	1.4	SEQ ID NO: 1428	ATAGDTHLGGEDFDNR

1	0.74	1.0	1.4	SEQ ID NO: 1429	AVITVPAYFNDSQR

2	0.79	1.1	1.4	SEQ ID NO: 1430	EIAEAYLGYPVTNAVITVP
					AYFNDSQR


3	0.78	1.1	1.4	SEQ ID NO: 1431	FEELCSDLFR

1	0.76	1.1	1.5	SEQ ID NO: 1432	FELSGIPPAPR

1	0.77	1.1	1.5	SEQ ID NO: 1433	HWPFQVINDGDKPK

3	0.77	1.0	1.4	SEQ ID NO: 1434	LLQDFFNGR

3	0.78	1.0	1.4	SEQ ID NO: 1435	LVNHFVEEFK

1	0.79	1.1	1.5	SEQ ID NO: 1436	LVNHFVEEFKR

1	0.75	1.0	1.4	SEQ ID NO: 1437	NQVALNPQNTVFDAK

1	0.77	1.1	1.5	SEQ ID NO: 1438	QTQIFTTYSDNQPGVLIQV
					YEGER

5.268 hypothetical protein LOC126321 isoform b [Homo sapiens]; hypothetical protein LOC126321 isoform c [Homo sapiens]; hypothetical protein LOC126321 isoform a [Homo sapiens]
Protein Accession gi|111378395 gi|111378391 gi|111378386

Mean Expression Ratio 0.954

Median Expression Ratio 0.952

Credible Interval (0.647, 1.41)

Associated Peptides 2

Associated Spectra 3

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.62 0.96 1.5 SEQ ID NO: 1439 GPGPPAAGAAPSPR

2 0.63 0.94 1.4 SEQ ID NO: 1440 VEPTQDISISDQLGGQD

VPVFR

5.269 PDZK1 interacting protein 1 [Homo sapiens]
Protein Accession gi|5031657

Mean Expression Ratio 0.954

Median Expression Ratio 0.954

Credible Interval (0.637, 1.43)

Associated Peptides 1

Associated Spectra 3

Coverage 0.149


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.64	0.94	1.4	SEQ ID NO: 1441	SSEHENAYENVPEEEGK

SEQ ID NO: 1442

1	M S A L S L L I L G L L T A V P P A S C Q Q G L G N L Q P W M Q G L I A V A V F
	L V L V A I A F A V N H F W C Q E E P E P A H M I L T V G N K A D G V L V G T D

81	G R Y S S M A A S F R S S E H E N A Y E N V P E E E G K V R S T P M

5.270 hexosaminidase A preproprotein [Homo sapiens]
Protein Accession gi|189181666

Mean Expression Ratio 0.954

Median Expression Ratio 0.954

Credible Interval (0.589, 1.53)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.57 0.95 1.6 SEQ ID NO: 1443 IQPDTIIQVWR

5.271 paralemmin isoform 1 [Homo sapiens]
Protein Accession gi|93141031

Mean Expression Ratio 1.05

Median Expression Ratio 1.05

Credible Interval (0.637, 1.73)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0491


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	1.1	1.8	SEQ ID NO: 1444	EPAPPNGSAAEPPTEAASR

SEQ ID NO: 1445

1	M E V L A A E T T S Q Q E R L Q A I A E K R K R Q A E I E N K R R Q L E D E R R
	Q L Q H L K S K A L R E R W L L E G T P S S A S E G D E D L R R Q M Q D D E Q K

81	T R L L E D S V S R L E K E I E V L E R G D S A P A T A K E N A A A P S P V R A P
	A P S P A K E E R K T E V V M N S Q Q T P V G T P K D K R V S N T P L R T V D

161	G S P M M K A A M Y S V E I T V E K D K V T G E T R V L S S T T L L P R Q P L
	P L G I K V Y E D E T K V V H A V D G T A E N G I H P L S S S E V D E L I H K A D

241	E V T L S E A G S T A G A A E T R G A V E G A A R T T P S R R E I T G V Q A Q P
	G E A T S G P P G I Q P G Q E P P V T M I F M G Y Q N V E D E A E T K K V L G L

321	Q D T I T A E L V V I E D A A E P K E P A P P N G S A A E P P T E A A S R E E N
	Q A G P E A T T S D P Q D L D M K K H R C K C C S I M

5.272 mannosidase, alpha, class 2B, member 2 [Homo sapiens]
Protein Accession gi|50659093

Mean Expression Ratio 1.04

Median Expression Ratio 1.05

Credible Interval (0.676, 1.62)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0238


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.66	1.1	1.7	SEQ ID NO: 1446	FIAVEQEFFR

1	0.65	1.0	1.7	SEQ ID NO: 1447	IEQEYQAGPLELNR

SEQ ID NO: 1448

1	M G Q L C W L P L L A P L L L L R P P G V Q S A G P I R A F V V P H S H M D V G
	W V Y T V Q E S M R A Y A A N V Y T S V V E E L A R G Q Q R R F I A V E Q E F F

81	R L W W D G V A S D Q Q K Y Q V R Q L L E E G R L E F V I G G Q V M H D E A
	V T H L D D Q I L Q L T E G H G F L Y E T F G I R P Q F S W H V D P F G A S A T T P

161	T L F A L A G F N A H L G S R I D Y D L K A A M Q E A R G L Q F V W R G S P S
	L S E R Q E I F T H I M D Q Y S Y C T P S H I P F S N R S G F Y W N G V A V F P K

241	P P Q D G V Y P N M S E P V T P A N I N L Y A E A L V A N V K Q R A A W F R T
	P H V L W P W G C D K Q F F N A S V Q F A N M D P L L D H I N S H A A E L G V S V

321	Q Y A T L G D Y F R A L H A L N V T W R V R D H H D F L P Y S T E P F Q A W
	T G F Y T S R S S L K G L A R R A S A L L Y A G E S M F T R Y L W P A P R G H L D P

401	T W A L Q Q L Q Q L R W A V S E V Q H H D A I T G T E S P K V R D M Y A T H
	L A S G M L G M R K L M A S I V L D E L Q P Q A P M A A S S D A G P A G H F A S
	V Y

481	N P L A W T V T T I V T L T V G F P G V R V T D E A G H P V P S Q I Q N S T E T
	P S A Y D L L I L T T I P G L S Y R H Y N I R P T A G A Q E G T Q E P A A T V A

561	S T L Q F G R R L R R R T S H A G R Y L V P V A N D C Y I V L L D Q D T N L M
	H S I W E R Q S N R T V R V T Q E F L E Y H V N G D V K Q G P I S D N Y L F T P G

641	K A A V P A W E A V E M E I V A G Q L V T E I R Q Y F Y R N M T A Q N Y T Y
	A I R S R L T H V P Q G H D G E L L C H R I E Q E Y Q A G P L E L N R E A V L R T S

721	T N L N S Q Q V I Y S D N N G Y Q M Q R R P Y V S Y V N N S I A R N Y Y P M V
	Q S A F M E D G K S R L V L L S E R A H G I S S Q G N G Q V E V M L H R R L W N N

801	F D W D L G Y N L T L N D T S V V H P V L W L L L G S W S L T T A L R Q R S A
	L A L Q H R P V V L F G D L A G T A P K L P G P Q Q Q E A V T L P P N L H L Q I L

881	S I P G W R Y S S N H T E H S Q N L R K G H R G E A Q A D L R R V L L R L Y H
	L Y E V G E D P V L S Q P V T V N L E A V L Q A L G S V V A V E E R S L T G T W D

961	L S M L H R W S W R T G P G R H R G D T T S P S R P P G G P I I T V H P K E I R
	T F F I H F Q Q Q

5.273 CD74 antigen isoform a [Homo sapiens]; CD74 antigen isoform c [Homo sapiens]; CD74 antigen isoform b [Homo sapiens]
Protein Accession gi|68448544 gi|68448537 gi|10835071

Mean Expression Ratio 1.04

Median Expression Ratio 1.04

Credible Interval (0.672, 1.58)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.65 1.1 1.7 SEQ ID NO: 1449 DLISNNEQLPMLGR

1 0.66 1.1 1.7 SEQ ID NO: 1450 RPGAPESK

5.274 dipeptidylpeptidase IV [Homo sapiens]
Protein Accession gi|18765694

Mean Expression Ratio 0.958

Median Expression Ratio 0.957

Credible Interval (0.749, 1.22)

Associated Peptides 9

Associated Spectra 12

Coverage 0.141


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.68	0.96	1.4	SEQ ID NO: 1451	CGIAVAPVSR

1	0.71	0.98	1.4	SEQ ID NO: 1452	FRPSEPHFTLDGNSFYK

1	0.66	0.94	1.3	SEQ ID NO: 1453	ISLQWLR

2	0.63	0.87	1.2	SEQ ID NO: 1454	LGTFEVEDQIEAAR

1	0.67	0.95	1.4	SEQ ID NO: 1455	SFYSDESLQYPK

1	0.7	0.98	1.4	SEQ ID NO: 1456	VWNNDIYVK

1	0.68	0.97	1.4	SEQ ID NO: 1457	WEYYDSVYTER

2	0.71	0.99	1.4	SEQ ID NO: 1458	YMGLPTPEDNLDHYR

2	0.7	0.97	1.3	SEQ ID NO: 1459	FWYQMILPPHFDK

SEQ ID NO: 1460

1	M K T P W K V L L G L L G A A A L V T I I T V P V V L L N K G T D D A T A D S R
	K T Y T L T D Y L K N T Y R L K L Y S L R W I S D H E Y L Y K Q E N N I L V F N

81	A E Y G N S S V F L E N S T F D E F G H S I N D Y S I S P D G Q F I L L E Y N Y V
	K Q W R H S Y T A S Y D I Y D L N K R Q L I T E E R I P N N T Q W V T W S P V

161	G H K L A Y V W N N D I Y V K I E P N L P S Y R I T W T G K E D I I Y N G I T D
	W V Y E E E V F S A Y S A L W W S P N G T F L A Y A Q F N D T E V P L I E Y S F

241	Y S D E S L Q Y P K T V R V P Y P K A G A V N P T V K F F V V N T D S L S S V
	T N A T S I Q I T A P A S M L I G D H Y L C D V T W A T Q E R I S L Q W L R R I Q

321	N Y S V M D I C D Y D E S S G R W N C L V A R Q H I E M S T T G W V G R F R P
	S E P H F T L D G N S F Y K I I S N E E G Y R H I C Y F Q I D K K D C T F I T K G

401	T W E V I G I E A L T S D Y L Y Y I S N E Y K G M P G G R N L Y K I Q L S D Y T
	K V T C L S C E L N P E R C Q Y Y S V S F S K E A K Y Y Q L R C S G P G L P L Y

481	T L H S S V N D K G L R V L E D N S A L D K M L Q N V Q M P S K K L D F I I L
	N E T K F W Y Q M I L P P H F D K S K K Y P L L L D V Y A G P C S Q K A D T V F R

561	L N W A T Y L A S T E N I I V A S F D G R G S G Y Q G D K I M H A I N R R L G T
	F E V E D Q I E A A R Q F S K M G F V D N K R I A I W G W S Y G G Y V T S M V L

641	G S G S G V F K C G I A V A P V S R W E Y Y D S V Y T E R Y M G L P T P E D N
	L D H Y R N S T V M S R A E N F K Q V E Y L L I H G T A D D N V H F Q Q S A Q I S

721	K A L V D V G V D F Q A M W Y T D E D H G I A S S T A H Q H I Y T H M S H F I
	K Q C F S L P

5.275 lipocalin 2 [Homo sapiens]
Protein Accession gi|38455402

Mean Expression Ratio 0.955

Median Expression Ratio 0.959

Credible Interval (0.658, 1.37)

Associated Peptides 3

Associated Spectra 4

Coverage 0.247


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.63	0.93	1.4	SEQ ID NO: 1461	SLGLPENHIVFPVPIDQCIDG

1	0.64	0.96	1.5	SEQ ID NO: 1462	VPLQQNFQDNQFQGK

1	0.63	0.97	1.5	SEQ ID NO: 1463	WYVVGLAGNAILR

SEQ ID NO: 1464

1	M P L G L L W L G L A L L G A L H A Q A Q D S T S D L I P A P P L S K V P L Q Q
	N F Q D N Q F Q G K W Y V V G L A G N A I L R E D K D P Q K M Y A T I Y E L K E

81	D K S Y N V T S V L F R K K K C D Y W I R T F V P G C Q P G E F T L G N I K S Y
	P G L T S Y L V R V V S T N Y N Q H A M V F F K K V S Q N R E Y F K I T L Y G R

161	T K E L T S E L K E N F I R F S K S L G L P E N H I V F P V P I D Q C I D G

5.276 zinc finger protein 262 [Homo sapiens]
Protein Accession gi|44890068

Mean Expression Ratio 0.956

Median Expression Ratio 0.959

Credible Interval (0.585, 1.54)

Associated Peptides 1

Associated Spectra 1

Coverage 0.00904


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.95	1.6	SEQ ID NO: 1465	SSAEMIENTNSLGK

SEQ ID NO: 1466

1	M A E R E V E S G P R K R F E Q K S G A V F D E I V E N C G G I M D T E M S E D I
	D H N L T P T L D S M S Y G M P N Q T G S E N S L L D E D D Y F L N S G D L A

81	G I P V V G S D N E D E Q D F S S K D N L V S S I H T D D S L E V E R R V T Q H
	E S D N E N E I Q I Q N K L K K D F P K Q F D Q V S V F K S I R K D F S L V R E

161	N S K E T F S G K E K N R D L T Y E R E K R L D K P H K D L D S R L K S S F F D
	K A A N Q V E E T L H T H L P Q T P E T N F R D S S Y P F A N K E S I G S E L G

241	N S F A S N I R I K E E P L D D E Y D K A M A P Q Q G L L D K I K D E P D N A Q
	E Y S H G Q Q Q K T Q E G E L K I S A V F S V S G S P L A P Q L T T G F Q P S L

321	A S S G M N K M L P S V P A T A V R V S C S G C K K I L Q K G Q T A Y Q R K G
	S T Q L F C S T L C L T G Y T V P P A R P P P P L T K K T C S S C S K D I L N P K

401	D V I S A Q F E N T T T S K D F C S Q S C L S T Y E L K K K P I V T I N T N S I S
	T K C S M C Q K N A V I R H E V N Y Q N V V H K L C S D A C F S K F R S A N N

481	L T M N C C E N C G G Y C Y S G S G Q C H M L Q I E G Q S K K F C S S S C I T
	A Y K Q K S A K I T P C A L C K S L R S S A E M I E N T N S L G K T E L F C S V N

561	C L S A Y R V K M V T S A G V Q V Q C N S C K T S A I P Q Y H L A M S D G S I
	R N F C S Y S C V V A F Q N L F N K P T G M N S S V V P L S Q G Q V I V S I P T G

641	S T V S A G G G S T S A V S P T S I S S S A A A G L Q R L A A Q S Q H V G F A R
	S V V K L K C Q H C N R L F A T K P E L L D Y K G K M F Q F C G K N C S D E Y K

721	K I N N V M A M C E Y C K I E K I V K E T V R F S G A D K S F C S E G C K L L
	Y K H D L A K R W G N H C K M C S Y C L Q T S P K L V Q N N L G G K V E E F C C E

801	E C M S K Y T V L F Y Q M A K C D A C K R Q G K L S E S L K W R G E M K H F
	C N L L C I L M F C N Q Q S V C D P P S Q N N A A N I S M V Q A A S A G P P S L R K

881	D S T P V I A N V V S L A S A P A A Q P T V N S N S V L Q G A V P T V T A K I I
	G D A S T Q T D A L K L P P S Q P P R L L K N K A L L C K P I T Q T K A T S C K

961	P H T Q N K E C Q T E D T P S Q P Q I I V V P V P V P V F V P I P L H L Y T Q Y A
	P V P F G I P V P M P V P M L I P S S M D S E D K V T E S I E D I K E K L P T

1041	H P F E A D L L E M A E M I A E D E E K K T L S Q G E S Q T S E H E L F L D T
	K I F E K D Q G S T Y S G D L E S E A V S T P H S W E E E L N H Y A L K S N A V Q

1121	E A D S E L K Q F S K G E T E Q D L E A D F P S D S F D P L N K G Q G I Q A R
	S R T R R R H R D G F P Q P R R R G R K K S I V A V E P R S L I Q G A F Q G C S V

1201	S G M T L K Y M Y G V N A W K N W V Q W K N A K E E Q G D L K C G G V E
	Q A S S S P R S D P L G S T Q D H A L S Q E S S E P G C R V R S I K L K E D I L S C T F

1281	A E L S L G L C Q F I Q E V R R P N G E K Y D P D S I L Y L C L G I Q Q Y L F E
	N G R I D N I F T E P Y S R F M I E L T K L L K I W E P T I L P N G Y M F S R I

1361	E E E H L W E C K Q L G A Y S P I V L L N T L L F F N T K Y F Q L K N V T E H
	L K L S F A H V M R R T R T L K Y S T K M T Y L R F F P P L Q K Q E S E P D K L T

1441	V G K R K R N E D D E V P V G V E M A E N T D N P L R C P V R L Y E F Y L S
	K C S E S V K Q R N D V F Y L Q P E R S C V P N S P M W Y S T F P I D P G T L D T M

1521	L T R I L M V R E V H E E L A K A K S E D S D V E L S D

5.277 angiotensin I converting enzyme isoform 1 precursor [Homo sapiens]
Protein Accession gi|4503273

Mean Expression Ratio 1.04

Median Expression Ratio 1.04

Credible Interval (0.681, 1.59)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0253


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.0	1.7	SEQ ID NO: 1467	SMYETPSLEQDLER

1	0.65	1.1	1.7	SEQ ID NO: 1468	RQEEAALLSQEFAEAWGQK

SEQ ID NO: 1469

1	M G A A S G R R G P G L L L P L P L L L L L P P Q P A L A L D P G L Q P G N F S A
	D E A G A Q L F A Q S Y N S S A E Q V L F Q S V A A S W A H D T N I T A E N A

81	R R Q E E A A L L S Q E F A E A W G Q K A K E L Y E P I W Q N F T D P Q L R R I
	I G A V R T L G S A N L P L A K R Q Q Y N A L L S N M S R I Y S T A K V C L P N

161	K T A T C W S L D P D L T N I L A S S R S Y A M L L F A W E G W H N A A G I P
	L K P L Y E D F T A L S N E A Y K Q D G F T D T G A Y W R S W Y N S P T F E D D L

241	E H L Y Q Q L E P L Y L N L H A F V R R A L H R R Y G D R Y I N L R G P I P A H
	L L G D M W A Q S W E N I Y D M V V P F P D K P N L D V T S T M L Q Q G W N A T

321	H M F R V A E E F F T S L E L S P M P P E F W E G S M L E K P A D G R E V V C
	H A S A W D F Y N R K D F R I K Q C T R V T M D Q L S T V H H E M G H I Q Y Y L Q

401	Y K D L P V S L R R G A N P G F H E A I G D V L A L S V S T P E H L H K I G L L
	D R V T N D T E S D I N Y L L K M A L E K I A F L P F G Y L V D Q W R W G V F S

481	G R T P P S R Y N F D W W Y L R T K Y Q G I C P P V T R N E T H F D A G A K F
	H V P N V T P Y I R Y F V S F V L Q F Q F H E A L C K E A G Y E G P L H Q C D I Y

561	R S T K A G A K L R K V L Q A G S S R P W Q E V L K D M V G L D A L D A Q P
	L L K Y F Q P V T Q W L Q E Q N Q Q N G E V L G W P E Y Q W H P P L P D N Y P E
	G I

641	D L V T D E A E A S K F V E E Y D R T S Q V V W N E Y A E A N W N Y N T N I
	T T E T S K I L L Q K N M Q I A N H T L K Y G T Q A R K F D V N Q L Q N T T I K R I

721	I K K V Q D L E R A A L P A Q E L E E Y N K I L L D M E T T Y S V A T V C H P
	N G S C L Q L E P D L T N V M A T S R K Y E D L L W A W E G W R D K A G R A I L Q

801	F Y P K Y V E L I N Q A A R L N G Y V D A G D S W R S M Y E T P S L E Q D L E
	R L F Q E L Q P L Y L N L H A Y V R R A L H R H Y G A Q H I N L E G P I P A H L L

881	G N M W A Q T W S N I Y D L V V P F P S A P S M D T T E A M L K Q G W T P R
	R M F K E A D D F F T S L G L L P V P P E F W N K S M L E K P T D G R E V V C H A S

961	A W D F Y N G K D F R I K Q C T T V N L E D L V V A H H E M G H I Q Y F M Q
	Y K D L P V A L R E G A N P G F H E A I G D V L A L S V S T P K H L H S L N L L S S

1041	E G G S D E H D I N F L M K M A L D K I A F I P F S Y L V D Q W R W R V F D
	G S I T K E N Y N Q E W W S L R L K Y Q G L C P P V P R T Q G D F D P G A K F H I P

1121	S S V P Y I R Y F V S F I I Q F Q F H E A L C Q A A G H T G P L H K C D I Y Q S
	K E A G Q R L A T A M K L G F S R P W P E A M Q L I T G Q P N M S A S A M L S Y

1201	F K P L L D W L R T E N E L H G E K L G W P Q Y N W T P N S A R S E G P L P
	D S G R V S F L G L D L D A Q Q A R V G Q W L L L F L G I A L L V A T L G L S Q R L

1281	F S I R H R S L H R H S H G P Q F G S E V E L R H S

5.278 skeletal muscle receptor tyrosine kinase [Homo sapiens]
Protein Accession gi|5031927

Mean Expression Ratio 0.956

Median Expression Ratio 0.96

Credible Interval (0.579, 1.54)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0196


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.56	0.94	1.6	SEQ ID NO: 1470	CIARQVAAGMAYLSERK

SEQ ID NO: 1471

1	M R E L V N I P L V H I L T L V A F S G T E K L P K A P V I T T P L E T V D A L V E
	E V A T F M C A V E S Y P Q P E I S W T R N K I L I K L F D T R Y S I R E N

81	G Q L L T I L S V E D S D D G I Y C C T A N N G V G G A V E S C G A L Q V K M
	K P K I T R P P I N V K I I E G L K A V L P C T T M G N P K P S V S W I K G D S P

161	L R E N S R I A V L E S G S L R I H N V Q K E D A G Q Y R C V A K N S L G T A
	Y S K V V K L E V E V F A R I L R A P E S H N V T F G S F V T L H C T A T G I P V

241	P T I T W I E N G N A V S S G S I Q E S V K D R V I D S R L Q L F I T K P G L Y T
	C I A T N K H G E K F S T A K A A A T I S I A E W S K P Q K D N K G Y C A Q Y

321	R G E V C N A V L A K D A L V F L N T S Y A D P E E A Q E L L V H T A W N E L
	K V V S P V C R P A A E A L L C N H I F Q E C S P G V V P T P I P I C R E Y C L A

401	V K E L F C A K E W L V M E E K T H R G L Y R S E M H L L S V P E C S K L P S
	M H W D P T A C A R L P H L D Y N K E N L K T F P P M T S S K P S V D I P N L P S

481	S S S S S F S V S P T Y S M T V I I S I M S S F A I F V L L T I T T L Y C C R R R K
	Q W K N K K R E S A A V T L T T L P S E L L L D R L H P N P M Y Q R M P L L

561	L N P K L L S L E Y P R N N I E Y V R D I G E G A F G R V F Q A R A P G L L P Y
	E P F T M V A V K M L K E E A S A D M Q A D F Q R E A A L M A E F D N P N I V K

641	L L G V C A V G K P M C L L F E Y M A Y G D L N E F L R S M S P H T V C S L S
	H S D L S M R A Q V S S P G P P P L S C A E Q L C I A R Q V A A G M A Y L S E R K

721	F V H R D L A T R N C L V G E N M V V K I A D F G L S R N I Y S A D Y Y K A N
	E N D A I P I R W M P P E S I F Y N R Y T T E S D V W A Y G V V L W E I F S Y G L

801	Q P Y Y G M A H E E V I Y Y V R D G N I L S C P E N C P V E L Y N L M R L C W
	S K L P A D R P S F T S I H R I L E R M C E R A E G T V S V

5.279 spastin isoform 2 [Homo sapiens]; spastin isoform 1 [Homo sapiens]
Protein Accession gi|40806170 gi|11875211

Mean Expression Ratio 1.04

Median Expression Ratio 1.04

Credible Interval (0.638, 1.69)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.64 1.0 1.8 SEQ ID NO: 1472 SSGAAPAPASASAPAPVPG

GEAER

5.280 allograft inflammatory factor 1 isoform 3 [Homo sapiens]
Protein Accession gi|14574568

Mean Expression Ratio 1.05

Median Expression Ratio 1.04

Credible Interval (0.698, 1.57)

Associated Peptides 1

Associated Spectra 3

Coverage 0.0748


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.71	1.1	1.6	SEQ ID NO: 1473	MSQTRDLQGGK

SEQ ID NO: 1474

1	M S Q T R D L Q G G K A F G L L K A Q Q E E R L D E I N K Q F L D D P K Y S S D
	E D L P S K L E G F K E K Y M E F D L N G N G D I D I M S L K R M L E K L G V P

81	K T H L E L K K L I G E V S S G S G E T F S Y P D F L R M M L G K R S A I L K M I
	L M Y E E K A R E K E K P T G P P A K K A I S E L P

5.281 carbonyl reductase 1 [Homo sapiens]
Protein Accession gi|4502599

Mean Expression Ratio 1.05

Median Expression Ratio 1.04

Credible Interval (0.726, 1.51)

Associated Peptides 2

Associated Spectra 4

Coverage 0.105


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.73	1.0	1.5	SEQ ID NO: 1475	FHQLDIDDLQSIR

1	0.68	1.1	1.6	SEQ ID NO: 1476	GQAAVQQLQAEGLSPR

SEQ ID NO: 1477

1	M S S G I H V A L V T G G N K G I G L A I V R D L C R L F S G D V V L T A R D V T
	R G Q A A V Q Q L Q A E G L S P R F H Q L D I D D L Q S I R A L R D F L R K E

81	Y G G L D V L V N N A G I A F K V A D P T P F H I Q A E V T M K T N F F G T R D
	V C T E L L P L I K P Q G R V V N V S S I M S V R A L K S C S P E L Q Q K F R S

161	E T I T E E E L V G L M N K F V E D T K K G V H Q K E G W P S S A Y G V T K I
	G V T V L S R I H A R K L S E Q R K G D K I L L N A C C P G W V R T D M A G P K A

241	T K S P E E G A E T P V Y L A L L P P D A E G P H G Q F V S E K R V E Q W

5.282 sodium/hydrogen exchanger regulatory factor 1 [Homo sapiens]
Protein Accession gi|4759140

Mean Expression Ratio 0.961

Median Expression Ratio 0.96

Credible Interval (0.78, 1.19)

Associated Peptides 10

Associated Spectra 19

Coverage 0.26


A	2.5	50	97.5	Sequence ID NO.	Sequence

6	0.75	0.97	1.2	SEQ ID NO: 1478	AQEAPGQAEPPAAAEVQGAGNENEPR

1	0.72	1	1.4	SEQ ID NO: 1479	EADKSHPEQR

1	0.69	0.96	1.4	SEQ ID NO: 1480	EALAEAALESPR

1	0.65	0.9	1.2	SEQ ID NO: 1481	EAPGQAEPPAAAEVQGAGNENEPR

3	0.75	1	1.4	SEQ ID NO: 1482	EPPAAAEVQGAGNENEPR

1	0.68	0.93	1.3	SEQ ID NO: 1483	QEAPGQAEPPAAAEVQGAGNENEPR

1	0.73	1.0	1.4	SEQ ID NO: 1484	SKPGQFIR

3	0.68	0.9	1.2	SEQ ID NO: 1485	VIPSQEHLNGPLPVPF

1	0.7	0.97	1.3	SEQ ID NO: 1486	ETDEFFK

1	0.69	0.97	1.3	SEQ ID NO: 1487	SVDPDSPAEASGLR

SEQ ID NO: 1488

1	M S A D A A A G A P L P R L C C L E K G P N G Y G F H L H G E K G K L G Q Y I R
	L V E P G S P A E K A G L L A G D R L V E V N G E N V E K E T H Q Q V V S R I R

81	A A L N A V R L L V V D P E T D E Q L Q K L G V Q V R E E L L R A Q E A P G Q
	A E P P A A A E V Q G A G N E N E P R E A D K S H P E Q R E L R P R L C T M K K G

161	P S G Y G F N L H S D K S K P G Q F I R S V D P D S P A E A S G L R A Q D R I V
	E V N G V C M E G K Q H G D V V S A I R A G G D E T K L L V V D R E T D E F F K

241	K C R V I P S Q E H L N G P L P V P F T N G E I Q K E N S R E A L A E A A L E S
	P R P A L V R S A S S D T S E E L N S Q D S P P K Q D S T A P S S T S S S D P I

321	L D F N I S L A M A K E R A H Q K R S S K R A P Q M D W S K K N E L F S N L

5.283 argininosuccinate synthetase 1 [Homo sapiens]; argininosuccinate synthetase 1 [Homo sapiens]
Protein Accession gi|53759107 gi|16950633

Mean Expression Ratio 1.04

Median Expression Ratio 1.04

Credible Interval (0.682, 1.58)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

A 2.5 50 97.5 Sequence ID NO. Sequence

1 0.65 1.1 1.7 SEQ ID NO: 1489 EFVEEFIWPAIQSSALYED

R

1 0.64 1.0 1.7 SEQ ID NO: 1490 APNTPDILEIEFK

5.284 spinster homolog 1 isoform 1 [Homo sapiens]; spinster homolog 1 isoform 1 [Homo sapiens]
Protein Accession gi|215490096 gi|14042968

Mean Expression Ratio 1.04

Median Expression Ratio 1.04

Credible Interval (0.707, 1.55)

Associated Peptides 2

Associated Spectra 3

Coverage NaN

A 2.5 50 97.5 Sequence ID NO. Sequence

1 0.66 1.0 1.6 SEQ ID NO: 1491 AQLHVQGLLHEAGSTDDR

2 0.7 1.1 1.6 SEQ ID NO: 1492 SEEPEVPDQEGLQR

5.285 quinolinate phosphoribosyltransferase [Homo sapiens]
Protein Accession gi|45269149

Mean Expression Ratio 1.04

Median Expression Ratio 1.04

Credible Interval (0.64, 1.67)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0539


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	1.0	1.7	SEQ ID NO: 1493	CSGIASAAAAAVEAAR

SEQ ID NO: 1494

1	M D A E G L A L L L P P V T L A A L V D S W L R E D C P G L N Y A A L V S G A G
	P S Q A A L W A K S P G V L A G Q P F F D A I F T Q L N C Q V S W F L P E G S K

81	L V P V A R V A E V R G P A H C L L L G E R V A L N T L A R C S G I A S A A A A
	A V E A A R G A G W T G H V A G T R K T T P G F R L V E K Y G L L V G G A A S H

161	R Y D L G G L V M V K D N H V V A A G G V E K A V R A A R Q A A D F A L K
	V E V E C S S L Q E A V Q A A E A G A D L V L L D N F K P E E L H P T A T V L K A
	Q F

241	P S V A V E A S G G I T L D N L P Q F C G P H I D V I S M G M L T Q A A P A L D
	F S L K L F A K E V A P V P K I H

5.286 transmembrane protein 106A [Homo sapiens]; PREDICTED: similar to Transmembrane protein 106A [Homo sapiens]; PREDICTED: similar to Transmembrane protein 106A isoform 3 [Homo sapiens]
Protein Accession gi|21450796 gi|169211133 gi 113427131

Mean Expression Ratio 0.97

Median Expression Ratio 0.965

Credible Interval (0.601, 1.58)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.58 0.96 1.6 SEQ ID NO: 1495 QLVALIPYGDQR

5.287 uroplakin 1A [Homo sapiens]
Protein Accession gi|5902148

Mean Expression Ratio 1.04

Median Expression Ratio 1.04

Credible Interval (0.64, 1.70)

Associated Peptides 1

Associated Spectra 1

Coverage 0.062


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	1.1	1.8	SEQ ID NO: 1496	AATPEVVFPWPPLCCR

SEQ ID NO: 1497

1	M A S A A A A E A E K G S P V V V G L L V V G N I I I L L S G L S L F A E T I W V
	T A D Q Y R V Y P L M G V S G K D D V F A G A W I A I F C G F S F F M V A S F

81	G V G A A L C R R R S M V L T Y L V L M L I V Y I F E C A S C I T S Y T H R D Y
	M V S N P S L I T K Q M L T F Y S A D T D Q G Q E L T R L W D R V M I E Q E C C

161	G T S G P M D W V N F T S A F R A A T P E V V F P W P P L C C R R T G N F I P L
	N E E G C R L G H M D Y L F T K G C F E H I G H A I D S Y T W G I S W F G F A I

241	L M W T L P V M L I A M Y F Y T M L

5.288 secretory carrier membrane protein 3 isoform 1 [Homo sapiens]
Protein Accession gi|16445419

Mean Expression Ratio 0.964

Median Expression Ratio 0.965

Credible Interval (0.593, 1.56)

Associated Peptides 1

Associated Spectra 1

Coverage 0.075


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.95	1.6	SEQ ID NO: 1498	EPPPAYEPPAPAPLPPPSAPSLQPSR

SEQ ID NO: 1499

1	M A Q S R D G G N P F A E P S E L D N P F Q D P A V I Q H R P S R Q Y A T L D V
	Y N P F E T R E P P P A Y E P P A P A P L P P P S A P S L Q P S R K L S P T E P

81	K N Y G S Y S T Q A S A A A A T A E L L K K Q E E L N R K A E E L D R R E R E L
	Q H A A L G G T A T R Q N N W P P L P S F C P V Q P C F F Q D I S M E I P Q E F

161	Q K T V S T M Y Y L W M C S T L A L L L N F L A C L A S F C V E T N N G A G F
	G L S I L W V L L F T P C S F V C W Y R P M Y K A F R S D S S F N F F V F F F I F

241	F V Q D V L F V L Q A I G I P G W G F S G W I S A L V V P K G N T A V S V L M
	L L V A L L F T G I A V L G I V M L K R I H S L Y R R T G A S F Q K A Q Q E F A A

321	G V F S N P A V R T A A A N A A A G A A E N A F R A P

5.289 guanine nucleotide binding protein (G protein), gamma 2 [Homo sapiens]
Protein Accession gi|54114974

Mean Expression Ratio 1.04

Median Expression Ratio 1.04

Credible Interval (0.635, 1.69)

Associated Peptides 1

Associated Spectra 1

Coverage 0.225

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.62 1.0 1.8 SEQ ID NO: 1500 EDPLLTPVPASENPFR

SEQ ID NO: 1501

1 M A S N N T A S I A Q A R K L V E Q L K M E A N I D R I K V S K A A A D L M A Y

C E A H A K E D P L L T P V P A S E N P F R E K K F F C A I L

5.290 sorbitol dehydrogenase [Homo sapiens]
Protein Accession gi|156627571

Mean Expression Ratio 0.967

Median Expression Ratio 0.967

Credible Interval (0.601, 1.58)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0476


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.58	0.95	1.6	SEQ ID NO: 1502	LENYPIPEPGPNEVLLR

SEQ ID NO: 1503

1	M A A A A K P N N L S L V V H G P G D L R L E N Y P I P E P G P N E V L L R M H
	S V G I C G S D V H Y W E Y G R I G N F I V K K P M V L G H E A S G T V E K V G

81	S S V K H L K P G D R V A I E P G A P R E N D E F C K M G R Y N L S P S I F F C A
	T P P D D G N L C R F Y K H N A A F C Y K L P D N V T F E E G A L I E P L S V

161	G I H A C R R G G V T L G H K V L V C G A G P I G M V T L L V A K A M G A A
	Q V V V T D L S A T R L S K A K E I G A D L V L Q I S K E S P Q E I A R K V E G Q L

241	G C K P E V T I E C T G A E A S I Q A G I Y A T R S G G N L V L V G L G S E M T
	T V P L L H A A I R E V D I K G V F R Y C N T W P V A I S M L A S K S V N V K P

321	L V T H R F P L E K A L E A F E T F K K G L G L K I M L K C D P S D Q N P

5.291 major facilitator superfamily domain containing 1 [Homo sapiens]
Protein Accession gi|112232393

Mean Expression Ratio 0.97

Median Expression Ratio 0.967

Credible Interval (0.601, 1.6)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0258


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.56	0.96	1.6	SEQ ID NO: 1504	ALLAGGPDEADR

SEQ ID NO: 1505

1	M E E E D E E A R A L L A G G P D E A D R G A P A A P G A L P A L C D P S R L A
	H R L L V L L L M C F L G F G S Y F C Y D N P A A L Q T Q V K R D M Q V N T T K

81	F M L L Y A W Y S W P N V V L C F F G G F L I D R V F G I R W G T I I F S C F V
	C I G Q V V F A L G G I F N A F W L M E F G R F V F G I G G E S L A V A Q N T Y

161	A V S W F K G K E L N L V F G L Q L S M A R I G S T V N M N L M G W L Y S K
	I E A L L G S A G H T T L G I T L M I G G V T C I L S L I C A L A L A Y L D Q R A E

241	R I L H K E Q G K T G E V I K L T D V K D F S L P L W L I F I I C V C Y Y V A V
	F P F I G L G K V F F T E K F G F S S Q A A S A I N S V V Y V I S A P M S P V F

321	G L L V D K T G K N I I W V L C A V A A T L V S H M M L A F T M W N P W I A
	M C L L G L S Y S L L A C A L W P M V A F V V P E H Q L G T A Y G F M Q S I Q N L G

401	L A I I S I I A G M I L D S R G Y L F L E V F F I A C V S L S L L S V V L L Y L V N
	R A Q G G N L N Y S A R Q R E E I K F S H T E

5.292 superoxide dismutase 3, extracellular precursor [Homo sapiens]
Protein Accession gi|118582275

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.669, 1.6)

Associated Peptides 2

Associated Spectra 2

Coverage 0.1


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1.1	1.7	SEQ ID NO: 1506	VTEIWQEVMQR

1	0.64	1.0	1.7	SEQ ID NO: 1507	AVVVHAGEDDLGR

SEQ ID NO: 1508

1	M L A L L C S C L L L A A G A S D A W T G E D S A E P N S D S A E W I R D M Y A
	K V T E I W Q E V M Q R R D D D G A L H A A C Q V Q P S A T L D A A Q P R V T G

81	V V L F R Q L A P R A K L D A F F A L E G F P T E P N S S S R A I H V H Q F G D L
	S Q G C E S T G P H Y N P L A V P H P Q H P G D F G N F A V R D G S L W R Y R

161	A G L A A S L A G P H S I V G R A V V V H A G E D D L G R G G N Q A S V E N
	G N A G R R L A C C V V G V C G P G L W E R Q A R E H S E R K K R R R E S E C K
	A A

5.293 nuclear transport factor 2 [Homo sapiens]
Protein Accession gi|5031985

Mean Expression Ratio 0.967

Median Expression Ratio 0.967

Credible Interval (0.599, 1.58)

Associated Peptides 1

Associated Spectra 1

Coverage 0.110


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.96	1.6	SEQ ID NO: 1509	NINDAWVCTNDMFR

SEQ ID NO: 1510

1	M G D K P I W E Q I G S S F I Q H Y Y Q L F D N D R T Q L G A I Y I D A S C L T W
	E G Q Q F Q G K A A I V E K L S S L P F Q K I Q H S I T A Q D H Q P T P D S C

81	I I S M V V G Q L K A D E D P I M G F H Q M F L L K N I N D A W V C T N D M F
	R L A L H N F G

5.294 hexosaminidase B preproprotein [Homo sapiens]
Protein Accession gi|4504373

Mean Expression Ratio 0.967

Median Expression Ratio 0.967

Credible Interval (0.686, 1.36)

Associated Peptides 4

Associated Spectra 4

Coverage 0.0971


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.64	0.97	1.4	SEQ ID NO: 1511	EISEVFPDQFIHLGGDEVEFK

1	0.63	0.96	1.5	SEQ ID NO: 1512	LAPGTIVEVWK

1	0.64	0.97	1.5	SEQ ID NO: 1513	VLDIIATINK

1	0.63	0.96	1.4	SEQ ID NO: 1514	YLDLISYGQDWR

SEQ ID NO: 1515

1	M E L C G L G L P R P P M L L A L L L A T L L A A M L A L L T Q V A L V V Q V A
	E A A R A P S V S A K P G P A L W P L P L S V K M T P N L L H L A P E N F Y I S

81	H S P N S T A G P S C T L L E E A F R R Y H G Y I F G F Y K W H H E P A E F Q A
	K T Q V Q Q L L V S I T L Q S E C D A F P N I S S D E S Y T L L V K E P V A V L

161	K A N R V W G A L R G L E T F S Q L V Y Q D S Y G T F T I N E S T I I D S P R F
	S H R G I L I D T S R H Y L P V K I I L K T L D A M A F N K F N V L H W H I V D

241	D Q S F P Y Q S I T F P E L S N K G S Y S L S H V Y T P N D V R M V I E Y A R L
	R G I R V L P E F D T P G H T L S W G K G Q K D L L T P C Y S R Q N K L D S F G

321	P I N P T L N T T Y S F L T T F F K E I S E V F P D Q F I H L G G D E V E F K C W
	E S N P K I Q D F M R Q K G F G T D F K K L E S F Y I Q K V L D I I A T I N K

401	G S I V W Q E V F D D K A K L A P G T I V E V W K D S A Y P E E L S R V T A S
	G F P V I L S A P W Y L D L I S Y G Q D W R K Y Y K V E P L D F G G T Q K Q K Q L

481	F I G G E A C L W G E Y V D A T N L T P R L W P R A S A V G E R L W S S K D V
	R D M D D A Y D R L T R H R C R M V E R G I A A Q P L Y A G Y C N H E N M

5.295 nucleoporin 188 kDa [Homo sapiens]
Protein Accession gi|62955803

Mean Expression Ratio 0.967

Median Expression Ratio 0.967

Credible Interval (0.665, 1.41)

Associated Peptides 1

Associated Spectra 4

Coverage 0.00515


A	2.5	50	97.5	Sequence ID No.	Sequence

4	0.67	0.96	1.4	SEQ ID NO: 1516	MLQHYLQNK

SEQ ID NO: 1517

1	M A A A A G G P C V R S S R E L W T I L L G R S A L R E L S Q I E A E L N K H W
	R R L L E G L S Y Y K P P S P S S A E K V K A N K D V A S P L K E L G L R I S K

81	F L G L D E E Q S V Q L L Q C Y L Q E D Y R G T R D S V K T V L Q D E R Q S Q
	A L I L K I A D Y Y Y E E R T C I L R C V L H L L T Y F Q D E R H P Y R V E Y A D

161	C V D K L E K E L V S K Y R Q Q F E E L Y K T E A P T W E T H G N L M T E R Q
	V S R W F V Q C L R E Q S M L L E I I F L Y Y A Y F E M A P S D L L V L T K M F K

241	E Q G F G S R Q T N R H L V D E T M D P F V D R I G Y F S A L I L V E G M D I E
	S L H K C A L D D R R E L H Q F A Q D G L I C Q D M D C L M L T F G D I P H H A

321	P V L L A W A L L R H T L N P E E T S S V V R K I G G T A I Q L N V F Q Y L T R
	L L Q S L A S G G N D C T T S T A C M C V Y G L L S F V L T S L E L H T L G N Q

401	Q D I I D T A C E V L A D P S L P E L F W G T E P T S G L G I I L D S V C G M F P
	H L L S P L L Q L L R A L V S G K S T A K K V Y S F L D K M S F Y N E L Y K H

481	K P H D V I S H E D G T L W R R Q T P K L L Y P L G G Q T N L R I P Q G T V G
	Q V M L D D R A Y L V R W E Y S Y S S W T L F T C E I E M L L H V V S T A D V I Q

561	H C Q R V K P I I D L V H K V I S T D L S I A D C L L P I T S R I Y M L L Q R L T
	T V I S P P V D V I A S C V N C L T V L A A R N P A K V W T D L R H T G F L P

641	F V A H P V S S L S Q M I S A E G M N A G G Y G N L L M N S E Q P Q G E Y G V
	T I A F L R L I T T L V K G Q L G S T Q S Q G L V P C V M F V L K E M L P S Y H K

721	W R Y N S H G V R E Q I G C L I L E L I H A I L N L C H E T D L H S S H T P S L
	Q F L C I C S L A Y T E A G Q T V I N I M G I G V D T I D M V M A A Q P R S D G

801	A E G Q G Q G Q L L I K T V K L A F S V T N N V I R L K P P S N V V S P L E Q A
	L S Q H G A H G N N L I A V L A K Y I Y H K H D P A L P R L A I Q L L K R L A T

881	V A P M S V Y A C L G N D A A A I R D A F L T R L Q S K I E D M R I K V M I L
	E F L T V A V E T Q P G L I E L F L N L E V K D G S D G S K E F S L G M W S C L H

961	A V L E L I D S Q Q Q D R Y W C P P L L H R A A I A F L H A L W Q D R R D S A
	M L V L R T K P K F W E N L T S P L F G T L S P P S E T S E P S I L E T C A L I M

1041	K I I C L E I Y Y V V K G S L D Q S L K D T L K K F S I E K R F A Y W S G Y V
	K S L A V H V A E T E G S S C T S L L E Y Q M L V S A W R M L L I I A T T H A D I

1121	M H L T D S V V R R Q L F L D V L D G T K A L L L V P A S V N C L R L G S M
	K C T L L L I L L R Q W K R E L G S V D E I L G P L T E I L E G V L Q A D Q Q L M E

1201	K T K A K V F S A F I T V L Q M K E M K V S D I P Q Y S Q L V L N V C E T L Q
	E E V I A L F D Q T R H S L A L G S A T E D K D S M E T D D C S R S R H R D Q R D

1281	G V C V L G L H L A K E L C E V D E D G D S W L Q V T R R L P I L P T L L T T
	L E V S L R M K Q N L H F T E A T L H L L L T L A R T Q Q G A T A V A G A G I T Q

1361	S I C L P L L S V Y Q L S T N G T A Q T P S A S R K S L D A P S W P G V Y R L S
	M S L M E Q L L K T L R Y N F L P E A L D F V G V H Q E R T L Q C L N A V R T V

1441	Q S L A C L E E A D H T V G F I L Q L S N F M K E W H F H L P Q L M R D I Q V
	N L G Y L C Q A C T S L L H S R K M L Q H Y L Q N K N G D G L P S A V A Q R V Q R

1521	P P S A A S A A P S S S K Q P A A D T E A S E Q Q A L H T V Q Y G L L K I L S
	K T L A A L R H F T P D V C Q I L L D Q S L D L A E Y N F L F A L S F T T P T F D

1601	S E V A P S F G T L L A T V N V A L N M L G E L D K K K E P L T Q A V G L S T
	Q A E G T R T L K S L L M F T M E N C F Y L L I S Q A M R Y L R D P A V H P R D K

1681	Q R M K Q E L S S E L S T L L S S L S R Y F R R G A P S S P A T G V L P S P Q G
	K S T S L S K A S P E S Q E P L I Q L V Q A F V R H M Q R

5.296 hypothetical protein LOC54978 [Homo sapiens]
Protein Accession gi|31542711

Mean Expression Ratio 0.965

Median Expression Ratio 0.967

Credible Interval (0.589, 1.58)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0323


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.95	1.6	SEQ ID NO: 1518	GRPLAEESEQER

SEQ ID NO: 1519

1	M A W T K Y Q L F L A G L M L V T G S I N T L S A K W A D N F M A E G C G G S
	K E H S F Q H P F L Q A V G M F L G E F S C L A A F Y L L R C R A A G Q S D S S V

81	D P Q Q P F N P L L F L P P A L C D M T G T S L M Y V A L N M T S A S S F Q M L
	R G A V I I F T G L F S V A F L G R R L V L S Q W L G I L A T I A G L V V V G L

161	A D L L S K H D S Q H K L S E V I T G D L L I I M A Q I I V A I Q M V L E E K F V
	Y K H N V H P L R A V G T E G L F G F V I L S L L L V P M Y Y I P A G S F S G

241	N P R G T L E D A L D A F C Q V G Q Q P L I A V A L L G N I S S I A F F N F A G I
	S V T K E L S A T T R M V L D S L R T V V I W A L S L A L G W E A F H A L Q I

321	L G F L I L L I G T A L Y N G L H R P L L G R L S R G R P L A E E S E Q E R L L G
	G T R T P I N D A S

5.297 disrupted in renal carcinoma 2 [Homo sapiens]
Protein Accession gi|14249552

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.705, 1.52)

Associated Peptides 2

Associated Spectra 3

Coverage 0.069


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.7	1.0	1.6	SEQ ID NO: 1520	EAAAAALPAAVPGPGR

1	0.66	1.0	1.6	SEQ ID NO: 1521	QPLLGPGLGPGLGASWR

SEQ ID NO: 1522

1	M G S R W S S E E E R Q P L L G P G L G P G L G A S W R S R E A A A A A L P A A
	V P G P G R V Y G R R W L V L L L F S L L A F V Q G L V W N T W G P I Q N S A R

81	Q A Y G F S S W D I A L L V L W G P I G F L P C F A F M W L L D K R G L R I T V
	L L T S F L M V L G T G L R C I P I S D L I L K R R L I H G G Q M L N G L A G P

161	T V M N A A P F L S T T W F S A D E R A T A T A I A S M L S Y L G G A C A F L
	V G P L V V P A P N G T S P L L A A E S S R A H I K D R I E A V L Y A E F G V V C

241	L I F S A T L A Y F P P R P P L P P S V A A A S Q R L S Y R R S V C R L L S N F R
	F L M I A L A Y A I P L G V F A G W S G V L D L I L T P A H V S Q V D A G W I

321	G F W S I V G G C V V G I A M A R F A D F I R G M L K L I L L L L F S G A T L S
	S T W F T L T C L N S I T H L P L T T V T L Y A S C I L L G V F L N S S V P I F

401	F E L F V E T V Y P V P E G I T C G V V T F L S N M F M G V L L F F L T F Y H T
	E L S W F N W C L P G S C L L S L L L I L C F R E S Y D R L Y L D V V V S V

5.298 adenine phosphoribosyltransferase isoform b [Homo sapiens]
Protein Accession gi|71773201

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.636, 1.69)

Associated Peptides 1

Associated Spectra 1

Coverage 0.097


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	1.0	1.7	SEQ ID NO: 1523	SFPDFPTPGVVFR

SEQ ID NO: 1524

1	M A D S E L Q L V E Q R I R S F P D F P T P G V V F R D I S P V L K D P A S F R A
	A I G L L A R H L K A T H G G R I D Y I A G L D S R G F L F G P S L A Q E L G

81	L G C V L I R K R G K L P G P T L W A S Y S L E Y G K A E L E I Q K D A L E P G
	Q R V V V V D D L L A T G V

5.299 GNAS complex locus XLas [Homo sapiens]
Protein Accession gi|117938759

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.755, 1.40)

Associated Peptides 4

Associated Spectra 7

Coverage 0.0501


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.7	0.98	1.4	SEQ ID NO: 1525	IEDYFPEFAR

1	0.69	1.0	1.5	SEQ ID NO: 1526	SNLVPPVELANPENQFR

2	0.8	1.1	1.6	SEQ ID NO: 1527	YTTPEDATPEPGEDPR

1	0.7	1.0	1.5	SEQ ID NO: 1528	LQEALNLFK

SEQ ID NO: 1529

1	M G V R N C L Y G N N M S G Q R D I P P E I G E Q P E Q P P L E A P G A A A P G
	A G P S P A E E M E T E P P H N E P I P V E N D G E A C G P P E V S R P N F Q V

81	L N P A F R E A G A H G S Y S P P P E E A M P F E A E Q P S L G G F W P T L E Q
	P G F P S G V H A G L E A F G P A L M E P G A F S G A R P G L G G Y S P P P E E

161	A M P F E F D Q P A Q R G C S Q L L L Q V P D L A P G G P G A A G V P G A P P
	E E P Q A L R P A K A G S R G G Y S P P P E E T M P F E L D G E G F G D D S P P P

241	G L S R V I A Q V D G S S Q F A A V A A S S A V R L T P A A N A P P L W V P G
	A I G S P S Q E A V R P P S N F T G S S P W M E I S G P P F E I G S A P A G V D D

321	T P V N M D S P P I A L D G P P I K V S G A P D K R E R A E R P P V E E E A A E
	M E G A A D A A E G G K V P S P G Y G S P A A G A A S A D T A A R A A P A A P A

401	D P D S G A T P E D P D S G T A P A D P D S G A F A A D P D S G A A P A A P A
	D P D S G A A P D A P A D P D S G A A P D A P A D P D A G A A P E A P A A P A A A

481	E T R A A H V A P A A P D A G A P T A P A A S A T R A A Q V R R A A S A A P A
	S G A R R K I H L R P P S P E I Q A A D P P T P R P T R A S A W R G K S E S S R G

561	R R V Y Y D E G V A S S D D D S S G D E S D D G T S G C L R W F Q H R R N R R
	R R K P Q R N L L R N F L V Q A F G G C F G R S E S P Q P K A S R S L K V K K V P

641	L A E K R R Q M R K E A L E K R A Q K R A E K K R S K L I D K Q L Q D E K M
	G Y M C T H R L L L L G A G E S G K S T I V K Q M R I L H V N G F N G E G G E E D P

721	Q A A R S N S D G E K A T K V Q D I K N N L K E A I E T I V A A M S N L V P P
	V E L A N P E N Q F R V D Y I L S V M N V P D F D F P P E F Y E H A K A L W E D E

801	G V R A C Y E R S N E Y Q L I D C A Q Y F L D K I D V I K Q A D Y V P S D Q D
	L L R C R V L T S G I F E T K F Q V D K V N F H M F D V G G Q R D E R R K W I Q C

881	F N D V T A I I F V V A S S S Y N M V I R E D N Q T N R L Q E A L N L F K S I W
	N N R W L R T I S V I L F L N K Q D L L A E K V L A G K S K I E D Y F P E F A R

961	Y T T P E D A T P E P G E D P R V T R A K Y F I R D E F L R I S T A S G D G R H
	Y C Y P H F T C A V D T E N I R R V F N D C R D I I Q R M H L R Q Y E L L

5.300 A kinase (PRKA) anchor protein 12 isoform 2 [Homo sapiens]
Protein Accession gi|21493024

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.673, 1.58)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0232


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.64	1.0	1.6	SEQ ID NO: 1530	EESQLPGTGGPEDVLQPVQR

1	0.65	1.0	1.7	SEQ ID NO: 1531	EVIAEEEPPTVTEPLPENR

SEQ ID NO: 1532

1	M L G T I T I T V G Q R D S E D V S K R D S D K E M A T K S A V V H D I T D D G
	Q E E T P E I I E Q I P S S E S N L E E L T Q P T E S Q A N D I G F K K V F K F

81	V G F K F T V K K D K T E K P D T V Q L L T V K K D E G E G A A G A G D H K D
	P S L G A G E A A S K E S E P K Q S T E K P E E T L K R E Q S H A E I S P P A E S

161	G Q A V E E C K E E G E E K Q E K E P S K S A E S P T S P V T S E T G S T F K K
	F F T Q G W A G W R K K T S F R K P K E D E V E A S E K K K E Q E P E K V D T E

241	E D G K A E V A S E K L T A S E Q A H P Q E P A E S A H E P R L S A E Y E K V
	E L P S E E Q V S G S Q G P S E E K P A P L A T E V F D E K I E V H Q E E V V A E

321	V H V S T V E E R T E E Q K T E V E E T A G S V P A E E L V E M D A E P Q E A
	E P A K E L V K L K E T C V S G E D P T Q G A D L S P D E K V L S K P P E G V V S

401	E V E M L S S Q E R M K V Q G S P L K K L F T S T G L K K L S G K K Q K G K R
	G G G D E E S G E H T Q V P A D S P D S Q E E Q K G E S S A S S P E E P E E I T C

481	L E K G L A E V Q Q D G E A E E G A T S D G E K K R E G V T P W A S F K K M
	V T P K K R V R R P S E S D K E D E L D K V K S A T L S S T E S T A S E M Q E E M K

561	G S V E E P K P E E P K R K V D T S V S W E A L I C V G S S K K R A R R G S S S
	D E E G G P K A M G G D H Q K A D E A G K D K E T G T D G I L A G S Q E H D P G

641	Q G S S S P E Q A G S P T E G E G V S T W E S F K R L V T P R K K S K S K L E E
	K S E D S I A G S G V E H S T P D T E P G K E E S W V S I K K F I P G R R K K R

721	P D G K Q E Q A P V E D A G P T G A N E D D S D V P A V V P L S E Y D A V E R
	E K M E A Q Q A Q K S A E Q P E Q K A A T E V S K E L S E S Q V H M M A A A V A D

801	G T R A A T I I E E R S P S W I S A S V T E P L E Q V E A E A A L L T E E V L E R
	E V I A E E E P P T V T E P L P E N R E A R G D T V V S E A E L T P E A V T A

881	A E T A G P L G A E E G T E A S A A E E T T E M V S A V S Q L T D S P D T T E E
	A T P V Q E V E G G V P D I E E Q E R R T Q E V L Q A V A E K V K E E S Q L P G

961	T G G P E D V L Q P V Q R A E A E R P E E Q A E A S G L K K E T D V V L K V D
	A Q E A K T E P F T Q G K V V G Q T T P E S F E K A P Q V T E S I E S S E L V T T

1041	C Q A E T L A G V K S Q E M V M E Q A I P P D S V E T P T D S E T D G S T P V
	A D F D A P G T T Q K D E I V E I H E E N E V A S G T Q S G G T E A E A V P A Q K

1121	E R P P A P S S F V F Q E E T K E Q S K M E D T L E H T D K E V S V E T V S I L
	S K T E G T Q E A D Q Y A D E K T K D V P F F E G L E G S I D T G I T V S R E K

1201	V T E V A L K G E G T E E A E C K K D D A L E L Q S H A K S P P S P V E R E M
	V V Q V E R E K T E A E P T H V N E E K L E H E T A V T V S E E V S K Q L L Q T V

1281	N V P I I D G A K E V S S L E G S P P P C L G Q E E A V C T K I Q V Q S S E A S
	F T L T A A A E E E K V L G E T A N I L E T G E T L E P A G A H L V L E E K S S

1361	E K N E D F A A H P G E D A V P T G P D C Q A K S T P V I V S A T T K K G L S
	S D L E G E K T T S L K W K S D E V D E Q V A C Q E V K V S V A I E D L E P E N G

1441	I L E L E T K S S K L V Q N I I Q T A V D Q F V R T E E T A T E M L T S E L Q T
	Q A H V I K A D S Q D A G Q E T E K E G E E P Q A S A Q D E T P I T S A K E E S

1521	E S T A V G Q A H S D I S K D M S E A S E K T M T V E V E G S T V N D Q Q L
	E E V V L P S E E E G G G A G T K S V P E D D G H A L L A E R I E K S L V E P K E D

1601	E K G D D V D D P E N Q N S A L A D T D A S G G L T K E S P D T N G P K Q K
	E K E D A Q E V E L Q E G K V H S E S D K A I T P Q A Q E E L Q K Q E R E S A K S E

1681	L T E S

5.301 orosomucoid 1 precursor [Homo sapiens]
Protein Accession gi|167857790

Mean Expression Ratio 0.97

Median Expression Ratio 0.97

Credible Interval (0.666, 1.44)

Associated Peptides 3

Associated Spectra 3

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	0.97	1.5	SEQ ID NO: 1533	WFYIASAFR

1	0.64	0.99	1.5	SEQ ID NO: 1534	EQLGEFYEALDCLR

1	0.61	0.95	1.5	SEQ ID NO: 1535	YVGGQEHFAHLLILR

5.302 lysozyme precursor [Homo sapiens]
Protein Accession gi|4557894

Mean Expression Ratio 0.969

Median Expression Ratio 0.97

Credible Interval (0.6, 1.57)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0811


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.58	0.96	1.6	SEQ ID NO: 1536	STDYGIFQINSR

SEQ ID NO: 1537

1	M K A L I V L G L V L L S V T V Q G K V F E R C E L A R T L K R L G M D G Y R G
	I S L A N W M C L A K W E S G Y N T R A T N Y N A G D R S T D Y G I F Q I N S R

81	Y W C N D G K T P G A V N A C H L S C S A L L Q D N I A D A V A C A K R V V R
	D P Q G I R A W V A W R N R C Q N R D V R Q Y V Q G C G V

5.303 vacuolar protein sorting 37C [Homo sapiens]
Protein Accession gi|57863314

Mean Expression Ratio 0.972

Median Expression Ratio 0.97

Credible Interval (0.658, 1.44)

Associated Peptides 3

Associated Spectra 3

Coverage 0.177


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	0.97	1.5	SEQ ID NO: 1538	FLEGEVPLETFLENFSSMR

1	0.64	1	1.6	SEQ ID NO: 1539	NLEFQGPLEISR

1	0.6	0.93	1.4	SEQ ID NO: 1540	TLQELEELQNDSEAIDQLALESPE
					VQDLQLER

SEQ ID NO: 1541

1	M E T L K D K T L Q E L E E L Q N D S E A I D Q L A L E S P E V Q D L Q L E R E
	M A L A T N R S L A E R N L E F Q G P L E I S R S N L S D R Y Q E L R K L V E R

81	C Q E Q K A K L E K F S S A L Q P G T L L D L L Q V E G M K I E E E S E A M A E
	K F L E G E V P L E T F L E N F S S M R M L S H L R R V R V E K L Q E V V R K P

161	R A S Q E L A G D A P P P R P P P P V R P V P Q G T P P V V E E Q P Q P P L A M
	P P Y P L P Y S P S P S L P V G P T A H G A L P P A P F P V V S Q P S F Y S G P

241	L G P T Y P A A Q L G P R G A A G Y S W S P Q R S M P P R P G Y P G T P M G A
	S G P G Y P L R G G R A P S P G Y P Q Q S P Y P A T G G K P P Y P I Q P Q L P S F

321	P G Q P Q P S V P L Q P P Y P P G P A P P Y G F P P P P G P A W P G Y

5.304 NAD(P)H dehydrogenase, quinone 2 [Homo sapiens]
Protein Accession gi|156564357

Mean Expression Ratio 0.972

Median Expression Ratio 0.97

Credible Interval (0.596, 1.58)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0779


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.58	0.97	1.6	SEQ ID NO: 1542	VLAPQISFAPEIASEEER

SEQ ID NO: 1543

1	M A G K K V L I V Y A H Q E P K S F N G S L K N V A V D E L S R Q G C T V T V S
	D L Y A M N L E P R A T D K D I T G T L S N P E V F N Y G V E T H E A Y K Q R S

81	L A S D I T D E Q K K V R E A D L V I F Q F P L Y W F S V P A I L K G W M D R V
	L C Q G F A F D I P G F Y D S G L L Q G K L A L L S V T T G G T A E M Y T K T G

161	V N G D S R Y F L W P L Q H G T L H F C G F K V L A P Q I S F A P E I A S E E E
	R K G M V A A W S Q R L Q T I W K E E P I P C T A H W H F G Q

5.305 cystatin B [Homo sapiens]
Protein Accession gi|4503117

Mean Expression Ratio 0.97

Median Expression Ratio 0.97

Credible Interval (0.603, 1.59)

Associated Peptides 1

Associated Spectra 1

Coverage 0.122


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.58	0.96	1.6	SEQ ID NO: 1544	VHVGDEDFVHLR

SEQ ID NO: 1545

1	M M C G A P S A T Q P A T A E T Q H I A D Q V R S Q L E E K E N K K F P V F K A

	V S F K S Q V V A G T N Y F I K V H V G D E D F V H L R V F Q S L P H E N K P L
81	T L S N Y Q T N K A K H D E L T Y F

5.306 triosephosphate isomerase 1 [Homo sapiens]
Protein Accession gi|4507645

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.635, 1.68)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0522


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	1.0	1.7	SEQ ID NO: 1546	TATPQQAQEVHEK

SEQ ID NO: 1547

1	M A P S R K F F V G G N W K M N G R K Q S L G E L I G T L N A A K V P A D T E
	V V C A P P T A Y I D F A R Q K L D P K I A V A A Q N C Y K V T N G A F T G E I S

81	P G M I K D C G A T W V V L G H S E R R H V F G E S D E L I G Q K V A H A L A
	E G L G V I A C I G E K L D E R E A G I T E K V V F E Q T K V I A D N V K D W S K

161	V V L A Y E P V W A I G T G K T A T P Q Q A Q E V H E K L R G W L K S N V S
	D A V A Q S T R I I Y G G S V T G A T C K E L A S Q P D V D G F L V G G A S L K P E

241	F V D I I N A K Q

5.307 nucleoside phosphorylase [Homo sapiens]
Protein Accession gi|157168362

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.725, 1.45)

Associated Peptides 4

Associated Spectra 5

Coverage 0.208


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.68	1.0	1.6	SEQ ID NO: 1548	LGADAVGMSTVPEVIVAR

1	0.68	1.0	1.5	SEQ ID NO: 1549	LTQAQIFDYGEIPNFPR

2	0.71	1.0	1.5	SEQ ID NO: 1550	DHINLPGFSGQNPLR

1	0.67	1.0	1.5	SEQ ID NO: 1551	FEVGDIMLIR

SEQ ID NO: 1552

1	M E N G Y T Y E D Y K N T A E W L L S H T K H R P Q V A I I C G S G L G G L T D
	K L T Q A Q I F D Y G E I P N F P R S T V P G H A G R L V F G F L N G R A C V M

81	M Q G R F H M Y E G Y P L W K V T F P V R V F H L L G V D T L V V T N A A G
	G L N P K F E V G D I M L I R D H I N L P G F S G Q N P L R G P N D E R F G D R F P

161	A M S D A Y D R T M R Q R A L S T W K Q M G E Q R E L Q E G T Y V M V A G
	P S F E T V A E C R V L Q K L G A D A V G M S T V P E V I V A R H C G L R V F G F
	S L

241	I T N K V I M D Y E S L E K A N H E E V L A A G K Q A A Q K L E Q F V S I L M
	A S I P L P D K A S

5.308 guanine nucleotide binding protein (G protein), alpha 13 [Homo sapiens]
Protein Accession gi|24111250

Mean Expression Ratio 0.97

Median Expression Ratio 0.972

Credible Interval (0.686, 1.38)

Associated Peptides 4

Associated Spectra 4

Coverage 0.138


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.61	0.93	1.4	SEQ ID NO: 1553	IIHGQDFDQR

1	0.63	0.96	1.5	SEQ ID NO: 1554	LGEPDYIPSQQDILLAR

1	0.65	0.98	1.5	SEQ ID NO: 1555	LTESLNIFETIVNNR

1	0.66	1	1.5	SEQ ID NO: 1556	VFLQYLPAIR

SEQ ID NO: 1557

1	M A D F L P S R S V L S V C F P G C L L T S G E A E Q Q R K S K E I D K C L S R E
	K T Y V K R L V K I L L L G A G E S G K S T F L K Q M R I I H G Q D F D Q R A

81	R E E F R P T I V S N V I K G M R V L V D A R E K L H I P W G D N S N Q Q H G D
	K M M S F D T R A P M A A Q G M V E T R V F L Q Y L P A I R A L W A D S G I Q N

161	A Y D R R R E F Q L G E S V K Y F L D N L D K L G E P D Y I P S Q Q D I L L A R
	R P T K G I H E Y D F E I K N V P F K M V D V G G Q R S E R K R W F E C F D S V

241	T S I L F L V S S S E F D Q V L M E D R L T N R L T E S L N I F E T I V N N R V F
	S N V S I I L F L N K T D L L E E K V Q I V S I K D Y F L E F E G D P H C L R

321	D V Q K F L V E C F R N K R R D Q Q Q K P L Y H H F T T A I N T E N I R L V F R
	D V K D T I L H D N L K Q L M L Q

5.309 phospholipid scramblase 3 [Homo sapiens]
Protein Accession gi|31543417

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.687, 1.54)

Associated Peptides 1

Associated Spectra 3

Coverage 0.0678


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.7	1.0	1.5	SEQ ID NO: 1558	EALTDADDFGLQFPLDLDVR

SEQ ID NO: 1559

1	M A G Y L P P K G Y A P S P P P P Y P V T P G Y P E P A L H P G P G Q A P V P A Q
	V P A P A P G F A L F P S P G P V A L G S A A P F L P L P G V P S G L E F L V

81	Q I D Q I L I H Q K A E R V E T F L G W E T C N R Y E L R S G A G Q P L G Q A A
	E E S N C C A R L C C G A R R P L R V R L A D P G D R E V L R L L R P L H C G C

161	S C C P C G L Q E M E V Q A P P G T T I G H V L Q T W H P F L P K F S I Q D A D
	R Q T V L R V V G P C W T C G C G T D T N F E V K T R D E S R S V G R I S K Q W

241	G G L V R E A L T D A D D F G L Q F P L D L D V R V K A V L L G A T F L I D Y
	M F F E K R G G A G P S A V T S

5.310 plasma glutamate carboxypeptidase [Homo sapiens]
Protein Accession gi|7706387

Mean Expression Ratio 0.974

Median Expression Ratio 0.972

Credible Interval (0.602, 1.57)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0233


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.59	0.96	1.6	SEQ ID NO: 1560	LALLVDTVGPR

SEQ ID NO: 1561

1	M K F L I F A F F G G V H L L S L C S G K A I C K N G I S K R T F E E I K E E I A S
	C G D V A K A I I N L A V Y G K A Q N R S Y E R L A L L V D T V G P R L S G

81	S K N L E K A I Q I M Y Q N L Q Q D G L E K V H L E P V R I P H W E R G E E S A
	V M L E P R I H K I A I L G L G S S I G T P P E G I T A E V L V V T S F D E L Q

161	R R A S E A R G K I V V Y N Q P Y I N Y S R T V Q Y R T Q G A V E A A K V G A
	L A S L I R S V A S F S I Y S P H T G I Q E Y Q D G V P K I P T A C I T V E D A E

241	M M S R M A S H G I K I V I Q L K M G A K T Y P D T D S F N T V A E I T G S K
	Y P E Q V V L V S G H L D S W D V G Q G A M D D G G G A F I S W E A L S L I K D L

321	G L R P K R T L R L V L W T A E E Q G G V G A F Q Y Y Q L H K V N I S N Y S L
	V M E S D A G T F L P T G L Q F T G S E K A R A I M E E V M S L L Q P L N I T Q V

401	L S H G E G T D I N F W I Q A G V P G A S L L D D L Y K Y F F F H H S H G D T
	M T V M D P K Q M N V A A A V W A V V S Y V V A D M E E M L P R S

5.311 bone marrow stromal cell antigen 1 precursor [Homo sapiens]
Protein Accession gi|168229159

Mean Expression Ratio 1.02

Median Expression Ratio 1.03

Credible Interval (0.626, 1.66)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.61 1.0 1.7 SEQ ID NO: 1562 SLFWENSHLLVNSFADNTR

5.312 solute carrier organic anion transporter family, member 4C1 [Homo sapiens]
Protein Accession gi|38679890

Mean Expression Ratio 0.974

Median Expression Ratio 0.973

Credible Interval (0.595, 1.57)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0221


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.58	0.97	1.6	SEQ ID NO: 1563	GIENLAFVPSSPDILR

SEQ ID NO: 1564

1	M K S A K G I E N L A F V P S S P D I L R R L S A S P S Q I E V S A L S S D P Q R E
	N S Q P Q E L Q K P Q E P Q K S P E P S L P S A P P N V S E E K L R S L S L

81	S E F E E G S Y G W R N F H P Q C L Q R C N T P G G F L L H Y C L L A V T Q G I
	V V N G L V N I S I S T V E K R Y E M K S S L T G L I S S S Y D I S F C L L S L

161	F V S F F G E R G H K P R W L A F A A F M I G L G A L V F S L P Q F F S G E Y K
	L G S L F E D T C V T T R N S T S C T S S T S S L S N Y L Y V F I L G Q L L L G

241	A G G T P L Y T L G T A F L D D S V P T H K S S L Y I G T G Y A M S I L G P A I
	G Y V L G G Q L L T I Y I D V A M G E S T D V T E D D P R W L G A W W I G F L L

321	S W I F A W S L I I P F S C F P K H L P G T A E I Q A G K T S Q A H Q S N S N A
	D V K F G K S I K D F P A A L K N L M K N A V F M C L V L S T S S E A L I T T G

401	F A T F L P K F I E N Q F G L T S S F A A T L G G A V L I P G A A L G Q I L G G F
	L V S K F R M T C K N T M K F A L F T S G V A L T L S F V F M Y A K C E N E P

481	F A G V S E S Y N G T G E L G N L I A P C N A N C N C S R S Y Y Y P V C G D G
	V Q Y F S P C F A G C S N P V A H R K P K V Y Y N C S C I E R K T E I T S T A E T

561	F G F E A K A G K C E T H C A K L P I F L C I F F I V I I F T F M A G T P I T V S I
	L R C V N H R Q R S L A L G I Q F M V L R L L G T I P G P I I F G F T I D S

641	T C I L W D I N D C G I K G A C W I Y D N I K M A H M L V A I S V T C K V I T
	M F F N G F A I F L Y K P P P S A T D V S F H K E N A V V T N V L A E Q D L N K I

721	V K E G

5.313 glucose transporter 14 [Homo sapiens]
Protein Accession gi|23592238

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.626, 1.68)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0173


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	1.0	1.7	SEQ ID NO: 1565	QVTVLELFR

SEQ ID NO: 1566

1	M E F H N G G H V S G I G G F L V S L T S R M K P H T L A V T P A L I F A I T V A
	T I G S F Q F G Y N T G V I N A P E T I I K E F I N K T L T D K A N A P P S E

81	V L L T N L W S L S V A I F S V G G M I G S F S V G L F V N R F G R R N S M L I
	V N L L A A T G G C L M G L C K I A E S V E M L I L G R L V I G L F C G L C T G

161	F V P M Y I G E I S P T A L R G A F G T L N Q L G I V I G I L V A Q I F G L E L I L
	G S E E L W P V L L G F T I L P A I L Q S A A L P C C P E S P R F L L I N R

241	K K E E N A T R I L Q R L W G T Q D V S Q D I Q E M K D E S A R M S Q E K Q V
	T V L E L F R V S S Y R Q P I I I S I V L Q L S Q Q L S G I N A V F Y Y S T G I F

321	K D A G V Q Q P I Y A T I S A G V V N T I F T L L S L F L V E R A G R R T L H M
	I G L G G M A F C S T L M T V S L L L K N H Y N G M S F V C I G A I L V F V A C

401	F E I G P G P I P W F I V A E L F S Q G P R P A A M A V A G C S N W T S N F L V
	G L L F P S A A Y Y L G A Y V F I I F T G F L I T F L A F T F F K V P E T R G R

481	T F E D I T R A F E G Q A H G A D R S G K D G V M G M N S I E P A K E T T T N V

5.314 PREDICTED: hypothetical protein [Homo sapiens]
Protein Accession gi|169218200

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.79, 1.35)

Associated Peptides 4

Associated Spectra 13

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.78	1.1	1.5	SEQ ID NO: 1567	ESNGQPENNYK

9	0.83	1.1	1.3	SEQ ID NO: 1568	GFYPSDIAVEWESNGQP
					ENNYK

1	0.7	1	1.4	SEQ ID NO: 1569	NQVSLTCLVK

1	0.68	0.98	1.4	SEQ ID NO: 1570	TTPPMLDSDGSFFLYSK

5.315 serine hydroxymethyltransferase 1 (soluble) isoform 2 [Homo sapiens]; serine hydroxymethyltransferase 1 (soluble) isoform 1 [Homo sapiens]
Protein Accession gi|22547189 gi|22547186

Mean Expression Ratio 0.972

Median Expression Ratio 0.974

Credible Interval (0.599, 1.56)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.58 0.97 1.6 SEQ ID NO: 1571 VNPDTGYINYDQLEENAR

5.316 calcium binding protein P22 [Homo sapiens]
Protein Accession gi|6005731

Mean Expression Ratio 1.02

Median Expression Ratio 1.03

Credible Interval (0.625, 1.65)

Associated Peptides 1

Associated Spectra 1

Coverage 0.082


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.61	1.0	1.7	SEQ ID NO: 1572	IINAFFPEGEDQVNFR

SEQ ID NO: 1573

1	M G S R A S T L L R D E E L E E I K K E T G F S H S Q I T R L Y S R F T S L D K G E
	N G T L S R E D F Q R I P E L A I N P L G D R I I N A F F P E G E D Q V N F

81	R G F M R T L A H F R P I E D N E K S K D V N G P E P L N S R S N K L H F A F R
	L Y D L D K D E K I S R D E L L Q V L R M M V G V N I S D E Q L G S I A D R T I

161	Q E A D Q D G D S A I S F T E F V K V L E K V D V E Q K M S I R F L H

5.317 sushi domain containing 2 [Homo sapiens]
Protein Accession gi|10092665

Mean Expression Ratio 0.975

Median Expression Ratio 0.975

Credible Interval (0.594, 1.57)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0170


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.57	0.97	1.6	SEQ ID NO: 1574	GEYVLLEAALTDLR

SEQ ID NO: 1575

1	M K P A L L P W A L L L L A T A L G P G P G P T A D A Q E S C S M R C G A L D G
	P C S C H P T C S G L G T C C L D F R D F C L E I L P Y S G S M M G G K D F V V

81	R H F K M S S P T D A S V I C R F K D S I Q T L G H V D S S G Q V H C V S P L L
	Y E S G R I P F T V S L D N G H S F P R A G T W L A V H P N K V S M M E K S E L

161	V N E T R W Q Y Y G T A N T S G N L S L T W H V K S L P T Q T I T I E L W G Y
	E E T G M P Y S Q E W T A K W S Y L Y P L A T H I P N S G S F T F T P K P A P P S

241	Y Q R W R V G A L R I I D S K N Y A G Q K D V Q A L W T N D H A L A W H L S
	D D F R E D P V A W A R T Q C Q A W E E L E D Q L P N F L E E L P D C P C T L T Q A

321	R A D S G R F F T D Y G C D M E Q G S V C T Y H P G A V H C V R S V Q A S L R
	Y G S G Q Q C C Y T A D G T Q L L T A D S S G G S T P D R G H D W G A P P F R T P

401	P R V P S M S H W L Y D V L S F Y Y C C L W A P D C P R Y M Q R R P S N D C
	R N Y R P P R L A S A F G D P H F V T F D G T N F T F N G R G E Y V L L E A A L T D

481	L R V Q A R A Q P G T M S N G T E T R G T G L T A V A V Q E G N S D V V E V
	R L A N R T G G L E V L L N Q E V L S F T E Q S W M D L K G M F L S V A A G D R
	V S

561	I M L A S G A G L E V S V Q G P F L S V S V L L P E K F L T H T H G L L G T L N
	N D P T D D F T L H S G R V L P P G T S P Q E L F L F G A N W T V H N A S S L L

641	T Y D S W F L V H N F L Y Q P K H D P T F E P L F P S E T T L N P S L A Q E A A
	K L C G D D H F C N F D V A A T G S L S T G T A T R V A H Q L H Q R R M Q S L Q

721	P V V S C G W L A P P P N G Q K E G N R Y L A G S T I Y F H C D N G Y S L A G
	A E T S T C Q A D G T W S S P T P K C Q P G R S Y A V L L G I I F G G L A V V A A
801	V A L V Y V L L R R R K G N T H V W G A Q P

5.318 occludin [Homo sapiens]
Protein Accession gi|4505487

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.708, 1.48)

Associated Peptides 2

Associated Spectra 4

Coverage 0.0766


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.71	1.1	1.6	SEQ ID NO: 1576	NVSAGTQDVPSPPSDYVER

2	0.67	1 1.	5	SEQ ID NO: 1577	STPVPEVVQELPLTSPVDDFR

SEQ ID NO: 1578

1	M S S R P L E S P P P Y R P D E F K P N H Y A P S N D I Y G G E M H V R P M L S Q
	P A Y S F Y P E D E I L H F Y K W T S P P G V I R I L S M L I I V M C I A I F

81	A C V A S T L A W D R G Y G T S L L G G S V G Y P Y G G S G F G S Y G S G Y G
	Y G Y G Y G Y G Y G G Y T D P R A A K G F M L A M A A F C F I A A L V I F V T S V

161	I R S E M S R T R R Y Y L S V I I V S A I L G I M V F I A T I V Y I M G V N P T A
	Q S S G S L Y G S Q I Y A L C N Q F Y T P A A T G L Y V D Q Y L Y H Y C V V D

241	P Q E A I A I V L G F M I I V A F A L I I F F A V K T R R K M D R Y D K S N I L W
	D K E H I Y D E Q P P N V E E W V K N V S A G T Q D V P S P P S D Y V E R V D

321	S P M A Y S S N G K V N D K R F Y P E S S Y K S T P V P E V V Q E L P L T S P V
	D D F R Q P R Y S S G G N F E T P S K R A P A K G R A G R S K R T E Q D H Y E T

401	D Y T T G G E S C D E L E E D W I R E Y P P I T S D Q Q R Q L Y K R N F D T G L
	Q E Y K S L Q S E L D E I N K E L S R L D K E L D D Y R E E S E E Y M A A A D E

481	Y N R L K Q V K G S A D Y K S K K N H C K Q L K S K L S H I K K M V G D Y D
	R Q K T

5.319 CD81 antigen [Homo sapiens]
Protein Accession gi|4757944

Mean Expression Ratio 1.03

Median Expression Ratio 1.03

Credible Interval (0.623, 1.68)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0847


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	1.0	1.7	SEQ ID NO: 1579	QFYDQALQQAVVDDDANNAK

SEQ ID NO: 1580

1	M G V E G C T K C I K Y L L F V F N F V F W L A G G V I L G V A L W L R H D P Q
	T T N L L Y L E L G D K P A P N T F Y V G I Y I L I A V G A V M M F V G F L G C

81	Y G A I Q E S Q C L L G T F F T C L V I L F A C E V A A G I W G F V N K D Q I A
	K D V K Q F Y D Q A L Q Q A V V D D D A N N A K A V V K T F H E T L D C C G S S

161	T L T A L T T S V L K N N L C P S G S N I I S N L F K E D C H Q K I D D L F S G K
	L Y L I G I A A I V V A V I M I F E M I L S M V L C C G I R N S S V Y

5.320 ectonucleotide pyrophosphatase/phosphodiesterase 6 [Homo sapiens]
Protein Accession gi|23503267

Mean Expression Ratio 0.977

Median Expression Ratio 0.976

Credible Interval (0.745, 1.27)

Associated Peptides 8

Associated Spectra 9

Coverage 0.225


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.72	1.0	1.5	SEQ ID NO: 1581	FVSPLTLVADEGWFITENR

1	0.69	0.99	1.4	SEQ ID NO: 1582	GIFLAFGPDFK

1	0.69	0.98	1.4	SEQ ID NO: 1583	IDVEGHHYGPASPQR

2	0.7	0.99	1.4	SEQ ID NO: 1584	LLVFLLDGFR

1	0.68	0.97	1.4	SEQ ID NO: 1585	NVPTDINFANAVSDALDSFK

1	0.66	0.97	1.4	SEQ ID NO: 1586	YISLNDLQQVK

1	0.68	0.96	1.4	SEQ ID NO: 1587	GWHGYDNELMDMR

1	0.64	0.92	1.3	SEQ ID NO: 1588	AFGPDFK

SEQ ID NO: 1589

1	M A V K L G T L L L A L A L G L A Q P A S A R R K L L V F L L D G F R S D Y I S
	D E A L E S L P G F K E I V S R G V K V D Y L T P D F P S L S Y P N Y Y T L M T

81	G R H C E V H Q M I G N Y M W D P T T N K S F D I G V N K D S L M P L W W N
	G S E P L W V T L T K A K R K V Y M Y Y W P G C E V E I L G V R P T Y C L E Y K
	N V

161	P T D I N F A N A V S D A L D S F K S G R A D L A A I Y H E R I D V E G H H Y G
	P A S P Q R K D A L K A V D T V L K Y M T K W I Q E R G L Q D R L N V I I F S D

241	H G M T D I F W M D K V I E L N K Y I S L N D L Q Q V K D R G P V V S L W P A
	P G K H S E I Y N K L S T V E H M T V Y E K E A I P S R F Y Y K K G K F V S P L T

321	L V A D E G W F I T E N R E M L P F W M N S T G R R E G W Q R G W H G Y D N
	E L M D M R G I F L A F G P D F K S N F R A A P I R S V D V Y N V M C N V V G I T P

401	L P N N G S W S R V M C M L K G R A S T A P P V W P S H C A L A L I L L F L L A

5.321 solute carrier family 5 (sodium/glucose cotransporter), member 2 [Homo sapiens]
Protein Accession gi|4507033

Mean Expression Ratio 1.02

Median Expression Ratio 1.02

Credible Interval (0.661, 1.58)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0283


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.66	1.0	1.6	SEQ ID NO: 1590	GGVGSPPPLTQEEAAAAAR

SEQ ID NO: 1591

1	M E E H T E A G S A P E M G A Q K A L I D N P A D I L V I A A Y F L L V I G V G L
	W S M C R T N R G T V G G Y F L A G R S M V W W P V G A S L F A S N I G S G H

81	F V G L A G T G A A S G L A V A G F E W N A L F V V L L L G W L F A P V Y L T
	A G V I T M P Q Y L R K R F G G R R I R L Y L S V L S L F L Y I F T K I S V D M F

161	S G A V F I Q Q A L G W N I Y A S V I A L L G I T M I Y T V T G G L A A L M Y T
	D T V Q T F V I L G G A C I L M G Y A F H E V G G Y S G L F D K Y L G A A T S L

241	T V S E D P A V G N I S S F C Y R P R P D S Y H L L R H P V T G D L P W P A L L
	L G L T I V S G W Y W C S D Q V I V Q R C L A G K S L T H I K A G C I L C G Y L

321	K L T P M F L M V M P G M I S R I L Y P D E V A C V V P E V C R R V C G T E V
	G C S N I A Y P R L V V K L M P N G L R G L M L A V M L A A L M S S L A S I F N S

401	S S T L F T M D I Y T R L R P R A G D R E L L L V G R L W V V F I V V V S V A
	W L P V V Q A A Q G G Q L F D Y I Q A V S S Y L A P P V S A V F V L A L F V P R V

481	N E Q G A F W G L I G G L L M G L A R L I P E F S F G S G S C V Q P S A C P A F
	L C G V H Y L Y F A I V L F F C S G L L T L T V S L C T A P I P R K H L H R L V

561	F S L R H S K E E R E D L D A D E Q Q G S S L P V Q N G C P E S A M E M N E P
	Q A P A P S L F R Q C L L W F C G M S R G G V G S P P P L T Q E E A A A A A R R L

641	E D I S E D P S W A R V V N L N A L L M M A V A V F L W G F Y A

5.322 MIT, microtubule interacting and transport, domain containing 1 [Homo sapiens]
Protein Accession gi|20270349

Mean Expression Ratio 1.03

Median Expression Ratio 1.02

Credible Interval (0.627, 1.65)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0723


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	1.0	1.7	SEQ ID NO: 1592	EYLNETVTEVWIEDPYIR

SEQ ID NO: 1593

1	M A K S G L R Q D P Q S T A A A T V L K R A V E L D S E S R Y P Q A L V C Y Q E
	G I D L L L Q V L K G T K D N T K R C N L R E K I S K Y M D R A E N I K K Y L D

81	Q E K E D G K Y H K Q I K I E E N A T G F S Y E S L F R E Y L N E T V T E V W I
	E D P Y I R H T H Q L Y N F L R F C E M L I K R P C K V K T I H L L T S L D E G

161	I E Q V Q Q S R G L Q E I E E S L R S H G V L L E V Q Y S S S I H D R E I R F N N
	G W M I K I G R G L D Y F K K P Q S R F S L G Y C D F D L R P C H E T T V D I

241	F H K K H T K N I

5.323 ring finger protein 167 [Homo sapiens]
Protein Accession gi|14149702

Mean Expression Ratio 0.976

Median Expression Ratio 0.98

Credible Interval (0.67, 1.40)

Associated Peptides 2

Associated Spectra 4

Coverage 0.0657


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	0.97	1.5	SEQ ID NO: 1594	GDEDQEEETQGQEEGDEGEPR

3	0.67	0.97	1.4	SEQ ID NO: 1595	GPGDEDQEEETQGQEEGDEGEPR

SEQ ID NO: 1596

1	M H P A A F P L P V V V A A V L W G A A P T R G L I R A T S D H N A S M D F A D
	L P A L F G A T L S Q E G L Q G F L V E A H P D N A C S P I A P P P P A P V N G

81	S V F I A L L R R F D C N F D L K V L N A Q K A G Y G A A V V H N V N S N E L
	L N M V W N S E E I Q Q Q I W I P S V F I G E R S S E Y L R A L F V Y E K G A R V

161	L L V P D N T F P L G Y Y L I P F T G I V G L L V L A M G A V M I A R C I Q H R
	K R L Q R N R L T K E Q L K Q I P T H D Y Q K G D Q Y D V C A I C L D E Y E D G

241	D K L R V L P C A H A Y H S R C V D P W L T Q T R K T C P I C K Q P V H R G P
	G D E D Q E E E T Q G Q E E G D E G E P R D H P A S E R T P L L G S S P T L P T S

321	F G S L A P A P L V F P G P S T D P P L S P P S S P V I L V

5.324 ubiquitin protein ligase E3C [Homo sapiens]
Protein Accession gi|187960100

Mean Expression Ratio 0.98

Median Expression Ratio 0.98

Credible Interval (0.6, 1.59)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.58 0.98 1.6 SEQ ID NO: 1597 LNRQIRQHCLAFR

5.325 syntaxin 8 [Homo sapiens]
Protein Accession gi|4759188

Mean Expression Ratio 0.98

Median Expression Ratio 0.98

Credible Interval (0.609, 1.57)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0763


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.59	0.98	1.6	SEQ ID NO: 1598	IIQEQDAGLDALSSIISR

SEQ ID NO: 1599

1	M A P D P W F S T Y D S T C Q I A Q E I A E K I Q Q R N Q Y E R K G E K A P K L T
	V T I R A L L Q N L K E K I A L L K D L L L R A V S T H Q I T Q L E G D R R Q

81	N L L D D L V T R E R L L L A S F K N E G A E P D L I R S S L M S E E A K R G A
	P N P W L F E E P E E T R G L G F D E I R Q Q Q Q K I I Q E Q D A G L D A L S S

161	I I S R Q K Q M G Q E I G N E L D E Q N E I I D D L A N L V E N T D E K L R N E
	T R R V N M V D R K S A S C G M I M V I L L L L V A I V V V A V W P T N

5.326 sorting nexin 3 [Homo sapiens]
Protein Accession gi|4507143

Mean Expression Ratio 0.981

Median Expression Ratio 0.98

Credible Interval (0.603, 1.60)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0494


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.59	0.98	1.6	SEQ ID NO: 1600	YSDFEWLR

SEQ ID NO: 1601

1	M A E T V A D T R R L I T K P Q N L N D A Y G P P S N F L E I D V S N P Q T V G V
	G R G R F T T Y E I R V K T N L P I F K L K E S T V R R R Y S D F E W L R S E

81	L E R E S K V V V P P L P G K A F L R Q L P F R G D D G I F D D N F I E E R K Q G
	L E Q F I N K V A G H P L A Q N E R C L H M F L Q D E I I D K S Y T P S K I R

161	H A

5.327 RAB7, member RAS oncogene family [Homo sapiens]
Protein Accession gi|34147513

Mean Expression Ratio 1.02

Median Expression Ratio 1.02

Credible Interval (0.798, 1.3)

Associated Peptides 9

Associated Spectra 12

Coverage 0.483


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.74	1	1.4	SEQ ID NO: 1602	DEFLIQASPR

1	0.72	1.0	1.5	SEQ ID NO: 1603	DPENFPFVVLGNK

2	0.77	1.1	1.5	SEQ ID NO: 1604	EAINVEQAFQTIAR

1	0.71	1.0	1.4	SEQ ID NO: 1605	FQSLGVAFYR

1	0.72	1.0	1.4	SEQ ID NO: 1606	LVTMQIWDTAGQER

2	0.72	1	1.4	SEQ ID NO: 1607	QETEVELYNEFPEPIK

1	0.71	1	1.4	SEQ ID NO: 1608	TLDSWRDEFLIQASPR

1	0.71	1	1.4	SEQ ID NO: 1609	FSNQYK

1	0.71	1.0	1.4	SEQ ID NO: 1610	NNIPYFETSAK

SEQ ID NO: 1611

1	M T S R K K V L L K V I I L G D S G V G K T S L M N Q Y V N K K F S N Q Y K A T
	I G A D F L T K E V M V D D R L V T M Q I W D T A G Q E R F Q S L G V A F Y R G

81	A D C C V L V F D V T A P N T F K T L D S W R D E F L I Q A S P R D P E N F P F
	V V L G N K I D L E N R Q V A T K R A Q A W C Y S K N N I P Y F E T S A K E A I

161	N V E Q A F Q T I A R N A L K Q E T E V E L Y N E F P E P I K L D K N D R A K A
	S A E S C S C

5.328 prenylcysteine oxidase 1 [Homo sapiens]
Protein Accession gi|166795301

Mean Expression Ratio 1.02

Median Expression Ratio 1.02

Credible Interval (0.714, 1.44)

Associated Peptides 4

Associated Spectra 4

Coverage NaN


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.65	1	1.5	SEQ ID NO: 1612	FGLNTVLTTDNS
					DLFINSIGIVPSVR


1	0.66	1	1.5	SEQ ID NO: 1613	FLNEMIAPVMR

1	0.66	1.0	1.5	SEQ ID NO: 1614	MHMWVEDVLDK

1	0.7	1.1	1.6	SEQ ID NO: 1615	SDFYDIVLVATPLNR

5.329 glucose phosphate isomerase [Homo sapiens]
Protein Accession gi|18201905

Mean Expression Ratio 1.02

Median Expression Ratio 1.02

Credible Interval (0.62, 1.63)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0305


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.61	1.0	1.7	SEQ ID NO: 1616	MIPCDFLIPVQTQHPIR

SEQ ID NO: 1617

1	M A A L T R D P Q F Q K L Q Q W Y R E H R S E L N L R R L F D A N K D R F N H F
	S L T L N T N H G H I L V D Y S K N L V T E D V M R M L V D L A K S R G V E A A

81	R E R M F N G E K I N Y T E G R A V L H V A L R N R S N T P I L V D G K D V M P
	E V N K V L D K M K S F C Q R V R S G D W K G Y T G K T I T D V I N I G I G G S

161	D L G P L M V T E A L K P Y S S G G P R V W Y V S N I D G T H I A K T L A Q L
	N P E S S L F I I A S K T F T T Q E T I T N A E T A K E W F L Q A A K D P S A V A

241	K H F V A L S T N T T K V K E F G I D P Q N M F E F W D W V G G R Y S L W S
	A I G L S I A L H V G F D N F E Q L L S G A H W M D Q H F R T T P L E K N A P V L L

321	A L L G I W Y I N C F G C E T H A M L P Y D Q Y L H R F A A Y F Q Q G D M E S
	N G K Y I T K S G T R V D H Q T G P I V W G E P G T N G Q H A F Y Q L I H Q G T K

401	M I P C D F L I P V Q T Q H P I R K G L H H K I L L A N F L A Q T E A L M R G K
	S T E E A R K E L Q A A G K S P E D L E R L L P H K V F E G N R P T N S I V F T

481	K L T P F M L G A L V A M Y E H K I F V Q G I I W D I N S F D Q W G V E L G K
	Q L A K K I E P E L D G S A Q V T S H D A S T N G L I N F I K Q Q R E A R V Q

5.330 galactosidase, beta 1 isoform a preproprotein [Homo sapiens]
Protein Accession gi|119372308

Mean Expression Ratio 0.981

Median Expression Ratio 0.982

Credible Interval (0.798, 1.20)

Associated Peptides 12

Associated Spectra 17

Coverage 0.183


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.74	1	1.4	SEQ ID NO: 1618	AGATLDLLVENMGR

2	0.73	0.99	1.3	SEQ ID NO: 1619	AYVAVDGIPQGVLER

2	0.79	1.1	1.5	SEQ ID NO: 1620	GQVWINGFNLGR

1	0.71	0.99	1.4	SEQ ID NO: 1621	LAHELGLLVILRPGPY

1	0.71	0.98	1.3	SEQ ID NO: 1622	TEAVASSLYDILAR

1	0.72	1	1.4	SEQ ID NO: 1623	TVGAALDILCPSGPIK

1	0.71	0.98	1.4	SEQ ID NO: 1624	VAVDGIPQGVLER

1	0.7	0.98	1.4	SEQ ID NO: 1625	WLGVLLPK

2	0.69	0.92	1.3	SEQ ID NO: 1626	HHLGDDVVLF

1	0.7	0.97	1.3	SEQ ID NO: 1627	ACDFDYLR

1	0.71	0.98	1.4	SEQ ID NO: 1628	VNYGAYINDFK

2	0.67	0.9	1.2	SEQ ID NO: 1629	LAHELGLLVILR

SEQ ID NO: 1630

1	M P G F L V R I L P L L L V L L L L G P T R G L R N A T Q R M F E I D Y S R D S F
	L K D G Q P F R Y I S G S I H Y S R V P R F Y W K D R L L K M K M A G L N A I

81	Q T Y V P W N F H E P W P G Q Y Q F S E D H D V E Y F L R L A H E L G L L V I L
	R P G P Y I C A E W E M G G L P A W L L E K E S I L L R S S D P D Y L A A V D K

161	W L G V L L P K M K P L L Y Q N G G P V I T V Q V E N E Y G S Y F A C D F D Y
	L R F L Q K R F R H H L G D D V V L F T T D G A H K T F L K C G A L Q G L Y T T V

241	D F G T G S N I T D A F L S Q R K C E P K G P L I N S E F Y T G W L D H W G Q P
	H S T I K T E A V A S S L Y D I L A R G A S V N L Y M F I G G T N F A Y W N G A

321	N S P Y A A Q P T S Y D Y D A P L S E A G D L T E K Y F A L R N I I Q K F E K V
	P E G P I P P S T P K F A Y G K V T L E K L K T V G A A L D I L C P S G P I K S

401	L Y P L T F I Q V K Q H Y G F V L Y R T T L P Q D C S N P A P L S S P L N G V H
	D R A Y V A V D G I P Q G V L E R N N V I T L N I T G K A G A T L D L L V E N M

481	G R V N Y G A Y I N D F K G L V S N L T L S S N I L T D W T I F P L D T E D A V
	R S H L G G W G H R D S G H H D E A W A H N S S N Y T L P A F Y M G N F S I P S

561	G I P D L P Q D T F I Q F P G W T K G Q V W I N G F N L G R Y W P A R G P Q L
	T L F V P Q H I L M T S A P N T I T V L E L E W A P C S S D D P E L C A V T F V D

641	R P V I G S S V T Y D H P S K P V E K R L M P P P P Q K N K D S W L D H V

5.331 GDP dissociation inhibitor 2 isoform 1 [Homo sapiens]
Protein Accession gi|6598323

Mean Expression Ratio 0.986

Median Expression Ratio 0.983

Credible Interval (0.61, 1.63)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0337


A	2.5	50	97.5	Sequence ID No. 1631	Sequence

1	0.59	0.98	1.6	SEQ ID NO: 1632	TDDYLDQPCYETINR

SEQ ID NO: 1633

1	M N E E Y D V I V L G T G L T E C I L S G I M S V N G K K V L H M D R N P Y Y G
	G E S A S I T P L E D L Y K R F K I P G S P P E S M G R G R D W N V D L I P K F

81	L M A N G Q L V K M L L Y T E V T R Y L D F K V T E G S F V Y K G G K I Y K V
	P S T E A E A L A S S L M G L F E K R R F R K F L V Y V A N F D E K D P R T F E G

161	I D P K K T T M R D V Y K K F D L G Q D V I D F T G H A L A L Y R T D D Y L D
	Q P C Y E T I N R I K L Y S E S L A R Y G K S P Y L Y P L Y G L G E L P Q G F A R

241	L S A I Y G G T Y M L N K P I E E I I V Q N G K V I G V K S E G E I A R C K Q L I
	C D P S Y V K D R V E K V G Q V I R V I C I L S H P I K N T N D A N S C Q I I

321	I P Q N Q V N R K S D I Y V C M I S F A H N V A A Q G K Y I A I V S T T V E T K
	E P E K E I R P A L E L L E P I E Q K F V S I S D L L V P K D L G T E S Q I F I

401	S R T Y D A T T H F E T T C D D I K N I Y K R M T G S E F D F E E M K R K K N
	D I Y G E D

5.332 solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform c [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform f [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform e [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform d [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform b [Homo sapiens]; solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform a [Homo sapiens]
Protein Accession gi|65506891 gi|61744483 gi|61744481 gi|61744479 gi|61744477 gi|61744475

Mean Expression Ratio 1.02

Median Expression Ratio 1.02

Credible Interval (0.627, 1.64)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.61 1.0 1.7 SEQ ID NO: 1634 LLTSFLPAQLLR

5.333 heat shock 70 kDa protein 8 isoform 1 [Homo sapiens]
Protein Accession gi|5729877

Mean Expression Ratio 1.02

Median Expression Ratio 1.02

Credible Interval (0.866, 1.20)

Associated Peptides 18

Associated Spectra 36

Coverage 0.302


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.75	1.0	1.4	SEQ ID NO: 1635	AVVTVPAYFNDSQR

2	0.74	0.98	1.3	SEQ ID NO: 1636	CNEIINWLDK

1	0.75	1.0	1.4	SEQ ID NO: 1637	DAGTIAGLNVLR

1	0.74	1.0	1.4	SEQ ID NO: 1638	FDDAVVQSDMK

5	0.8	1.0	1.3	SEQ ID NO: 1639	FEELNADLFR

1	0.75	1.0	1.4	SEQ ID NO: 1640	FELTGIPPAPR

2	0.76	1.0	1.4	SEQ ID NO: 1641	LLQDFFNGK

2	0.78	1.0	1.4	SEQ ID NO: 1642	MVNHFIAEFK

1	0.74	1.0	1.4	SEQ ID NO: 1643	NQTAEKEEFEHQQK

1	0.74	1	1.4	SEQ ID NO: 1644	NQVAMNPTNTVFDAK

1	0.75	1.0	1.4	SEQ ID NO: 1645	QTQTFTTYSDNQPGVLIQVYEGER

2	0.77	1.0	1.4	SEQ ID NO: 1646	RFDDAVVQSDMK

2	0.78	1.0	1.4	SEQ ID NO: 1647	SQIHDIVLVGGSTR

5	0.76	0.98	1.3	SEQ ID NO: 1648	STAGDTHLGGEDFDNR

6	0.77	0.98	1.2	SEQ ID NO: 1649	TVTNAVVTVPAYFNDSQR

1	0.77	1.0	1.4	SEQ ID NO: 1650	MVVNDAGRPK

1	0.76	1.0	1.4	SEQ ID NO: 1651	VQVEYK

1	0.77	1.0	1.4	SEQ ID NO: 1652	HWPFMVVNDAGRPK

SEQ ID NO: 1653

1	M S K G P A V G I D L G T T Y S C V G V F Q H G K V E I I A N D Q G N R T T P S Y
	V A F T D T E R L I G D A A K N Q V A M N P T N T V F D A K R L I G R R F D D

81	A V V Q S D M K H W P F M V V N D A G R P K V Q V E Y K G E T K S F Y P E E
	V S S M V L T K M K E I A E A Y L G K T V T N A V V T V P A Y F N D S Q R Q A T
	K D

161	A G T I A G L N V L R I I N E P T A A A I A Y G L D K K V G A E R N V L I F D L
	G G G T F D V S I L T I E D G I F E V K S T A G D T H L G G E D F D N R M V N H

241	F I A E F K R K H K K D I S E N K R A V R R L R T A C E R A K R T L S S S T Q A
	S I E I D S L Y E G I D F Y T S I T R A R F E E L N A D L F R G T L D P V E K A

321	L R D A K L D K S Q I H D I V L V G G S T R I P K I Q K L L Q D F F N G K E L N
	K S I N P D E A V A Y G A A V Q A A I L S G D K S E N V Q D L L L L D V T P L S

401	L G I E T A G G V M T V L I K R N T T I P T K Q T Q T F T T Y S D N Q P G V L I
	Q V Y E G E R A M T K D N N L L G K F E L T G I P P A P R G V P Q I E V T F D I

481	D A N G I L N V S A V D K S T G K E N K I T I T N D K G R L S K E D I E R M V Q
	E A E K Y K A E D E K Q R D K V S S K N S L E S Y A F N M K A T V E D E K L Q G

561	K I N D E D K Q K I L D K C N E I I N W L D K N Q T A E K E E F E H Q Q K E L E
	K V C N P I I T K L Y Q S A G G M P G G M P G G F P G G G A P P S G G A S S G P

641	T I E E V D

5.334 RAB9A, member RAS oncogene family [Homo sapiens]
Protein Accession gi|4759012

Mean Expression Ratio 1.02

Median Expression Ratio 1.02

Credible Interval (0.627, 1.66)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0697


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.61	1.0	1.7	SEQ ID NO: 1654	DATNVAAAFEEAVR

SEQ ID NO: 1655

1	M A G K S S L F K V I L L G D G G V G K S S L M N R Y V T N K F D T Q L F H T I
	G V E F L N K D L E V D G H F V T M Q I W D T A G Q E R F R S L R T P F Y R G S

81	D C C L L T F S V D D S Q S F Q N L S N W K K E F I V Y A D V K E P E S F P F V I
	L G N K I D I S E R Q V S T E E A Q A W C R D N G D Y P Y F E T S A K D A T N

161	V A A A F E E A V R R V L A T E D R S D H L I Q T D T V N L H R K P K P S S S C C

5.335 complement component 8, gamma polypeptide [Homo sapiens]
Protein Accession gi|166197660

Mean Expression Ratio 1.02

Median Expression Ratio 1.02

Credible Interval (0.627, 1.65)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.61 1.0 1.7 SEQ ID NO: 1656 SLPVSDSVLSGFEQR

5.336 MAPK scaffold protein 1 [Homo sapiens]
Protein Accession gi|11496277

Mean Expression Ratio 0.986

Median Expression Ratio 0.985

Credible Interval (0.667, 1.45)

Associated Peptides 2

Associated Spectra 3

Coverage 0.210


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.64	0.97	1.5	SEQ ID NO: 1657	ELAPLFEELR

1	0.64	1	1.6	SEQ ID NO: 1658	KLPSVEGLHAIVVSDR

SEQ ID NO: 1659

1	M A D D L K R F L Y K K L P S V E G L H A I V V S D R D G V P V I K V A N D N A
	P E H A L R P G F L S T F A L A T D Q G S K L G L S K N K S I I C Y Y N T Y Q V

81	V Q F N R L P L V V S F I A S S S A N T G L I V S L E K E L A P L F E E L R Q V V
	E V S

5.337 transketolase isoform 1 [Homo sapiens]; transketolase isoform 2 [Homo sapiens]; transketolase isoform 1 [Homo sapiens]
Protein Accession gi|4507521 gi|205277465 gi|205277463

Mean Expression Ratio 1.01

Median Expression Ratio 1.01

Credible Interval (0.618, 1.61)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.62 1 1.7 SEQ ID NO: 1660 LDNLVAILDINR

5.338 complement factor B preproprotein [Homo sapiens]
Protein Accession gi|67782358

Mean Expression Ratio 0.989

Median Expression Ratio 0.988

Credible Interval (0.646, 1.52)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0314


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	0.99	1.6	SEQ ID NO: 1661	LLQEGQALEYVCPSGFYPYPVQTR

1	0.62	1	1.6	SEQ ID NO: 1662	VCPSGFYPYPVQTR

SEQ ID NO: 1663

1	M G S N L S P Q L C L M P F I L G L L S G G V T T T P W S L A R P Q G S C S L E G
	V E I K G G S F R L L Q E G Q A L E Y V C P S G F Y P Y P V Q T R T C R S T G

81	S W S T L K T Q D Q K T V R K A E C R A I H C P R P H D F E N G E Y W P R S P Y
	Y N V S D E I S F H C Y D G Y T L R G S A N R T C Q V N G R W S G Q T A I C D N

161	G A G Y C S N P G I P I G T R K V G S Q Y R L E D S V T Y H C S R G L T L R G S
	Q R R T C Q E G G S W S G T E P S C Q D S F M Y D T P Q E V A E A F L S S L T E

241	T I E G V D A E D G H G P G E Q Q K R K I V L D P S G S M N I Y L V L D G S D S
	I G A S N F T G A K K C L V N L I E K V A S Y G V K P R Y G L V T Y A T Y P K I

321	W V K V S E A D S S N A D W V T K Q L N E I N Y E D H K L K S G T N T K K A
	L Q A V Y S M M S W P D D V P P E G W N R T R H V I I L M T D G L H N M G G D P
	I T

401	V I D E I R D L L Y I G K D R K N P R E D Y L D V Y V F G V G P L V N Q V N I N
	A L A S K K D N E Q H V F K V K D M E N L E D V F Y Q M I D E S Q S L S L C G M

481	V W E H R K G T D Y H K Q P W Q A K I S V I R P S K G H E S C M G A V V S E
	Y F V L T A A H C F T V D D K E H S I K V S V G G E K R D L E I E V V L F H P N Y N

561	I N G K K E A G I P E F Y D Y D V A L I K L K N K L K Y G Q T I R P I C L P C T E
	G T T R A L R L P P T T T C Q Q Q K E E L L P A Q D I K A L F V S E E E K K L

641	T R K E V Y I K N G D K K G S C E R D A Q Y A P G Y D K V K D I S E V V T P R
	F L C T G G V S P Y A D P N T C R G D S G G P L I V H K R S R F I Q V G V I S W G

721	V V D V C K N Q K R Q K Q V P A H A R D F H I N L F Q V L P W L K E K L Q D
	E D L G F L

5.339 cyclin M3 isoform 1 [Homo sapiens]; cyclin M3 isoform 2 [Homo sapiens]
Protein Accession gi|40068049 gi|40068047

Mean Expression Ratio 0.987

Median Expression Ratio 0.989

Credible Interval (0.601, 1.59)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

Sequence

A 2.5 50 97.5 ID No. Sequence

1 0.58 0.98 1.6 SEQ ID NO: AQNLPQSPENTDLQVIPGSQTR

1664

5.340 solute carrier family 9 (sodium/hydrogen exchanger), isoform 3 [Homo sapiens]
Protein Accession gi|194239733

Mean Expression Ratio 0.993

Median Expression Ratio 0.989

Credible Interval (0.608, 1.62)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

Sequence

A 2.5 50 97.5 ID No. Sequence

1 0.59 0.99 1.7 SEQ ID DTASDSPAGIDNPVFSPDEALDR

NO: 1665

5.341 solute carrier family 12 (potassium/chloride transporters), member 9 [Homo sapiens]
Protein Accession gi|31881740

Mean Expression Ratio 0.989

Median Expression Ratio 0.99

Credible Interval (0.652, 1.51)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0438


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.62	0.99	1.6	SEQ ID NO: 1666	AEVQEVVWGEGAGAGEPEAEEEG
					DFVNSGR


1	0.62	1	1.6	SEQ ID NO: 1667	YLALLETLTR

SEQ ID NO: 1668

1	M A S E S S P L L A Y R L L G E E G V A L P A N G A G G P G G A S A R K L S T F
	L G V V V P T V L S M F S I V V F L R I G F V V G H A G L L Q A L A M L L V A Y

81	F I L A L T V L S V C A I A T N G A V Q G G G A Y F M I S R T L G P E V G G S I G
	L M F Y L A N V C G C A V S L L G L V E S V L D V F G A D A T G P S G L R V L

161	P Q G Y G W N L L Y G S L L L G L V G G V C T L G A G L Y A R A S F L T F L L
	V S G S L A S V L I S F V A V G P R D I R L T P R P G P N G S S L P P R F G H F T

241	G F N S S T L K D N L G A G Y A E D Y T T G A V M N F A S V F A V L F N G C T
	G I M A G A N M S G E L K D P S R A I P L G T I V A V A Y T F F V Y V L L F F L S

321	S F T C D R T L L Q E D Y G F F R A I S L W P P L V L I G I Y A T A L S A S M S S
	L I G A S R I L H A L A R D D L F G V I L A P A K V V S R G G N P W A A V L Y

401	S W G L V Q L V L L A G K L N T L A A V V T V F Y L V A Y A A V D L S C L S L
	E W A S A P N F R P T F S L F S W H T C L L G V A S C L L M M F L I S P G A A G G

481	S L L L M G L L A A L L T A R G G P S S W G Y V S Q A L L F H Q V R K Y L L R
	L D V R K D H V K F W R P Q L L L L V G N P R G A L P L L R L A N Q L K K G G L Y

561	V L G H V T L G D L D S L P S D P V Q P Q Y G A W L S L V D R A Q V K A F V
	D L T L S P S V R Q G A Q H L L R I S G L G G M K P N T L V L G F Y D D A P P Q D H

641	F L T D P A F S E P A D S T R E G S S P A L S T L F P P P R A P G S P R A L N P Q
	D Y V A T V A D A L K M N K N V V L A R A S G A L P P E R L S R G S G G T S Q

721	L H H V D V W P L N L L R P R G G P G Y V D V C G L F L L Q M A T I L G M V P
	A W H S A R L R I F L C L G P R E A P G A A E G R L R A L L S Q L R I R A E V Q E

801	V V W G E G A G A G E P E A E E E G D F V N S G R G D A E A E A L A R S A N
	A L V R A Q Q G R G T G G G P G G P E G G D A E G P I T A L T F L Y L P R P P A D P

881	A R Y P R Y L A L L E T L T R D L G P T L L V H G V T P V T C T D L

5.342 RAB5C, member RAS oncogene family isoform a [Homo sapiens]; RAB5C, member RAS oncogene family isoform b [Homo sapiens]
Protein Accession gi|41393614 gi|41393545

Mean Expression Ratio 1.01

Median Expression Ratio 1.01

Credible Interval (0.624, 1.64)

Associated Peptides 1

Associated Spectra 1

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

1 0.6 1 1.7 SEQ ID NO: 1669 FEIWDTAGQER

5.343 pyruvate kinase, liver and RBC isoform 1 [Homo sapiens]
Protein Accession gi|10835121

Mean Expression Ratio 1.01

Median Expression Ratio 1.01

Credible Interval (0.63, 1.67)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0348


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.61	1	1.7	SEQ ID NO: 1670	GVNLPGAQVDLPGLSEQDVR

SEQ ID NO: 1671

1	M S I Q E N I S S L Q L R S W V S K S Q R D L A K S I L I G A P G G P A G Y L R R
	A S V A Q L T Q E L G T A F F Q Q Q Q L P A A M A D T F L E H L C L L D I D S

81	E P V A A R S T S I I A T I G P A S R S V E R L K E M I K A G M N I A R L N F S H
	G S H E Y H A E S I A N V R E A V E S F A G S P L S Y R P V A I A L D T K G P

161	E I R T G I L Q G G P E S E V E L V K G S Q V L V T V D P A F R T R G N A N T V
	W V D Y P N I V R V V P V G G R I Y I D D G L I S L V V Q K I G P E G L V T Q V

241	E N G G V L G S R K G V N L P G A Q V D L P G L S E Q D V R D L R F G V E H G
	V D I V F A S F V R K A S D V A A V R A A L G P E G H G I K I I S K I E N H E G V

321	K R F D E I L E V S D G I M V A R G D L G I E I P A E K V F L A Q K M M I G R C
	N L A G K P V V C A T Q M L E S M I T K P R P T R A E T S D V A N A V L D G A D

401	C I M L S G E T A K G N F P V E A V K M Q H A I A R E A E A A V Y H R Q L F E
	E L R R A A P L S R D P T E V T A I G A V E A A F K C C A A A I I V L T T T G R S

481	A Q L L S R Y R P R A A V I A V T R S A Q A A R Q V H L C R G V F P L L Y R E
	P P E A I W A D D V D R R V Q F G I E S G K L R G F L R V G D L V I V V T G W R P

561	G S G Y T N I M R V L S I S

5.344 glutathione transferase [Homo sapiens]
Protein Accession gi|4504183

Mean Expression Ratio 1.01

Median Expression Ratio 1.01

Credible Interval (0.713, 1.41)

Associated Peptides 3

Associated Spectra 5

Coverage 0.205


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.71	1.0	1.4	SEQ ID NO: 1672	DQQEAALVDMVNDGVEDLR

1	0.67	1.0	1.5	SEQ ID NO: 1673	FQDGDLTLYQSNTILR

1	0.66	1	1.5	SEQ ID NO: 1674	TVVYFPVR

SEQ ID NO: 1675

1	M P P Y T V V Y F P V R G R C A A L R M L L A D Q G Q S W K E E V V T V E T W
	Q E G S L K A S C L Y G Q L P K F Q D G D L T L Y Q S N T I L R H L G R T L G L Y

81	G K D Q Q E A A L V D M V N D G V E D L R C K Y I S L I Y T N Y E A G K D D Y
	V K A L P G Q L K P F E T L L S Q N Q G G K T F I V G D Q I S F A D Y N L L D L L

161	L I H E V L A P G C L D A F P L L S A Y V G R L S A R P K L K A F L A S P E Y V
	N L P I N G N G K Q

5.345 ATPase, H+ transporting, lysosomal 70kD, V1 subunit A, isoform 1 [Homo sapiens]
Protein Accession gi|19913424

Mean Expression Ratio 1.01

Median Expression Ratio 1.01

Credible Interval (0.726, 1.41)

Associated Peptides 5

Associated Spectra 5

Coverage 0.104


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.68	1.0	1.5	SEQ ID NO: 1676	FTMVQVWPVR

1	0.66	1	1.5	SEQ ID NO: 1677	HFTEFVPLR

1	0.69	1.0	1.5	SEQ ID NO: 1678	SDYAQLLEDMQNAFR

1	0.66	1	1.5	SEQ ID NO: 1679	LPANHPLLTGQR

1	0.7	1.0	1.6	SEQ ID NO: 1680	EILQEEEDLAEIVQLVGK

SEQ ID NO: 1681

1	M D F S K L P K I L D E D K E S T F G Y V H G V S G P V V T A C D M A G A A M Y
	E L V R V G H S E L V G E I I R L E G D M A T I Q V Y E E T S G V S V G D P V L

81	R T G K P L S V E L G P G I M G A I F D G I Q R P L S D I S S Q T Q S I Y I P R G V
	N V S A L S R D I K W D F T P C K N L R V G S H I T G G D I Y G I V S E N S

161	L I K H K I M L P P R N R G T V T Y I A P P G N Y D T S D V V L E L E F E G V K
	E K F T M V Q V W P V R Q V R P V T E K L P A N H P L L T G Q R V L D A L F P C

241	V Q G G T T A I P G A F G C G K T V I S Q S L S K Y S N S D V I I Y V G C G E R
	G N E M S E V L R D F P E L T M E V D G K V E S I M K R T A L V A N T S N M P V

321	A A R E A S I Y T G I T L S E Y F R D M G Y H V S M M A D S T S R W A E A L R
	E I S G R L A E M P A D S G Y P A Y L G A R L A S F Y E R A G R V K C L G N P E R

401	E G S V S I V G A V S P P G G D F S D P V T S A T L G I V Q V F W G L D K K L A
	Q R K H F P S V N W L I S Y S K Y M R A L D E Y Y D K H F T E F V P L R T K A K

481	E I L Q E E E D L A E I V Q L V G K A S L A E T D K I T L E V A K L I K D D F L
	Q Q N G Y T P Y D R F C P F Y K T V G M L S N M I A F Y D M A R R A V E T T A Q

561	S D N K I T W S I I R E H M G D I L Y K L S S M K F K D P L K D G E A K I K S D
	Y A Q L L E D M Q N A F R S L E D

5.346 DnaJ (Hsp40) homolog, subfamily A, member 1 [Homo sapiens]
Protein Accession gi|4504511

Mean Expression Ratio 0.986

Median Expression Ratio 0.99

Credible Interval (0.634, 1.49)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0479


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.63	0.98	1.5	SEQ ID NO: 1682	NVVHQLSVTLEDLYNGATR

SEQ ID NO: 1683

1	M V K E T T Y Y D V L G V K P N A T Q E E L K K A Y R K L A L K Y H P D K N P
	N E G E K F K Q I S Q A Y E V L S D A K K R E L Y D K G G E Q A I K E G G A G G G

81	F G S P M D I F D M F F G G G G R M Q R E R R G K N V V H Q L S V T L E D L Y
	N G A T R K L A L Q K N V I C D K C E G R G G K K G A V E C C P N C R G T G M Q I

161	R I H Q I G P G M V Q Q I Q S V C M E C Q G H G E R I S P K D R C K S C N G R
	K I V R E K K I L E V H I D K G M K D G Q K I T F H G E G D Q E P G L E P G D I I

241	I V L D Q K D H A V F T R R G E D L F M C M D I Q L V E A L C G F Q K P I S T L
	D N R T I V I T S H P G Q I V K H G D I K C V L N E G M P I Y R R P Y E K G R L

321	I I E F K V N F P E N G F L S P D K L S L L E K L L P E R K E V E E T D E M D Q
	V E L V D F D P N Q E R R R H Y N G E A Y E D D E H H P R G G V Q C Q T S

5.347 aquaporin 2 [Homo sapiens]
Protein Accession gi|4502179

Mean Expression Ratio 0.99

Median Expression Ratio 0.991

Credible Interval (0.645, 1.52)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0886


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.6	0.97	1.5	SEQ ID NO: 1684	QSVELHSPQSLPR

1	0.63	1.0	1.6	SEQ ID NO: 1685	GLEPDTDWEER

SEQ ID NO: 1686

1	M W E L R S I A F S R A V F A E F L A T L L F V F F G L G S A L N W P Q A L P S V
	L Q I A M A F G L G I G T L V Q A L G H I S G A H I N P A V T V A C L V G C H

81	V S V L R A A F Y V A A Q L L G A V A G A A L L H E I T P A D I R G D L A V N A
	L S N S T T A G Q A V T V E L F L T L Q L V L C I F A S T D E R R G E N P G T P

161	A L S I G F S V A L G H L L G I H Y T G C S M N P A R S L A P A V V T G K F D D
	H W V F W I G P L V G A I L G S L L Y N Y V L F P P A K S L S E R L A V L K G L

241	E P D T D W E E R E V R R R Q S V E L H S P Q S L P R G T K A

5.348 serine incorporator 1 [Homo sapiens]
Protein Accession gi|24308213

Mean Expression Ratio 1.01

Median Expression Ratio 1.01

Credible Interval (0.624, 1.63)

Associated Peptides 1

Associated Spectra 1

Coverage 0.0375


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.61	1	1.7	SEQ ID NO: 1687	LTLTSDESTLIEDGGAR

SEQ ID NO: 1688

1	M G S V L G L C S M A S W I P C L C G S A P C L L C R C C P S G N N S T V T R L I
	Y A L F L L V G V C V A C V M L I P G M E E Q L N K I P G F C E N E K G V V P

81	C N I L V G Y K A V Y R L C F G L A M F Y L L L S L L M I K V K S S S D P R A A
	V H N G F W F F K F A A A I A I I I G A F F I P E G T F T T V W F Y V G M A G A

161	F C F I L I Q L V L L I D F A H S W N E S W V E K M E E G N S R C W Y A A L L S
	A T A L N Y L L S L V A I V L F F V Y Y T H P A S C S E N K A F I S V N M L L C

241	V G A S V M S I L P K I Q E S Q P R S G L L Q S S V I T V Y T M Y L T W S A M T
	N E P E T N C N P S L L S I I G Y N T T S T V P K E G Q S V Q W W H A Q G I I G

321	L I L F L L C V F Y S S I R T S N N S Q V N K L T L T S D E S T L I E D G G A R S
	D G S L E D G D D V H R A V D N E R D G V T Y S Y S F F H F M L F L A S L Y I

401	M M T L T N W Y R Y E P S R E M K S Q W T A V W V K I S S S W I G I V L Y V
	W T L V A P L V L T N R D F D

5.349 syntaxin 7 [Homo sapiens]
Protein Accession gi|170932494

Mean Expression Ratio 1.01

Median Expression Ratio 1.01

Credible Interval (0.748, 1.35)

Associated Peptides 4

Associated Spectra 8

Coverage NaN


				Sequence
A	2.5	50	97.5	ID No.	Sequence

1	0.69	1.0	1.5	SEQ ID	EFGSLPTTPSEQR
				NO: 1689

4	0.72	0.98	1.3	SEQ ID	NLVSWESQTQPQVQVQDEEITEDDLR
				NO: 1690

1	0.7	1.0	1.5	SEQ ID	QLEADIMDINEIFK
				NO: 1691

2	0.72	1.0	1.4	SEQ ID	TLNQLGTPQDSPELR
				NO: 1692

5.350 carbonic anhydrase XII isoform 2 precursor [Homo sapiens]; carbonic anhydrase XII isoform 1 precursor [Homo sapiens]
Protein Accession gi|45935383 gi|4502515

Mean Expression Ratio 0.991

Median Expression Ratio 0.993

Credible Interval (0.66, 1.49)

Associated Peptides 1

Associated Spectra 3

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

3 0.67 0.99 1.5 SEQ ID NO: 1693 GQEAFVPGFNIEELLPER

5.351 major histocompatibility complex, class II, DR alpha precursor [Homo sapiens]
Protein Accession gi|52426774

Mean Expression Ratio 1.00

Median Expression Ratio 1.01

Credible Interval (0.754, 1.32)

Associated Peptides 5

Associated Spectra 9

Coverage 0.209


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.7	0.98	1.4	SEQ ID NO: 1694	FHYLPFLPSTEDVYDCR

3	0.76	1.1	1.5	SEQ ID NO: 1695	NGKPVTTGVSETVFLPR

2	0.73	1.0	1.4	SEQ ID NO: 1696	VEHWGLDEPLLK

1	0.69	1	1.5	SEQ ID NO: 1697	KFHYLPFLPSTEDVYDCR

1	0.66	0.95	1.4	SEQ ID NO: 1698	EDHLFR

SEQ ID NO: 1699

1	M A I S G V P V L G F F I I A V L M S A Q E S W A I K E E H V I I Q A E F Y L N P D
	Q S G E F M F D F D G D E I F H V D M A K K E T V W R L E E F G R F A S F E

81	A Q G A L A N I A V D K A N L E I M T K R S N Y T P I T N V P P E V T V L T N S
	P V E L R E P N V L I C F I D K F T P P V V N V T W L R N G K P V T T G V S E T

161	V F L P R E D H L F R K F H Y L P F L P S T E D V Y D C R V E H W G L D E P L L
	K H W E F D A P S P L P E T T E N V V C A L G L T V G L V G I I I G T I F I I K

241	G L R K S N A A E R R G P L

5.352 cytosolic phosphoenolpyruvate carboxykinase 1 [Homo sapiens]
Protein Accession gi|187281517

Mean Expression Ratio 0.996

Median Expression Ratio 0.994

Credible Interval (0.7, 1.43)

Associated Peptides 3

Associated Spectra 4

Coverage NaN

A 2.5 50 97.5 Sequence ID No. Sequence

2 0.67 1 1.5 SEQ ID NO: 1700 IFHVNWFR

1 0.65 1 1.5 SEQ ID NO: 1701 LLGQMEEEGILR

1 0.65 1 1.5 SEQ ID NO: 1702 FLWPGFGENSR

5.353 glutathione peroxidase 3 precursor [Homo sapiens]
Protein Accession gi|6006001

Mean Expression Ratio 0.996

Median Expression Ratio 0.994

Credible Interval (0.723, 1.37)

Associated Peptides 4

Associated Spectra 6

Coverage 0.217


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.7	1	1.4	SEQ ID NO: 1703	FLVGPDGIPIMR

1	0.67	1	1.5	SEQ ID NO: 1704	FYTFLK

1	0.66	0.97	1.4	SEQ ID NO: 1705	QEPGENSEILPTLK

2	0.72	1.0	1.5	SEQ ID NO: 1706	YVRPGGGFVPNFQLFEK

SEQ ID NO: 1707

1	M A R L L Q A S C L L S L L L A G F V S Q S R G Q E K S K M D C H G G I S G T I Y
	E Y G A L T I D G E E Y I P F K Q Y A G K Y V L F V N V A S Y U G L T G Q Y I

81	E L N A L Q E E L A P F G L V I L G F P C N Q F G K Q E P G E N S E I L P T L K Y
	V R P G G G F V P N F Q L F E K G D V N G E K E Q K F Y T F L K N S C P P T S

161	E L L G T S D R L F W E P M K V H D I R W N F E K F L V G P D G I P I M R W H
	H R T T V S N V K M D I L S Y M R R Q A A L G V K R K

5.354 transmembrane 7 superfamily member 3 [Homo sapiens]
Protein Accession gi|7706575

Mean Expression Ratio 1.00

Median Expression Ratio 1.00

Credible Interval (0.7, 1.44)

Associated Peptides 4

Associated Spectra 4

Coverage 0.0842


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.67	1	1.5	SEQ ID NO: 1708	GRPFFPPHPYK

1	0.68	1.0	1.6	SEQ ID NO: 1709	LQYDVYQYFLPENDLTEEMLLK

1	0.65	0.99	1.5	SEQ ID NO: 1710	QYFLPENDLTEEMLLK

1	0.65	1	1.5	SEQ ID NO: 1711	VTNILDPSYHIPPLR

SEQ ID NO: 1712

1	M G F L Q L L V V A V L A S E H R V A G A A E V F G N S S E G L I E F S V G K F
	R Y F E L N R P F P E E A I L H D I S S N V T F L I F Q I H S Q Y Q N T T V S F

81	S P T L L S N S S E T G T A S G L V F I L R P E Q S T C T W Y L G T S G I Q P V Q
	N M A I L L S Y S E R D P V P G G C N L E F D L D I D P N I Y L E Y N F F E T

161	T I K F A P A N L G Y A R G V D P P P C D A G T D Q D S R W R L Q Y D V Y Q Y
	F L P E N D L T E E M L L K H L Q R M V S V P Q V K A S A L K V V T L T A N D K T

241	S V S F S S L P G Q G V I Y N V I V W D P F L N T S A A Y I P A H T Y A C S F E
	A G E G S C A S L G R V S S K V F F T L F A L L G F F I C F F G H R F W K T E L

321	F F I G F I I M G F F F Y I L I T R L T P I K Y D V N L I L T A V T G S V G G M F L
	V A V W W R F G I L S I C M L C V G L V L G F L I S S V T F F T P L G N L K

401	I F H D D G V F W V T F S C I A I L I P V V F M G C L R I L N I L T C G V I G S Y
	S V V L A I D S Y W S T S L S Y I T L N V L K R A L N K D F H R A F T N V P F

481	Q T N D F I I L A V W G M L A V S G I T L Q I R R E R G R P F F P P H P Y K L W
	K Q E R E R R V T N I L D P S Y H I P P L R E R L Y G R L T Q I K G L F Q K E Q

561	P A G E R T P L L L

5.355 cathelicidin antimicrobial peptide [Homo sapiens]
Protein Accession gi|39753970

Mean Expression Ratio 0.997

Median Expression Ratio 0.996

Credible Interval (0.668, 1.49)

Associated Peptides 1

Associated Spectra 3

Coverage 0.0529


A	2.5	50	97.5	Sequence ID No.	Sequence

3	0.67	1	1.5	SEQ ID NO: 1713	FALLGDFFR

SEQ ID NO: 1714

1	M K T Q R D G H S L G R W S L V L L L L G L V M P L A I I A Q V L S Y K E A V L
	R A I D G I N Q R S S D A N L Y R L L D L D P R P T M D G D P D T P K P V S F T

81	V K E T V C P R T T Q Q S P E D C D F K K D G L V K R C M G T V T L N Q A R G
	S F D I S C D K D N K R F A L L G D F F R K S K E K I G K E F K R I V Q R I K D F

161	L R N L V P R T E S

5.356 transmembrane protein 55B isoform 1 [Homo sapiens]; transmembrane protein 55B isoform 2 [Homo sapiens]
Protein Accession gi|154816186 gi|154816184

Mean Expression Ratio 0.995

Median Expression Ratio 0.996

Credible Interval (0.652, 1.53)

Associated Peptides 2

Associated Spectra 2

Coverage NaN

Sequence

A 2.5 50 97.5 ID No. Sequence

1 0.63 1 1.6 SEQ ID NTFLWTEFTDR

NO: 1715

1 0.61 0.98 1.6 SEQ ID IINLGPVHPGPLSPEPQPMGVR

NO: 1716

5.357 aconitase 1 [Homo sapiens]
Protein Accession gi|8659555

Mean Expression Ratio 0.996

Median Expression Ratio 0.997

Credible Interval (0.645, 1.56)

Associated Peptides 1

Associated Spectra 2

Coverage 0.0214


A	2.5	50	97.5	Sequence ID No.	Sequence

2	0.65	0.99	1.6	SEQ ID NO: 1717	VILQDFTGVPAVVDFAAMR

SEQ ID NO: 1718

1	M S N P F A H L A E P L D P V Q P G K K F F N L N K L E D S R Y G R L P F S I R V
	L L E A A I R N C D E F L V K K Q D I E N I L H W N V T Q H K N I E V P F K P

81	A R V I L Q D F T G V P A V V D F A A M R D A V K K L G G D P E K I N P V C P
	A D L V I D H S I Q V D F N R R A D S L Q K N Q D L E F E R N R E R F E F L K W G

161	S Q A F H N M R I I P P G S G I I H Q V N L E Y L A R V V F D Q D G Y Y Y P D S
	L V G T D S H T T M I D G L G I L G W G V G G I E A E A V M L G Q P I S M V L P

241	Q V I G Y R L M G K P H P L V T S T D I V L T I T K H L R Q V G V V G K F V E F
	F G P G V A Q L S I A D R A T I A N M C P E Y G A T A A F F P V D E V S I T Y L

321	V Q T G R D E E K L K Y I K K Y L Q A V G M F R D F N D P S Q D P D F T Q V V
	E L D L K T V V P C C S G P K R P Q D K V A V S D M K K D F E S C L G A K Q G F K

401	G F Q V A P E H H N D H K T F I Y D N T E F T L A H G S V V I A A I T S C T N T
	S N P S V M L G A G L L A K K A V D A G L N V M P Y I K T S L S P G S G V V T Y

481	Y L Q E S G V M P Y L S Q L G F D V V G Y G C M T C I G N S G P L P E P V V E
	A I T Q G D L V A V G V L S G N R N F E G R V H P N T R A N Y L A S P P L V I A Y

561	A I A G T I R I D F E K E P L G V N A K G Q Q V F L K D I W P T R D E I Q A V E
	R Q Y V I P G M F K E V Y Q K I E T V N E S W N A L A T P S D K L F F W N S K S

641	T Y I K S P P F F E N L T L D L Q P P K S I V D A Y V L L N L G D S V T T D H I S
	P A G N I A R N S P A A R Y L T N R G L T P R E F N S Y G S R R G N D A V M A

721	R G T F A N I R L L N R F L N K Q A P Q T I H L P S G E I L D V F D A A E R Y Q
	Q A G L P L I V L A G K E Y G A G S S R D W A A K G P F L L G I K A V L A E S Y

801	E R I H R S N L V G M G V I P L E Y L P G E N A D A L G L T G Q E R Y T I I I P E
	N L K P Q M K V Q V K L D T G K T F Q A V M R F D T D V E L T Y F L N G G I L

881	N Y M I R K M A K

5.358 nicastrin precursor [Homo sapiens]
Protein Accession gi|24638433

Mean Expression Ratio 0.997

Median Expression Ratio 0.997

Credible Interval (0.656, 1.51)

Associated Peptides 2

Associated Spectra 2

Coverage 0.031


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.63	1	1.6	SEQ ID NO: 1719	GKFPVQLENVDSFVELGQVALR

1	0.63	1	1.6	SEQ ID NO: 1720	FPVQLENVDSFVELGQVALR

SEQ ID NO: 1721

1	M A T A G G G S G A D P G S R G L L R L L S F C V L L A G L C R G N S V E R K I
	Y I P L N K T A P C V R L L N A T H Q I G C Q S S I S G D T G V I H V V E K E E

81	D L Q W V L T D G P N P P Y M V L L E S K H F T R D L M E K L K G R T S R I A
	G L A V S L T K P S P A S G F S P S V Q C P N D G F G V Y S N S Y G P E F A H C R

161	E I Q W N S L G N G L A Y E D F S F P I F L L E D E N E T K V I K Q C Y Q D H N
	L S Q N G S A P T F P L C A M Q L F S H M H A V I S T A T C M R R S S I Q S T F

241	S I N P E I V C D P L S D Y N V W S M L K P I N T T G T L K P D D R V V V A A T
	R L D S R S F F W N V A P G A E S A V A S F V T Q L A A A E A L Q K A P D V T T

321	L P R N V M F V F F Q G E T F D Y I G S S R M V Y D M E K G K F P V Q L E N V
	D S F V E L G Q V A L R T S L E L W M H T D P V S Q K N E S V R N Q V E D L L A T

401	L E K S G A G V P A V I L R R P N Q S Q P L P P S S L Q R F L R A R N I S G V V
	L A D H S G A F H N K Y Y Q S I Y D T A E N I N V S Y P E W L S P E E D L N F V

481	T D T A K A L A D V A T V L G R A L Y E L A G G T N F S D T V Q A D P Q T V T
	R L L Y G F L I K A N N S W F Q S I L R Q D L R S Y L G D G P L Q H Y I A V S S P

561	T N T T Y V V Q Y A L A N L T G T V V N L T R E Q C Q D P S K V P S E N K D L
	Y E Y S W V Q G P L H S N E T D R L P R C V R S T A R L A R A L S P A F E L S Q W

641	S S T E Y S T W T E S R W K D I R A R I F L I A S K E L E L I T L T V G F G I L I F
	S L I V T Y C I N A K A D V L F I A P R E P G A V S Y

5.359 carboxymethylenebutenolidase [Homo sapiens]
Protein Accession gi|20270371

Mean Expression Ratio 0.995

Median Expression Ratio 0.997

Credible Interval (0.672, 1.45)

Associated Peptides 3

Associated Spectra 3

Coverage 0.135


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.64	1	1.6	SEQ ID NO: 1722	AVIVIQDIFGWQLPNTR

1	0.63	1	1.5	SEQ ID NO: 1723	EVQVEHIK

1	0.63	0.98	1.5	SEQ ID NO: 1724	NLIEWLNK

SEQ ID NO: 1725

1	M A N E A Y P C P C D I G H R L E Y G G L G R E V Q V E H I K A Y V T K S P V D
	A G K A V I V I Q D I F G W Q L P N T R Y I A D M I S G N G Y T T I V P D F F V

81	G Q E P W D P S G D W S I F P E W L K T R N A Q K I D R E I S A I L K Y L K Q Q
	C H A Q K I G I V G F C W G G T A V H H L M M K Y S E F R A G V S V Y G I V K D

161	S E D I Y N L K N P T L F I F A E N D V V I P L K D V S L L T Q K L K E H C K V
	E Y Q I K T F S G Q T H G F V H R K R E D C S P A D K P Y I D E A R R N L I E W

241	L N K Y M

5.360 major histocompatibility complex, class II, DR beta 3 precursor [Homo sapiens]
Protein Accession gi|17986005

Mean Expression Ratio 1

Median Expression Ratio 1

Credible Interval (0.679, 1.47)

Associated Peptides 2

Associated Spectra 3

Coverage 0.094


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.66	1.0	1.6	SEQ ID NO: 1726	SVSGFYPGSIEVR

2	0.66	1	1.5	SEQ ID NO: 1727	TQPLQHHNLLVCSVSGFYPGSIEVR

SEQ ID NO: 1728

1	M V C L K L P G G S S L A A L T V T L M V L S S R L A F A G D T R P R F L E L R
	K S E C H F F N G T E R V R Y L D R Y F H N Q E E F L R F D S D V G E Y R A V T

81	E L G R P V A E S W N S Q K D L L E Q K R G R V D N Y C R H N Y G V G E S F T
	V Q R R V H P Q V T V Y P A K T Q P L Q H H N L L V C S V S G F Y P G S I E V R W

161	F R N G Q E E K A G V V S T G L I Q N G D W T F Q T L V M L E T V P R S G E V
	Y T C Q V E H P S V T S A L T V E W R A R S E S A Q S K M L S G V G G F V L G L L

241	F L G A G L F I Y F R N Q K G H S G L Q P T G F L S

5.361 hypothetical protein LOC51571 [Homo sapiens]
Protein Accession gi|42734438

Mean Expression Ratio 0.997

Median Expression Ratio 1

Credible Interval (0.648, 1.52)

Associated Peptides 2

Associated Spectra 2

Coverage 0.0988


A	2.5	50	97.5	Sequence ID No.	Sequence

1	0.61	1	1.6	SEQ ID NO: 1729	INNVPAEGENEVNNELANR

1	0.63	1	1.6	SEQ ID NO: 1730	DAEGILEDLQSYR

SEQ ID NO: 1731

1	M G N L L K V L T C T D L E Q G P N F F L D F E N A Q P T E S E K E I Y N Q V N
	V V L K D A E G I L E D L Q S Y R G A G H E I R E A I Q H P A D E K L Q E K A W

81	G A V V P L V G K L K K F Y E F S Q R L E A A L R G L L G A L T S T P Y S P T Q
	H L E R E Q A L A K Q F A E I L H F T L R F D E L K M T N P A I Q N D F S Y Y R

161	R T L S R M R I N N V P A E G E N E V N N E L A N R M S L F Y A E A T P M L K
	T L S D A T T K F V S E N K N L P I E N T T D C L S T M A S V C R V M L E T P E Y

241	R S R F T N E E T V S F C L R V M V G V I I L Y D H V H P V G A F A K T S K I D
	M K G C I K V L K D Q P P N S V E G L L N A L R Y T T K H L N D E T T S

III. Renal Status Assay Measurements

The ability of a particular renal biomarker assay measurement to distinguish between two populations can be established using ROC analysis. For example, ROC curves established from a “first” subpopulation (i.e., for example, a population predisposed to one or more future changes in renal status) and a “second” subpopulation (i.e., for example, a population not predisposed to one or more future changes in renal status). Calculation of these ROC curves and establishing the area under these ROC curves quantitate the predictive power of the specific assay measurement. In some embodiments, predictive power established by assay measurements described herein comprise an AUC ROC greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95.
A. Immunoassays
In general, immunoassays involve contacting a sample containing, or suspected of containing, a biomarker of interest with at least one antibody that specifically binds to the biomarker. A detectable signal is then generated indicative of the presence or amount of complexes formed by the binding of polypeptides in the sample to the antibody. The detectable signal is then related to the presence or amount of the biomarker in the sample. Numerous methods and devices have been reported regarding the detection and analysis of biological biomarkers. See, e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792, and The Immunoassay Handbook, David Wild, ed. Stockton Press, New York, 1994, each of which is herein incorporated by reference in its entirety, including all tables, figures and claims.
Numerous immunoassay devices and methods can utilize labeled molecules in various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of the biomarker of interest. Suitable assay formats also include chromatographic, mass spectrographic, and protein “blotting” methods. Additionally, certain methods and devices, such as biosensors and optical immunoassays, may be employed to determine the presence or amount of analytes without the need for a labeled molecule. See, e.g., U.S. Pat. Nos. 5,631,171; and 5,955,377, each of which is herein incorporated by reference in its entirety, including all tables, figures and claims. Robotic instrumentation for performing these immunoassays are commercially available including, but not limited to, Beckman ACCESS®, Abbott AXSYM®, Roche ELECSYS®, Dade Behring STRATUS® systems. But any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like.
Antibodies or other polypeptides may be immobilized onto a variety of solid supports for use in immunoassays. Solid phases that may be used to immobilize specific binding members include, but are not limited to those developed and/or used as solid phases in solid phase binding assays. Examples of suitable solid phases include, but are not limited to, membrane filters, cellulose-based papers, beads (including polymeric, latex and paramagnetic particles), glass, silicon wafers, microparticles, nanoparticles, TentaGels, AgroGels, PEGA gels, SPOCC gels, and multiple-well plates. For example, an assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip could then be dipped into the test sample and then processed quickly through washes and detection steps to generate a measurable signal, such as a colored spot. Antibodies or other polypeptides may be bound to specific zones of assay devices either by conjugating directly to an assay device surface, or by indirect binding. In an example of the later case, antibodies or other polypeptides may be immobilized on particles or other solid supports, and that solid support immobilized to the device surface.
In certain embodiments, a urinary renal biomarker assay method comprises an immunoassay. For example, antibodies for use in such assays may specifically bind an epitope of a renal biomarker of interest, and may also bind one or more polypeptides that are “related” thereto, as that term is defined hereinafter. In one embodiment, the renal biomarker of interest is a fully length marker (i.e., for example, a protein). In one embodiment, the renal biomarker of interest is a protein fragment marker (i.e., for example, a peptide). Numerous immunoassay formats are available compatible with body fluid samples including, but not limited to, urine, blood, serum, saliva, tears, and plasma.
In this regard, detectable signals obtained from an immunoassay may be a direct result of complexes formed between one or more antibodies and the target biomolecule (i.e., for example, an analyte) and polypeptides containing the necessary epitope(s) to which the antibodies bind. While such assays may detect the full length biomarker and the assay result be expressed as a concentration of a biomarker of interest, the signal from the assay may actually be a result of all such “immunoreactive” polypeptides present in the sample. Expression of biomarkers may also be determined by means other than immunoassays, including protein measurements (i.e., for example, dot blots, western blots, chromatographic methods, mass spectrometry, etc.) and nucleic acid measurements (mRNA quantitation). This list is not meant to be limiting.
The foregoing method steps should not be interpreted to mean that the renal biomarker assay measurements is/are used in isolation in the methods described herein. Rather, additional variables or other clinical indicia may be included in the methods described herein. For example, risk stratification, diagnostic, classification, monitoring, etc. methods as described herein may be combined with one or more clinical indicia relevant to the patient population including, but not limited to, demographic information (e.g., weight, sex, age, race), medical history (e.g., family history, type of surgery, pre-existing disease such as aneurism, congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, or sepsis, type of toxin exposure such as NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin), clinical variables (e.g., blood pressure, temperature, respiration rate), risk scores (APACHE score, PREDICT score, TIMI Risk Score for UA/NSTEMI, Framingham Risk Score), a glomerular filtration rate, an estimated glomerular filtration rate, a urine production rate, a serum or plasma creatinine concentration, a urine creatinine concentration, a fractional excretion of sodium, a urine sodium concentration, a urine creatinine to serum or plasma creatinine ratio, a urine specific gravity, a urine osmolality, a urine urea nitrogen to plasma urea nitrogen ratio, a plasma BUN to creatnine ratio, a renal failure index calculated as urine sodium/(urine creatinine/plasma creatinine), a serum or plasma neutrophil gelatinase (NGAL) concentration, a urine NGAL concentration, a serum or plasma cystatin C concentration, a serum or plasma cardiac troponin concentration, a serum or plasma BNP concentration, a serum or plasma NTproBNP concentration, and a serum or plasma proBNP concentration. Other measures of renal function which may be combined with one or more renal biomarker assay measurements are described hereinafter. In: Harrison's Principles of Internal Medicine, 17th Ed., McGraw Hill, New York, pages 1741-1830; and In: Current Medical Diagnosis & Treatment 2008, 47th Ed, McGraw Hill, New York, pages 785-815, each of which are herein incorporated by reference in their entirety.
When more than one biomarker is measured, the individual biomarkers may be measured in samples obtained at the same time, or may be determined from samples obtained at different (e.g., an earlier or later) times. The individual biomarkers may also be measured on the same or different body fluid samples. For example, one renal biomarker may be measured in a serum or plasma sample and another renal biomarker may be measured in a urine sample. In addition, assignment of a likelihood may combine a renal biomarker assay measurement with temporal changes in one or more additional variables.
B. Detectable Labels
Generation of a detectable signal from the detectable label can be performed using various optical, acoustical, and electrochemical methods. Examples of detection modes include, but are not limited to, fluorescence, radiochemical detection, reflectance, absorbance, amperometry, conductance, impedance, interferometry, ellipsometry, etc. In certain of these methods, the solid phase antibody may be coupled to a transducer (e.g., a diffraction grating, electrochemical sensor, etc) for generation of a signal, while in others, a signal is generated by a transducer that is spatially separate from the solid phase antibody (e.g., a fluorometer that employs an excitation light source and an optical detector). This list is not meant to be limiting. Antibody-based biosensors may also be employed to determine the presence or amount of analytes that optionally eliminate the need for a labeled molecule.
Biological assays require methods for detection, and one of the most common methods for quantitation of assay measurements is to conjugate a detectable label to a protein or nucleic acid that has affinity for one of the components in the biological system being studied. Detectable labels used in the immunoassays described above may include, but are not limited to, molecules that are themselves detectable (e.g., fluorescent moieties, electrochemical labels, ecl (electrochemical luminescence) labels, metal chelates, colloidal metal particles, etc.) as well as molecules that may be indirectly detected by production of a detectable reaction product (e.g., enzymes such as horseradish peroxidase, alkaline phosphatase, etc.) or through the use of a specific binding molecule which itself may be detectable (e.g., a labeled antibody that binds to the second antibody, biotin, digoxigenin, maltose, oligohistidine, 2,4-dintrobenzene, phenylarsenate, ssDNA, dsDNA, etc.).
Preparation of solid phases and detectable label conjugates often comprise the use of chemical cross-linkers. Cross-linking reagents may involve at least two reactive groups, and are divided generally into homofunctional cross-linkers (containing identical reactive groups) and heterofunctional cross-linkers (containing non-identical reactive groups). Homobifunctional cross-linkers that couple through amines, sulfhydryls or react non-specifically are available from many commercial sources. Maleimides, alkyl and aryl halides, alpha-haloacyls and pyridyl disulfides are thiol reactive groups and are believed to react with sulfhydryls to form thiol ether bonds, while pyridyl disulfides react with sulfhydryls to produce mixed disulfides. The pyridyl disulfide product is cleavable. Imidoesters are also very useful for protein-protein cross-links. A variety of heterobifunctional cross-linkers, each combining different attributes for successful conjugation, are commercially available.
D. Assay Correlations
In some embodiments, the renal biomarker assay measurement is/are correlated to one or more future changes in renal function. In one embodiment, risk stratification comprises determining a subject's likelihood (i.e., for example, probability) for a future improvement in renal function.
In one embodiment, the renal biomarker assay measurement is/are correlated to a likelihood of such a future improvement in renal function. In one embodiment, the method correlates a likelihood of such a future injury to renal function. In one embodiment, the risk stratification comprises determining a subject's risk for progression to acute renal failure (ARF).
In one embodiment, the renal biomarker assay measurement is/are correlated to a likelihood of such progression to acute renal failure (ARF). In one embodiment, the risk stratification method comprises determining a subject's outcome risk.
In one embodiment, the assay measurement is/are correlated to a likelihood of the occurrence of a clinical outcome related to a renal injury suffered by the subject.
Consequently, the measured concentration value(s) may each be compared to a threshold value, wherein either a “positive going kidney injury marker”, or a “negative going kidney injury marker” is identified. In one embodiment, the risk stratification comprises determining a subject's risk for future reduced renal function. In some embodiments, the method assigns a likelihood, risk, or probability that such that an event of interest is more or less likely to occur within 180 Days of the time at which the body fluid sample is obtained from the subject. In some embodiments, the assigned likelihood, risk, or probability relates to an event of interest occurring within a time period including, but not limited to, 18 months, 120 Days, 90 Days, 60 Days, 45 Days, 30 Days, 21 Days, 14 Days, 7 Days, 5 Days, 96 hours, 72 hours, 48 hours, 36 hours, 24 hours, 12 hours, or less. Alternatively, assigning a risk at 0 hours of the time at which the body fluid sample is obtained from the subject is equivalent to diagnosis of a current condition.
Selecting a diagnostic threshold involves, among other things, consideration of the probability of disease, distribution of true and false diagnoses at different test thresholds, and estimates of the consequences of treatment (or a failure to treat) based on the diagnosis. For example, when considering administering a specific therapy which is highly efficacious and has a low level of risk, few tests are needed because clinicians can accept substantial diagnostic uncertainty. On the other hand, in situations where treatment options are less effective and more risky, clinicians often need a higher degree of diagnostic certainty. Thus, a cost/benefit analysis is involved in selecting a diagnostic threshold.
1. Thresholds
Suitable thresholds may be determined in a variety of ways. For example, one recommended diagnostic threshold for the diagnosis of acute myocardial infarction uses cardiac troponin, wherein the diagnostic threshold is set at the 97.5th percentile of the cardiac troponin concentration measured in a normal population. Another method to determine a diagnostic threshold comprises measuring serial samples from the same patient, where a prior “baseline” result is used to monitor for temporal changes in a biomarker level.
Population studies may also be used to select thresholds. For example, Receiver Operating Characteristic (“ROC”) arose from the field of signal detection theory developed during World War II for the analysis of radar images, and ROC analysis is often used to select a threshold to distinguish a “diseased” subpopulation from a “nondiseased” subpopulation. Predictive power balances the occurrences of false positives (i.e., for example, when the person tests positive, but actually does not have the disease) and false negatives (i.e., for example, when the person tests negative, suggesting they are healthy, when they actually do have the disease). To draw a ROC curve, the true positive rate (TPR) and false positive rate (FPR) are determined as the decision threshold is varied continuously. Since TPR is equivalent with sensitivity and FPR is equal to (1−specificity), the ROC graph is sometimes called the sensitivity vs (1−specificity) plot. A perfect test will have an area under the ROC curve of 1.0; a random test will have an area of 0.5. A threshold value is selected to provide an acceptable level of specificity and sensitivity usually determined by summing specificity values with sensitivity values. Consequently, the larger the calculated threshold value the greater the predicative power of the specific assay measurement under analysis.
In this context, “diseased” is meant to refer to a population having one characteristic (i.e., for example, the presence of a disease or condition or the occurrence of some outcome) and “nondiseased” population lacking the same characteristic. While a single decision threshold is the simplest application of such a method, multiple decision thresholds may be used. For example, below a first threshold, the absence of disease may be assigned with relatively high confidence, and above a second threshold the presence of disease may also be assigned with relatively high confidence. Between the two thresholds may be considered indeterminate. This is meant to be exemplary in nature only.
In addition to threshold value comparisons, other methods for correlating assay measurements to a patient classification (i.e., for example, occurrence or nonoccurrence of disease, likelihood of an outcome, etc.) include, but are not limited to, decision trees, rule sets, Bayesian methods, and neural network methods. These methods can produce probability values representing the degree to which a subject or patient belongs to one classification out of a plurality of classifications.
Multiple thresholds may also be used to assess renal status in a subject and/or patient. For example, a multiple thresholding method may combine a “first” subpopulation which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc., with a “second” subpopulation which is not so predisposed into a single group. This combination group is then subdivided into three or more equal parts (i.e., for example, tertiles, quartiles, quintiles, etc., depending on the number of subdivisions). An odds ratio is assigned to subjects based on which subdivision they fall into. If one considers a tertile embodiment, the lowest or highest tertile can be used as a reference for comparison of the other subdivisions. This reference subdivision is assigned an odds ratio of 1. The second tertile is assigned an odds ratio that is relative to that first tertile. That is, someone in the second tertile might be 3 times more likely to suffer one or more future changes in renal status in comparison to someone in the first tertile. The third tertile is also assigned an odds ratio that is relative to that first tertile.
2. Specificity and Sensitivity
In some embodiments, a measured concentration of one or more renal biomarkers, or a composite of such biomarkers, may be treated as continuous variables. For example, any particular biomarker concentration can be converted into a corresponding probability of a future reduction in renal function for the subject, the occurrence of an injury, a classification, etc. Alternatively, a threshold value can provide an acceptable level of specificity and sensitivity in separating a population of subjects into “bins” such as a “first” subpopulation (e.g., which is predisposed to one or more future changes in renal status, the occurrence of an injury, a classification, etc.) and a “second” subpopulation which is not so predisposed.
In one embodiment, a threshold value is selected to separate a first and a second population by one or more of the following measures of test accuracy:

- i) an odds ratio greater than 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less;
- ii) a specificity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;
- iii) a sensitivity of greater than 0.5, preferably at least about 0.6, more preferably at least about 0.7, still more preferably at least about 0.8, even more preferably at least about 0.9 and most preferably at least about 0.95, with a corresponding specificity greater than 0.2, preferably greater than about 0.3, more preferably greater than about 0.4, still more preferably at least about 0.5, even more preferably about 0.6, yet more preferably greater than about 0.7, still more preferably greater than about 0.8, more preferably greater than about 0.9, and most preferably greater than about 0.95;
- iv) at least about 75% sensitivity, combined with at least about 75% specificity; a positive likelihood ratio (calculated as sensitivity/(1−specificity)) of greater than 1, at least about 2, more preferably at least about 3, still more preferably at least about 5, and most preferably at least about 10; or
- v) a negative likelihood ratio (calculated as (1−sensitivity)/specificity) of less than 1, less than or equal to about 0.5, more preferably less than or equal to about 0.3, and most preferably less than or equal to about 0.1.

Various measures of test accuracy have been reported and used to determine the effectiveness of a given biomarker. Fischer et al., Intensive Care Med. 29:1043-1051 (2003). These accuracy measures include, but are not limited to, sensitivity and specificity, predictive values, likelihood ratios, diagnostic odds ratios, and AUC ROC values. For example, AUC ROC values are equal to the probability that a classifier will rank a randomly chosen positive instance higher than a randomly chosen negative one. Consequently, an AUC ROC value may be thought of as equivalent to the Mann-Whitney U test, which tests for the median difference between scores obtained in the two groups considered if the groups are of continuous data, or to the Wilcoxon test of ranks.
As discussed above, suitable tests may exhibit one or more of the following results on these various measures: a specificity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding sensitivity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; a sensitivity of greater than 0.5, preferably at least 0.6, more preferably at least 0.7, still more preferably at least 0.8, even more preferably at least 0.9 and most preferably at least 0.95, with a corresponding specificity greater than 0.2, preferably greater than 0.3, more preferably greater than 0.4, still more preferably at least 0.5, even more preferably 0.6, yet more preferably greater than 0.7, still more preferably greater than 0.8, more preferably greater than 0.9, and most preferably greater than 0.95; at least 75% sensitivity, combined with at least 75% specificity; a ROC curve area of greater than 0.5, preferably at least 0.6, more preferably 0.7, still more preferably at least 0.8, even more preferably at least 0.9, and most preferably at least 0.95; an odds ratio different from 1, preferably at least about 2 or more or about 0.5 or less, more preferably at least about 3 or more or about 0.33 or less, still more preferably at least about 4 or more or about 0.25 or less, even more preferably at least about 5 or more or about 0.2 or less, and most preferably at least about 10 or more or about 0.1 or less; a positive likelihood ratio (calculated as sensitivity/(1−specificity)) of greater than 1, at least 2, more preferably at least 3, still more preferably at least 5, and most preferably at least 10; and or a negative likelihood ratio (calculated as (1−sensitivity)/specificity) of less than 1, less than or equal to 0.5, more preferably less than or equal to 0.3, and most preferably less than or equal to 0.1.
G. Conventional Renal Diagnostics
As noted above, the terms “acute renal (or kidney) injury” and “acute renal (or kidney) failure” as used herein are generally defined, in part, in terms of changes in serum creatinine from a baseline value. Most conventional definitions of ARF have common elements, including but not limited to the use of serum creatinine and, often, urine output. Patients may present with renal dysfunction without an available baseline measure of renal function for use in this comparison. In such an event, one may estimate a baseline serum creatinine value by assuming the patient initially had a normal GFR.
1. Glomerular Filtration Rate And Creatinine
Glomerular filtration rate (GFR) is generally defined as the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. Glomerular filtration rate (GFR) can be calculated by measuring any chemical that has a steady level in the blood, and is freely filtered but neither reabsorbed nor secreted by the kidneys. GFR is typically expressed in units of ml/min:
By normalizing the GFR to the body surface area, a GFR of approximately 75-100 ml/min per 1.73 m²can be assumed. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood.
There are several different techniques used to calculate or estimate the glomerular filtration rate (GFR or eGFR). In clinical practice, however, creatinine clearance is used to measure GFR. Creatinine is produced naturally by the body (creatinine is a metabolite of creatine, which is found in muscle). It is freely filtered by the glomerulus, but also actively secreted by the renal tubules in very small amounts such that creatinine clearance overestimates actual GFR by 10-20%. This margin of error is acceptable considering the ease with which creatinine clearance is measured.
Creatinine clearance (CCr) can be calculated if values for creatinine's urine concentration (UCr), urine flow rate (V), and creatinine's plasma concentration (PCr) are known. Since the product of urine concentration and urine flow rate yields creatinine's excretion rate, creatinine clearance is also said to be its excretion rate (UCr×V) divided by its plasma concentration. This is commonly represented mathematically as:
$C_{Cr} = \frac{U_{Cr}  V}{P_{Cr}}$
Commonly a 24 hour urine collection is undertaken, from empty-bladder one morning to the contents of the bladder the following morning, with a comparative blood test then taken:
$C_{Cr} = \frac{U_{Cr}  24 - hour volume}{P_{Cr}  24  60 mins}$
To allow comparison of results between people of different sizes, the CCr is often corrected for the body surface area (BSA) and expressed compared to the average sized man as ml/min/1.73 m². While most adults have a BSA that approaches 1.7 (1.6-1.9), extremely obese or slim patients should have their CCr corrected for their actual BSA:
$C_{Cr - corrected} = \frac{C_{Cr}  1.73}{BSA}$
The accuracy of a creatinine clearance measurement (even when collection is complete) is limited because as glomerular filtration rate (GFR) falls creatinine secretion is increased, and thus the rise in serum creatinine is less. Thus, creatinine excretion is much greater than the filtered load, resulting in a potentially large overestimation of the GFR (as much as a twofold difference). However, for clinical purposes it is important to determine whether renal function is stable or getting worse or better. This is often determined by monitoring serum creatinine alone. Like creatinine clearance, the serum creatinine will not be an accurate reflection of GFR in the non-steady-state condition of ARF. Nonetheless, the degree to which serum creatinine changes from baseline will reflect the change in GFR. Serum creatinine is readily and easily measured and it is specific for renal function.
For purposes of determining urine output on a mL/kg/hr basis, hourly urine collection and measurement is adequate. In the case where, for example, only a cumulative 24-h output was available and no patient weights are provided, minor modifications of the RIFLE urine output criteria have been described. For example, some have assumed an average patient weight of 70 kg, wherein patients are assigned a RIFLE classification based on the following: <35 mL/h (Risk), <21 mL/h (Injury) or <4 mL/h (Failure). Bagshaw et al., Nephrol. Dial. Transplant. 23:1203-1210 (2008).
2. Treatment Regimen Selection
Once a renal diagnosis is obtained, the clinician can readily select a treatment regimen that is compatible with the diagnosis, such as initiating renal replacement therapy, withdrawing delivery of compounds that are known to be damaging to the kidney, kidney transplantation, delaying or avoiding procedures that are known to be damaging to the kidney, modifying diuretic administration, initiating goal directed therapy, etc. Various appropriate treatments for numerous diseases have been previously discussed in relation to the methods of diagnosis described herein. See, e.g., Merck Manual of Diagnosis and Therapy, 17th Ed. Merck Research Laboratories, Whitehouse Station, N J, 1999. In addition, since the methods and compositions described herein provide prognostic information, the renal biomarkers of the present invention may be used to monitor a course of treatment. For example, an improved prognostic state or a worsened prognostic state may indicate that a particular treatment is or is not efficacious.

IV. Antibodies

Antibodies used in the immunoassays described herein preferably specifically bind to a kidney injury marker of the present invention. The term “specifically binds” is not intended to indicate that an antibody binds exclusively to its intended target since, as noted above, an antibody binds to any polypeptide displaying the epitope(s) to which the antibody binds. Rather, an antibody “specifically binds” if its affinity for its intended target is about 5-fold greater when compared to its affinity for a non-target molecule which does not display the appropriate epitope(s). Preferably the affinity of the antibody will be at least about 5 fold, preferably 10 fold, more preferably 25-fold, even more preferably 50-fold, and most preferably 100-fold or more, greater for a target molecule than its affinity for a non-target molecule. In some embodiments, antibodies bind with affinities of at least about 10⁷M⁻¹, and preferably between about 10⁸M⁻¹to about 10⁹M⁻¹, about 10⁹M⁻¹to about 10¹⁰M⁻¹, or about 10¹⁰M⁻¹to about 10¹²M⁻¹.
Affinity may be calculated as K_d=k_off/k_on(k_offis the dissociation rate constant, K_onis the association rate constant and Kd is the equilibrium constant). Affinity can be determined at equilibrium by measuring the fraction bound (r) of labeled ligand at various concentrations (c). The data are graphed using the Scatchard equation: r/c=K(n−r): where r=moles of bound ligand/mole of receptor at equilibrium; c=free ligand concentration at equilibrium; K=equilibrium association constant; and n=number of ligand binding sites per receptor molecule. By graphical analysis, r/c is plotted on the Y-axis versus r on the X-axis, thus producing a Scatchard plot. Antibody affinity measurement by Scatchard analysis is well known in the art. See, e.g., van Erp et al., J. Immunoassay 12:425-443 (1991); and Nelson et al., Comput. Methods Programs Biomed. 27: 65-68 (1988).
Numerous publications discuss the use of phage display technology to produce and screen libraries of polypeptides for binding to a selected analyte. See, e.g, Cwirla et al., Proc. Natl. Acad. Sci. USA 87: 6378-6382 (1990); Devlin et al., Science 249:404-406 (1990); Scott et al., Science 249:386-388 (1990); and Ladner et al., U.S. Pat. No. 5,571,698 (all references herein incorporated by reference). A basic concept of phage display methods is the establishment of a physical association between DNA encoding a polypeptide to be screened and the polypeptide. This physical association is provided by the phage particle, which displays a polypeptide as part of a capsid enclosing the phage genome which encodes the polypeptide. The establishment of a physical association between polypeptides and their genetic material allows simultaneous mass screening of very large numbers of phage bearing different polypeptides. Phage displaying a polypeptide with affinity to a target bind to the target and these phage are enriched by affinity screening to the target. The identity of polypeptides displayed from these phage can be determined from their respective genomes. Using these methods a polypeptide identified as having a binding affinity for a desired target can then be synthesized in bulk by conventional means. See, e.g., U.S. Pat. No. 6,057,098, which is hereby incorporated in its entirety, including all tables, figures, and claims.
Antibodies generated by these methods may then be selected by first screening for affinity and specificity with the purified polypeptide of interest and, if required, comparing the results to the affinity and specificity of the antibodies with polypeptides that are desired to be excluded from binding. The screening procedure can involve immobilization of the purified polypeptides in separate wells of microtiter plates. The solution containing a potential antibody or groups of antibodies is then placed into the respective microtiter wells and incubated for about 30 min to 2 h. The microtiter wells are then washed and a labeled secondary antibody (for example, an anti-mouse antibody conjugated to alkaline phosphatase if the raised antibodies are mouse antibodies) is added to the wells and incubated for about 30 min and then washed. Substrate is added to the wells and a color reaction will appear where antibody to the immobilized polypeptide(s) are present.
Antibodies so identified may then be further analyzed for affinity and specificity in the assay design selected. In the development of immunoassays for a target protein, the purified target protein acts as a standard with which to judge the sensitivity and specificity of the immunoassay using the antibodies that have been selected. Because the binding affinity of various antibodies may differ; certain antibody pairs (e.g., in sandwich assays) may interfere with one another sterically, etc., assay performance of an antibody may be a more important measure than absolute affinity and specificity of an antibody.

V. Kits

In some embodiments, the present invention also contemplates devices and kits for performing the methods described herein. Suitable kits comprise reagents sufficient for performing an assay for at least one of the described kidney injury markers, together with instructions for performing the described threshold comparisons.
In certain embodiments, reagents for performing such assays are provided in an assay device, and such assay devices may be included in such a kit. Preferred reagents can comprise one or more solid phase antibodies, the solid phase antibody comprising antibody that detects the intended biomarker target(s) bound to a solid support. In the case of sandwich immunoassays, such reagents can also include one or more detectably labeled antibodies, the detectably labeled antibody comprising antibody that detects the intended biomarker target(s) bound to a detectable label. Additional optional elements that may be provided as part of an assay device are described hereinafter.
In some embodiments, the present invention provides kits for the analysis of the described kidney injury markers. The kit comprises reagents for the analysis of at least one test sample which comprise at least one antibody that a kidney injury marker. The kit can also include devices and instructions for performing one or more of the diagnostic and/or prognostic correlations described herein. Preferred kits will comprise an antibody pair for performing a sandwich assay, or a labeled species for performing a competitive assay, for the analyte. Preferably, an antibody pair comprises a first antibody conjugated to a solid phase and a second antibody conjugated to a detectable label, wherein each of the first and second antibodies that bind a kidney injury marker. Most preferably each of the antibodies are monoclonal antibodies. The instructions for use of the kit and performing the correlations can be in the form of labeling, which refers to any written or recorded material that is attached to, or otherwise accompanies a kit at any time during its manufacture, transport, sale or use. For example, the term labeling encompasses advertising leaflets and brochures, packaging materials, instructions, audio or video cassettes, computer discs, as well as writing imprinted directly on kits.

EXPERIMENTAL

Example I

BioMaRK Data Collection Method

Patients and Study Design

BioMaRK was an observational cohort study conducted as an ancillary study to the Veterans Affairs/National Institutes of Health (VA/NIH) Acute Renal Failure Trial Network study (ATN study). The ATN study was a multicenter, prospective trial of two strategies for renal replacement therapy in critically ill patients with acute kidney injury. Coca et al., “Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review” Kidney Int, 73:1008-1016 (2008). Adult patients (18 years or older) with AKI and requiring renal-replacement therapy (RRT), as well as failure of one or more non-renal organ systems or sepsis were eligible. As a sub-study to the ATN study, 109 patients were enrolled at The University of Pittsburgh Medical Center, The VA Pittsburgh Healthcare System, The Cleveland Clinical Foundation, The University of Texas Health Science Center at Houston, and Washington University Medical Center to undergo serial blood and urine sampling. Incomplete data including unavailability of urine samples precluded inclusion of 33 subjects; consequently the remaining 76 formed the analysis cohort. Approval from the Institutional Review Boards was received from the University of Pittsburgh and all participating sites.

Data Collection/Laboratory Measurements

Medical records of study participants were prospectively reviewed to retrieve hospitalization data including baseline demographic characteristics, serial renal function, daily urine volume, and severity of illness scores. The presence of sepsis was defined by international consensus criteria. Levy et al., “2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference” Crit Care Med, 31:1250-1256 (2003). Recovery of renal function was defined by survival and dialysis independence at Day 60 post AKI. For purposes of primary analysis, partial recovery (i.e. failure to return to baseline renal function but free of dialysis) was included in the recovery group. Similarly, all deaths were included in the non-recovery group.
Fresh urine samples were obtained on Days 1, 7, and 14 post AKI. Immediately upon obtaining a well-mixed 30 ml sample, a protease inhibitor tablet (Roche Diagnostics Corporation, IN, USA) was added. After processing, the sample was frozen (at −80° C.) until analyzed. Samples were assayed in duplicate, and data were analyzed using Bio-Rad Bio-Plex Manager Software (version 4.1). Urine creatinine concentrations were measured using a non-enzymatic assay (DICT-500, BioAssay Systems, CA, USA).

Example II

Proteomics Analysis

Urine collected in accordance with Example I from fourteen (14) patients with severe AKI was evaluated with an unbiased proteomics discovery platform.
Data collected from seven (7) patients that did not recover renal function after AKI was compared to data collected from seven (7) patients that did recover renal function after AKI. The two groups were matched for age (e.g., +/−5 yrs) and gender.
The data presented herein show that approximately thirty (30) proteins were differentially expressed between the Recovery Group and the Non-Recovery Group. A preliminary analysis has categorized these proteins into groups including, but not limited to:

- 1. Ferritin, alpha and beta globin, or catalase that may be involved in providing protection from reactive oxygen species
- 2. Complement factor H or complement component 4 BP that may be involved in regulation of complement activation
- 3. Olfactomedin-4, leucine rich alpha-2 glycoprotein or ring finger protein 167 that may be involved in cell survival and proliferation.
- 4. Inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, (N-acylsphingosine aminohydrolase and saposin) that may be involved in basement membrane, matrix proteins or sphingolipid turnover.

Although it is not necessary to understand the mechanism of an invention, it is believed that the differential expression of proteins categorized in Group 3 and Group 4 might be directly involved in renal recovery because of their involvement with cell proliferation and/or rebuilding of the basement membrane.

FFPEDVSEELIQEITQR

1. A composition comprising an renal injury biomarker, wherein said biomarker comprises at least a fragment of at least one protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotein, carbonic anhydrase, and uromodulin precursor.

2. The composition of claim 1, wherein said composition further comprises a biological fluid sample.

3. The composition of claim 2, wherein said biological fluid sample is collected from a patient between 1 day and 14 days after a kidney injury.

4. The composition of claim 2, wherein said biological fluid sample is a human urine sample.

5. The composition of claim 1, wherein said renal injury biomarker in said biological fluid sample is at at least one level selected from the group consisting of at least 2.5 fold higher, at least 2.0 fold higher, at least 1.5 fold higher, at least 1.25 fold higher as compared to an expected level in a renal recovery group.

6. The composition of claim 1, wherein said renal injury biomarker in said biological fluid sample is at at least one level selected from the group consisting of at least 2.5 fold lower, at least 2.0 fold lower, at least 1.5 fold lower and at least 1.25 fold lower as compared to an expected level in a renal recovery group.

7-10. (canceled)

11. A kit, comprising:

a) a first container comprising an antibody is specifically directed to at least one of a plurality of renal injury biomarkers, wherein said biomarkers comprise at least a fragment of a protein selected from the group consisting of ferritin, beta globin, catalase, alpha globin, epidermal growth factor receptor pathway substrate 8, mucin isoform precursor, ezrin, delta globin, moesin, phosphoprotein isoform, annexin A2, myoglobin, hemopexin, serine proteinase inhibitor, serpine peptidase inhibitor, CD14 antigen precursor, fibronectin isoform preprotein, angiotensinogen preprotein, complement component precursor, carbonic anhydrase, uromodulin precursor, complement factor H, complement component 4 BP, heparan sulfate proteoglycan 2, olfactomedian-4, leucine rich alpha-2 glycoprotein, ring finger protein 167, inter-alpha globulin inhibitor H4, heparan sulfate proteoglycan 2, N-acylshingosine aminohydrolase, serine proteinase inhibitor clade A member 1, mucin 1, clusterin isoform 1, brain abundant membrane attached signal protein 1, dipeptidase 1, fibronectin 1 isoform 5 preprotein, angiotensinogen preproprotein, carbonic anhydrase, and uromodulin precursor;

b) instructions for determining whether said biomarker is overexpressed as compared to a renal recovery group comprising individuals without an acute renal injury;

c) instructions for determining whether said biomarker is underexpressed as compared to said renal recovery group; and

d) instructions for determining a probability value of renal non-recovery for a patient from an acute renal injury by a combination of receiver operated characteristic area under the curve determinations for overexpression or underexpression of said biomarker as compared to a plurality of diagnostic threshold values.

12. The kit of claim 11, wherein said antibody is a monoclonal antibody.

13. The kit of claim 12, wherein said monoclonal antibody is specifically directed to said biomarker protein fragment.

14. The kit of claim 11, further comprising instructions for treating said patient during the development of said renal disease with a treatment regimen selected from the group consisting of: i) said treatment regimen comprising adverse effects when said probability value of non-recovery from said acute injury is greater than 50%, and ii) said treatment regimen without adverse effects when said probability value of non-recovery from said acute renal injury is less than 50%.

15. The kit of claim 14, wherein said instructions identify that said treatment regimen as selected from the group consisting of initiating renal replacement therapy, withdrawing kidney damaging compounds, kidney transplantation, delaying or avoiding kidney damaging procedures and modifying diuretic administration.

16. The kit of claim 11, wherein said interactions identify that said overexpressed biomarker is between approximately 1.5 fold-1.5 fold higher in comparison to said renal recovery group.

17. The kit of claim 11, wherein said instructions identify that said underexpressed biomarker is between approximately 1.5 fold-2.0 fold lower in comparison to said renal recovery group.

18. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is less than 10%.

19. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is greater than 75%.

20. The kit of claim 11, wherein said instructions identify that said probability value of non-recovery from said acute renal injury is greater than 90%.